| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Retevmo (selpercatinib) Early-stage (IB-IIIA) RET fusion-positive non-small cell lung cancer, adjuvant therapy | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology | |
Phase 3 data readout example | Retevmo (selpercatinib) Early-stage (IB-IIIA) RET fusion-positive non-small cell lung cancer, adjuvant therapy | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology | |
Phase 3 data readout example | Retevmo (selpercatinib) Early-stage (IB-IIIA) RET fusion-positive non-small cell lung cancer, adjuvant therapy | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Eli Lilly and Company
$1,115.7
-7 (-0.62%)
A 95Pipeline Score Overvalued Pharma · Commercial
Market Cap
1050.27 B
EPS
29.97
P/E Ratio
37.23 $
Value Trade
3.68 B
-2.93 %
Week
-8.57 %
1 Month
-1.53 %
3 Month
13.26 %
6 Month
432.5 %
5 Year
37,819.33 %
All Time
Cash Data
Cash Position
-
Cash Flow
Profitable
Overview
Volume
1.83 M
52 Week Range
712.05 - 1,292.65
% held by Insiders
9.88 %
% held by Institutions
76.27 %
Enterprise Value
1088.78 B
Total Shares
940.94 M
Short %
0.93 %
Float Shares
849.67 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Eli Lilly and Company
2626Total events
48Upcoming
1103Tier-1 (high impact)
2011 – 2030Coverage
Upcoming catalysts 2
TBD
T2Oral Presentation
Subscribe to view catalyst details
TBD
T3Enrollment Milestone
Subscribe to view catalyst details
Event history 2
TBD
▲Full ResultsIxekizumabApprovedClinical Data
Subscribe to view catalyst details
TBD
▲Full ResultsZepboundApprovedClinical Data
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-09 | Ebglyss (lebrikizumab-lbkz) | PDUFA Date | PDUFA | Approved | – | – | – |
2026-06-09 | Ebglyss (lebrikizumab-lbkz) | PDUFA Date | PDUFA | Approved | – | – | – |
2026-06-09 | Ebglyss (lebrikizumab-lbkz) | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
A95
Pipeline Score $272.6B
Pipeline ValueOvervalued
Valuation Signal389
Drugs Scored0.3x
rNPV / MCap Top 100%
Large Pharma (rank 1 of 938)
Percentile RankEli Lilly and Company earns an A-grade pipeline score (95/100), with $272.6B risk-adjusted pipeline value, led by LY2189265 in Diabetes Mellitus, Type 2 (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LY2189265 Monoclonal antibody | Diabetes Mellitus, Type 2 | Phase 3 | NCT01408888 | 61% | $15.8B | COMPLETED | 8,059 | - | - | Apr 1, 2012 | - | Oct 7, 2014 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Taltz and Zepbound | psoriatic disease and obesity | Phase 3b | 2026-08-31 | At Week 52, Taltz and Zepbound maintained or further improved psoriasis or psoriatic arthritis disease activity from Week 36, when statistically superior improvements versus Taltz alone were observed. Read More | New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity At Week 52, Taltz and Zepbound maintained or further improved psoriasis or psoriatic arthritis disease activity from Week 36, when statistically... Read More | |
Taltz and Zepbound | psoriatic disease and obesity | Phase 3b | 2026-08-31 | At Week 52, Taltz and Zepbound maintained or further improved psoriasis or psoriatic arthritis disease activity from Week 36, when statistically superior improvements versus Taltz alone were observed. Read More | New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity At Week 52, Taltz and Zepbound maintained or further improved psoriasis or psoriatic arthritis disease activity from Week 36, when statistically... Read More | |
Taltz and Zepbound | psoriatic disease and obesity | Phase 3b | 2026-08-31 | At Week 52, Taltz and Zepbound maintained or further improved psoriasis or psoriatic arthritis disease activity from Week 36, when statistically superior improvements versus Taltz alone were observed. Read More | New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity At Week 52, Taltz and Zepbound maintained or further improved psoriasis or psoriatic arthritis disease activity from Week 36, when statistically... Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LLY
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LLY Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-02 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-02 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-02 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LLY▼ -0.6%today
Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
Eli Lilly has successfully completed its acquisition of AtaiBeckley Inc., a company focused on developing rapid-acting neuroplastogens for mental health conditions, particularly treatment-resistant depression. This acquisition aims to advance innovative therapies that could provide new treatment options for patients. The transaction received shareholder approval, highlighting confidence in the potential benefits of the merger.
Read more →LLYLilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
Eli Lilly and Company will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. Ilya Yuffa, the executive vice president, will engage in a fireside chat at 1:50 p.m. Eastern time. A live audio webcast will be available on Lilly's investor website, along with a replay for 90 days.
Read more →LLYNew Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity At Week 52, Taltz and Zepbound maintained or further improved psoriasis or psoriatic arthritis disease activity from Week 36, when statistically...
Eli Lilly announced positive results from the TOGETHER-PsO and TOGETHER-PsA Phase 3b trials, demonstrating that the combination of Taltz (ixekizumab) and Zepbound (tirzepatide) maintained or improved disease activity in adults with psoriatic disease and obesity over 52 weeks. The trials showed statistically superior outcomes compared to Taltz alone, with improvements in systemic inflammation and metabolic health. No new safety concerns were reported, supporting the efficacy of this combined treatment approach.
Read more →LLYFDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide), a dual GIP and...
Eli Lilly's Mounjaro (tirzepatide) has received FDA approval to reduce cardiovascular risks in adults with type 2 diabetes. This makes it the first dual GIP and GLP-1 receptor agonist to be approved for this purpose. The approval is based on the SURPASS-CVOT trial, which showed Mounjaro's efficacy in lowering the risk of major cardiovascular events compared to Trulicity. The drug also maintains its benefits in managing blood sugar and weight.
Read more →LLYLa FDA aprueba Mounjaro (tirzepatida) de Lilly para reducir el riesgo cardiovascular en adultos con diabetes tipo 2 Eli Lilly and Company (NYSE: LLY) anunció hoy que la Administración de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en inglés)...
Eli Lilly's Mounjaro (tirzepatida) has received FDA approval to reduce cardiovascular risks in adults with type 2 diabetes. This approval marks Mounjaro as the first medication of its kind to show a reduction in major cardiovascular events. The decision is based on the SURPASS-CVOT study, which demonstrated Mounjaro's efficacy compared to Trulicity. The drug also maintains its established benefits in controlling blood sugar and weight.
Read more →LLYZepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study Eli Lilly and Company (NYSE: LLY) today announced results from a real-world study of adults over 55 with overweight or obesity, which found that...
Eli Lilly's real-world study reveals that Zepbound (tirzepatide) significantly lowers healthcare costs for adults over 55 with obesity. The study found that sustained use of Zepbound resulted in reduced hospital admissions and emergency visits, leading to substantial cost savings. After 12 months, the savings from lower healthcare costs surpassed the treatment costs, highlighting the potential economic benefits of obesity management in older populations.
Read more →LLYLilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
Eli Lilly has filed six lawsuits against U.S. entities selling illegal retatrutide products, aiming to protect patients from the dangers of the black market. The company is urging online platforms and payment processors to help combat this illicit activity. Retatrutide is currently in Phase 3 trials and has not been approved for human use, highlighting the risks associated with unverified products.
Read more →LLYVeeva Vault CRM Selected by Eli Lilly and Company
Eli Lilly and Company has selected Veeva Vault CRM for global implementation, enhancing its commercial model using AI technology. This strategic partnership aims to improve patient access to Lilly's innovative medicines. Veeva's CEO expressed pride in this collaboration, highlighting the potential benefits for both companies.
Read more →LLYVeeva Vault CRM von Eli Lilly and Company ausgewählt
Eli Lilly and Company has chosen Veeva Vault CRM to enhance its commercial operations. This decision is part of a strategic collaboration aimed at improving patient access to medications through advanced technology. Veeva's Vault CRM will support Lilly's new sales model, leveraging AI to ensure more patients receive the right treatments.
Read more →LLYVeeva Vault CRM seleccionado por Eli Lilly and Company
Eli Lilly and Company has committed to implementing Veeva Vault CRM globally, enhancing its strategic collaboration with Veeva Systems. This CRM solution is designed to support Lilly's innovative drug distribution model, utilizing AI to reach more patients. The partnership aims to improve patient access to Lilly's medications, reflecting a commitment to innovation in the life sciences sector.
Read more →LLYLilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress Revenue in Q2 2026 increased 48% to $23.0 billion driven primarily by Mounjaro and Zepbound volume. Q2 2026 EPS increased by 26% to $7.94 on a...
Eli Lilly reported a 48% revenue increase in Q2 2026, reaching $23.0 billion, primarily due to strong sales of Mounjaro and Zepbound. The company raised its full-year revenue guidance and highlighted regulatory approvals for key products. Despite the positive growth, Lilly faced challenges with increased IPR&D charges and declining realized prices.
Read more →LLYLilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
Eli Lilly's olomorasib has been granted Breakthrough Therapy designation by the FDA for treating advanced pancreatic cancer in patients with a KRAS G12C mutation. This designation aims to expedite the drug's development due to its potential to significantly improve treatment outcomes. Olomorasib is a selective inhibitor designed to target KRAS G12C mutations, which are prevalent in pancreatic cancer cases.
Read more →LLYLilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from...
Eli Lilly announced positive topline results from two Phase 3 trials, TRIUMPH-2 and TRIUMPH-3, for retatrutide, a triple hormone receptor agonist. In TRIUMPH-2, participants with obesity and type 2 diabetes lost up to 49.6 lbs, while those in TRIUMPH-3 with severe obesity and cardiovascular disease lost up to 55.8 lbs. Lilly plans to submit a BLA for retatrutide in Q1 2027.
Read more →LLYLilly confirms date and conference call for second-quarter 2026 financial results announcement
Eli Lilly and Company will announce its second-quarter 2026 financial results on August 5, 2026. A conference call will follow at 10 a.m. Eastern time, aimed at providing further details to investors and the media. The call will be accessible via a live webcast, with a replay available afterward.
Read more →LLY/C O R R E C T I O N -- Eli Lilly and Company/
Eli Lilly and Company announced it will present 16 abstracts at the 2026 Alzheimer's Association International Conference, showcasing new data on Alzheimer's diagnostics and treatment, particularly focusing on P-tau217 blood tests and the efficacy of Kisunla (donanemab-azbt). The presentations will cover various aspects of Alzheimer's research, including safety and long-term treatment insights.
Read more →LLY▲ +7.1%on this news
Lilly launches "The Memory Radio Station" across Europe, inviting the public to visually reconstruct fading memories through GenAI
Eli Lilly has launched 'The Memory Radio Station' in Geneva, a campaign aimed at raising awareness of Alzheimer's disease and its early symptoms. This initiative invites the public to share personal memories and utilize generative AI to visualize them. The campaign will travel across multiple European countries, highlighting the importance of recognizing memory changes early.
Read more →LLY▲ +7.1%on this newsshared move
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society...
Eli Lilly's Jaypirca (pirtobrutinib) received a positive opinion from the CHMP for treating adults with chronic lymphocytic leukemia (CLL) across all therapy lines. This recommendation is based on promising results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials. The decision is now pending final action from the European Commission, expected in one to two months.
Read more →LLYWhat Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management Eli Lilly and Company (NYSE: LLY) today announced additional details regarding the Medicare GLP-1 Bridge* program taking effect July 1, 2026. Under...
Eli Lilly has announced the Medicare GLP-1 Bridge program, effective July 1, 2026, which will allow eligible Medicare Part D patients to access its obesity treatments, Foundayo (orforglipron) and Zepbound (tirzepatide), for $50 per month. This program marks a significant milestone in the coverage of weight management medications under Medicare, addressing the needs of older adults facing obesity. Both medications have shown promising results in clinical trials, particularly for patients aged 65 and older.
Read more →LLYLilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Eli Lilly has completed its acquisition of Centessa Pharmaceuticals, focusing on developing orexin receptor 2 agonists for narcolepsy and other sleep-wake disorders. Lilly's executive emphasizes the importance of the orexin system in brain health and the urgent need for effective treatments. The acquisition aims to leverage Centessa's clinical portfolio to address significant unmet needs in this area.
Read more →LLYLilly declares third-quarter 2026 dividend
Eli Lilly and Company has announced a dividend of $1.73 per share for the third quarter of 2026. This dividend is set to be paid on September 10, 2026, to shareholders recorded by August 14, 2026. The company emphasizes its commitment to advancing healthcare solutions and ensuring accessibility to its medicines.
Read more →LLYNew 5W AI Visibility Index: Pharma Spends Billions on DTC Ads. The AI Engines Talk About Eli Lilly and Novo Nordisk Anyway
The 5W AI Visibility Index 2026 reveals that Eli Lilly and Novo Nordisk dominate AI citation share despite not being the highest spenders on direct-to-consumer advertising. The report indicates that consumer research significantly influences drug visibility, with a notable disconnect between ad spend and AI citation outcomes. This trend suggests a shift in how patients seek information about medications.
Read more →LLYLilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca (pirtobrutinib), a non-covalent...
Eli Lilly has announced positive results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca (pirtobrutinib), which showed a 45% reduction in the risk of disease progression or death when added to a venetoclax and rituximab regimen in patients with previously treated CLL/SLL. This trial is notable as it is the first to demonstrate superiority in a venetoclax-containing treatment regimen. The findings will be presented at the 2026 EHA Annual Meeting, highlighting the potential of Jaypirca in shifting treatment standards in CLL. Lilly plans to submit these results to global regulatory authorities for label expansion.
Read more →LLYLilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
Eli Lilly announced promising initial data from the Phase 1 AJX-101 study of its type II JAK2 inhibitor, AJ1-11095, for myelofibrosis patients previously treated with type I JAK2 inhibitors. The results indicate a favorable safety profile and significant clinical activity, including reductions in spleen size and symptom improvement. This data will be presented at the 2026 EHA Annual Meeting.
Read more →LLYZepbound® (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable Eli Lilly and Company (NYSE: LLY) today announced that basketball legend and cultural icon Shaquille O'Neal is sharing his personal experience with...
Eli Lilly and Company announced a national campaign featuring Shaquille O'Neal to raise awareness about moderate obstructive sleep apnea (OSA). O'Neal candidly discusses his struggles with the condition and the transformative impact of Zepbound (tirzepatide) on his health journey. The campaign aims to inform the public about the symptoms of OSA and encourage individuals to consult their doctors for proper diagnosis and treatment. Zepbound is highlighted as a key treatment option that should be combined with lifestyle changes.
Read more →LLYConvatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions
Convatec and the Lilly Foundation have announced a $5 million commitment to Partners In Health. This funding aims to enhance care for non-communicable diseases and chronic conditions. The partnership reflects a significant investment in improving healthcare outcomes for affected populations.
Read more →LLYFDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
Eli Lilly's EBGLYSS (lebrikizumab-lbkz) has received FDA approval for a maintenance dose of one injection every eight weeks for patients aged 12 and older with moderate-to-severe atopic dermatitis. This new regimen allows for as few as six injections per year, enhancing patient convenience and reducing treatment burden. The approval is based on positive long-term clinical trial data.
Read more →LLYLilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced detailed results from three Phase 3 trials in the ACHIEVE...
Eli Lilly announced that its oral GLP-1 treatment, Foundayo (orforglipron), showed superior efficacy in controlling blood sugar and reducing weight in three Phase 3 clinical trials. The trials demonstrated that Foundayo outperformed oral semaglutide and achieved significant improvements in A1C levels and weight loss among adults with type 2 diabetes. Lilly plans to submit Foundayo for FDA approval by the end of the second quarter, aiming to position it as a frontline therapy option. Despite promising results, some gastrointestinal adverse events were noted, which may impact patient tolerability.
Read more →LLYLilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results demonstrating that women with obesity or overweight...
Eli Lilly and Company announced significant findings from the ATTAIN-1 and ATTAIN-2 trials, showcasing that their oral GLP-1 drug, Foundayo (orforglipron), contributes to substantial weight loss in women at all stages of menopause. Women treated with Foundayo reported up to 30.4 lbs of weight loss in perimenopausal and 28.2 lbs in post-menopausal participants. Additionally, reductions in waist circumference were noted, which is linked to a decrease in abdominal fat and cardiometabolic risks. However, potential serious side effects, including thyroid tumors, remain a concern.
Read more →LLYLilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer...
Eli Lilly's investigational drug retatrutide has shown promising results in Phase 3 trials, TRIUMPH-1 and TRANSCEND-T2D-1, demonstrating significant weight loss and improvements in conditions associated with obesity. Participants lost an average of 70.3 lbs over 80 weeks, with many achieving a BMI under 30 and substantial reductions in A1C levels. The treatment offered positive outcomes for knee osteoarthritis pain and obstructive sleep apnea. While the drug exhibited efficacy, it was linked with some mild to moderate adverse events, including nausea and diarrhea.
Read more →LLYLilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting
Eli Lilly will showcase its hematology portfolio at the 2026 EHA Annual Meeting, featuring results from the Phase 3 BRUIN CLL-322 study on pirtobrutinib. Ajax Therapeutics will present data on its type II JAK2 inhibitor for myelofibrosis, while Kelonia Therapeutics will share findings on its CAR-T therapy for multiple myeloma. These presentations highlight Lilly's strategic acquisitions and ongoing commitment to hematology.
Read more →LLYLilly’s Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
Eli Lilly announced that Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death in early-stage RET fusion-positive lung cancer patients in the Phase 3 LIBRETTO-432 trial. The study's results are set to be published in the New England Journal of Medicine and presented at the 2026 ASCO Annual Meeting. This trial highlights the importance of comprehensive biomarker testing and may establish a new standard of care for this patient population.
Read more →LLYLilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
Eli Lilly's Phase 3 LIBRETTO-432 trial showed that Retevmo (selpercatinib) significantly reduces the risk of disease recurrence or death by 83% in early-stage RET fusion-positive lung cancer patients. The trial met its primary endpoint, demonstrating improved event-free survival compared to placebo. These findings may lead to changes in treatment practices for this patient population.
Read more →LLYLilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care Phase 3 ACHIEVE results showed Foundayo, an oral GLP-1 taken without food or water restrictions, outperformed oral semaglutide and dapagliflozin in...
Eli Lilly will present new data on its cardiometabolic portfolio, including findings for Foundayo and retatrutide, at the American Diabetes Association's 86th Scientific Sessions. Phase 3 results indicated Foundayo, an oral GLP-1, significantly outperformed traditional medications in managing type 2 diabetes. Additionally, retatrutide showed promising efficacy in treating obesity and diabetes-related conditions. These developments aim to enhance patient choice and redefine treatment standards in diabetes and obesity care.
Read more →LLYFoundayo and Zepbound now covered for millions of Americans
Eli Lilly announced that CVS Caremark will begin covering Foundayo on June 1 and resume coverage for Zepbound by October 1. This development allows millions of Americans to access these FDA-approved obesity treatments through their insurance. Eligible patients may pay as little as $25 a month for their medications, significantly improving access to effective obesity care.
Read more →LLYLilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
Eli Lilly and Company will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Kenneth Custer, the executive vice president, will engage in a fireside chat. A live audio webcast will be available, along with a replay for 90 days on Lilly's investor website.
Read more →LLYLilly announces three acquisitions to build infectious disease portfolio Eli Lilly and Company (NYSE: LLY) today announced agreements to acquire three companies, Curevo Inc. (Curevo), LimmaTech Biologics AG (LimmaTech...
Eli Lilly and Company (NYSE: LLY) has announced the acquisition of three companies: Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, aimed at enhancing its infectious disease portfolio. These acquisitions focus on developing vaccines for viral and bacterial pathogens, addressing serious long-term health risks. Notably, Curevo's shingles vaccine candidate is expected to improve vaccination rates by reducing side effects. Lilly's strategy emphasizes disease prevention at the source rather than managing consequences, reinforcing its commitment to public health.
Read more →LLYA single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
Eli Lilly announced positive results from the Phase 1b Heart-2 trial for VERVE-102, a base editing medicine aimed at lowering PCSK9 and LDL-C levels. The trial showed dose-dependent reductions in PCSK9 by up to 88% and LDL-C by up to 62%, with effects lasting up to 18 months. Lilly plans to start a Phase 2 study by year-end.
Read more →LLYLilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
Eli Lilly and Company will present its oncology portfolio at the 2026 ASCO Annual Meeting, showcasing advancements in treatments for various cancers. Key highlights include the Phase 3 LIBRETTO-432 study of Retevmo for RET fusion-positive NSCLC and an investigator-initiated study of Verzenio in dedifferentiated liposarcoma. Additional presentations will cover new data from Kelonia Therapeutics and investigational therapies targeting Nectin-4.
Read more →LLYLilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥30% weight...
Eli Lilly's TRIUMPH-1 trial results indicate that retatrutide, a triple hormone receptor agonist, significantly aids weight loss in participants with obesity or overweight. Over 80 weeks, those on the 12 mg dose lost an average of 70.3 lbs, with 45.3% achieving at least 30% weight reduction. Improvements in cardiometabolic health measures were also observed. While adverse events were reported, the treatment is seen as a promising option against obesity, with ongoing evaluations planned in future clinical trials.
Read more →LLYLilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting Phase 3 LIBRETTO-432 study evaluating Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive NSCLC to be featured in the Plenary Session...
Eli Lilly will present key findings from its oncology portfolio at the 2026 ASCO Annual Meeting, including results from the Phase 3 LIBRETTO-432 study of Retevmo in RET fusion-positive NSCLC. The company will also showcase an investigator-initiated study of Verzenio in dedifferentiated liposarcoma and data from its acquisition of Kelonia Therapeutics. These presentations highlight Lilly's commitment to advancing cancer therapies.
Read more →LLYLilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference
Eli Lilly and Company will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 28, 2026. Daniel M. Skovronsky, M.D., Ph.D., will engage in a fireside chat during the event. A live audio webcast will be available on Lilly's investor website, with a replay accessible for 90 days.
Read more →LLYLilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth The Caitlin Clark Foundation, in partnership with Eli Lilly and Company (NYSE: LLY) and Musco Lighting, has opened three new multi-sport community...
Eli Lilly and Company, in collaboration with the Caitlin Clark Foundation and Musco Lighting, has inaugurated three multi-sport community courts in Indianapolis. This initiative aims to provide year-round access to high-quality sports facilities for youth as part of Lilly's 150th anniversary. The courts, which include locations at local schools and a public park, will support physical activity and community engagement for families and young people. This partnership underscores Lilly's commitment to enhancing community health beyond just medicine.
Read more →LLYLilly and UNICEF collaborate to give millions of children a healthier start Eli Lilly and Company (NYSE: LLY) and UNICEF USA announced today a collaboration aiming to improve non-communicable disease (NCD) prevention and care ...
Eli Lilly and UNICEF USA have announced a six-year collaboration focused on improving non-communicable disease (NCD) prevention and care for children in low- and middle-income countries. Lilly is committing $50 million to bolster primary healthcare systems, which will enhance the detection and management of NCDs among children and adolescents. The initiative aims to reach over 30 million young people and caregivers and is designed to integrate prevention and care into routine health services. This effort coincides with Lilly's 150th anniversary and aligns with its broader 30x30 initiative to enhance healthcare access in underserved areas.
Read more →LLYLilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
Eli Lilly announced positive results from two late-phase trials, ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN, demonstrating that participants maintained significant weight loss after switching from higher doses of injectable incretin therapy to either Foundayo or lower-dose Zepbound. The findings, presented at the European Congress on Obesity, highlight the potential of these medications for long-term weight maintenance. Both trials met their primary and secondary endpoints, reinforcing Lilly's commitment to obesity treatment.
Read more →LLYIn honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries
Eli Lilly and Company has launched an initiative to support nutritious food distribution as part of its 150th anniversary. The company will provide charitable support to community organizations, enabling the distribution of approximately 500,000 meals across 15 communities. Additionally, Lilly's support will help establish cold storage infrastructure at 150 food pantries, facilitating the delivery of five million protein-rich meals annually.
Read more →LLYLilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials In ATTAIN-MAINTAIN, participants who transitioned from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo maintained all but 0.9 kg...
Eli Lilly announced positive results from two late-phase trials, ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN, showing that participants maintained significant weight loss after switching from higher doses of injectable incretin therapy to either Foundayo or lower-dose Zepbound. The trials demonstrated that both medications effectively support long-term weight maintenance, addressing a critical challenge in obesity treatment. Findings were presented at the 33rd European Congress on Obesity and published in leading medical journals.
Read more →LLYThe Next Generation of the GLP-1 Revolution Is Already Underway
The article discusses the rapid evolution of GLP-1 receptor agonists in treating obesity and type 2 diabetes, highlighting SureNano Science's GEP-44 as a promising next-generation therapy. With the global GLP-1 market expected to grow significantly, innovations in drug delivery and efficacy are becoming critical. Eli Lilly's recent FDA approval of Foundayo marks a notable advancement in this field.
Read more →LLYLilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
Eli Lilly and Company has announced an additional $4.5 billion investment in its Indiana manufacturing sites, bringing its total commitments since 2020 to over $21 billion. This investment includes the opening of the Lilly Lebanon Advanced Therapies, the company's first dedicated genetic medicine manufacturing facility. The expansion aims to meet the anticipated demand for advanced therapies and will support both clinical and commercial production.
Read more →LLYLilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
Eli Lilly's Omvoh (mirikizumab-mrkz) has demonstrated durable disease clearance in ulcerative colitis patients over four years of treatment, with 63.5% of those achieving clearance at one year maintaining it. This marks a significant milestone as it is the first IL-23p19 inhibitor to achieve such results. The findings will be presented at Digestive Disease Week 2026.
Read more →LLYLilly declares second-quarter 2026 dividend
Eli Lilly and Company has announced a dividend of $1.73 per share for the second quarter of 2026, payable on June 10, 2026, to shareholders of record by May 15, 2026. This decision highlights the company's ongoing commitment to returning value to its shareholders, despite acknowledging potential risks in its business operations and research activities.
Read more →LLY▲ +9.8%on this newsshared move
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines
Eli Lilly reported a strong first quarter in 2026 with a 56% increase in revenue, driven by significant growth in key products like Mounjaro and Zepbound. The company also received FDA approval for Foundayo, enhancing access to GLP-1 medications. Despite challenges such as lower realized prices and increased R&D expenses, Lilly raised its full-year revenue guidance by $2 billion.
Read more →LLYLilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. ( Ajax ), a biopharmaceutical company developing next generation JAK inhibitors for...
Eli Lilly and Company has announced a definitive agreement to acquire Ajax Therapeutics, a biopharmaceutical firm focused on developing next-generation JAK inhibitors for myeloproliferative neoplasms. Ajax's lead asset, AJ1-11095, is a Type II JAK2 inhibitor currently in Phase 1 trials, showing promise for providing patients with improved disease control. The acquisition, which could amount to $2.3 billion, is aimed at enhancing Lilly's capabilities in blood cancer treatment. The closure of the deal is contingent on regulatory approvals and other customary conditions, with potential risks surrounding its success.
Read more →LLYLilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies Eli Lilly and Company (NYSE: LLY) and Kelonia Therapeutics, Inc. ( Kelonia ), a clinical-stage biotechnology company pioneering in vivo gene...
Eli Lilly has announced its acquisition of Kelonia Therapeutics, a company specializing in in vivo CAR-T cell therapies. This acquisition is aimed at enhancing Lilly's capabilities in genetic medicine, particularly with Kelonia's lead program, KLN-1010, which is in Phase 1 trials for relapsed/refractory multiple myeloma. The deal is valued at up to $7 billion, including an upfront payment of $3.25 billion, with additional payments based on clinical milestones. The transaction is expected to close in the second half of 2026, pending regulatory approvals.
Read more →LLYLilly confirms date and conference call for first-quarter 2026 financial results announcement
Eli Lilly and Company will announce its first-quarter 2026 financial results on April 30, 2026. A conference call will follow at 10 a.m. Eastern time, providing details on the company's performance. The call will be accessible via a live webcast, with a replay available afterward.
Read more →LLYACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
The Phase 3 ACHIEVE-4 trial of Foundayo (orforglipron) has shown positive results, meeting its primary objective of non-inferiority compared to insulin glargine. The trial revealed a significant reduction in major adverse cardiovascular events and all-cause mortality. Eli Lilly plans to submit Foundayo for FDA approval for treating type 2 diabetes by the end of Q2 2026.
Read more →LLYLinden Lake Labs Applauds Acquisition of Portfolio Company CrossBridge Bio by Eli Lilly and Company
Eli Lilly and Company has acquired CrossBridge Bio, a portfolio company of Linden Lake Labs. This acquisition is seen as a strategic move to enhance Lilly's capabilities and expand its product offerings. The deal reflects Lilly's commitment to growth and innovation in the biopharma sector.
Read more →LLYLilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
Eli Lilly announced positive results from the Phase 3 BRUIN CLL-322 trial, showing that the addition of Jaypirca (pirtobrutinib) to a venetoclax regimen significantly improved progression-free survival in patients with relapsed or refractory CLL/SLL. The study met its primary endpoint and demonstrated consistent results across subgroups. Overall survival data is still maturing, but trending positively. Detailed results will be presented at a medical congress and submitted for regulatory review.
Read more →LLYLifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
LifeMD has announced the availability of Foundayo (orforglipron), a new oral GLP-1 medication for weight management, developed by Eli Lilly. Approved by the FDA on April 1, 2026, Foundayo is now accessible to eligible patients through LifeMD's weight management program. The medication is priced at $149 per month, with potential savings for insured patients. This addition enhances LifeMD's offerings in clinically guided weight management care.
Read more →LLYFoundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.
Eli Lilly has announced the availability of Foundayo™ (orforglipron), an oral GLP-1 medication for weight loss, following FDA approval. This once-daily pill can be taken without food or water restrictions and is accessible through LillyDirect and telehealth providers. Clinical trials demonstrated an average weight loss of 27 pounds at the highest dose, but it carries potential risks, including thyroid tumors.
Read more →LLYWeight Watchers Launches Eli Lilly and Company’s New Oral GLP-1 Foundayo® Available Through LillyDirect
Weight Watchers has announced the availability of Eli Lilly's new oral GLP-1 medication, Foundayo® (orforglipron), through its Med+ offering. This FDA-approved treatment provides a once-daily, injection-free option for adults with obesity or weight-related medical issues. Members will receive clinical support and access to the GLP-1 Success program to enhance their treatment experience.
Read more →LLYAmazon Pharmacy to Offer Eli Lilly and Company’s New GLP-1 Pill Foundayo via Same-Day Delivery
Amazon Pharmacy has begun offering Eli Lilly's newly approved GLP-1 medication, Foundayo, which is designed for adults dealing with obesity or weight-related health issues. Customers can order the medication with a valid prescription and benefit from real-time availability and transparent pricing. The service includes same-day delivery to enhance accessibility for patients.
Read more →LLYGoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide
GoodRx has partnered with Eli Lilly to enhance access to the newly FDA-approved oral GLP-1 medication, Foundayo. Self-pay patients can obtain Foundayo through GoodRx at a starting price of $149 per month. This initiative aims to provide transparent pricing and improve medication accessibility across more than 70,000 pharmacies nationwide.
Read more →LLYFoundayo™ (orforglipron), la nueva pastilla GLP-1 de Lilly que se administra por vía oral para la pérdida de peso, ahora está disponible en Estados Unidos. Eli Lilly and Company (NYSE: LLY) ha anunciado hoy que Foundayo™ (orforglipron) ya está disponible para adultos con obesidad o con sobrepeso, que...
Eli Lilly and Company has announced the availability of Foundayo™ (orforglipron) in the U.S. for adults with obesity or overweight. Approved by the FDA, this GLP-1 medication is unique as it is taken orally once daily without dietary restrictions, starting at a cost of $25 per month for insured patients. Clinical trials demonstrated an average weight loss of 27 pounds, showcasing its effectiveness. However, the medication is accompanied by potential serious side effects, including the risk of thyroid tumors and pancreatitis.
Read more →LLYLa FDA aprueba Foundayo™ (orforglipron) de Lilly, la única pastilla GLP-1 para la pérdida de peso que puede tomarse a cualquier hora del día sin restricciones de comida o aguaUSA - españolUSA - English
Eli Lilly has received FDA approval for Foundayo (orforglipron), a new oral medication for adults with obesity or overweight. In clinical trials, patients lost an average of 27 pounds, demonstrating significant efficacy. Foundayo will be available through LillyDirect for home delivery, with various pricing options. The drug aims to provide a flexible treatment option for individuals managing obesity.
Read more →LLYFDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
Eli Lilly's Foundayo (orforglipron) has received FDA approval as the first oral GLP-1 medication for weight loss, allowing flexible dosing without food or water restrictions. In clinical trials, participants lost an average of 27 pounds, demonstrating its efficacy. Foundayo will be available through LillyDirect, with pricing starting at $25 per month for insured patients.
Read more →LLYLilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders Eli Lilly and Company (NYSE: LLY) and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for...
Eli Lilly and Company announced its agreement to acquire Centessa Pharmaceuticals, which specializes in a new class of medicines targeting sleep-wake disorders. The acquisition focuses on advancing Centessa's OX2R agonist pipeline, including the promising candidate cleminorexton for conditions like narcolepsy. This deal could enhance Lilly's capabilities in neuroscience and expedite the development of innovative treatments for numerous neurological disorders. However, the transaction is subject to regulatory and shareholder approval, and contingent payments based on milestones are not guaranteed.
Read more →LLYLilly’s EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
Eli Lilly's EBGLYSS (lebrikizumab-lbkz) has shown promising long-term results in the ADlong Phase 3b study, demonstrating durable disease control for patients with moderate-to-severe atopic dermatitis. Nearly all patients achieved significant skin improvement over four years, with many experiencing itch relief and maintaining results without topical corticosteroids. The study's findings highlight the potential of EBGLYSS to transform treatment approaches for this condition.
Read more →LLYPhase 3b data presented at AAD Annual Meeting show Lilly’s Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
Eli Lilly presented positive results from the TOGETHER-PsA Phase 3b trial at the AAD Annual Meeting, demonstrating that the combination of Taltz and Zepbound significantly improves outcomes for adults with psoriatic arthritis and obesity. The treatment showed early efficacy in reducing disease activity and enhancing quality of life. Adverse events were generally mild to moderate, consistent with known safety profiles.
Read more →LLYPhase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity Eli Lilly and Company (NYSE: LLY) today announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the...
Eli Lilly presented positive results from the TOGETHER-PsA Phase 3b trial, demonstrating that the combination of Taltz and Zepbound is more effective than Taltz monotherapy for treating adults with psoriatic arthritis and obesity. Patients on the combination therapy showed notable reductions in disease activity and improvements in various health metrics within just four weeks. The findings suggest a shift in treatment strategies for managing these interlinked conditions, although mild to moderate adverse events were noted. Full results were shared at the AAD Annual Meeting and published in a medical journal.
Read more →LLYLilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
Eli Lilly's EBGLYSS (lebrikizumab-lbkz) demonstrated long-term efficacy in patients with moderate-to-severe atopic dermatitis, achieving significant skin improvement and itch relief for up to four years. The Phase 3b ADlong study revealed that a majority of patients maintained results without the need for topical corticosteroids. The treatment's safety profile remained consistent, with no new safety signals identified.
Read more →LLYLilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes Eli Lilly and Company (NYSE: LLY) today announced positive topline results from TRANSCEND-T2D-1, a Phase 3 clinical trial evaluating the efficacy and ...
Eli Lilly announced positive results from its Phase 3 trial of retatrutide, a novel triple agonist for type 2 diabetes. The trial showed significant reductions in A1C levels, averaging between 1.7% and 2.0%, and substantial weight loss of up to 36.6 lbs over 40 weeks. Additionally, retatrutide met both primary and secondary endpoints, outperforming placebo. While adverse events were reported, they are consistent with similar treatments and generally resolved during the study.
Read more →LLYLilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis Eli Lilly and Company (NYSE: LLY) today announced positive, topline results from the Phase 3 ADorable-1 trial evaluating the safety and efficacy of...
Eli Lilly announced positive topline results from the Phase 3 ADorable-1 trial of EBGLYSS (lebrikizumab-lbkz) in pediatric patients aged 6 months to 18 years with moderate-to-severe atopic dermatitis. The trial demonstrated that 63% of participants achieved significant skin improvement, while 44% experienced nearly clear skin. EBGLYSS displayed a favorable safety profile consistent with earlier studies, addressing a critical need for effective treatments in younger patients suffering from atopic dermatitis. Lilly plans to submit these promising results to regulators for potential label updates.
Read more →LLYLilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients
Eli Lilly has launched the Employer Connect platform to improve access to obesity treatment in the U.S. The platform allows employers to work with independent program administrators to create tailored benefit designs that lower costs for employees. Zepbound, an obesity management medication, is available through this platform at a discounted price, promoting broader access to effective treatment options.
Read more →LLYLilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
The CHMP has recommended Olumiant (baricitinib) for adolescents with severe alopecia areata in the EU, based on positive results from the Phase 3 BRAVE-AA-PEDS study. The study showed that 42% of participants achieved over 80% scalp hair coverage at 36 weeks. Lilly is also seeking approval in the U.S., with a decision expected in 2026.
Read more →LLYLilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
Eli Lilly's orforglipron demonstrated superior efficacy in controlling blood sugar and promoting weight loss compared to oral semaglutide in the Phase 3 ACHIEVE-3 trial. The study involved 1,698 participants and showed significant improvements in A1C levels and weight loss. Orforglipron can be taken without food or water restrictions, making it a potentially more convenient option for patients. Regulatory submissions for orforglipron are ongoing in over 40 countries, with U.S. action expected in 2026.
Read more →LLYLilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
Eli Lilly's orforglipron demonstrated superior efficacy in controlling blood sugar and promoting weight loss compared to oral semaglutide in the Phase 3 ACHIEVE-3 trial. The study involved 1,698 participants and showed significant improvements in A1C levels and weight loss. Orforglipron's convenience of administration without food or water restrictions may enhance patient adherence. Regulatory submissions for the drug are ongoing in over 40 countries, with a U.S. action expected in Q2 2026.
Read more →LLYZepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen
Eli Lilly has announced the FDA's approval for a label expansion of Zepbound (tirzepatide), now available in a multi-dose KwikPen. This new delivery method allows patients to receive a full month of treatment in one device, enhancing accessibility. Zepbound is recognized as the leading injectable obesity management medication, with patients achieving significant weight loss. The medication is available through LillyDirect at a starting price of $299 per month.
Read more →LLYPatients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz) Landmark VIVID-2 data showed more than 90% of patients who achieved steroid-free remission at one year maintained steroid-free control through three...
Eli Lilly's Omvoh (mirikizumab-mrkz) has shown impressive long-term efficacy in treating Crohn's disease, with over 90% of patients maintaining steroid-free remission for three years. The recent data, presented at the ECCO Congress, also highlighted significantly low rates of surgery and hospitalization among Omvoh-treated patients. This makes Omvoh the only IL-23p19 inhibitor to demonstrate strong and durable effectiveness. Clinical experts express confidence in Omvoh's long-term outcomes, marking a potential shift in the treatment landscape for inflammatory bowel disease.
Read more →LLYLilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
Eli Lilly's TOGETHER-PsO Phase 3b trial demonstrated that the combination of Taltz and Zepbound significantly outperformed Taltz monotherapy in achieving complete skin clearance and weight loss in adults with psoriasis and obesity. The study found that 27.1% of participants on the combination therapy achieved PASI 100 and at least 10% weight loss, compared to 5.8% in the monotherapy group. This trial marks a significant advancement in treating patients with both conditions simultaneously.
Read more →LLYLilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete ...
Eli Lilly's TOGETHER-PsO study demonstrated that the combination of Taltz (ixekizumab) and Zepbound (tirzepatide) significantly outperformed Taltz alone in achieving complete skin clearance and weight loss in adults with psoriasis and obesity. At 36 weeks, 27.1% of participants on the combination therapy reached PASI 100, compared to 5.8% on Taltz monotherapy. The study highlights the importance of addressing both psoriasis and obesity simultaneously.
Read more →LLYScribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company
Scribe Therapeutics has successfully achieved a second milestone in its collaboration with Eli Lilly, focusing on in vivo CRISPR-based genetic medicines for neurological and neuromuscular disorders. This milestone underscores the effectiveness of Scribe's X-Editor technology and the companies' commitment to innovation in genetic medicine. The collaboration is set to yield significant financial benefits, with Scribe eligible for over $1.5 billion in milestone payments.
Read more →LLYLilly to participate in TD Cowen's 46th Annual Health Care Conference
Eli Lilly and Company will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026. CFO Lucas Montarce will engage in a fireside chat, which will be available via live audio webcast. The event reflects Lilly's ongoing commitment to sharing insights and advancements in healthcare.
Read more →LLYLilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
Eli Lilly announced positive topline results from the Phase 3 LIBRETTO-432 trial, showing Retevmo (selpercatinib) significantly improves event-free survival in early-stage RET fusion-positive non-small cell lung cancer (NSCLC). The study met its primary endpoint, reinforcing the value of genomic testing. Overall survival data are still immature, but safety profiles align with previous studies.
Read more →LLYUSOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company The United States Olympic & Paralympic Committee (USOPC) today announced the Team USA Athlete Recovery Program in partnership with Lilly, reinforcing ...
The United States Olympic & Paralympic Committee (USOPC) has announced the Team USA Athlete Recovery Program in partnership with Eli Lilly, aimed at enhancing athlete health and recovery beyond competition. Lilly will serve as the presenting partner, supporting access to vital rehabilitation resources for athletes through major upcoming events like the Milano Cortina 2026 and LA28 Olympic Games. Following the program's successful pilot in 2024, which assisted athletes in earning four medals at Paris 2024, the USOPC plans to expand its reach to a broader network of Team USA athletes over the next three years.
Read more →LLYLilly to acquire Orna Therapeutics to advance cell therapies
Eli Lilly has announced its acquisition of Orna Therapeutics, which specializes in in vivo CAR-T therapies. This acquisition aims to enhance Lilly's capabilities in genetic medicine and address B cell-driven autoimmune diseases. Orna's innovative circular RNA technology is expected to provide durable therapeutic solutions. The deal could be worth up to $2.4 billion, contingent on clinical milestones.
Read more →LLYLilly to acquire Orna Therapeutics to advance cell therapies Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced ...
Eli Lilly has announced its acquisition of Orna Therapeutics to enhance its capabilities in cell therapies. Orna's innovative circular RNA technology aims to develop in vivo CAR-T therapies for B cell-driven autoimmune diseases. The deal, potentially worth up to $2.4 billion, reflects Lilly's commitment to advancing genetic medicine and improving patient care.
Read more →LLY▲ +10.3%on this newsshared move
Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance
Eli Lilly and Company reported a robust financial performance for Q4 2025, with a 43% increase in worldwide revenue, driven by strong demand for key products like Mounjaro and Zepbound. The company also provided optimistic financial guidance for 2026, highlighting its expanded manufacturing capacity and ongoing product launches. However, challenges such as lower realized prices and increased expenses were noted.
Read more →LLYLilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
Eli Lilly has announced a $3.5 billion investment in a new manufacturing facility in Lehigh Valley, Pennsylvania, aimed at producing next-generation weight-loss therapies, including retatrutide. The facility is expected to create over 2,800 jobs, including 850 high-value positions. Construction is set to begin in 2026, with operations starting in 2031. This investment is part of Lilly's broader strategy to enhance domestic medicine production.
Read more →LLYLilly confirms date and conference call for fourth-quarter 2025 financial results announcement
Eli Lilly and Company will announce its fourth-quarter 2025 financial results on February 4, 2026. A conference call will follow at 10 a.m. Eastern time, allowing investors and the media to discuss the company's financial performance. The event will be accessible via a live webcast, with a replay available afterward.
Read more →LLYLilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer
Eli Lilly has received Breakthrough Therapy designation from the FDA for sofetabart mipitecan, aimed at treating adult patients with platinum-resistant ovarian cancer. This designation is based on encouraging preliminary results from Phase 1 trials, which suggest significant improvement over current therapies. The company has initiated a Phase 3 trial to further investigate the drug's efficacy.
Read more →LLYLilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight
Eli Lilly announced positive results from the TOGETHER-PsA Phase 3b trial, which evaluated the combination of Taltz and Zepbound in adults with active psoriatic arthritis and obesity. The study met its primary endpoint, showing a significant improvement in PsA activity and weight reduction compared to Taltz alone. This trial represents a pioneering approach to treating patients with both conditions simultaneously.
Read more →LLYLilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to...
Eli Lilly's TOGETHER-PsA trial demonstrated that the combination of Taltz (ixekizumab) and Zepbound (tirzepatide) significantly improved outcomes for adults with active psoriatic arthritis and obesity. The study met its primary endpoint of a 50% improvement in PsA activity and showed a 64% increase in patients achieving ACR50 compared to Taltz alone. This trial is notable for being the first to evaluate an incretin therapy alongside a PsA biologic, highlighting a potential shift in treatment paradigms.
Read more →LLYLilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (Nasdaq: VTYX), a San Diego-based clinical-stage biopharmaceutical company focused on...
Eli Lilly and Company has announced its plans to acquire Ventyx Biosciences to enhance its portfolio of oral therapies aimed at inflammatory-mediated diseases. The deal is valued at approximately $1.2 billion, with Lilly offering $14.00 per share for all outstanding shares of Ventyx. This acquisition is expected to close in the first half of 2026, pending stockholder and regulatory approvals. Ventyx's clinical pipeline includes NLRP3 inhibitors with significant potential for treating conditions like chronic inflammation, neurodegenerative diseases, and cardiometabolic disorders.
Read more →LLYLilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study evaluated orforglipron,...
Eli Lilly announced positive topline results from the Phase 3 ATTAIN-MAINTAIN trial, demonstrating that orforglipron, an oral GLP-1 receptor agonist, effectively maintained weight loss for participants previously treated with Wegovy or Zepbound. On average, those switching to orforglipron retained almost all their previously lost weight after 52 weeks, showing promising efficacy compared to placebo. The investigational drug is being evaluated for its potential to offer a convenient oral option for individuals with obesity, with a new drug application submitted to the FDA for regulatory review.
Read more →LLYLilly to participate in J.P. Morgan Healthcare Conference
Eli Lilly and Company will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2025. CEO David A. Ricks will host a fireside chat on January 13 at 5:15 p.m. Eastern time. A live audio webcast will be available, along with a replay for 90 days on Lilly's investor website.
Read more →LLYUpdated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
Eli Lilly announced updated results from the Phase 3 EMBER-3 study of Inluriyo (imlunestrant) for ER+, HER2- advanced breast cancer. The study showed that imlunestrant as monotherapy improved median overall survival by 11.4 months compared to endocrine therapy. Additionally, the combination with abemaciclib achieved a median progression-free survival of 10.9 months and delayed time to chemotherapy significantly. These findings will be presented at the San Antonio Breast Cancer Symposium.
Read more →LLYLilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
Eli Lilly announced positive results from the Phase 3 TRIUMPH-4 trial of retatrutide, showing an average weight loss of 28.7% and significant pain relief in knee osteoarthritis patients. The trial involved 445 participants and met all primary and secondary endpoints. Retatrutide is a triple hormone receptor agonist, and further trials are planned to assess its efficacy in obesity and related conditions.
Read more →LLYLilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Eli Lilly announced a $6 billion investment in a new manufacturing facility in Huntsville, Alabama, aimed at producing small molecule synthetic and peptide medicines, including orforglipron. This facility will create 3,450 jobs and is part of Lilly's strategy to enhance domestic production capabilities. Construction is set to begin in 2026, with completion expected in 2032.
Read more →LLYLilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
Eli Lilly and Company has completed its tender offer for Adverum Biotechnologies, acquiring approximately 64% of its shares. The acquisition is expected to enhance Lilly's capabilities in gene therapy, particularly for age-related conditions. The transaction is set to be finalized on December 9, 2025, following the satisfaction of all conditions.
Read more →LLYLilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
Eli Lilly announced that Jaypirca (pirtobrutinib) significantly improved progression-free survival in treatment-naïve CLL/SLL patients, reducing the risk of progression or death by 80% compared to chemoimmunotherapy. The results from the Phase 3 BRUIN CLL-313 trial will be presented at the 2025 ASH Annual Meeting and published in the Journal of Clinical Oncology. The findings highlight the potential of pirtobrutinib as a treatment option for newly diagnosed patients.
Read more →LLYLilly declares first-quarter 2026 dividend
Eli Lilly and Company has announced a dividend of $1.73 per share for the first quarter of 2026. This dividend will be payable on March 10, 2026, to shareholders who are on record by February 13, 2026. The announcement reflects Lilly's ongoing commitment to delivering value to its shareholders while continuing its mission in healthcare innovation.
Read more →LLYCarolyn Bertozzi returns to Lilly board of directors
Eli Lilly and Company has re-elected Carolyn R. Bertozzi, Ph.D., to its board of directors, effective December 8, 2025. Bertozzi, a Nobel Prize-winning chemist, will contribute to the Science and Technology and Ethics and Compliance committees. Her previous tenure from 2017 to 2021 and her expertise in developing targeted cancer therapies are expected to enhance Lilly's ongoing efforts in oncology and immunology.
Read more →LLYLilly’s Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
Eli Lilly's Phase 3 BRUIN CLL-314 trial demonstrated that Jaypirca (pirtobrutinib) met its primary endpoint of non-inferiority in overall response rate compared to Imbruvica (ibrutinib). Pirtobrutinib showed an 87% response rate versus 78.5% for ibrutinib. Additionally, there were promising trends in progression-free survival, particularly in treatment-naïve patients. The results will be presented at the upcoming ASH Annual Meeting.
Read more →LLYLilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
Eli Lilly announced that Jaypirca (pirtobrutinib) met its primary endpoint of non-inferiority in the Phase 3 BRUIN CLL-314 study against Imbruvica (ibrutinib) for chronic lymphocytic leukemia. Pirtobrutinib demonstrated a higher overall response rate of 87.0% compared to 78.5% for ibrutinib. Additionally, it showed a favorable trend in progression-free survival, particularly in treatment-naïve patients. The results will be presented at the upcoming American Society of Hematology Annual Meeting.
Read more →LLYU.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
The U.S. FDA has approved an expanded indication for Lilly's Jaypirca (pirtobrutinib) for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a covalent BTK inhibitor. This approval is based on the BRUIN CLL-321 trial, which is the only randomized Phase 3 study in this patient population. The expanded label allows for earlier treatment and converts the previous accelerated approval to a traditional one.
Read more →LLYLilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
Eli Lilly announced that it will present updated results from key clinical trials at the 2025 San Antonio Breast Cancer Symposium. Highlights include findings from the Phase 3 EMBER-3 trial for Inluriyo and subgroup analyses from the Phase 3 monarchE trial. Lilly aims to demonstrate progress in treating hormone receptor-positive breast cancer, a prevalent form of the disease.
Read more →LLYLilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
Eli Lilly announced that data from two Phase 3 studies of Jaypirca (pirtobrutinib) will be presented at the upcoming ASH Annual Meeting. The studies include the BRUIN CLL-314, a head-to-head comparison with Imbruvica, and BRUIN CLL-313, both focusing on treatment-naïve CLL/SLL patients. These presentations highlight the drug's potential in treating B-cell malignancies.
Read more →LLYLilly announces plans to open Lilly Gateway Labs site in Philadelphia
Eli Lilly and Company has announced plans to open a new Lilly Gateway Labs site in Philadelphia, aimed at supporting early-stage biotech companies. The site will provide 44,000 square feet of lab space and strategic scientific engagement. This expansion is part of Lilly's strategy to enhance its presence in key life sciences innovation hubs across the U.S.
Read more →LLYLilly to participate in Citi's 2025 Global Healthcare Conference Eli Lilly and Company (NYSE:LLY) will participate in the Citi's 2025 Global Healthcare Conference on December 2, 2025. Ilya Yuffa, executive vice...
Eli Lilly and Company (NYSE: LLY) will participate in the Citi's 2025 Global Healthcare Conference on December 2, 2025. Executive Vice President Ilya Yuffa will engage in a fireside chat during the event, scheduled for 10:30 a.m. Eastern time. Investors can access a live audio webcast through Lilly's investor website, with a replay available for 90 days following the conference.
Read more →LLYQueer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection' For Tan France, clothing has always been about more than appearance – it's about self-expression. As a stylist and advocate, he's spent years helping ...
Tan France, in partnership with Lilly, has launched the Changing the Thread Collection to combat obesity bias by using clothing as a medium for personal stories. This innovative campaign aims to educate the public about obesity as a chronic disease while promoting a cultural shift toward understanding and acceptance. Zepbound, an injectable treatment for obesity, is central to this initiative, which combines storytelling with a medical solution to support individuals on their weight loss journeys. The collection seeks to empower those living with obesity to express their resilience and challenge societal misconceptions.
Read more →LLYLilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth
Eli Lilly has announced the appointment of two new Executive Committee members, Carole Ho and Adrienne Brown, to enhance its leadership team. Ho will lead Lilly Neuroscience, while Brown will oversee Lilly Immunology. The company aims to accelerate its ambitious pipeline and improve patient access to medicines. Daniel Skovronsky and Jacob Van Naarden will also expand their roles to support these initiatives.
Read more →LLYLilly and U.S. government agree to expand access to obesity medicines to millions of Americans
Eli Lilly has reached an agreement with the U.S. government to enhance access to its obesity treatments, specifically Zepbound and orforglipron, for Medicare beneficiaries at a reduced cost of $50 per month. This initiative aims to benefit nearly 40 million Americans suffering from obesity, addressing a significant health crisis linked to various diseases. Lilly's commitment to innovation and affordability is underscored by its previous initiatives, including capping insulin costs.
Read more →LLYLilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight
Eli Lilly announced positive Phase 2 trial results for eloralintide, a selective amylin receptor agonist, showing significant weight loss in adults with obesity. The trial demonstrated weight reductions ranging from 9.5% to 20.1% compared to placebo. Lilly plans to initiate Phase 3 studies by the end of the year, highlighting eloralintide's potential as a new obesity treatment.
Read more →LLYLilly plans to build a new €2.6 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide
Eli Lilly plans to invest €2.6 billion in a new manufacturing facility in Katwijk, Netherlands, aimed at boosting its production capacity for oral medicines. This facility will create 500 permanent jobs and 1,500 construction jobs, while incorporating advanced technologies to enhance manufacturing efficiency. The expansion is part of Lilly's strategy to strengthen its global supply chain and respond to regional demand.
Read more →LLYLilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within...
Eli Lilly and Company announced plans to build a $3 billion manufacturing facility in Katwijk, Netherlands, aimed at boosting oral medicine production. This new site will create 500 permanent jobs and an estimated 1,500 construction jobs, enhancing the company's global supply chain. Notably, it will support the manufacturing of orforglipron, an innovative treatment for obesity. Lilly's investment is contingent on obtaining necessary permits and approvals, with a commitment to sustainable operations and carbon neutrality built into the project.
Read more →LLYLilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance
Eli Lilly reported a strong third-quarter for 2025, achieving a 54% increase in revenue driven by demand for its incretin portfolio. The company advanced its orforglipron drug through multiple Phase 3 trials and received FDA approval for Inluriyo, enhancing its pipeline. Lilly also announced plans to expand manufacturing capacity with new facilities in Virginia and Texas, while raising its full-year revenue guidance.
Read more →LLYLilly anuncia una inversión de más de 1,200 millones de dólares en su planta de Puerto Rico para aumentar la capacidad de manufactura de medicamentos orales en Estados UnidosUSA - españolUSA - English
Eli Lilly announced a planned investment of over $1.2 billion to expand its manufacturing facility in Puerto Rico. This expansion aims to increase production capacity for oral medications, including orforglipron, an oral GLP-1 receptor agonist. The project is expected to create 1,100 jobs and incorporates advanced manufacturing technologies. The initiative underscores Lilly's commitment to enhancing its manufacturing capabilities in the U.S.
Read more →LLYLilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United StatesUSA - EnglishUSA - español
Eli Lilly announced a $1.2 billion investment to enhance its manufacturing site in Puerto Rico. This expansion aims to boost production capacity for oral solid medicines, including orforglipron, and will create numerous jobs. The project is part of Lilly's broader commitment to U.S. manufacturing and is expected to begin construction in 2026.
Read more →LLYLillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials...
Eli Lilly and Walmart announced a collaboration to enhance patient access to Zepbound through LillyDirect, allowing users to obtain self-pay single-dose vials at Walmart pharmacies nationwide. This partnership represents a strategic effort to offer convenient and cost-effective options for patients managing obesity. By mid-November, the vials will be available with pricing that provides over 50% discount compared to other obesity medications. This development aims to reduce the burden of managing chronic conditions while expanding the reach of Lilly's innovative healthcare services.
Read more →LLYLilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients Eli Lilly and Company (NYSE: LLY) today announced it is building the most powerful supercomputer owned and operated by a pharmaceutical company, in...
Eli Lilly and Company has announced the development of the industry's most powerful supercomputer in collaboration with NVIDIA. This AI-driven supercomputer aims to transform drug discovery, making the process faster and more efficient by allowing extensive molecule experimentation. Additionally, Lilly plans to leverage this technology for manufacturing improvements and enhanced medical imaging, contributing to more personalized patient care. However, the endeavor includes risks associated with the implementation and success of AI in drug research.
Read more →LLYLilly announces roster of Team USA athletes for the Olympic and Paralympic Games Milano Cortina 2026, pledges to translate U.S. Olympic and Paralympic milestones into meaningful community impact Eli Lilly and Company (NYSE: LLY) today announced its roster of Team USA athletes for the Olympic and Paralympic Winter Games Milano Cortina 2026,...
Eli Lilly and Company (NYSE: LLY) has announced its support for Team USA athletes participating in the 2026 Olympic and Paralympic Winter Games in Milano Cortina. The initiative emphasizes the connection between athletic performance and holistic health, showcasing diverse athletes who advocate for health and well-being. Lilly also extends its Milestones into Meaning™ program, pledging $5,000 donations to U.S. nonprofits for each medal won, aiming to enhance community health care access. This partnership reflects Lilly's commitment to turning athletic achievements into lasting community impact.
Read more →LLYLilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis Phase 3b LUCENT-URGE is the first study in inflammatory bowel disease to assess bowel urgency across three measures — severity, frequency and stool...
Eli Lilly’s Omvoh (mirikizumab-mrkz) demonstrated promising results in the Phase 3b LUCENT-URGE study, focusing on bowel urgency for ulcerative colitis patients. By Week 28, a substantial number of participants experienced significant improvements in bowel urgency severity, frequency, and deferred stool times. Safety data remained consistent with previous findings, showing no new safety signals. This study represents a pivotal step in addressing the daily challenges faced by patients suffering from ulcerative colitis.
Read more →LLYLilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea Basketball legend, entrepreneur and entertainer Shaquille O'Neal partners with Lilly to shine a spotlight on moderate-to-severe obstructive sleep...
Eli Lilly has partnered with basketball legend Shaquille O'Neal for a nationwide awareness campaign on moderate-to-severe obstructive sleep apnea (OSA). The campaign, titled 'Don't Sleep on OSA,' seeks to educate the public about the symptoms and health impacts of this underdiagnosed condition. O'Neal will share his experiences with OSA to encourage those suffering from related symptoms to seek medical advice. This initiative targets the estimated 24 million adults affected by OSA in the U.S.
Read more →LLYLilly declares fourth-quarter 2025 dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding...
Eli Lilly and Company has announced a dividend of $1.50 per share for the fourth quarter of 2025, payable on December 10, 2025. Shareholders of record will be eligible for these dividends if they hold shares as of November 14, 2025. The announcement illustrates the company's commitment to returning value to shareholders amidst ongoing business activities.
Read more →LLYLilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a single-injection, once-monthly...
Eli Lilly has received FDA approval for a single-injection maintenance regimen of Omvoh (mirikizumab-mrkz) for adults with moderately to severely active ulcerative colitis. This new regimen replaces the previous two-injection approach, providing a more convenient treatment option. The approval follows two earlier approvals this year for Crohn's disease and a citrate-free formulation of Omvoh. Available in early 2026, the single-injection product aims to simplify patient management while maintaining treatment efficacy.
Read more →LLYLilly to Acquire Adverum Biotechnologies Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene...
Eli Lilly and Company has announced its acquisition of Adverum Biotechnologies, a clinical-stage company focusing on gene therapy for vision loss associated with wet age-related macular degeneration (wAMD). The lead product candidate, Ixo-vec, is a Phase 3 gene therapy aimed at offering a one-time treatment option for this chronic condition. The merger includes a cash offer of $3.56 per share along with potential milestone payments, with the expectation that the transaction will close in Q4 2025. This acquisition is anticipated to enhance Lilly's portfolio in genetic medicine and expand the accessibility of innovative treatments for millions of patients.
Read more →LLYLilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) with EBGLYSS with half...
Eli Lilly's EBGLYSS (lebrikizumab-lbkz) has shown promising results in long-term studies, with around 80% of patients achieving significant skin improvement using a maintenance dosing schedule of once every eight weeks. This approach could offer a less burdensome alternative to the current monthly regimen for treating moderate-to-severe atopic dermatitis. The company has submitted this data to the FDA for a label update, potentially establishing EBGLYSS as a first-line biologic therapy. The findings will be presented at the upcoming Fall Clinical Dermatology Conference.
Read more →LLYLilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often...
Eli Lilly's Phase 3 BRAVE-AA-PEDS trial for baricitinib has shown that 71% of adolescents aged 12 to under 18 with severe alopecia areata achieved successful scalp hair regrowth after one year. This trial, the largest of its kind, aims to provide treatment options for a demographic that has historically been underrepresented in clinical studies. Following the positive results, Lilly plans to seek a label update from global regulators regarding the use of baricitinib in adolescents.
Read more →LLYLilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−,...
Eli Lilly announced that Verzenio (abemaciclib) has extended survival in patients with HR+, HER2- high-risk early breast cancer, according to findings from the Phase 3 monarchE trial. The trial revealed that two years of Verzenio plus endocrine therapy reduced mortality risk by 15.8%. Results also highlighted sustained benefits in disease-free survival and reflected positive safety findings, with no new adverse events noted. This study presents Verzenio as a significant advancement in breast cancer treatment, especially for high-risk patients.
Read more →LLYLilly confirms date and conference call for third-quarter 2025 financial results announcement Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2025 financial results on October 30, 2025. Lilly will also conduct a conference...
Eli Lilly and Company (NYSE: LLY) has announced that it will release its third-quarter 2025 financial results on October 30, 2025. The company will hold a conference call on the same day to discuss its financial performance in detail with the investment community and media. Investors and the general public can access a live webcast of the call through Lilly's website.
Read more →LLYLilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials. ACHIEVE-2, the second...
Eli Lilly and Company has reported positive results from two Phase 3 trials, ACHIEVE-2 and ACHIEVE-5, evaluating its oral GLP-1 treatment, orforglipron. In these trials, orforglipron showed significant reductions in A1C levels compared to active comparators, confirming its effectiveness in managing type 2 diabetes. The trials demonstrated that orforglipron not only lowered blood sugar levels effectively but also resulted in weight loss. Safety profiles indicated common mild adverse events, aligning with previous findings. Lilly plans to submit orforglipron for regulatory approval in 2026.
Read more →LLYLilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer ...
Lilly announces it will present new clinical data at the 2025 European Society for Medical Oncology Annual Meeting, showcasing findings from the Phase 3 monarchE trial of Verzenio in high-risk early breast cancer. The presentations will also include results from studies on investigational therapies for various cancers, including ovarian and lung cancers. Lilly's ongoing commitment to advancing cancer care is highlighted by the breadth of its oncology pipeline set for late-stage studies.
Read more →LLYLilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis New data from Eli Lilly and Company (NYSE: LLY) showed Omvoh (mirikizumab-mrkz) is the first and only interleukin-23p19 (IL-23p19) to help patients...
Eli Lilly's Omvoh (mirikizumab-mrkz) has become the first IL-23p19 antagonist to demonstrate over four years of clinical and endoscopic remission in patients with ulcerative colitis. Recent data from the LUCENT-3 study highlighted that 80% of patients who achieved remission at one year maintained their condition without corticosteroids. Additionally, these outcomes included significant improvements in bowel urgency. While the long-term safety profile appears consistent, some patients reported serious adverse events necessitating treatment discontinuation.
Read more →LLYLilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem Eli Lilly and Company (NYSE: LLY) today announced the official opening of its newest Lilly Gateway Labs (LGL) site in San Diego, California,...
Eli Lilly and Company has officially opened its newest Lilly Gateway Labs site in San Diego, designed to support early-stage biotechnology companies. This facility spans 82,514 square feet and offers flexible lab spaces for up to 15 biotech firms. By fostering collaboration between startups and Lilly’s scientific resources, the initiative aims to accelerate drug development and innovation. The opening underscores Lilly's commitment to enhancing the local biotechnology ecosystem and contributing to advanced therapies.
Read more →LLYLilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease Eli Lilly and Company (NYSE: LLY) announced today that the European Commission (EC) has granted marketing authorization for Kisunla (donanemab) for...
Eli Lilly's Kisunla (donanemab) has received marketing authorization from the European Commission for treatment of early symptomatic Alzheimer's disease. The therapy showed significant efficacy in slowing cognitive and functional decline, especially when started early in affected patients. Kisunla is unique in that it allows for the completion of treatment once amyloid plaques are minimally reduced, potentially reducing the treatment burden. However, patients may be at risk for serious side effects associated with amyloid-related imaging abnormalities.
Read more →LLYU.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Inluriyo (imlunestrant, 200 mg...
Eli Lilly's Inluriyo (imlunestrant) has received FDA approval for treating adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer. The approval is based on the EMBER-3 trial, which demonstrated that Inluriyo reduced the risk of progression or death by 38% compared to endocrine therapy. With a once-daily oral dosing option, Inluriyo aims to improve patient treatment experiences. However, the product's label includes a warning for potential embryo-fetal toxicity and reports of serious adverse events.
Read more →LLYLilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas Eli Lilly and Company (NYSE: LLY) announced today that it plans to build a new $6.5 billion manufacturing facility at Generation Park in Houston,...
Eli Lilly and Company has announced plans to build a $6.5 billion facility in Houston, Texas, aimed at manufacturing active pharmaceutical ingredients. This site will focus on small molecule synthetic medicines and is expected to create over 4,600 jobs, enhancing the local economy. The facility will also produce Lilly's oral GLP-1 receptor agonist, orforglipron, targeting obesity treatment. This investment marks Lilly's ongoing commitment to expand its manufacturing capabilities in the U.S., potentially positioning Texas as a leader in health care innovation.
Read more →LLYLilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial Eli Lilly and Company (NYSE: LLY) today announced positive topline results from ACHIEVE-3, an open-label randomized Phase 3 clinical trial evaluating ...
Eli Lilly announced positive results from the Phase 3 ACHIEVE-3 trial, showing that orforglipron significantly outperformed oral semaglutide in lowering A1C levels and promoting weight loss. Over 1,600 adults with type 2 diabetes participated in the trial, which lasted 52 weeks and compared various doses of both drugs. Orforglipron not only met its primary endpoint but also demonstrated superior performance across key secondary endpoints. While the safety profile was consistent with earlier studies, orforglipron had higher discontinuation rates due to adverse effects when compared to its competitor.
Read more →LLYLilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURPASS-PEDS, the first Phase 3 trial to evaluate the safety and efficacy of...
Eli Lilly announced positive results from the SURPASS-PEDS trial, showing Mounjaro (tirzepatide) effectively reduced A1C levels by an average of 2.2% in children and adolescents with type 2 diabetes after 30 weeks. The trial met all key endpoints, including significant improvements in body mass index (BMI) and fasting serum glucose. Mounjaro's safety profile aligned with findings from adult studies, suggesting its potential as an effective treatment option for this underserved pediatric population. The results will be submitted for regulatory review to expand treatment indications for Mounjaro.
Read more →LLYLilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine Eli Lilly and Company (NYSE: LLY) today announced detailed results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of...
Eli Lilly announced positive results from its Phase 3 ATTAIN-1 trial for orforglipron, an oral GLP-1 receptor agonist, which showed significant weight loss and cardiometabolic improvements. Participants taking the drug lost an average of 27.3 lbs over 72 weeks, with notable reductions in waist circumference and improvements in blood sugar levels among those with prediabetes. While the safety profile aligned with other GLP-1 medications, gastrointestinal side effects were the most common adverse events. Lilly is advancing orforglipron towards global regulatory submissions for the treatment of obesity.
Read more →LLYLilly announces plans to build $5 billion manufacturing facility in Virginia Eli Lilly and Company (NYSE: LLY) today announced that it plans to build a $5 billion manufacturing facility just west of Richmond, Virginia, in...
Eli Lilly and Company plans to build a $5 billion manufacturing facility in Goochland County, Virginia, which will create 2,450 jobs and support advanced pharmaceutical production. This site, expected to open in five years, is part of Lilly's broader commitment to expanding U.S. manufacturing capabilities. The facility will focus on developing active pharmaceutical ingredients for therapies in oncology and autoimmune diseases. Lilly's investment reflects their long-term vision to enhance local economies and innovate in medicine production.
Read more →LLYLilly to participate in Bernstein's 2nd Annual Healthcare Forum Eli Lilly and Company (NYSE: LLY) will participate in the Bernstein's 2nd Annual Healthcare Forum on September 25, 2025. Lucas Montarce, executive...
Eli Lilly and Company (NYSE: LLY) will participate in the Bernstein's 2nd Annual Healthcare Forum on September 25, 2025. Lucas Montarce, the executive vice president and chief financial officer, is scheduled to engage in a fireside chat at 8 a.m. Eastern time. A live audio webcast of the event will be accessible on Lilly's investor website, along with a replay available for around 90 days.
Read more →LLYLilly launches new Brain Health Matters campaign in partnership with Julianne Moore, empowering the public to prioritize brain health Acclaimed actress, author, and advocate Julianne Moore joins cause in the United States to encourage early, ongoing brain health conversations...
Eli Lilly and Company has launched the 'Brain Health Matters' campaign, aimed at encouraging proactive brain health discussions between individuals and their healthcare providers. The campaign partners with actress Julianne Moore to emphasize the importance of early detection of Alzheimer's disease and routine cognitive assessments. As the population ages, Lilly seeks to promote brain health awareness through various media channels, empowering people to include brain health in their overall wellness plans. The initiative is also timed to coincide with World Alzheimer's Month and aims to expand globally in the future.
Read more →LLYLilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment Eli Lilly and Company (NYSE: LLY) today announced the launch of Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that...
Eli Lilly and Company has launched Lilly TuneLab, an AI and machine learning platform aimed at enhancing drug discovery for biotechnology firms. This initiative builds on over $1 billion of Lilly's proprietary research data, providing partners access to valuable AI models. The platform is designed to support early-stage drug development by allowing smaller companies to benefit from advanced AI capabilities. Lilly anticipates that this open-access model will accelerate the creation of new medicines for patients.
Read more →LLYLilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful...
Eli Lilly and Company announced positive results from the Phase 3 BRUIN CLL-313 trial for Jaypirca (pirtobrutinib), a reversible BTK inhibitor, demonstrating a statistically significant improvement in progression-free survival compared to bendamustine plus rituximab in treatment-naive patients with CLL/SLL. This study represents the third successful Phase 3 trial for pirtobrutinib, supporting potential label expansions. Safety data aligns with previous findings but highlights serious infection risks. Overall survival data is still pending and expected to mature in 2026.
Read more →LLYLilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to...
Eli Lilly and Company announced that the FDA has granted Breakthrough Therapy designation to olomorasib, an investigational drug for treating patients with KRAS G12C-mutant advanced non-small cell lung cancer. This designation is based on encouraging results from clinical trials that suggest olomorasib in combination with KEYTRUDA may improve patient outcomes. Updates on its efficacy and safety will be shared at the IASLC 2025 World Conference on Lung Cancer. However, uncertainties regarding the drug's development and approval status remain.
Read more →LLYLilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival...
Eli Lilly announced positive topline results from the Phase 3 monarchE trial, showing that two years of Verzenio plus endocrine therapy significantly improved overall survival in patients with high-risk early breast cancer. The seven-year analysis demonstrated benefits in invasive disease-free and distant relapse-free survival. This positions Verzenio as the standard of care for hormone receptor positive, HER2 negative, node-positive patients. However, concerns remain regarding adverse effects such as high rates of diarrhea and neutropenia.
Read more →LLY▲ +5.9%on this newsshared move
Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ATTAIN-2 trial, evaluating orforglipron, an...
Eli Lilly and Company announced positive topline results from the Phase 3 ATTAIN-2 trial for orforglipron, an oral GLP-1 receptor agonist. The trial demonstrated significant weight loss averaging 22.9 lbs and substantial reductions in A1C levels among participants with obesity or overweight and type 2 diabetes. All primary and secondary endpoints were met, leading Lilly to plan for global regulatory submissions this year. While the treatment showed promise, there were reported gastrointestinal adverse events that could impact patient adherence.
Read more →LLYLilly to participate in Morgan Stanley 23rd Annual Global Healthcare Conference Eli Lilly and Company (NYSE:LLY) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 8, 2025. Jacob Van Naarden, ...
Eli Lilly and Company (NYSE: LLY) is set to participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025. Key executives, including Jacob Van Naarden and David Hyman, will engage in a fireside chat at 9:15 a.m. Eastern time. A live webcast will be accessible on Lilly's investor website, providing an opportunity for investors and stakeholders to follow the discussion.
Read more →LLYLilly to participate in Wells Fargo 20th Annual Healthcare Conference Eli Lilly and Company (NYSE:LLY) will participate in the Wells Fargo 20th Annual Healthcare Conference on Sept. 5, 2025. Patrik Jonsson, executive...
Eli Lilly and Company (NYSE: LLY) will participate in the upcoming Wells Fargo 20th Annual Healthcare Conference scheduled for September 5, 2025. Patrik Jonsson, the executive vice president and president of Lilly International, is set to take part in a discussion during the event. A live audio webcast of the presentation will be made available on Lilly's investor website, along with a replay for 90 days post-event. This participation emphasizes Lilly's active role in the healthcare sector.
Read more →LLYAnne White to Retire as Executive Vice President and President, Lilly Neuroscience Eli Lilly and Company (NYSE: LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience, will be retiring from...
Anne White, the Executive Vice President and President of Lilly Neuroscience at Eli Lilly and Company, is set to retire on December 31, 2025, after 30 years with the company. Her tenure has been marked by significant advancements in medicines for challenging diseases, including the launch of Alzheimer's treatments. Lilly is currently searching for her successor, with White continuing to serve until her official retirement date. Her contributions have been recognized both internally and externally, highlighting her commitment to inclusion and innovation in medicine.
Read more →LLY▼ -14.1%on this news
Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity In ATTAIN-1, the investigational once-daily oral pill showed significant efficacy, and a safety and tolerability profile consistent with injectable...
Eli Lilly announced positive results from the Phase 3 ATTAIN-1 trial for orforglipron, an oral GLP-1 receptor agonist aimed at treating obesity. The trial involved 3,127 adults and revealed that participants using the highest dose lost an average of 27.3 lbs over 72 weeks, meeting all primary and secondary endpoints. Lilly is preparing to submit the drug for regulatory approval by the end of the year, although common side effects were noted. The trial results highlight orforglipron's potential as a convenient alternative to injectables in obesity management.
Read more →LLY▼ -14.1%on this news
Lilly reports second-quarter 2025 financial results and raises guidance Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. Increased the midpoint of our 2025 full-year...
Eli Lilly and Company reported a strong financial performance for Q2 2025, with revenue increasing by 38% to $15.56 billion, attributed mainly to rising sales of Zepbound and Mounjaro. The company also highlighted positive advancements in its drug pipeline, particularly in oncology and cardiometabolic health. Net income nearly doubled from the previous year to $5.66 billion, and earnings per share rose to $6.29. Additionally, Lilly raised its full-year revenue guidance to a range of $60 billion to $62 billion, reflecting sustained business growth.
Read more →LLYLilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease Eli Lilly and Company (NYSE: LLY) today announced topline results from SURPASS-CVOT, a first-of-its-kind head-to-head Phase 3 cardiovascular outcomes ...
Eli Lilly announced positive topline results for Mounjaro from the SURPASS-CVOT trial, which demonstrated its non-inferiority to Trulicity in terms of major adverse cardiovascular events. The trial revealed additional benefits of Mounjaro, including a 16% reduction in all-cause mortality and improvements in weight and A1C levels. Conducted over four and a half years, this study enrolled over 13,000 participants across 30 countries, reinforcing Mounjaro's safety and efficacy profile. Plans are in place to submit detailed results to regulatory authorities and present findings at future medical conferences.
Read more →LLYLilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study showing that...
Eli Lilly announced encouraging results from the long-term extension of the Phase 3 TRAILBLAZER-ALZ 2 study for its Alzheimer's treatment Kisunla (donanemab-azbt). Over a three-year period, participants demonstrated a gradual slowing of cognitive decline, particularly benefiting from early treatment initiation. Although the therapy showed strong clinical benefits, it is associated with potential side effects, including serious ARIA complications. These findings underscore the importance of early intervention in managing Alzheimer's disease.
Read more →LLY▼ -5.6%on this newsshared move
Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-314 clinical trial of Jaypirca (pirtobrutinib), ...
Eli Lilly announced positive results from the Phase 3 BRUIN CLL-314 trial of Jaypirca (pirtobrutinib), a reversible BTK inhibitor, showing non-inferiority in response rate compared to Imbruvica in patients with CLL/SLL. The trial is notable for including treatment-naive patients and the results trend positively for progression-free survival. Further analysis on progression-free survival is planned for the future. Jaypirca's safety profile remains consistent with earlier studies.
Read more →LLYLilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a ...
Eli Lilly has successfully completed its acquisition of Verve Therapeutics, a Boston-based company focused on developing genetic medicines for cardiovascular diseases. This acquisition aims to foster innovative treatments that could provide lifelong cardiovascular risk reduction through a single administration. Lilly officials express optimism about the potential transformation of treatment paradigms for millions of patients worldwide. However, they also acknowledge that the acquisition involves certain risks and uncertainties that could affect the expected outcomes.
Read more →LLYDonanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP)...
Eli Lilly's donanemab has received a positive opinion from the European Medicines Agency's CHMP for treating early symptomatic Alzheimer's disease. This approval is based on clinical trial data showing that donanemab significantly slowed cognitive and functional decline. However, the treatment carries risks, including the potential for serious side effects such as ARIA. Lilly continues to commit resources to further development and trials for donanemab in Europe.
Read more →LLYLilly confirms date and conference call for second-quarter 2025 financial results announcement Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2025 financial results on August 7, 2025. Lilly will also conduct a conference...
Eli Lilly and Company (NYSE: LLY) is set to announce its financial results for the second quarter of 2025 on August 7, 2025. The company will also host a conference call on the same day at 8:30 a.m. Eastern time to discuss the financial performance in detail. Investors and the public can access a live webcast of this call via Lilly's website, with a replay available afterward.
Read more →LLYLilly and Verve announce expiration of Verve tender offer Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to purchase all of the issued and ...
Eli Lilly and Verve Therapeutics announced the expiration of a tender offer to purchase all outstanding shares of Verve at $10.50 each, along with contingent value rights. As of the expiration time on July 23, 2025, over 55% of shares were validly tendered. The acquisition is poised to be finalized on July 25, 2025, subject to the terms of the definitive agreement. Both companies are addressing legal and financial advisory support as they move forward.
Read more →LLYFDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended ...
Eli Lilly and Company announced that the FDA has approved a label update for Kisunla, their amyloid-targeting therapy for early symptomatic Alzheimer's disease. The new dosing regimen significantly reduces the incidence of amyloid-related imaging abnormalities (ARIA-E) compared to the original schedule while maintaining efficacy. This advancement aims to enhance patient safety and confidence in treatment options. The label update is based on findings from the TRAILBLAZER-ALZ 6 study, which demonstrated the benefits of the updated dosing strategy.
Read more →LLYLilly declares third-quarter 2025 dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding...
Eli Lilly and Company (NYSE: LLY) has announced a dividend of $1.50 per share for the third quarter of 2025, payable on September 10, 2025. Shareholders of record on August 15, 2025, will be eligible for this payment. The announcement reflects Lilly's confidence in its financial health, although it also includes caution about potential risks in pharmaceutical research and development. The company emphasizes the possibility of variance in actual results compared to expectations due to various uncertainties.
Read more →LLYLilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety...
Eli Lilly has reported promising results from three Phase 3 clinical trials evaluating its investigational once-weekly insulin efsitora alfa for adults with type 2 diabetes. The trials demonstrated that efsitora achieved non-inferior A1C reductions compared to established daily insulins, with reduced rates of hypoglycemic events. Lilly plans to submit efsitora for regulatory approval globally by the end of this year. The potential simplified dosing regimen may ease the burden of insulin therapy for patients.
Read more →LLYLilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-1, a Phase 3 trial evaluating the safety and efficacy of orforglipron ...
Eli Lilly announced positive Phase 3 results for orforglipron, an oral GLP-1 receptor agonist for type 2 diabetes. The trial demonstrated significant reductions in A1C levels and weight loss without food and water intake restrictions. The safety profile was consistent with established GLP-1 therapies, although gastrointestinal side effects were noted. Further global trials are forthcoming as Lilly aims for regulatory submission by the end of 2023.
Read more →LLYLilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for ...
Eli Lilly and Company has announced a definitive agreement to acquire Verve Therapeutics for approximately $1 billion, aiming to advance innovative one-time gene editing treatments for cardiovascular disease. Verve's lead product, VERVE-102, targets a gene linked to cholesterol levels and has entered Phase 1b trials with Fast Track designation by the FDA. The agreement includes a contingent value right, potentially increasing the total consideration to $1.3 billion, pending specific developmental milestones. The acquisition enhances Lilly's capabilities in genetic medicines and is expected to close in the third quarter of 2025 upon meeting customary conditions.
Read more →LLYLilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available...
Eli Lilly and Company announced the availability of the highest doses of Zepbound (tirzepatide) in single-dose vials for $499 per month, accessible through their LillyDirect Self Pay Pharmacy Solutions. This program, launching on July 7, will allow patients struggling with obesity to access all approved doses regardless of insurance. Clinical trials demonstrate that Zepbound can lead to significant weight loss for adults with obesity and weight-related medical issues. However, usage comes with risks such as thyroid cancer and other severe side effects, emphasizing the need for careful medical supervision.
Read more →LLYLilly to participate in Goldman Sachs 46th Annual Global Health Care Conference Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 46th Annual Global Health Care Conference on June 10, 2025. Lucas Montarce,...
Eli Lilly and Company (NYSE: LLY) is set to participate in the Goldman Sachs 46th Annual Global Health Care Conference scheduled for June 10, 2025. Lucas Montarce, the company's executive vice president and chief financial officer, will be featured in a fireside chat at 8 a.m. ET. The event aims to provide insights into Lilly's operations and future directions, with a live audio webcast available on the company's investor website.
Read more →LLYLilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC)...
Eli Lilly has presented promising Phase 1 clinical data for its investigational FRα targeting antibody-drug conjugate (LY4170156) at the 2025 ASCO Annual Meeting. The ADC showed a preliminary ORR of 55% and a favorable safety profile in women with platinum-resistant ovarian cancer, including patients previously treated with mirvetuximab soravtansine. Lilly plans to advance this therapy into Phase 3 clinical trials based on these initial results, which suggested efficacy across various FRα expression levels. Notably, about 51% of participants had tumors with low FRα expression.
Read more →LLYLilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), ...
Eli Lilly and Company (NYSE: LLY) announced that it will present new studies on several investigational diabetes medications at the upcoming American Diabetes Association's 85th Scientific Sessions in Chicago from June 20-23, 2025. Key presentations will include results from Phase 3 trials of orforglipron, insulin efsitora alfa, and tirzepatide, reflecting significant advancements in diabetes treatment options. Additionally, Lilly will host an investor event during the meetings to discuss insights from its cardiometabolic health portfolio.
Read more →LLYLilly to expand its pain pipeline with acquisition of SiteOne Therapeutics Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ( SiteOne ), a private biotechnology company developing small molecule inhibitors of ...
Eli Lilly and Company has announced a definitive agreement to acquire SiteOne Therapeutics, a clinical-stage biopharmaceutical company focused on non-opioid pain therapies. This acquisition includes STC-004, a Phase 2 ready Nav1.8 inhibitor aimed at treating chronic pain. Lilly's commitment underscores its intent to address the growing demand for effective pain management solutions without the risk of addiction. The deal involves up to $1 billion in cash for SiteOne stakeholders, contingent upon achieving specified milestones.
Read more →LLYLilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced that data from studies of imlunestrant, an investigational oral selective estrogen receptor...
Eli Lilly and Company (NYSE: LLY) has announced details about its presentations scheduled for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Key presentations will include findings from studies on investigational drugs imlunestrant, olomorasib, LY4170156, and the existing drug Verzenio. These presentations will cover patient-reported outcomes and safety analyses, along with updates on the efficacy of treatments for advanced breast cancer and KRAS G12C-mutant cancers. The event will be held from May 30 to June 3 in Chicago.
Read more →LLYLilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease Eli Lilly and Company (NYSE: LLY) announced today that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for...
Eli Lilly and Company has received marketing authorization for Kisunla (donanemab) in Australia, marking a significant milestone in Alzheimer's treatment. The therapy is intended for adults with early symptomatic Alzheimer's disease, particularly those who are ApoE ε4 heterozygotes or non-carriers. Kisunla has demonstrated efficacy in slowing cognitive decline and functional impairment, with data from Phase 3 clinical trials showing promising results. However, the treatment is associated with potential side effects, including serious ARIA events that necessitate careful monitoring.
Read more →LLYZepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and...
Eli Lilly announced positive results from the SURMOUNT-5 trial demonstrating that Zepbound (tirzepatide) outperformed Wegovy (semaglutide) in weight loss efficacy among adults with obesity or overweight conditions. Participants receiving Zepbound achieved an average weight loss of 20.2% compared to 13.7% for those on Wegovy over a 72-week period. Key secondary endpoints also favored Zepbound, with greater responses in both weight loss targets and waist circumference reduction. The findings were shared at the European Congress on Obesity and published in The New England Journal of Medicine.
Read more →LLYLilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly's planned ...
Eli Lilly and Purdue University have announced a significant expansion of their collaboration, committing up to $250 million over eight years. The Lilly-Purdue 360 Initiative aims to accelerate pharmaceutical innovation by enhancing the discovery and delivery of medicines, improving supply chain efficiency, and fostering workforce development. This expanded partnership includes the initiation of four new projects and the integration of existing programs, thus extending the agreement to 2032. Purdue will provide facilities for Lilly researchers, facilitating further collaboration between the institutions.
Read more →LLYLilly announces transitions in executive leadership Eli Lilly and Company (NYSE: LLY) today announced executive leadership transitions that will further enhance the company's ability to drive...
Eli Lilly and Company announced key executive leadership transitions aimed at enhancing its growth strategy. Ilya Yuffa will lead the U.S. business, while Patrik Jonsson will focus on international markets. Kenneth Custer has been promoted to oversee Lilly's Cardiometabolic Health division. These changes are expected to drive sustained growth and improve commercialization of upcoming product launches. The company's leadership underscores a commitment to advancing therapeutic capabilities worldwide.
Read more →LLYLilly declares second-quarter 2025 dividend The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2025 of $1.50 per share on outstanding...
Eli Lilly and Company has announced a dividend of $1.50 per share for the second quarter of 2025. This dividend will be payable on June 10, 2025, to shareholders who are on record as of May 16, 2025. The announcement highlights Lilly's commitment to returning value to its shareholders, although it also includes caution regarding uncertainties in pharmaceutical research and development. The statement underscores the need for investors to be aware of potential risks that could affect expected outcomes.
Read more →LLYLilly to participate in Bank of America Securities 2025 Healthcare Conference Eli Lilly and Company (NYSE:LLY) will participate in the Bank of America Securities 2025 Healthcare Conference, May 15, 2025. Lucas Montarce, Lilly...
Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Securities 2025 Healthcare Conference on May 15, 2025. Lucas Montarce, the company's executive vice president and CFO, is scheduled to take part in a fireside chat at 11:40 a.m. Eastern time. A live audio webcast of the session will be accessible via Lilly's investor website, and a replay will be available for approximately 90 days.
Read more →LLY▼ -11.7%on this newsshared move
Lilly reports first-quarter 2025 financial results and highlights pipeline momentum Revenue in Q1 2025 increased 45% to $12.73 billion driven by volume growth from Mounjaro and Zepbound. Pipeline progress included positive Phase 3...
Eli Lilly and Company reported robust financial results for Q1 2025, showcasing a 45% increase in revenue to $12.73 billion, driven largely by strong sales of its products Mounjaro and Zepbound. The company highlighted notable progress in its pipeline, including a positive Phase 3 trial result for its oral incretin orforglipron. Despite some challenges with pricing and rising research and development costs, Lilly plans to expand manufacturing to meet growing global demand for its medicines. The financial guidance for 2025 remains optimistic, reaffirming a revenue outlook between $58 billion and $61 billion.
Read more →LLY▲ +14.3%on this news
Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial Eli Lilly and Company (NYSE: LLY) today announced positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron ...
Eli Lilly announced positive Phase 3 results for orforglipron, the first oral GLP-1 receptor agonist, showing significant A1C reduction and weight loss. The trial demonstrated an average A1C decrease of 1.3% to 1.6% and an average weight loss of 16.0 lbs at the highest dosage. The safety profile was consistent with existing injectable GLP-1 therapies, although gastrointestinal side effects were reported. Following this success, Lilly plans further data presentations and anticipates regulatory submissions for both diabetes and weight management applications.
Read more →LLY▲ +14.3%on this news
Lilly confirms date and conference call for first-quarter 2025 financial results announcement Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2025 financial results on May 1, 2025. Lilly will also conduct a conference call...
Eli Lilly and Company (NYSE: LLY) has confirmed that it will announce its first-quarter 2025 financial results on May 1, 2025. A conference call will follow on the same day to discuss the company’s financial performance with the investment community and media. This will allow for a live webcast accessible on Lilly's website, ensuring stakeholders can stay informed.
Read more →LLYLilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy...
Eli Lilly announced promising Phase 2 results for lepodisiran, an investigational siRNA therapy aimed at reducing lipoprotein(a), a known cardiovascular risk factor. The study demonstrated a significant average reduction of approximately 93.9% in Lp(a) levels among patients treated with the highest dose over a duration of 180 days. Additionally, sustained reductions were observed for nearly 1.5 years in some cases. While the results highlight the potential of lepodisiran as a treatment option, there were some reported adverse events and a death in one of the dose groups.
Read more →LLYLillyDirect platform expands to facilitate access to Alzheimer's disease care Eli Lilly and Company (LLY) has expanded its LillyDirect digital healthcare platform to offer connections to independent in-person and telehealth...
Eli Lilly and Company has expanded its LillyDirect digital healthcare platform to enhance access to in-person and telehealth providers for Alzheimer's disease care. This initiative aims to tackle the long wait times for diagnosis, particularly affecting patients in rural and underserved areas. The new resources focus on facilitating timely diagnosis and management of the disease, addressing the urgent needs expressed by both healthcare providers and patients. Lilly's commitment is further emphasized by the inclusion of independent provider connections, which aim to alleviate barriers to care.
Read more →LLYLilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be...
Eli Lilly and Company (NYSE: LLY) announced the forthcoming presentation of preclinical data targeting SMARCA2 and KRAS mutations at the 2025 AACR Annual Meeting. The data will be shared in oral presentations, highlighting the effectiveness of their selective inhibitors in preclinical models. Both LY4050784 and LY4066434 are currently advancing in Phase 1 studies, showcasing Lilly's commitment to developing innovative cancer therapies.
Read more →LLYLilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe...
Late-breaking results from the Phase 3 BRAVE-AA-PEDS study demonstrated that adolescent patients with severe alopecia areata who received baricitinib showed significant hair regrowth. At Week 36, 42.4% achieved 80% or more scalp hair coverage. Additionally, patients experienced eyebrow and eyelash regrowth compared to those receiving a placebo. The treatment's safety profile was consistent with previous studies, although common adverse events included acne and respiratory infections. Further data from this study will be presented in future meetings.
Read more →LLYLilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis Among EBGLYSS Week 16 responders from the monotherapy trials, 50% achieved highest bar of complete skin clearance (EASI 100 or IGA 0) and 87%...
Eli Lilly's EBGLYSS (lebrikizumab-lbkz) has shown promising results for patients with moderate-to-severe atopic dermatitis, with data from a long-term extension study revealing that 50% of patients achieved complete skin clearance over three years. The treatment not only demonstrated a high clearance rate but also significantly improved related symptoms like itch and skin pain. Approved as a monotherapy in 2024, EBGLYSS is hailed by experts as a viable first-line biologic treatment option. These results will be presented at the American Academy of Dermatology Annual Meeting.
Read more →LLYLilly to participate in Leerink Partners Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in Leerink Partners Global Healthcare Conference on March 10, 2025. Lucas Montarce, Lilly...
Eli Lilly and Company (NYSE: LLY) will participate in the Leerink Partners Global Healthcare Conference on March 10, 2025. Lucas Montarce, the executive vice president and CFO of Lilly, will engage in a fireside chat at 9:20 a.m. Eastern time. A live audio webcast of the discussion will be available on the company's investor website, along with a replay for approximately 90 days following the event.
Read more →LLYLilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP)...
Eli Lilly announced a positive opinion from the EMA's CHMP for Jaypirca (pirtobrutinib), targeting adults with relapsed or refractory chronic lymphocytic leukemia. This recommendation was based on the results of the BRUIN CLL-321 Phase 3 trial, the first randomized study focused solely on patients who have been previously treated with a BTK inhibitor. The trial demonstrated significant improvements in progression-free survival and time to next treatment. Jaypirca offers a new treatment option for a patient group facing considerable unmet medical needs.
Read more →LLYLilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion Eli Lilly and Company (NYSE: LLY) today announced at a press conference in Washington, D.C., plans to bolster its domestic medicine production across ...
Eli Lilly and Company announced plans to invest over $50 billion in U.S. manufacturing, significantly boosting its domestic medicine production. The company is set to build four new pharmaceutical manufacturing sites, creating approximately 13,000 high-wage jobs and reshoring key capabilities. This investment reflects Lilly's optimism about its therapeutic pipeline and commitment to enhancing American innovation in the pharmaceutical sector. The expansion aims to meet anticipated demands for safe and reliable medicines while positively impacting local economies.
Read more →LLYLilly launches additional Zepbound vial doses and offers new savings for self-pay patients Today Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with...
Eli Lilly & Company has announced the launch of new single-dose vials of Zepbound (tirzepatide) in 7.5 mg and 10 mg doses, priced at $499 each as part of their Self Pay Journey Program. In addition, the prices of their existing 2.5 mg and 5 mg vials have been reduced to make the medication more affordable for self-pay patients. This move is part of Lilly's broader initiative to enhance accessibility to obesity treatment amid growing concerns about healthcare systemic coverage for such treatments. While the changes have been positively received, industry experts emphasize the need for comprehensive coverage solutions for patients with obesity.
Read more →LLYLilly to participate in TD Cowen's 45th Annual Health Care Conference Eli Lilly and Company (NYSE: LLY) will participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Jake Van Naarden, executive...
Eli Lilly and Company (NYSE: LLY) is set to participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Jake Van Naarden, the executive vice president and president of Lilly Oncology, will partake in a fireside chat at 1:50 p.m. Eastern time. A live audio webcast will be available on Lilly's investor website, with a replay accessible for approximately 90 days.
Read more →LLYMost patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with...
Eli Lilly and Company reported promising results from the VIVID-2 study, showing that more than 90% of patients treated with Omvoh (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission over two years. Additionally, nearly 90% maintained endoscopic response during the same period. This underscores Omvoh's position as a leading treatment in its class, with approvals already secured in multiple regions. The long-term safety profile remains consistent with previous findings, although a small percentage of patients did experience adverse events.
Read more →LLYLilly reports full Q4 2024 financial results and provides 2025 guidance Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared...
Eli Lilly and Company reported a remarkable 45% increase in revenue to $13.53 billion for Q4 2024, largely fueled by strong sales of Mounjaro and Zepbound. The company's net income more than doubled, growing to $4.41 billion, and earnings per share saw a significant rise. Despite these positive results, Lilly faced challenges with declining sales from Trulicity and lower realized prices affecting the overall revenue. Looking ahead, the company is optimistic about maintaining momentum into 2025 with several promising clinical trials on the horizon.
Read more →LLYLilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025. Lilly will...
Eli Lilly and Company will announce its fourth-quarter 2024 financial results and provide guidance for 2025 on February 6, 2025. The company will host a conference call at 10 a.m. Eastern time to discuss its financial performance with investors and media. A live webcast will be accessible via Lilly's website, along with a replay for those unable to attend the live event.
Read more →LLYFDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the...
Eli Lilly's Omvoh (mirikizumab-mrkz) has received FDA approval for the treatment of moderately to severely active Crohn's disease in adults, following its prior approval for ulcerative colitis. The decision is based on positive results from the Phase 3 VIVID-1 trial, which showcased significant benefits, including high rates of clinical remission and endoscopic response. With both FDA approvals, Omvoh positions itself as a novel treatment option for patients suffering from inflammatory bowel diseases. Eli Lilly is also pursuing global regulatory approvals to increase access to this therapy.
Read more →LLY▼ -6.6%on this newsshared move
Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance Eli Lilly and Company (NYSE: LLY) today announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, which...
Eli Lilly and Company has updated its revenue guidance for 2024, forecasting worldwide revenue to reach approximately $45 billion, reflecting a 32% increase year-over-year. Additionally, the company set its 2025 revenue expectations between $58 billion and $61 billion, bolstered by strong performances from several key products. However, the Q4 2024 revenue outlook has been reduced by $400 million compared to previous guidance due to slower-than-anticipated growth and inventory issues. Despite these challenges, the company aims to enhance production capacity significantly in the coming year.
Read more →LLYLilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ( Scorpion ), a private biotechnology company developing small molecule precision...
Eli Lilly and Company has announced the acquisition of Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program, which includes the promising drug STX-478. This acquisition aims to enhance Lilly's oncology pipeline and potentially address treatment needs in hormone-positive breast cancer, with STX-478 currently in Phase 1/2 clinical trials. The unique mechanism of STX-478 selectively targets cancerous cells while sparing healthy ones, promising improved efficacy and tolerability. However, the transaction is subject to customary closing conditions and involves inherent risks in drug development.
Read more →LLYLilly to participate in J.P. Morgan Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025. David A. Ricks, Lilly chair and...
Eli Lilly and Company (NYSE: LLY) is set to participate in the 43rd Annual J.P. Morgan Healthcare Conference scheduled from January 13-16, 2025. CEO David A. Ricks will conduct a fireside chat on January 14 at 5:15 p.m. Eastern time. Interested parties can access a live audio webcast through Lilly's investor website, with a replay available for 30 days following the event.
Read more →LLYFDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only...
Eli Lilly's Zepbound (tirzepatide) has received FDA approval as the first and only prescription medication for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. Clinical trials showed that Zepbound significantly reduced breathing interruptions during sleep and helped patients achieve substantial weight loss. After one year of treatment, up to 50% of participants no longer exhibited OSA symptoms. However, the approval comes with warnings about serious side effects, including potential thyroid tumors.
Read more →LLYLilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™...
Eli Lilly and Company announced that its Alzheimer’s treatment Kisunla™ (donanemab-azbt) has been approved by China's National Medical Products Administration (NMPA). This approval marks Kisunla’s entry into the Chinese market, following successful approvals in the US, Japan, and Great Britain. The treatment targets early symptomatic Alzheimer's disease, demonstrating significant results in slowing cognitive decline, especially in patients with mild symptoms. However, caution is warranted due to potential serious side effects, including amyloid-related imaging abnormalities.
Read more →LLYLilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company...
Eli Lilly and EVA Pharma have received regulatory approval for insulin glargine injection in Egypt, marking a significant advancement in diabetes management. This collaboration aims to increase access to affordable insulin for up to one million people living with diabetes in low- and middle-income countries by 2030. The project involves substantial technology transfer and local manufacturing by EVA Pharma, enhancing sustainability in the supply of insulin. Lilly's initiative is part of a broader strategy to improve healthcare access globally, particularly in resource-limited settings.
Read more →LLYLilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease The Phase 3 VIVID-1 trial evaluated the safety and efficacy of Omvoh in patients with or without prior biologic failure and was the basis for the...
Eli Lilly's Omvoh® (mirikizumab) has received a positive opinion from the European CHMP for treating adults with moderately to severely active Crohn's disease. This recommendation is based on results from the Phase 3 VIVID-1 trial, which highlighted significant improvements in clinical outcomes and histologic measures of inflammation. If approved by the European Commission, Omvoh will offer a new treatment option for patients who have previously failed other therapies. The findings were recently published in The Lancet and presented at an annual gastroenterology meeting.
Read more →LLYLilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer As monotherapy, imlunestrant significantly reduced the risk of progression or death by 38% compared to standard endocrine therapy (ET) in patients...
Eli Lilly announced positive results from the Phase 3 EMBER-3 study of imlunestrant in patients with ER+, HER2- advanced breast cancer. As a monotherapy, imlunestrant showed a 38% reduction in risk of progression or death compared to standard therapy. Notably, in combination with Verzenio, it achieved a 43% risk reduction. These findings, which will be presented at the San Antonio Breast Cancer Symposium, signify a potential new oral treatment option for patients previously treated with aromatase inhibitors.
Read more →LLYPhase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent (reversible)...
Eli Lilly announced positive results from the Phase 3 BRUIN CLL-321 trial, which evaluated pirtobrutinib in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma previously treated with covalent BTK inhibitors. The trial showed that pirtobrutinib reduced the risk of disease progression or death by 46% compared to the control group and prolonged the median time to next treatment by 23.9 months. This study is significant as it is the first randomized Phase 3 trial conducted solely in BTK inhibitor pre-treated patients, addressing a critical need for new treatment options in this population. The results will be presented at the upcoming ASH Annual Meeting.
Read more →LLYLilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase Today, the board of directors of Eli Lilly and Company (NYSE: LLY) approved a new $15 billion share repurchase program. The company's prior $5...
Eli Lilly and Company has announced a new $15 billion share repurchase program, following the completion of a previous $5 billion program. Additionally, for the seventh consecutive year, the company will increase its quarterly dividend by 15%, declaring a dividend of $1.50 per share for Q1 2025. The company's executive vice president mentioned a strong growth profile and a commitment to returning capital to shareholders while continuing to invest in research and development. The share repurchase program will be executed over the next three years at management's discretion.
Read more →LLYCORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses® Parade CORE Kidney, a patient support and advocacy group that helps patients with kidney disease navigate their complex journey, today announced its...
CORE Kidney has partnered with Boehringer Ingelheim and Eli Lilly to promote kidney health at the 2025 Tournament of Roses Parade. The initiative aims to educate those at risk of kidney disease, particularly individuals with type 2 diabetes and high blood pressure, about the need for comprehensive testing. The float titled "It's In Your Hands: It Takes 2" will visually and musically engage the public on the importance of blood and urine tests for kidney health. The event features Pro Football Hall of Famer Brian Dawkins, emphasizing the necessity of proactive health management among at-risk communities.
Read more →LLYLilly announces $3 billion expansion of its recently acquired manufacturing facility in Wisconsin Eli Lilly and Company (NYSE: LLY) today announced a $3 billion expansion of the Kenosha County, Wisconsin, manufacturing facility that the company...
Eli Lilly and Company (NYSE: LLY) has announced a $3 billion expansion of its manufacturing facility in Kenosha County, Wisconsin. This expansion will enhance the production of diabetes, obesity, and future pipeline medicines, while also creating 750 highly skilled jobs. Construction is set to begin next year, contributing to Lilly's ongoing strategy of extensive investment in manufacturing capabilities. The initiative will also integrate advanced automation technologies to improve efficiency in their operations, further solidifying Wisconsin's role in Lilly's global manufacturing network.
Read more →LLYLilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound®...
Eli Lilly announced favorable topline results from the SURMOUNT-5 trial, showing that its weight-loss drug, Zepbound (tirzepatide), significantly outperformed Wegovy (semaglutide) in weight loss effectiveness. After 72 weeks, patients on Zepbound lost an average of 20.2% of their body weight, compared to 13.7% for those on Wegovy. The results indicate that 31.6% of patients on Zepbound experienced a loss of at least 25% body weight. Despite its effectiveness, both treatments reported mild to moderate gastrointestinal side effects, and Zepbound carries significant risks linked to serious adverse effects.
Read more →LLYLilly announces changes on board of directors Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors, effective Dec. 1, 2024....
Eli Lilly and Company (NYSE: LLY) announced the election of Jon Moeller to its board of directors, effective December 1, 2024, while Karen Walker will resign from her position on December 31, 2024, but will continue to collaborate with the company on digital initiatives. Moeller, currently the CEO of Procter & Gamble, is expected to bring valuable insights from his extensive experience in strategic and operational leadership to Lilly's board. Walker has been a significant contributor since 2018, mentoring leaders and providing insights into talent development and technology strategy.
Read more →LLYLilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally administered...
Eli Lilly announced positive results from the Phase 2 study of muvalaplin, an oral treatment for elevated lipoprotein(a) levels associated with cardiovascular risk. The study found that muvalaplin significantly lowered Lp(a) levels in adults at multiple tested doses, meeting primary and secondary endpoints effectively. These findings represent a potential advancement in cardiovascular disease management, as existing therapies do not address Lp(a) levels. The treatment was generally well tolerated, with no reported deaths.
Read more →LLYLilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity Eli Lilly and Company (NYSE: LLY) today announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk...
Eli Lilly and Company has announced promising results from the SUMMIT Phase 3 trial, where tirzepatide demonstrated a significant 38% reduction in the risk of worsening heart failure events in adults suffering from heart failure with preserved ejection fraction (HFpEF) and obesity. The study also showed improvements in exercise capacity and symptoms related to heart failure. With submissions for regulatory approval already initiated, if approved, tirzepatide could become a groundbreaking treatment option for this patient population. The trial met all primary and secondary endpoints, marking a potential new standard of care in managing obesity-related heart failure.
Read more →LLYTreatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks Eli Lilly and Company (NYSE: LLY) announced today detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the...
Eli Lilly and Company announced positive results from the Phase 3 SURMOUNT-1 study, which assessed tirzepatide in adults with pre-diabetes and obesity. The study found that participants experienced an average weight loss of 22.9% and demonstrated a 94% reduction in the risk of progressing to type 2 diabetes over a 176-week period. Nearly all participants remained diabetes-free by the study's conclusion, highlighting the potential of tirzepatide as a long-term therapeutic option for weight management and diabetes prevention.
Read more →LLYLilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine...
Eli Lilly and Company (NYSE: LLY) has announced that data from studies of Jaypirca® (pirtobrutinib), a Bruton's tyrosine kinase inhibitor, will be presented at the 2024 American Society of Hematology Annual Meeting. The Phase 3 BRUIN CLL-321 study results will compare Jaypirca against other treatment options in patients previously treated with BTK inhibitors. Additionally, poster presentations will cover real-world data analyses related to chronic lymphocytic leukemia and a novel bispecific antibody for B-cell malignancies.
Read more →LLYLilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium Eli Lilly and Company (NYSE: LLY) today announced that data from the Phase 3 trial (EMBER-3) for imlunestrant, an oral selective estrogen receptor...
Eli Lilly recently announced it will present data from its Phase 3 EMBER-3 study of imlunestrant, an oral selective estrogen receptor degrader, at the upcoming San Antonio Breast Cancer Symposium. The EMBER-3 trial evaluates imlunestrant's efficacy in combination with the CDK4/6 inhibitor Verzenio among patients with advanced ER+, HER2- breast cancer who have undergone prior endocrine therapy. Additionally, Lilly will share further findings related to breast cancer treatment and investigational new therapies during the symposium.
Read more →LLY▼ -6.3%on this newsshared move
Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from...
Eli Lilly and Company reported its Q3 2024 financial results, showcasing a notable 42% revenue increase when excluding divestiture activities. This growth is primarily attributed to strong performances from new products Mounjaro and Zepbound, contributing to a 20% overall revenue increase compared to Q3 2023. Despite the positive results, international revenue experienced a decline, largely influenced by prior divestitures and inventory adjustments in the U.S. market. The company's focus on oncology, immunology, and neuroscience continues to bolster its growth trajectory, evidencing a solid foundation for future performance.
Read more →LLYModified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study A change in the initiation of donanemab dosing, shifting one vial of donanemab from the first infusion to the third infusion, lowered ARIA-E to 14%...
Eli Lilly announced positive results from the Phase 3b TRAILBLAZER-ALZ 6 study, which demonstrated a modified dosing regimen of donanemab reduces ARIA-E rates in early symptomatic Alzheimer's patients. The study showed a decrease in ARIA-E from 24% to 14% compared to traditional dosing, while maintaining similar levels of amyloid plaque reduction. Lilly plans to submit these findings to global regulators for a potential label update for its Alzheimer's treatment, Kisunla. The study indicates a promising direction for optimizing therapy in Alzheimer's disease with the modified titration regimen.
Read more →LLYLilly declares fourth-quarter 2024 dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2024 of $1.30 per share on outstanding...
Eli Lilly and Company has announced a dividend of $1.30 per share for the fourth quarter of 2024, payable on December 10, 2024, to shareholders recorded by November 15, 2024. This move showcases the company's ongoing commitment to providing returns to its investors. Lilly has a rich history of advancing medical science and is actively working on solutions for significant health challenges, including diabetes and cancer. The announcement comes amid the company's focus on enhancing patient accessibility to its medicines.
Read more →LLYLilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease Eli Lilly and Company (NYSE: LLY) announced results from two, multi-year, Phase 3 studies that showed patients treated with mirikizumab sustained...
Eli Lilly and Company announced results from two Phase 3 studies showing that their drug, mirikizumab, sustained long-term remission in patients with inflammatory bowel diseases. Data revealed that more than 80% of patients with moderately to severely active ulcerative colitis maintained remission over three years, while over 50% of Crohn's disease patients did the same for up to five years. Mirikizumab is the first IL23p19 antagonist to report these long-term efficacy results and is FDA-approved for ulcerative colitis. It currently awaits FDA review for Crohn's disease treatment.
Read more →LLYLilly's EBGLYSS™ (lebrikizumab-lbkz) demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with moderate-to-severe atopic dermatitis who discontinued dupilumab In first dedicated study of a selective IL-13 inhibitor in patients previously treated with dupilumab, the majority of patients had a history of...
Eli Lilly's EBGLYSS has demonstrated significant efficacy in improving skin clearance and itch relief for patients with moderate-to-severe atopic dermatitis who previously stopped dupilumab treatment. In a Phase 3b study, a majority of subjects showed improvement in challenging areas such as the face and hands. The drug maintained a consistent safety profile, with few adverse events leading to discontinuation. These findings will be presented at the Fall Clinical Dermatology Conference and support EBGLYSS as a viable first-line treatment option.
Read more →LLYLilly's Kisunla™ (donanemab-azbt) Receives Marketing Authorization in Great Britain for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in Adult Patients Who Are Apolipoprotein E Ε4 Heterozygotes or Non-Carriers Eli Lilly and Company (NYSE: LLY) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing...
Eli Lilly's donanemab, marketed as Kisunla, has received marketing authorization from the Medicines and Healthcare products Regulatory Agency in Great Britain for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in eligible adults. This approval, the third major market authorization for donanemab after the U.S. and Japan, allows treatment specifically for apolipoprotein E4 heterozygotes and non-carriers. Donanemab has shown significant results in clinical trials, demonstrating efficacy in slowing cognitive decline. However, it is associated with serious side effects, including ARIA, which require careful monitoring.
Read more →LLYLilly confirms date and conference call for third-quarter 2024 financial results announcement Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2024 financial results on Oct. 30, 2024. Lilly will also conduct a conference call...
Eli Lilly and Company (NYSE: LLY) is set to announce its third-quarter 2024 financial results on October 30, 2024. Along with the results, the company will host a conference call that is slated to start at 10 a.m. Eastern time. This call aims to provide further insights into Lilly's financial performance, facilitating communication with investors and the media. A live webcast of the call will be available on the company's website, with a replay offered thereafter.
Read more →LLYSurvey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies Results from the national Urgent Conversations survey, announced today by Eli Lilly and Company (NYSE: LLY), found that over half (60%) of the...
Eli Lilly's recent survey reveals that a significant majority of Americans with ulcerative colitis face challenges locating public restrooms during emergencies. The survey, which involved 1,800 participants, indicated that 84% of those with ulcerative colitis struggle to find accessible facilities. In response, the Crohn's & Colitis Foundation launched the 'We Can't Wait' app to help locate public restrooms and improve access. Additionally, Eli Lilly's newly approved treatment Omvoh offers promise for better management of ulcerative colitis symptoms.
Read more →LLYLilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's disease treated with...
Eli Lilly announced positive results from a Phase 3 study showing that mirikizumab achieved better histologic responses in patients with moderately to severely active Crohn's disease compared to ustekinumab. The study, named VIVID-1, is noted for its rigorous analysis aligned with recent European guidelines on mucosal evaluation. The results, which were presented at UEG Week in Vienna, reflect a growing body of evidence supporting mirikizumab as a promising treatment option. Additionally, Lilly has submitted marketing applications for mirikizumab in several regions globally.
Read more →LLYLilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials Eli Lilly and Company (NYSE: LLY) today announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced...
Eli Lilly and Company announced a $4.5 billion investment in the Lilly Medicine Foundry, a new facility in Indiana aimed at advancing drug production and development. The center will uniquely combine research and manufacturing to optimize processes and scale production for clinical trials. This investment raises Lilly's total U.S. capital commitment since 2020 to over $23 billion and is expected to create 400 high-skilled jobs. The site, located in the LEAP Research and Innovation District, will also focus on reducing costs and environmental impact.
Read more →LLYNew data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis More than 80 percent of adults and adolescents with moderate-to-severe atopic dermatitis who responded to EBGLYSS™ treatment at Week 16 in the...
Eli Lilly announced that more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis who responded to EBGLYSS treatment at Week 16 maintained sustained skin clearance for up to three years. Nearly 87% of participants did not need high-potency topical corticosteroids or systemic treatments throughout the study duration. The results demonstrate durable efficacy and consistent safety over the long term, reinforcing EBGLYSS as a viable treatment option for patients. The data will be presented at the European Academy of Dermatology and Venereology Congress in Amsterdam.
Read more →LLYLilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli ...
Eli Lilly's Kisunla (donanemab-azbt) has been approved in Japan for treating adults with early symptomatic Alzheimer's disease. This is the second major market approval for the drug, following its initial approval in the United States in July 2024. The approval is based on positive results from the TRAILBLAZER-ALZ 2 Phase 3 study, which demonstrated significant cognitive and functional benefits for patients. However, the drug's use comes with potential serious side effects, including amyloid-related imaging abnormalities.
Read more →LLYFDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 ...
Eli Lilly's EBGLYSS (lebrikizumab-lbkz) has received FDA approval for treating moderate-to-severe atopic dermatitis in adults and children aged 12 and older. This biologic therapy offers a new first-line option for patients who have not effectively controlled their condition with topical treatments. Clinical studies demonstrated significant improvements in skin clearance and itch relief within weeks of treatment. EBGLYSS will be available soon in the U.S., supported by a patient access program for eligible individuals.
Read more →LLYLilly expands manufacturing footprint in Ireland with $1.8 billion investment Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of...
Eli Lilly and Company has announced a major $1.8 billion investment to expand its manufacturing footprint in Ireland, including a $1 billion enhancement of its Limerick site. This expansion aims to increase production of biologic active ingredients for Alzheimer's treatments and other medicines. Additionally, Lilly is investing $800 million in its Kinsale facility for diabetes and obesity treatments. The initiative is expected to create 150 new jobs and is part of Lilly's broader strategy to enhance its global manufacturing capabilities while committing to sustainability.
Read more →LLYWith once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-5 phase 3 trial evaluating once-weekly insulin efsitora alfa...
Eli Lilly announced positive results from the QWINT-5 phase 3 trial of insulin efsitora alfa, a once-weekly insulin treatment for type 1 diabetes. The trial showed that efsitora achieved a comparable reduction in A1C levels to that of the daily insulin degludec, with similar overall rates of hypoglycemic events. Despite its potential benefits, efsitora was associated with a higher incidence of severe hypoglycemia in the early treatment period. The findings were presented at the EASD Annual Meeting and published in The Lancet.
Read more →LLYOnce-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-2 phase 3 trial evaluating once-weekly insulin efsitora alfa...
Eli Lilly and Company announced positive results from the QWINT-2 phase 3 trial for once-weekly insulin efsitora alfa, showing it delivered a significant A1C reduction that is comparable to daily insulin degludec. Efsitora achieved a reduction of 1.34% in A1C levels, and participants benefited from increased time in target glucose range without added hypoglycemia risk. The findings were published in The New England Journal of Medicine and presented at the EASD Annual Meeting 2024, highlighting the potential of efsitora to ease treatment burden for those starting insulin therapy. The results suggest that efsitora could greatly impact the management of type 2 diabetes patients seeking more convenient treatment options.
Read more →LLYLilly appoints Lucas Montarce as executive vice president and chief financial officer Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and ...
Eli Lilly and Company has appointed Lucas Montarce as its new executive vice president and chief financial officer, effective immediately. Montarce has held various finance leadership positions since joining Lilly in 2001, most recently serving as president and general manager for the Spain, Portugal, and Greece hub. CEO David Ricks expressed confidence in Montarce's ability to build on Lilly's financial foundation and drive the company's long-term success, especially during a pivotal moment in its history.
Read more →LLYIn a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-1 and QWINT-3 phase 3 clinical trials evaluating once...
Eli Lilly announced positive topline results from the QWINT-1 and QWINT-3 clinical trials, which evaluated once-weekly insulin efsitora alfa in adults with type 2 diabetes. Efsitora showed non-inferior A1C reduction when compared to daily insulins such as glargine and degludec. The trials indicate that efsitora's fixed-dose regimen may simplify insulin management for patients and improve their quality of life. Both studies' positive results suggest promising applications for efsitora in diabetes care.
Read more →LLYLilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries Eli Lilly and Company (NYSE: LLY) and EVA Pharma announced today that the companies have entered into an agreement to expand access to baricitinib to ...
Eli Lilly and EVA Pharma have entered a collaboration to expand access to baricitinib for immunological diseases in 49 low- to middle-income countries in Africa. The initiative targets the treatment of an estimated 20,000 individuals by 2030. This effort aligns with Lilly's 30x30 initiative, aiming to provide healthcare access to 30 million people annually. EVA Pharma plans to begin local production of baricitinib by 2026, bolstering its supply chain and addressing essential healthcare needs in the region.
Read more →LLYLilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Eli Lilly and Company (NYSE: LLY) today announced Zepbound® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients...
Eli Lilly has announced the release of Zepbound® (tirzepatide) single-dose vials at a significantly reduced price, offering better access for adults living with obesity. The new vials are available for self-pay patients, priced at over 50% less than comparable medicines. Clinical studies indicate that Zepbound can facilitate an average weight loss of 15% over 72 weeks when combined with lifestyle changes. However, there are warnings regarding serious side effects, including thyroid tumors and potential kidney issues, along with insurance coverage gaps for obesity treatments.
Read more →LLYLilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 22nd Annual Global Healthcare Conference on Sept. 5, 2024. Jacob Van Naarden,...
Eli Lilly and Company (NYSE: LLY) is set to participate in the Morgan Stanley 22nd Annual Global Healthcare Conference scheduled for September 5, 2024. Jacob Van Naarden, the executive vice president and president of Lilly Oncology, will engage in a fireside chat during the event. Attendees can access a live audio webcast of the session through Lilly's Investor website, and a replay will be accessible for approximately 90 days following the event.
Read more →LLYTirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight Eli Lilly and Company (NYSE: LLY) announced today positive topline results from the SURMOUNT-1 three-year study (176-week treatment period)...
Eli Lilly announced promising results from the SURMOUNT-1 study, demonstrating that tirzepatide significantly reduces the risk of type 2 diabetes by 94% in adults with pre-diabetes and obesity. The long-term, 176-week trial also indicated a substantial average weight loss of 22.9% among participants using the 15 mg dose. Despite the positive outcomes, some participants faced weight regain during a follow-up period after treatment cessation, with certain gastrointestinal side effects reported. The findings will be submitted for peer review and presented at ObesityWeek 2024.
Read more →LLYLilly announces retirement of Marschall S. Runge from its Board of Directors Eli Lilly and Company (NYSE: LLY) announced today that Marschall S. Runge, M.D., Ph.D. is retiring from his role as an independent director of...
Eli Lilly and Company (NYSE: LLY) has announced the retirement of Marschall S. Runge, M.D., Ph.D. from its Board of Directors effective August 31, 2024. Dr. Runge has been a director since 2013, serving on the Science and Technology and Ethics and Compliance Committees. He is also the CEO of Michigan Medicine and plans to retire from that position in June 2025, although he will continue to engage with the Medical School as a faculty member. Lilly's CEO, David A. Ricks, thanked Dr. Runge for his contributions during his tenure.
Read more →LLYLilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ: MORF). Morphic is a...
Eli Lilly and Company has successfully completed its acquisition of Morphic Holding, Inc., enhancing its immunology pipeline with Morphic's oral integrin therapies for inflammatory bowel disease. This strategic move is part of Lilly's commitment to delivering innovative treatments in gastroenterology, building on its existing products like Omvoh. The acquisition allows for potential combination treatments that could improve patient outcomes. Despite the optimism, challenges remain regarding the approval timelines of Morphic's products and the effects on Lilly's operations.
Read more →LLYLilly opens state-of-the-art research and development center in the Boston Seaport Eli Lilly and Company (NYSE: LLY) today announced the opening of the Lilly Seaport Innovation Center (LSC), a research and development facility in...
Eli Lilly and Company has inaugurated the Lilly Seaport Innovation Center (LSC) in Boston, a 346,000 square foot facility aimed at enhancing its research in genetic medicine. The center will accommodate around 500 researchers and includes the first Lilly Gateway Labs on the East Coast, fostering collaboration with emerging biotech firms. The facility seeks to accelerate the development of innovative therapies targeting various diseases, while also facing inherent uncertainties related to its future success and scientific objectives.
Read more →LLY▲ +9.5%on this newsshared move
Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion Revenue in Q2 2024 increased 36%, driven by Mounjaro, Zepbound and Verzenio. When excluding $579.0 million of revenue from the sale of rights for...
Eli Lilly and Company reported impressive financial results for Q2 2024, with a 36% increase in revenue driven by strong sales of Mounjaro, Zepbound, and Verzenio. The company also announced the approval of Kisunla for Alzheimer's disease, marking a significant milestone in treatment options. Despite the overall positive results, declines in Trulicity sales and costs related to anticipated litigation payments could pose challenges. Lilly has also indicated an increase in research and development expenses as part of its growth strategy.
Read more →LLYLilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity Eli Lilly and Company (NYSE: LLY) announced today positive topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy...
Eli Lilly's tirzepatide has shown promising results in the SUMMIT phase 3 clinical trial, demonstrating a 38% reduction in heart failure outcomes among adults with heart failure with preserved ejection fraction (HFpEF) and obesity. In addition to significant improvements in symptoms and physical limitations, participants experienced a 15.7% weight loss. The trial met all key secondary endpoints, and safety profiles were consistent with previous studies, though some gastrointestinal adverse effects were observed. Lilly plans to submit these results to regulatory agencies for approval.
Read more →LLYLilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024. Lilly will also conduct a conference call...
Eli Lilly and Company will announce its second-quarter 2024 financial results on August 8, 2024. A conference call will be held on the same day at 10 a.m. Eastern time for investors, media, and the public. The call will provide detailed insights into the company's financial performance, with a live webcast available on Lilly's website. A replay of the call will also be accessible thereafter.
Read more →LLYLilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic, a...
Eli Lilly and Company has announced a definitive agreement to acquire Morphic Holding, Inc. for a purchase price of $57 per share, totaling approximately $3.2 billion. This acquisition aims to bolster Lilly's immunology pipeline with Morphic's lead oral small molecule inhibitor, MORF-057, intended for treating inflammatory bowel disease. The agreement has been approved by both companies' boards and is expected to close in Q3 2024, pending customary closing conditions. Morphic's technology and ongoing development efforts in integrin therapeutics are anticipated to align well with Lilly's strategic goals in gastroenterology.
Read more →LLYLilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease Kisunla slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study and reduced participants'...
The FDA has approved Lilly's Kisunla (donanemab-azbt) for treating early symptomatic Alzheimer's disease, showing promising results in slowing cognitive decline. In clinical trials, Kisunla reduced cognitive decline by up to 35% and allowed many patients to stop the treatment after achieving minimal amyloid plaque levels. The treatment has a limited-duration regimen and can minimize costs for patients by reducing the number of infusions needed. However, potential side effects include amyloid-related imaging abnormalities and allergic reactions related to infusions.
Read more →LLYLilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel...
Eli Lilly and Company has announced a collaboration with OpenAI to leverage generative AI for the discovery of novel antimicrobials targeting drug-resistant pathogens. This partnership aims to address the critical issue of antimicrobial resistance (AMR), which poses significant health risks worldwide. Diogo Rau from Lilly emphasized the groundbreaking nature of this collaboration in the fight against AMR. However, the announcement includes a cautionary note about the associated risks and uncertainties in the drug development process.
Read more →LLYLilly Declares Third-Quarter 2024 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2024 of $1.30 per share on outstanding...
Eli Lilly and Company has announced a dividend of $1.30 per share for the third quarter of 2024, payable on September 10, 2024. Shareholders of record will be those listed by August 15, 2024. The announcement reflects the company's ongoing commitment to rewarding shareholders amid its extensive efforts in addressing critical health challenges globally.
Read more →LLYLilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution In the primary endpoint, tirzepatide reduced moderate-to-severe OSA severity by up to 62.8% (about 30 fewer events per hour) In a key secondary...
Eli Lilly's tirzepatide has shown promising results in treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, achieving a remarkable 62.8% reduction in severity and enabling 51.5% of participants to meet criteria for disease resolution. This was observed in two phase 3 clinical studies, supporting a strong case for FDA approval for this new indication. The drug also demonstrated positive impacts on related cardiometabolic health measures. However, gastrointestinal side effects led to some treatment discontinuations, which will need to be managed in clinical settings.
Read more →LLYLilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks Eli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to...
Eli Lilly and Company disclosed encouraging results from the SYNERGY-NASH trial, a phase 2 study involving 190 participants with metabolic dysfunction-associated steatohepatitis (MASH). The results revealed that a significant percentage of participants treated with tirzepatide achieved MASH resolution and improvement in fibrosis within 52 weeks compared to placebo. Common side effects were mainly mild to moderate gastrointestinal issues. The company plans to engage with regulatory authorities regarding the next steps for tirzepatide in treating MASH.
Read more →LLYLilly announces departure of Anat Ashkenazi, chief financial officer Eli Lilly and Company (NYSE: LLY) announced today that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside...
Eli Lilly and Company has announced the resignation of Anat Ashkenazi as chief financial officer, who is leaving to pursue a career opportunity outside the pharmaceutical industry. Ashkenazi will continue to serve in her role until July 2024 while an internal and external search for her successor takes place. Lilly's chair and CEO, David A. Ricks, praised Ashkenazi for her 23 years of service and noted the significant growth the company experienced during her tenure as CFO. Her departure marks a notable change in the company's financial leadership.
Read more →LLYMelissa Seymour to join Lilly as executive vice president of Global Quality Eli Lilly and Company (NYSE: LLY) announced today that Melissa Seymour will join the company as executive vice president of Global Quality and member ...
Eli Lilly and Company (NYSE: LLY) has announced the appointment of Melissa Seymour as executive vice president of Global Quality, effective July 22, 2024. Seymour previously served as chief quality officer at Bristol Myers Squibb and has extensive experience in quality leadership across various pharmaceutical companies. She will succeed Johna Norton, who is retiring after 34 years with the company. Seymour's experience is expected to further Lilly's commitment to high-quality standards amid their expanding global operations and pipeline growth.
Read more →LLYUpdated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients...
Eli Lilly and Company presented updated data on olomorasib, a second-generation KRAS G12C inhibitor, at the 2024 ASCO Annual Meeting. The findings indicate promising monotherapy activity in various KRAS G12C-mutant advanced solid tumors, particularly non-small cell lung cancer (NSCLC), and highlight its tolerability when combined with pembrolizumab. Efficacy results showed a significant objective response rate in patients, even in those previously treated with a KRAS G12C inhibitor. Ongoing studies aim to further explore olomorasib's potential in first-line treatments, addressing an unmet need for effective options in this patient population.
Read more →LLYLilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases During the World Health Assembly today, Eli Lilly and Company (NYSE: LLY) announced it will donate $6.5 million to the United States Fund for UNICEF...
Eli Lilly and Company has announced a $6.5 million donation to UNICEF to support health initiatives for children at risk of noncommunicable diseases in India. This new funding contributes to a total commitment exceeding $20 million since 2022 aimed at improving health outcomes. The initiative seeks to strengthen health systems and enhance the capacity of health workers, focusing on prevention and management of diseases like type 1 diabetes and respiratory illnesses. Lilly's efforts align with its broader initiative to improve access to healthcare for millions in resource-limited settings by 2030.
Read more →LLYLilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024. Patrik Jonsson,...
Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference scheduled for June 10, 2024. Patrik Jonsson, an executive vice president and president of Lilly Diabetes and Obesity, will take part in a fireside chat. A live audio webcast will be accessible on Lilly's Investor website, with a replay available for 90 days post-event.
Read more →LLYLilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines Eli Lilly and Company (NYSE: LLY) announced today that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new ...
Eli Lilly has announced an expansion of its Lebanon, Indiana facility, committing an additional $5.3 billion, bringing total investment to $9 billion. This marks the largest investment in synthetic medicine active pharmaceutical ingredient manufacturing in the U.S. history. The expansion is designed to enhance production capacity for its diabetes medications, Zepbound and Mounjaro, while also creating 200 new high-skilled jobs. The initiative is supported by state infrastructure improvements and aligns with Lilly's long-term strategy to boost manufacturing and economic growth within Indiana.
Read more →LLYLilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), Retevmo® (selpercatinib; a...
Eli Lilly and Company (NYSE: LLY) announced that it will present data on its oncology pipeline, including studies on Verzenio, Retevmo, olomorasib, and imlunestrant at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Highlights include late-breaking data for Verzenio and updates on pediatric trials of Retevmo. The presentations are aimed at showcasing new insights into treatment strategies for advanced cancers. An investor event will accompany these presentations to discuss Lilly's ongoing oncology efforts.
Read more →LLYMore than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure In Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's disease, with or without...
In the Phase 3 VIVID-1 study, Eli Lilly's mirikizumab demonstrated significant efficacy in treating Crohn's disease, with over half of patients achieving clinical remission within a year. The study included both naïve patients and those with prior biologic failure, with mirikizumab showing improved outcomes compared to placebo and ustekinumab for several clinical endpoints. Despite a favorable safety profile, the study noted that some patients still experienced adverse events and inadequate treatment responses. Lilly plans to pursue further regulatory submissions for mirikizumab in Crohn's disease.
Read more →LLYWith Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-2 and QWINT-4 phase 3 clinical trials evaluating...
Eli Lilly & Company announced positive topline results from phase 3 trials, QWINT-2 and QWINT-4, for once-weekly insulin efsitora alfa in type 2 diabetes. Efsitora demonstrated non-inferior A1C reduction compared to the daily insulins insulin degludec and insulin glargine, showing its potential as a safer and more convenient treatment option. Participants on efsitora achieved significant blood sugar control with fewer treatment burdens and improved adherence possibilities. Further detailed results will be presented at the EASD Annual Meeting 2024.
Read more →LLYAlonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer Eli Lilly and Company (NYSE: LLY) today announced that Alonzo Weems, executive vice president of enterprise risk management and chief ethics and...
Eli Lilly and Company announced the retirement of Alonzo Weems, the executive vice president of enterprise risk management and chief ethics and compliance officer, effective December 31, 2024. Weems has served the company for 27 years and has played a vital role in the organization's strategic guidance and ethical standards. His leadership helped Lilly achieve significant business performance while emphasizing the importance of integrity. The company will seek a successor to fill his role during his remaining time with the company.
Read more →LLYLilly Declares Second-Quarter 2024 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2024 of $1.30 per share on outstanding...
Eli Lilly and Company (NYSE: LLY) announced a dividend of $1.30 per share for the second quarter of 2024, payable on June 10, 2024, to shareholders of record by May 16, 2024. The company's ongoing commitment to healthcare advancements continues, with a focus on addressing significant health challenges such as diabetes and Alzheimer's disease. Additionally, Lilly emphasizes the importance of diversity in clinical trials and aims to ensure the accessibility of its medications.
Read more →LLY▲ +6%on this news
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance. Pipeline progress included positive results from two Phase 3...
Eli Lilly and Company (LLY) has announced strong financial results for Q1 2024, reflecting a 26% increase in revenue to $8.77 billion. This growth was driven by robust sales of Mounjaro and Zepbound, alongside a notable rise in earnings per share. Despite these successes, Lilly is facing challenges with declining sales of Trulicity and capacity issues due to high demand for its incretin medicines. The company remains optimistic, having raised its full-year revenue guidance by $2 billion.
Read more →LLYTirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide...
Eli Lilly announced positive topline results from the SURMOUNT-OSA phase 3 trials, demonstrating that tirzepatide significantly reduced the apnea-hypopnea index in adults with obstructive sleep apnea and obesity. The trials achieved all primary and key secondary endpoints, showcasing marked improvements in sleep apnea symptoms and a noteworthy reduction in body weight among participants. Based on these findings, Lilly plans regulatory submissions for approval. However, some adverse events were reported, including gastrointestinal issues and thyroid-related risks.
Read more →LLYLilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2024 financial results on April 30, 2024. Lilly will also conduct a conference call ...
Eli Lilly and Company (NYSE: LLY) is set to announce its first-quarter 2024 financial results on April 30, 2024. The announcement will be accompanied by a conference call at 10 a.m. Eastern time, aimed at providing further details to the investment community and media. Investors and the general public will be able to access a live webcast of the conference call via Lilly's website, and a replay will be available after the event.
Read more →LLYMore than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of...
Eli Lilly announced promising results from a Phase 3 study of lebrikizumab, an investigational treatment for moderate-to-severe atopic dermatitis, specifically targeting patients with skin of color. The study showed significant improvements in skin clearance and itch relief among participants, addressing the historical lack of representation in clinical trials for this group. No new safety concerns were identified, and Lilly plans to continue research aimed at enhancing care for these patients. Further results from the trial will be shared at upcoming congresses, emphasizing Lilly's commitment to health equity in dermatology.
Read more →LLYU.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) expects to convene a meeting of the Peripheral and ...
Eli Lilly announced that the FDA will convene an Advisory Committee Meeting to discuss the TRAILBLAZER-ALZ 2 trial of donanemab, aimed at treating early symptomatic Alzheimer's disease. This meeting will focus on the safety and efficacy results, especially considering the unique trial design. While this review stage is unusual and might delay FDA action, Lilly's executives express confidence in donanemab's potential benefits. However, serious risks associated with the treatment, such as amyloid-related imaging abnormalities, remain a concern.
Read more →LLYLilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care Eli Lilly and Company (NYSE: LLY) today launched the next phase of its Get Better corporate branding campaign with a new focus on obesity. Earlier...
Eli Lilly and Company has launched the next phase of its 'Get Better' campaign, focusing on obesity treatment. Two films, 'Shame' and 'Big Night', highlight obesity as a serious disease and the responsible use of anti-obesity medications. The campaign aims to improve public understanding and discussion about obesity. However, Lilly acknowledges the potential risks in achieving the campaign's objectives, particularly regarding misconceptions about medication use.
Read more →LLYLilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting Nectin-4, KRAS G12D, and BRM (SMARCA2) will be presented ...
Eli Lilly and Company (NYSE: LLY) announced that it will present preclinical data related to several agents targeting Nectin-4, KRAS G12D, and BRM (SMARCA2) at the AACR Annual Meeting in April. The company will showcase three significant presentations, including an anti-Nectin-4 antibody, a KRAS G12D inhibitor, and a selective BRM inhibitor in collaboration with Foghorn Therapeutics. Lilly plans to file IND applications for these programs in 2024, though the company notes inherent risks and uncertainties in drug development.
Read more →LLYLilly to Participate in Cowen's 44th Annual Health Care Conference Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 44th Annual Health Care Conference on March 6, 2024. Anat Ashkenazi, executive vice...
Eli Lilly and Company (NYSE: LLY) has announced its participation in Cowen's 44th Annual Health Care Conference, scheduled for March 6, 2024. Anat Ashkenazi, the executive vice president and chief financial officer, will join a fireside chat at 9:10 a.m. ET. The event will be available for live listening via an audio webcast on Lilly's Investor website, ensuring that investors and stakeholders can access the information. A replay of the discussion will be accessible for 90 days following the event.
Read more →LLYPhilip Johnson to Retire as Lilly Treasurer Eli Lilly and Company (NYSE:LLY) today announced that after more than 28 years, Philip Johnson, group vice president and treasurer, will retire from...
Eli Lilly and Company has announced the retirement of Philip Johnson, its treasurer, after more than 28 years with the company. Johnson has significantly influenced Lilly's financial operations and talent development. His contributions included leading investor relations and initiatives for underrepresented groups. A successor will be named in the future, but the company acknowledges potential risks associated with this leadership transition.
Read more →LLYLilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance Revenue in Q4 2023 increased 28%. New Products(i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth...
Eli Lilly and Company reported strong financial results for Q4 2023, with revenues reaching $9.35 billion, a 28% increase year-over-year. Key drivers included significant contributions from new products, particularly Mounjaro and Zepbound. Gross margins also improved, reflecting strong pricing strategies despite some decreases in revenue from established products like Trulicity. The company highlighted its focus on enhancing its pipeline and addressing healthcare challenges as it looks forward to 2024.
Read more →LLYJohna Norton to Retire as Lilly Executive Vice President of Global Quality Eli Lilly and Company (NYSE: LLY) today announced that Johna Norton, executive vice president of Global Quality, will be retiring after 34 years of...
Eli Lilly announced the retirement of Johna Norton, Executive Vice President of Global Quality, effective July 31, 2024, after 34 years of service. Throughout her tenure, she has played a crucial role in enhancing quality standards and overseeing expansions at Lilly's manufacturing sites. An internal and external search for her successor is currently underway. Norton's contributions have made a significant impacts on the company and its patients, and she has been recognized in the industry for her leadership.
Read more →LLYPositive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), today announced positive initial clinical results from the Phase 1/2...
Akouos, Inc., a subsidiary of Eli Lilly, announced promising initial results from its Phase 1/2 clinical trial of AK-OTOF, a gene therapy for OTOF-mediated hearing loss. The trial demonstrated significant hearing restoration within 30 days of treatment in the first participant, marking a potential breakthrough for patients suffering from this genetic condition. The study will present detailed findings at the upcoming ARO MidWinter Meeting. While optimism surrounds the results, the company acknowledges inherent risks and uncertainties in the drug development process.
Read more →LLYLilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024. Lilly will...
Eli Lilly and Company (NYSE: LLY) announced that it will disclose its fourth-quarter 2023 financial results and provide 2024 financial guidance on February 6, 2024. The company will hold a conference call at 10 a.m. Eastern time to discuss these matters with investors and the media. A live webcast will be available for access, along with a replay on their website following the call.
Read more →LLYLilly Launches End-to-End Digital Healthcare Experience through LillyDirect™ Eli Lilly and Company (NYSE: LLY) today announced LillyDirect™, a new digital healthcare experience for patients in the U.S. living with obesity,...
Eli Lilly and Company has launched LillyDirect, a comprehensive digital healthcare experience tailored for patients in the U.S. with obesity, migraine, and diabetes. This initiative provides resources such as access to healthcare providers and home delivery of select medications, aimed at easing the patient management process for chronic diseases. LillyDirect is expected to evolve with updates and additional services to enhance patient adherence and healthcare access.
Read more →LLYLilly to Participate in J.P. Morgan Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the 42nd Annual J.P. Morgan Healthcare Conference, Jan. 8-11, 2024. David A. Ricks, Lilly's chair and...
Eli Lilly and Company is scheduled to attend the 42nd Annual J.P. Morgan Healthcare Conference from January 8-11, 2024. David A. Ricks, Lilly's chair and CEO, will engage in a fireside chat on January 9 at 5:15 p.m. Eastern time. Investors and media will be able to access a live audio webcast of the discussion on Lilly's Investor website, with a replay available for approximately 30 days thereafter.
Read more →LLYLilly Completes Acquisition of POINT Biopharma Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a...
Eli Lilly announced the successful acquisition of POINT Biopharma, specializing in radiopharmaceutical therapies for cancer. The acquisition was completed following a tender offer that saw 67.97% of POINT's shares tendered. Lilly's management expressed optimism about developing innovative therapies through this addition, though the press release also highlighted potential risks associated with the acquisition and drug development processes. The deal signifies Lilly's strategic move into next-generation cancer treatment options.
Read more →LLYLilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023 Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding...
Eli Lilly and Company has announced the extension of its tender offer to acquire POINT Biopharma Global Inc. until December 22, 2023. This decision comes after obtaining all necessary regulatory approvals. So far, around 22.81% of POINT's shares have been validly tendered up to the previous expiration date. However, the company also acknowledges inherent risks related to completing the acquisition and potential competing proposals.
Read more →LLYUpdated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent ...
Eli Lilly and Company announced encouraging updated clinical data from the Phase 1/2 BRUIN trial of their non-covalent BTK inhibitor pirtobrutinib. Presented at the 2023 ASH Annual Meeting, the data reflects efficacy and tolerability in patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). Notably, pirtobrutinib showed an overall response rate of 81.6% in CLL/SLL patients, while combination treatment with venetoclax achieved a remarkable 96% response rate. The trial's ongoing investigation will further explore the longevity of response and potential for broad clinical utility.
Read more →LLYLilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks Detailed results from SURMOUNT-4, which showed Zepbound™ (tirzepatide) injection achieved superior mean percent change in body weight compared to...
Lilly's Zepbound™ (tirzepatide) demonstrated significant efficacy in the SURMOUNT-4 study, achieving a total mean weight loss of 26.0% over 88 weeks. The study enrolled adults with obesity or overweight and showed that participants on Zepbound maintained their weight loss compared to those on placebo, who experienced a mean weight regain. The results were published in JAMA, confirming Zepbound's superiority in weight management. Despite the positive outcomes, there were concerns regarding gastrointestinal adverse events, which were the most frequently reported issues during the study.
Read more →LLYLilly Announces 15% Dividend Increase, First-Quarter 2024 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for the...
Eli Lilly and Company has announced a 15% increase in its quarterly dividend, now set at $1.30 per share, payable on March 8, 2024. This decision reflects the company's strong financial health and commitment to returning value to shareholders. The dividend is declared for shareholders of record as of February 15, 2024. Lilly remains focused on advancing healthcare innovations and addressing significant health challenges globally.
Read more →LLYLilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium Results from MONARCH 3 show a numerical improvement in overall survival (OS) of 13.1 months for women with HR+, HER2- metastatic breast cancer...
Eli Lilly announced a late-breaking presentation of results from the MONARCH 3 clinical trial at the 2023 San Antonio Breast Cancer Symposium. The trial demonstrated a numerical improvement in overall survival of 13.1 months for women with HR+, HER2- metastatic breast cancer treated with Verzenio plus an aromatase inhibitor. However, these outcomes did not reach statistical significance. Additional analyses regarding Verzenio's use, along with imlunestrant, are also set to be presented, contributing to the ongoing dialogue about treatment efficacy in this patient population.
Read more →LLYZepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity Eli Lilly and Company (NYSE: LLY) today announced that Zepbound™ (tirzepatide) injection is now available. Zepbound is indicated for adults with...
Eli Lilly has announced the availability of Zepbound™ (tirzepatide) injection for adults struggling with obesity or overweight. Approved by the FDA, Zepbound can be accessed through pharmacies in several dosage options following its inclusion in national formularies. The company emphasizes the need for collaboration to improve access for individuals in need. Safety warnings include potential severe side effects such as thyroid tumors and pancreatitis, underscoring the importance of physician oversight during treatment.
Read more →LLYLilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023 Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding...
Eli Lilly and Company has extended its tender offer to acquire POINT Biopharma Global Inc. until December 15, 2023. This extension allows both companies to satisfy the necessary minimum tender condition, with approximately 24.75% of POINT's shares already tendered as of December 1, 2023. All required regulatory approvals for the acquisition have been obtained. However, there are uncertainties regarding shareholder participation and potential competing offers that may impact the acquisition process.
Read more →LLYJaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved Jaypirca® (pirtobrutinib, 100 mg & 50 mg...
Eli Lilly's Jaypirca (pirtobrutinib) has received FDA approval for treating adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have undergone at least two lines of prior therapy. This approval is based on results from the BRUIN Phase 1/2 trial, where 72% of participants showed an overall response rate. Jaypirca is noted for being the first non-covalent BTK inhibitor, indicating a novel approach in therapeutic strategies for patients with prior treatment failures. However, the continued approval of Jaypirca relies on further verification of its clinical benefits in ongoing studies.
Read more →LLYLilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego Eli Lilly and Company (NYSE: LLY) today announced plans to open its first-ever Lilly Gateway Labs location in San Diego, Calif. in the first half of...
Eli Lilly and Company has announced plans to open its first Lilly Gateway Labs location in San Diego in the first half of 2024. This new facility will provide state-of-the-art lab space and unique access to Lilly scientists, fostering collaboration and innovation among early-stage biotech companies. Located in the University Town Center, the site will offer flexible lab space for ten companies and is part of Lilly's broader strategy to support external scientific innovation. This expansion reflects Lilly's commitment to enhancing the life sciences ecosystem in San Diego.
Read more →LLYLilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany Eli Lilly and Company (NYSE: LLY) today announced plans to construct a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate,...
Eli Lilly and Company has announced plans to construct a new $2.5 billion high-tech manufacturing facility in Alzey, Germany, aimed at expanding its injectable product manufacturing. This investment will create up to 1,000 skilled jobs and is part of Lilly's strategy to bolster its production capabilities to meet growing demand for its medicines. Alongside the new site, Lilly also plans to invest up to $100 million in the German life sciences ecosystem to foster innovation and strengthen relationships with local partners. The facility is projected to commence operations in 2027, contingent on government approvals.
Read more →LLYLilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023 Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding...
Eli Lilly and Company has extended its tender offer to acquire POINT Biopharma Global Inc. until December 1, 2023, allowing more time to meet the minimum tender condition. The tender offer price is set at $12.50 per share in cash. As of the previous deadline, about 26.45% of POINT's outstanding shares have been validly tendered. While necessary regulatory approvals are in place, uncertainties still surround the completion of the acquisition.
Read more →LLYLilly to Participate in Evercore ISI HealthCONx Conference Eli Lilly and Company (NYSE: LLY) will attend the sixth annual Evercore ISI HealthCONx Conference on Nov. 28, 2023. Daniel Skovronsky, M.D., Ph.D.,...
Eli Lilly and Company (NYSE: LLY) will attend the upcoming Evercore ISI HealthCONx Conference on November 28, 2023. The event will feature a participation from Daniel Skovronsky, M.D., Ph.D., the company's chief scientific and medical officer. A live audio webcast of the session will be available on Lilly's Investor website, with a replay accessible for 90 days following the event.
Read more →LLYLilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Nuclear Regulatory Commission ( NRC ) has issued its consent for the indirect...
Eli Lilly and Company announced that it has received consent from the U.S. Nuclear Regulatory Commission for the indirect transfer of control of POINT Biopharma's radioactive materials license. This approval is the final regulatory step necessary for Lilly's tender offer to acquire all outstanding shares of POINT Biopharma at a price of $12.50 per share. The tender offer is set to expire on November 16, 2023. Although the acquisition is progressing, Lilly acknowledges inherent risks and uncertainties involved in completing the deal.
Read more →LLYLilly Announces Extension of Tender Offer to Acquire POINT Biopharma Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding...
Eli Lilly and Company has announced an extension of its tender offer to acquire POINT Biopharma Global Inc. The offer, initially set to expire on November 9, 2023, will now continue until November 16, 2023, to meet outstanding closing conditions. As of November 8, about 14.16% of POINT's outstanding shares have been tendered. The acquisition is anticipated to close near the end of 2023, depending on satisfying various conditions and receiving a majority of outstanding shares.
Read more →LLYFDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only...
Eli Lilly's Zepbound™ (tirzepatide) has received FDA approval for chronic weight management in adults with obesity or overweight with related medical problems. This treatment activates both GIP and GLP-1 hormone receptors, offering a novel mechanism for weight loss. Clinical trials indicated an average weight loss of 48 lb at the highest dosage, with a notable percentage of patients achieving significant weight loss. However, Zepbound is associated with risks including gastrointestinal side effects and has specific contraindications that must be considered prior to use.
Read more →LLYLilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) ...
Eli Lilly and Company has announced the upcoming presentations of pirtobrutinib at the 2023 ASH Annual Meeting, to be held from December 9-12 in San Diego. The presentations will cover a range of safety and efficacy data from the Phase 1/2 BRUIN study, with a focus on various B-cell malignancies. Specific topics include treatment outcomes for patients with high-risk mantle cell lymphoma and chronic lymphocytic leukemia. Research will also explore resistance mechanisms in treated patients, emphasizing the drug's role as a reversible Bruton's tyrosine kinase inhibitor.
Read more →LLYLilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity Revenue in Q3 2023 increased 37%, driven by growth from Mounjaro, Verzenio and Jardiance, as well as $1.42 billion from the sale of rights for the...
Eli Lilly and Company reported its financial results for the third quarter of 2023, posting a revenue increase of 37% to $9.5 billion, driven largely by strong sales of Mounjaro and Verzenio. Despite the overall revenue growth, the company experienced a substantial net loss of $57.4 million, compared to a profit of $1.45 billion in the same quarter last year. Lilly's focus on business development saw multiple acquisitions, aiming to expand its product pipeline amidst mixed financial outcomes.
Read more →LLYHip-Hop Classic It Takes Two Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease More than 35 million adults in the U.S. have chronic kidney disease (CKD). However, as many as 90% of them are unaware of their condition. This is...
Eli Lilly and Boehringer Ingelheim have launched a health initiative named 'It Takes 2' to raise awareness about chronic kidney disease (CKD) among adults, particularly those at risk due to type 2 diabetes and high blood pressure. The initiative features a remix of the classic hip-hop song 'It Takes Two' by Rob Base to emphasize the importance of complete testing for CKD. With tailored resources for healthcare professionals and at-risk individuals, the initiative encourages the use of both eGFR and UACR tests for early diagnosis. The partnership aims to improve awareness and testing compliance to reduce the long-term impacts of CKD.
Read more →LLYLilly Declares Fourth-Quarter 2023 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2023 of $1.13 per share on outstanding...
Eli Lilly and Company (NYSE: LLY) announced a dividend of $1.13 per share for the fourth quarter of 2023, payable on December 8, 2023, to shareholders of record by November 15, 2023. The announcement highlights Lilly's ongoing commitment to enhancing shareholder value while reflecting on its long history of medical innovations that serve millions worldwide. Lilly emphasizes its continuous advancements in various health challenges, including diabetes care and cancer treatment, while acknowledging the inherent uncertainties associated with its business strategies.
Read more →LLYFDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh™ (mirikizumab-mrkz) infusion...
Eli Lilly's Omvoh (mirikizumab-mrkz) has received FDA approval as the first interleukin-23p19 antagonist for adults with moderately to severely active ulcerative colitis. Significant efficacy was demonstrated in pivotal trials, with many patients achieving clinical remission over one year of treatment. The approval marks an advancement in treatment options for those who have struggled with other therapies. While there are identified risks associated with the drug, such as potential hypersensitivity reactions and infections, the positive results offer new hope for patients seeking effective treatment alternatives.
Read more →LLYLilly to Participate in UBS Biopharma Conference 2023 Eli Lilly and Company (NYSE: LLY) will attend the UBS Biopharma Conference on Nov. 8, 2023. Patrik Jonsson, executive vice president; president,...
Eli Lilly and Company (NYSE: LLY) is scheduled to participate in the UBS Biopharma Conference on November 8, 2023. Patrik Jonsson, the executive vice president, will lead a fireside chat during the event. Investors can access a live audio webcast of the chat, along with a replay available for approximately 90 days on Lilly's Investor website. The event underscores Lilly's commitment to open communication with stakeholders.
Read more →LLYLilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 2023 Eli Lilly and Company (NYSE: LLY) today announced results from both the LIBRETTO-431 Phase 3 study, which evaluated Retevmo® (selpercatinib) versus...
Eli Lilly announced significant results from the LIBRETTO-431 and LIBRETTO-531 Phase 3 studies of Retevmo (selpercatinib), demonstrating improved progression-free survival in patients with RET fusion-positive non-small cell lung cancer and RET-mutant medullary thyroid cancer. The findings were presented at the ESMO Congress 2023 and published in the New England Journal of Medicine. Notably, Retevmo showed a median PFS of 24.8 months versus 11.2 months with standard therapy in NSCLC patients and provided a 72% improvement in PFS for MTC patients. Despite its promising efficacy, the safety profile indicates potential risks that clinicians must consider.
Read more →LLYLilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2023 financial results on Thursday, Nov. 2, 2023. Lilly will also conduct a...
Eli Lilly and Company (NYSE: LLY) is set to announce its third-quarter 2023 financial results on November 2, 2023. The company will conduct a conference call at 9 a.m. Eastern time to discuss its financial performance in detail. Investors and the media will have access to a live webcast, with a replay available afterward on Lilly's website.
Read more →LLYLandmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)'s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer Eli Lilly and Company (NYSE: LLY) today announced five-year outcomes from a pre-planned analysis of the Phase 3 monarchE study evaluating two years...
Eli Lilly and Company announced positive five-year outcomes from the Phase 3 monarchE study, demonstrating that Verzenio (abemaciclib) combined with endocrine therapy significantly lowers the risk of cancer recurrence in patients with high-risk early breast cancer. The data, presented at the 2023 ESMO Congress, showed a 32% reduction in the risk of invasive disease and a 7.6% increase in invasive disease-free survival. The study reinforces Verzenio's role as the standard of care for this patient population, highlighting sustained benefits beyond the two-year treatment period.
Read more →LLYNearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two years Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced...
Eli Lilly's investigational drug, lebrikizumab, has shown promising two-year results in treating patients with moderate-to-severe atopic dermatitis. The ADjoin long-term extension study demonstrated that a significant proportion of patients maintained clear or almost clear skin, relieving itch and reducing disease severity with monthly dosing. The safety profile of lebrikizumab was consistent with previous studies, with common mild to moderate side effects reported. These findings reinforce the drug's potential as a first-line therapy for atopic dermatitis, with further presentations planned at the Fall Clinical Dermatology Conference.
Read more →LLYLilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks Detailed results from Eli Lilly and Company's (NYSE: LLY) phase 3 SURMOUNT-3 clinical trial evaluating tirzepatide in adults with obesity or...
Eli Lilly's phase 3 SURMOUNT-3 trial results reveal that tirzepatide significantly aids weight loss in adults with obesity or overweight with weight-related comorbidities. After 84 weeks, participants on tirzepatide achieved a mean weight loss of 26.6%, compared to just 3.8% for those on placebo. The trial demonstrated both the efficacy and safety of tirzepatide, which is currently under review by the FDA and EMA for treating obesity. While effective, mild to moderate gastrointestinal side effects were noted in participants taking the drug.
Read more →LLYLilly's Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab (an investigational interleukin-23p19 antagonist) met the co-primary and all major ...
Eli Lilly announced that mirikizumab, an investigational treatment for Crohn's disease, successfully met all primary and secondary endpoints in its Phase 3 VIVID-1 trial. The treatment demonstrated significant efficacy, with over half of the patients achieving clinical remission at Week 52 compared to placebo. Lilly plans to submit marketing applications for mirikizumab to the FDA and other regulatory agencies globally in 2024. While the drug showed promise, some adverse events were reported, and it did not surpass ustekinumab in endoscopic response.
Read more →LLYLilly Announces Details of Presentations at ESMO Congress 2023 Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), Retevmo® (selpercatinib; a...
Eli Lilly announced the presentation of clinical data at the upcoming ESMO Congress 2023, focusing on three key treatments: Verzenio for breast cancer, Retevmo for certain lung and thyroid cancers, and the investigational drug imlunestrant for breast cancer. Notably, the results from the Phase 3 monarchE study for Verzenio will include a five-year analysis, while Retevmo studies will present interim analyses comparing its efficacy against other therapies. These findings aim to shed light on treatment strategies and outcomes for patients with specific cancer types.
Read more →LLYLoxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that preclinical data for agents targeting KRAS G12D, multiple...
Loxo@Lilly, a subsidiary of Eli Lilly and Company, announced the presentation of preclinical data for three new oncology programs at the upcoming AACR-NCI-EORTC conference. These include a potent inhibitor targeting KRAS G12D, a pan-KRAS inhibitor, and an anti-Nectin-4 antibody drug conjugate. All three candidates are set to enter clinical trials in 2024, highlighting significant advancements in cancer treatment. Jacob Van Naarden, the president of Loxo@Lilly, emphasized the importance of these developments in addressing unmet medical needs in oncology.
Read more →LLYLilly Announces Leadership Transitions Eli Lilly and Company (NYSE: LLY) today announced changes to its executive leadership team. Mike Mason, executive vice president and president of...
Eli Lilly and Company has announced significant changes to its executive leadership team, including the retirement of Mike Mason and the appointment of Patrik Jonsson as the new president of Lilly Diabetes and Obesity. Daniel Skovronsky will take on additional responsibilities as president of Lilly Immunology. CEO David A. Ricks expressed confidence in the new leadership's ability to drive future growth and innovation in the company's product portfolio. Additionally, Leigh Ann Pusey will leave the company, leading to reassignment of her responsibilities among executives.
Read more →LLYLilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies Eli Lilly and Company (NYSE: LLY) and POINT Biopharma Global, Inc. (NASDAQ: PNT) today announced a definitive agreement for Lilly to acquire POINT, a ...
Eli Lilly and Company has announced its acquisition of POINT Biopharma Global, aimed at expanding its oncology capabilities in radioligand therapies for cancer treatment. The acquisition will involve a cash payment of $12.50 per share, valuing POINT at approximately $1.4 billion and bringing advanced therapeutic prospects for conditions such as metastatic castration-resistant prostate cancer. The merger is expected to close by the end of 2023, pending regulatory approvals and shareholder participation. CEO Jacob Van Naarden expressed optimism about integrating POINT's assets with Lilly's resources to develop new, effective cancer treatments.
Read more →LLYU.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings at Third-Party Manufacturer Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the...
Eli Lilly and Company announced that the FDA issued a complete response letter for the biologic license application of lebrikizumab, intended for the treatment of moderate-to-severe atopic dermatitis. While the letter raised no issues regarding clinical data or patient safety, it cited findings from an inspection of a third-party manufacturer. Lilly remains confident in the potential of lebrikizumab and plans to collaborate with both the FDA and the manufacturer to resolve the identified issues. The approval timeline for the drug may be impacted by these findings.
Read more →LLYUS FDA approves Jardiance® for the treatment of adults with chronic kidney disease The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in...
Jardiance® (empagliflozin) has been approved by the U.S. FDA for adults with chronic kidney disease (CKD) at risk of progression. The approval is based on findings from the EMPA-KIDNEY trial, which showed a 28% relative reduction in the risk of kidney disease progression and cardiovascular death. Jardiance is specifically not recommended for patients with type 1 diabetes or those with an eGFR below 30 mL/min/1.73 m²., emphasizing its targeted use. This approval marks the fourth for Jardiance stemming from the EMPOWER program, enhancing treatment options for CKD patients.
Read more →LLYLilly to Participate in Morgan Stanley 21st Annual Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 21st Annual Global Healthcare Conference, Sept. 11-12, 2023. Daniel Skovronsky,...
Eli Lilly and Company (NYSE: LLY) will be participating in the Morgan Stanley 21st Annual Global Healthcare Conference, set to take place on September 11-12, 2023. Daniel Skovronsky, the company's chief scientific and medical officer, is scheduled to take part in a fireside chat on September 11. Investors and interested parties will have access to a live audio webcast of the event, with a replay available for 90 days afterward.
Read more →LLYLilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-531 study evaluating Retevmo versus physician's choice of the...
Eli Lilly and Company announced topline results from the LIBRETTO-531 study, which evaluated Retevmo against multikinase inhibitors as a treatment for RET-mutant medullary thyroid cancer. The study achieved its primary endpoint of improved progression-free survival, highlighting Retevmo as a preferred initial treatment option. While the results are promising, associated adverse events were consistent with previous findings, including hepatotoxicity and interstitial lung disease. Full trial results will be shared with the medical community in future presentations.
Read more →LLYLilly Completes Acquisition of Versanis Bio Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Versanis Bio. The acquisition expands Lilly's...
Eli Lilly and Company has successfully completed its acquisition of Versanis Bio, which strengthens Lilly's portfolio by including bimagrumab, currently in a Phase 2b study for obesity treatments. The acquisition is anticipated to yield significant advancements in cardiometabolic disease therapies, as noted by Lilly executives. Notably, the deal involves potential payments totaling up to $1.925 billion based on development milestones. However, the announcement also highlights various risks associated with drug development and the potential impact on financial outcomes.
Read more →LLYLilly Completes Acquisition of Sigilon Therapeutics Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. (NASDAQ: SGTX). The...
Eli Lilly and Company has successfully completed its acquisition of Sigilon Therapeutics, enabling continued research and development of encapsulated cell therapies for type 1 diabetes. The acquisition includes an upfront cash payment and contingent value rights tied to performance milestones. Following the merger, Sigilon's common stock will be delisted, transitioning it into a wholly-owned subsidiary of Lilly. However, Lilly acknowledges inherent risks and uncertainties associated with drug development and the integration process.
Read more →LLYLilly Completes Acquisition of DICE Therapeutics Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The...
Eli Lilly and Company has finalized its acquisition of DICE Therapeutics, significantly enhancing its immunology portfolio with new oral therapeutic candidates. The tender offer for DICE shares concluded successfully, with a substantial majority of shares being tendered. The integration of DICE's innovative approaches into Lilly is expected to advance its development of treatments for chronic immunological diseases. However, there are inherent risks related to the acquisition that may impact financial results and operational stability.
Read more →LLY▲ +14.9%on this newsshared move
Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements Revenue in Q2 2023 increased 28% as a result of volume-driven growth from Mounjaro, Verzenio, Jardiance and Taltz, as well as $579.0 million from the ...
Eli Lilly and Company reported its financial results for Q2 2023, showcasing a remarkable 28% increase in revenue compared to Q2 2022, largely driven by the strong performance of Mounjaro and its Growth Products. Net income also saw a robust increase of 85%, reaching $1.76 billion, alongside significant investments in research and development. The company highlighted promising developments in its pipeline, including breakthroughs in Alzheimer's disease and obesity treatments. Looking forward, Lilly anticipates multiple product launches by year's end to enhance patient access worldwide.
Read more →LLYLilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy for Adults with Newly-Diagnosed Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy...
Eli Lilly announced that their targeted therapy Retevmo has shown to improve progression-free survival in patients with advanced RET fusion-positive non-small cell lung cancer, compared to standard chemotherapy plus a PD-1 inhibitor. This finding is based on the LIBRETTO-431 study, which met its primary endpoint according to an independent data monitoring committee. Retevmo is now officially recognized as a more effective treatment option in this specific patient population, although it is associated with various serious adverse events that require monitoring and caution. Detailed results are set to be shared at upcoming medical forums and peer-reviewed journals.
Read more →LLYTirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies Eli Lilly and Company (NYSE: LLY) announced results of two phase 3 tirzepatide studies in adults with obesity or overweight with weight-related...
Eli Lilly announced positive results from two Phase 3 trials for tirzepatide, focusing on weight loss in adults with obesity or overweight. In the SURMOUNT-3 trial, participants achieved a mean weight loss of 26.6% over 84 weeks, while the SURMOUNT-4 trial reported a similar loss of 26.0% over 88 weeks. Both studies demonstrated superiority of tirzepatide compared to placebo, with a favorable safety profile mainly consisting of mild to moderate gastrointestinal-related adverse events. The findings suggest tirzepatide could redefine weight management solutions as a chronic treatment.
Read more →LLYLilly Confirms Date and Conference Call for Second-Quarter 2023 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2023 financial results on Tuesday, Aug. 8, 2023. Lilly will also conduct a...
Eli Lilly and Company (NYSE: LLY) has scheduled the announcement of its second-quarter 2023 financial results for August 8, 2023. The company will also conduct a conference call on that day to discuss its financial performance further. Investors and the public can access the call via a live webcast, with a replay available afterward, enhancing investor communication and transparency.
Read more →LLYLilly Announces Extension of Tender Offer to Acquire DICE Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding...
Eli Lilly and Company has announced an extension of its tender offer to acquire DICE Therapeutics, raising the expiration date to August 8, 2023. The offer price remains at $48 per share, with 20.05% of shares already tendered as of July 24, 2023. The acquisition is anticipated to close in the third quarter of 2023, although it remains subject to customary closing conditions, including necessary antitrust clearance. Lilly has also disclosed potential risks that could affect the completion of the acquisition.
Read more →LLYResults from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMA Donanemab significantly slowed cognitive and functional decline for amyloid-positive early symptomatic Alzheimer's disease patients, lowering their...
Eli Lilly recently presented results from its Phase 3 TRAILBLAZER-ALZ 2 trial, showing that donanemab significantly slows cognitive decline in early symptomatic Alzheimer's disease. The study found that nearly 50% of participants did not experience clinical progression after one year, with additional benefits observed in those at earlier disease stages. FDA submission for traditional approval has been completed, with a decision expected by the end of the year. However, there are risks associated with the treatment, including potential adverse effects such as ARIA.
Read more →LLYLilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage...
Eli Lilly aims to acquire Versanis Bio, focusing on improving treatments for cardiometabolic diseases. Versanis is known for its clinical-stage asset, bimagrumab, which is being tested for efficacy in reducing fat mass while maintaining muscle composition. The deal, worth up to $1.925 billion, hinges on the achievement of certain developmental and sales milestones. Lilly anticipates the acquisition will leverage its expertise alongside Versanis's innovative approaches, potentially benefiting patients significantly. However, the acquisition is subject to typical closing conditions and faces inherent uncertainties.
Read more →LLYLilly Announces Webcast to Provide Alzheimer's Disease Update at AAIC Eli Lilly and Company (NYSE: LLY) will host a webcast on Monday, July 17, 2023 at the Alzheimer's Association International Conference. The webcast...
Eli Lilly and Company will host a webcast on July 17, 2023, during the Alzheimer's Association International Conference. The event will focus primarily on the results of the donanemab TRAILBLAZER-ALZ 2 clinical trial, providing important updates in the Alzheimer's disease landscape. Attendees will be able to access the live audio webcast and later view a replay on Lilly's Investor website.
Read more →LLYNew England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that The New England Journal of Medicine (NEJM) published...
Eli Lilly's oncology unit, Loxo@Lilly, announced that the New England Journal of Medicine has published results from the BRUIN Phase 1/2 trial, which evaluated pirtobrutinib's efficacy and safety in adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were previously treated with a BTK inhibitor. The study included 247 patients and reported a 73.3% overall response rate. While the safety profile appeared consistent with earlier studies, patients had high rates of treatment-emergent adverse events. The findings suggest potential for pirtobrutinib as a significant option for this difficult-to-treat patient group.
Read more →LLYLilly to Acquire Sigilon Therapeutics Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced a definitive agreement for Lilly to acquire Sigilon,...
Eli Lilly and Company has entered a definitive agreement to acquire Sigilon Therapeutics for approximately $34.6 million in cash plus contingent value rights that could increase the total consideration. This acquisition is expected to enhance Lilly's capabilities in developing innovative cell therapies for type 1 diabetes, leveraging their past partnership with Sigilon. Completion of the acquisition is subject to certain conditions and is anticipated to close in the third quarter of 2023.
Read more →LLYLilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight Eli Lilly and Company (NYSE: LLY) announced today new phase 2 data from retatrutide, Lilly's investigational molecule being studied for the treatment ...
Eli Lilly announced promising phase 2 results for retatrutide, an investigational obesity treatment, achieving a mean weight reduction of 17.5% at 24 weeks. In follow-up results, a significant 24.2% reduction was observed at 48 weeks. Alongside effective weight management, improvements in key cardiometabolic measures were reported. The company aims to explore retatrutide's potential further in phase 3 trials, focusing on obesity and related complications.
Read more →LLYLilly Declares Third-Quarter 2023 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2023 of $1.13 per share on outstanding...
Eli Lilly and Company has announced a quarterly dividend of $1.13 per share for the third quarter of 2023, payable on September 8, 2023. This dividend reflects the company's strong performance and commitment to возвращение value to shareholders. Additionally, Lilly’s ongoing initiatives in biotechnology and medicine aim to address significant global health challenges, including diabetes and Alzheimer's disease.
Read more →LLYLilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes Detailed results from SURMOUNT-2, a phase 3 clinical trial evaluating the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) tirzepatide (10...
Eli Lilly's tirzepatide, evaluated in the SURMOUNT-2 trial, demonstrated significant efficacy in weight reduction for adults with obesity and type 2 diabetes, achieving a mean reduction of 15.7% at 15 mg. The drug met both co-primary and key secondary endpoints, showing improvements in various cardiometabolic health indicators. Despite the promising results, gastrointestinal side effects were noted as common adverse events. Lilly has submitted the treatment for FDA approval, anticipating action by the end of 2023.
Read more →LLYLilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight Eli Lilly and Company (NYSE: LLY) announced today new phase 2 data for orforglipron, its first nonpeptide oral glucagon-like peptide-1 (GLP-1)...
Eli Lilly recently announced promising phase 2 results for orforglipron, a novel oral GLP-1 receptor agonist aimed at weight management and type 2 diabetes. The study showed significant weight reductions, achieving an average decrease of up to 14.7% after 36 weeks of treatment. Notably, gastrointestinal side effects were observed but were generally mild-to-moderate. Lilly plans to advance orforglipron into phase 3 trials for further evaluation of its efficacy and safety.
Read more →LLYUS FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and...
The U.S. FDA has approved Jardiance (empagliflozin) for treating type 2 diabetes in children aged 10 years and older, marking a critical advancement in pediatric diabetes care. This approval addresses the growing issue of type 2 diabetes among youth, with the prevalence nearly doubling in the past two decades. Results from the DINAMO trial demonstrated a significant reduction in A1c levels in young patients when Jardiance was added to their treatment regimen. However, caution is advised as the medication is not suitable for those with type 1 diabetes or severe kidney issues.
Read more →LLYLilly to present new research in the treatment of diabetes and obesity at the American Diabetes Association's® 83rd Scientific Sessions Eli Lilly and Company (NYSE: LLY) will present 40 abstracts across its diabetes and obesity portfolio and pipeline at the American Diabetes...
Eli Lilly and Company (NYSE: LLY) will present 40 abstracts at the American Diabetes Association's 83rd Scientific Sessions from June 23 to 26, focusing on diabetes and obesity treatments. This includes findings from the SURMOUNT-2 trial on tirzepatide for weight management and promising phase 2 results from investigational drugs retatrutide and orforglipron. Lilly emphasizes its commitment to enhancing treatment options for chronic diseases with its diverse pipeline. Presentations will cover the efficacy and safety profiles of these medications, highlighting their potential roles in managing obesity and type 2 diabetes.
Read more →LLYLilly Teams up with the American Diabetes Association and Adam Duvall to Launch Tap the Cap Eli Lilly and Company (NYSE: LLY) is teaming up with the American Diabetes Association® (ADA) and Adam Duvall, American professional baseball player, ...
Eli Lilly and the American Diabetes Association have launched the 'Tap the Cap' campaign to raise awareness about affordable insulin access for those living with diabetes. The campaign emphasizes Lilly's monthly insulin cap of $35 and includes contributions to ADA summer camps for children with diabetes. It features Adam Duvall, a professional baseball player and type 1 diabetes advocate, who shares his personal experiences with the condition. The initiative seeks to educate insulin users on affordability options amidst the growing concern for insulin accessibility.
Read more →LLYLilly to Acquire DICE Therapeutics to Advance Innovation in Immunology Eli Lilly and Company (NYSE: LLY) and DICE Therapeutics, Inc. (NASDAQ: DICE) today announced a definitive agreement for Lilly to acquire DICE. DICE...
Eli Lilly and Company has announced a definitive agreement to acquire DICE Therapeutics for $48 per share, totaling approximately $2.4 billion. The acquisition aims to leverage DICE's DELSCAPE technology platform to enhance Lilly's drug discovery in immunology. The deal has been approved by both companies' boards and is expected to close in Q3 2023, pending customary conditions including antitrust clearance. DICE's Board of Directors recommends that shareholders tender their shares as part of this acquisition process.
Read more →LLYFirst-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention Eli Lilly and Company (NYSE: LLY) announced results of the CHALLENGE-MIG clinical trial of Emgality® (galcanezumab-gnlm) and Nurtec® ODT (rimegepant...
Eli Lilly announced the results of the CHALLENGE-MIG clinical trial, comparing its migraine treatment Emgality to Nurtec ODT. Although Emgality showed robust efficacy, it did not surpass Nurtec on the primary endpoint of reducing monthly migraine days. Nonetheless, it performed better on key secondary endpoints and maintained a safety profile consistent with previous studies. The results highlight the ongoing efforts in migraine research and the need for accessible treatment options.
Read more →LLYLilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting New analyses from the Phase 3 monarchE trial of two years of Verzenio treatment in node-positive, high risk early breast cancer show similar efficacy ...
Eli Lilly presented new data on Verzenio (abemaciclib) and Jaypirca (pirtobrutinib) at the 2023 ASCO Annual Meeting. The analyses from the Phase 3 monarchE trial revealed that Verzenio maintains its efficacy in treating high-risk early breast cancer across different age groups, and quality of life scores were comparable to endocrine therapy alone. Updated findings from the Phase 1/2 BRUIN trial of Jaypirca showed durable efficacy in relapsed or refractory mantle cell lymphoma without newly identified safety concerns. Both treatments are demonstrating promise in their respective indications.
Read more →LLYLilly to Participate in Goldman Sachs Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 44th Annual Global Healthcare Conference, June 12-13, 2023. Anat Ashkenazi, Lilly...
Eli Lilly and Company (NYSE: LLY) is set to participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 12-13, 2023. Anat Ashkenazi, the company's executive vice president and chief financial officer, will take part in a fireside chat on June 12 at 4:20 p.m. Eastern time. Investors and interested parties can access a live audio webcast of this event on Lilly's Investor website. A recording will be available for approximately 90 days following the presentation.
Read more →LLYLilly ESG Report Highlights Progress Towards Sustainability Goals Eli Lilly and Company (NYSE: LLY) today released its latest Environmental, Social and Governance (ESG) report showing progress towards the company's...
Eli Lilly and Company (NYSE: LLY) has released its latest Environmental, Social and Governance (ESG) report, highlighting significant progress towards sustainability goals. The report details a 20% reduction in greenhouse gas emissions and notable improvements in healthcare access for patients in resource-limited settings. Additionally, the company has intensified its commitment to diversity, equity, and inclusion by increasing its spending with Black-owned businesses significantly. Lilly's sustainability strategy aims to support its mission of delivering innovative medicines globally.
Read more →LLYLilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine The New England Journal of Medicine today published detailed results from Eli Lilly and Company's (NYSE: LLY) phase 2a study of peresolimab in...
Eli Lilly and Company's phase 2a trial of peresolimab for rheumatoid arthritis has shown promising results, with the treatment meeting its primary efficacy endpoint. This trial, published in The New England Journal of Medicine, indicates a novel approach in stimulating the PD-1 pathway for RA treatment. The study found that peresolimab maintained similar rates of adverse events compared to placebo, suggesting a favorable safety profile. Despite the positive outcomes, there are cautions about the drug's regulatory approval and future consistency in results.
Read more →LLYLoxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that data from its oncology portfolio will be presented at the...
Loxo@Lilly, the oncology division of Eli Lilly and Company, announced details of presentations regarding its oncology portfolio at the upcoming 2023 European Hematology Association Annual Meeting. Key studies focus on the company's drug Jaypirca (pirtobrutinib), including its effectiveness in treating patients with B-cell malignancies. The provided data reflects findings from the BRUIN Phase 1/2 trial and highlight important safety information related to the treatment. The event is set to take place from June 8 to 11 in Frankfurt, Germany, both in-person and virtually.
Read more →LLYLilly's Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation Eli Lilly and Company (NYSE: LLY) has allocated an additional $50 million to its now $300 million Social Impact Venture Capital Portfolio, reflecting ...
Eli Lilly and Company has announced an additional $50 million allocation to its Social Impact Venture Capital Portfolio, raising the total to $300 million. This initiative is intended to foster healthcare solutions that benefit historically marginalized communities while addressing racial injustice. The portfolio includes support for venture capital firms focused on healthcare accessibility in low- and middle-income countries. Lilly's commitment since 2020 has also included funding directed towards diverse and innovative healthcare approaches for underserved populations.
Read more →LLYLilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis Eli Lilly and Company (NYSE: LLY) announced today new investigational data for mirikizumab in patients with moderately to severely active ulcerative...
Eli Lilly and Company announced new investigational data for mirikizumab as a treatment for moderately to severely active ulcerative colitis. The data includes interim Phase 2 results from pediatric patients and a new analysis from adult Phase 3 studies. The findings suggest mirikizumab may significantly improve quality of life, particularly in relation to bowel urgency symptoms. Additionally, upcoming Phase 3 studies in pediatric patients are anticipated to commence later this year, addressing a critical unmet need in this demographic.
Read more →LLY▲ +6.7%on this news
Lilly to Participate in Bank of America Securities 2023 Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Securities 2023 Healthcare Conference, May 9-11, 2023. Patrik Jonsson,...
Eli Lilly and Company (NYSE: LLY) is set to participate in the Bank of America Securities 2023 Healthcare Conference taking place from May 9-11, 2023. Patrik Jonsson, an executive vice president, will be featured in a fireside chat scheduled for May 10 at 1 p.m. Eastern time. The company is providing an audio webcast of the event, which will also have a replay available for 90 days on their investor website.
Read more →LLY▲ +6.7%on this news
Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease Eli Lilly and Company (NYSE: LLY) announced today positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slowed ...
Eli Lilly announced positive outcomes from the Phase 3 TRAILBLAZER-ALZ 2 study of donanemab, which significantly slowed cognitive decline in early Alzheimer's disease patients by 35% compared to placebo. The study met its primary and all secondary endpoints, demonstrating substantial clinical benefits. The company plans to expedite regulatory submissions in hopes of receiving FDA approval soon. Despite the promising results, the treatment is associated with risks such as ARIA-related side effects and infusion reactions, which are typical of amyloid-targeting therapies.
Read more →LLYLilly Provides $500,000 in Grants to Support Equitable Access to Education for Dreamers in Indiana To remove barriers and create more equitable, affordable post-high school education opportunities for Indiana's growing immigrant population, Eli...
Eli Lilly and Company has announced a $500,000 grant initiative aimed at providing educational assistance for Deferred Action for Childhood Arrivals (DACA) recipients in Indiana. This funding will support four local nonprofits focused on improving access to post-high school education for the state's immigrant population. Indiana currently does not offer DACA students in-state tuition, creating financial barriers to higher education. Lilly's efforts are intended to address these challenges and foster a more skilled workforce in the state.
Read more →LLYLilly Declares Second-Quarter 2023 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2023 of $1.13 per share on outstanding...
Eli Lilly and Company has announced a dividend of $1.13 per share for the second quarter of 2023. This dividend will be paid on June 9, 2023, to shareholders recorded by May 15, 2023. Lilly continues to advance its mission by pioneering new medicines aimed at significant health challenges, impacting millions of lives worldwide. The announcement reflects the company's ongoing commitment to shareholder value and innovative healthcare solutions.
Read more →LLYUp to 73% of Atopic Dermatitis Patients Taking Lilly's Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis New secondary analysis from Eli Lilly and Company's (NYSE: LLY) Phase 3 clinical development program showed patients receiving lebrikizumab who were...
Eli Lilly's lebrikizumab shows promising results in recent analyses, with up to 73% of atopic dermatitis patients achieving improved or cleared skin on their face or hands after 16 weeks of treatment. Long-term data indicates sustained effectiveness, as 80% of patients maintained their treatment benefits after one year. These findings highlight lebrikizumab's potential as a significant advancement in managing this challenging skin condition, particularly for visible areas that are often stigmatized.
Read more →LLYLilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum Revenue in Q1 2023 decreased 11% driven by a $1.47 billion decline in revenue from COVID-19 antibodies. Excluding COVID-19 antibodies, revenue in Q1...
Eli Lilly and Company (LLY) reported its first-quarter financial results for 2023, revealing a revenue decline of 11% primarily affected by the loss of COVID-19 antibody sales. However, core business growth, particularly from products like Mounjaro, contributed positively to the company’s performance. While new products are showing promising revenue contribution, overall net income and earnings per share decreased by nearly 29% year-over-year. The company continues to focus on expanding its pipeline and improving affordability for patients.
Read more →LLYLilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2 Eli Lilly and Company (NYSE: LLY) announced today that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72 weeks of ...
Eli Lilly announced that tirzepatide, administered at 10 mg and 15 mg doses, demonstrated significant weight loss in adults with obesity or overweight and type 2 diabetes in the SURMOUNT-2 trial. Participants lost up to 15.7% of their body weight, achieving co-primary and secondary objectives. The safety profile was comparable to previous studies, although some gastrointestinal side effects were reported. Lilly intends to complete FDA submission soon with expectations for regulatory approval by late 2023.
Read more →LLYLilly to Divest BAQSIMI to Amphastar In an effort to continue expanding the availability of BAQSIMI® to patients, Eli Lilly and Company (NYSE: LLY) and Amphastar Pharmaceuticals, Inc....
Eli Lilly and Amphastar Pharmaceuticals have entered an agreement for Amphastar to acquire the worldwide rights to BAQSIMI, the first nasally administered glucagon for severe hypoglycemia in diabetes patients. The deal involves an initial payment of $500 million and potential additional payments based on sales milestones. Lilly aims to enhance patient access to BAQSIMI, while Amphastar seeks to strengthen its diabetes product portfolio. The transaction is expected to close in the 2023 second or third quarter, pending customary closing conditions.
Read more →LLYLilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities Eli Lilly and Company (NYSE: LLY) announced today that it will invest an additional $1.6 billion and add another 200 new jobs at its two new...
Eli Lilly and Company (NYSE: LLY) announced a historic $1.6 billion investment in its manufacturing operations in Boone County, Indiana, which will result in the creation of 200 new highly skilled jobs. This commitment brings Lilly’s total investment to $3.7 billion in the area, highlighting the company’s significant role in the local economy. Additionally, Lilly is pledging $15 million to the Ivy Tech Foundation to establish scholarships aimed at enhancing education and training in pharmaceutical manufacturing. This move underscores Lilly's dedication to innovation and community development in Indiana.
Read more →LLYU.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the mirikizumab...
Eli Lilly and Company announced that the U.S. FDA issued a complete response letter for the biologic license application of mirikizumab for ulcerative colitis treatment. The letter cited concerns related to the proposed manufacturing process, but stated there were no issues with the clinical data or safety profile of the drug. Lilly remains confident in the efficacy of mirikizumab and is actively working with the FDA to address the issues mentioned in the response letter.
Read more →LLYLilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023. Lilly will also conduct a...
Eli Lilly and Company has announced that it will release its first-quarter 2023 financial results on April 27, 2023. Along with the announcement, the company plans to host a conference call at 10 a.m. Eastern time to discuss its financial performance in detail. The call will be accessible to investors, media, and the public via a live webcast, with a replay available afterward.
Read more →LLYLilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the American Association for Cancer...
Eli Lilly announced that it will present data from its oncology portfolio at the upcoming 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando. Among the highlights are Phase 1 clinical data for two new inhibitors targeting KRAS G12C and IDH mutations, as well as a Phase 2 study of Verzenio in prostate cancer. Additionally, preclinical data on the binding mechanism of Jaypirca™ will be shared. These presentations underscore Lilly’s continued commitment to advancing cancer therapy options.
Read more →LLYLilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease Eli Lilly and Company (NYSE:LLY) announced today that solanezumab did not slow the progression of cognitive decline due to Alzheimer's disease (AD)...
Eli Lilly announced that solanezumab failed to slow cognitive decline in participants with preclinical Alzheimer's disease in the A4 Study. The treatment did not meet its primary and secondary endpoints, indicating that targeting soluble amyloid beta is ineffective in this patient population. However, Lilly aims to leverage the data generated from this study to inform future Alzheimer's research and enhance clinical trial designs. Other investigational treatments, donanemab and remternetug, are still in Phase 3 trials and target amyloid plaques directly.
Read more →LLYUS FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes The U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) investigating a...
The FDA has accepted a supplemental New Drug Application for Jardiance (empagliflozin) to treat children aged 10 years and older with type 2 diabetes. This decision is based on positive results from the DINAMO phase III trial, which showed a significant reduction in A1c levels compared to placebo. If approved, Jardiance would offer a new oral treatment option for this underserved population, as current oral treatments are limited. The safety profile observed in the trial was consistent with previous data for Jardiance.
Read more →LLYIntensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world study Providing clinics with a coordinated, multifaceted intervention, with assessment of barriers, care pathways and feedback, improved the likelihood...
A recent study presented at the American College of Cardiology Conference revealed that a coordinated, multifaceted intervention improved the adherence to guideline-directed therapies among patients with type 2 diabetes and cardiovascular disease. The study, named COORDINATE-Diabetes, showed that patients receiving the intervention were significantly more likely to be prescribed critical medications compared to those who received usual care. This underscores the importance of collaboration among healthcare providers in managing chronic diseases effectively. Despite significant improvements in medication prescriptions, changes in surrogate outcome measures like blood pressure and cholesterol were not statistically significant.
Read more →LLYU.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Verzenio®...
Eli Lilly announced that the FDA has approved an expanded indication for Verzenio® (abemaciclib) for high-risk early breast cancer patients. This approval allows for patient selection based solely on nodal status, tumor size, and grade, without needing the Ki-67 score. Supported by data from the four-year monarchE trial, Verzenio added to endocrine therapy demonstrated a 35% reduction in recurrence risk. The update also broadens the drug’s use to include metastatic breast cancer in relevant populations.
Read more →LLYLilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month Eli Lilly and Company (NYSE: LLY) today announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin...
Eli Lilly and Company (NYSE: LLY) has announced a 70% reduction in the list prices of its commonly prescribed insulins and will cap out-of-pocket costs for patients at $35 per month. These measures aim to improve access to insulin for diabetic patients amidst concerns regarding affordability in the healthcare system. Additionally, Lilly intends to launch a public awareness campaign to inform users about these changes and various affordability solutions already in place. This initiative reflects the company's long-standing efforts to address insulin accessibility issues in the U.S. healthcare landscape.
Read more →LLYLilly to Participate in Cowen's 43rd Annual Health Care Conference Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 43rd Annual Health Care Conference on Monday, March 6, 2023. Mike Mason, executive vice ...
Eli Lilly and Company (NYSE: LLY) is set to participate in Cowen's 43rd Annual Health Care Conference on March 6, 2023. Mike Mason, the executive vice president and president of Lilly Diabetes and Obesity, will engage in a fireside chat during the event. A live audio webcast of the presentation will be accessible on Lilly's Investor website, with a replay available for 90 days after the event.
Read more →LLYLilly to Participate in SVB Securities Global Biopharma Conference Eli Lilly and Company (NYSE: LLY) will participate in the SVB Securities Global Biopharma Conference on Thursday, Feb. 16, 2023. Ilya Yuffa,...
Eli Lilly and Company (NYSE: LLY) is set to participate in the SVB Securities Global Biopharma Conference on February 16, 2023. Ilya Yuffa, the executive vice president and president of Lilly International, will be featured in a virtual fireside chat. A live audio webcast will be available for attendees, with a replay accessible for 90 days on the company's investor website.
Read more →LLYLilly to Participate in Guggenheim Oncology Conference Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Oncology Conference on Thursday, Feb. 9, 2023. Jacob Van Naarden, executive vice ...
Eli Lilly and Company is set to participate in the Guggenheim Oncology Conference on February 9, 2023. Key executives, including CEO Jacob Van Naarden, will engage in a fireside chat during the event. An audio webcast will be accessible, providing an opportunity for stakeholders and the public to follow the discussions and insights shared at the conference.
Read more →LLYLilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook Revenue in Q4 2022 decreased 9%. Excluding COVID-19 antibodies, revenue in Q4 2022 increased 5%, or 10% on a constant currency basis, driven by...
Eli Lilly and Company reported its financial results for the fourth quarter of 2022, marking a 9% decrease in total revenue year-over-year, primarily driven by lower volume and unfavorable currency impacts. Despite this decline, the company highlighted a 5% increase in revenue when excluding COVID-19 antibody sales. Executives projected significant growth for 2023, with plans to launch several new treatments and an optimistic mid-teen growth target for its core business. Additionally, key growth products contributed to a strong performance, representing a significant portion of the revenue.
Read more →LLYU.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that the U.S. Food and Drug Administration (FDA) approved...
The U.S. FDA has approved Jaypirca™ (pirtobrutinib), developed by Loxo@Lilly, as the first non-covalent BTK inhibitor for adults with relapsed or refractory mantle cell lymphoma after two lines of systemic therapy. This approval is based on data from the BRUIN Phase 1/2 trial, showing a 50% overall response rate among patients previously treated with covalent BTK inhibitors. However, further confirmation of clinical benefit is required to maintain its approval status. Jaypirca provides a new option for patients with limited alternatives, becoming available in the U.S. soon.
Read more →LLYLilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold Chain Capacity Eli Lilly and Company (NYSE: LLY) and Direct Relief today announced a new initiative to expand access to medicines in low- and middle-income...
Eli Lilly and Company has partnered with Direct Relief to improve access to medicines in low- and middle-income countries by enhancing cold chain capacity. With a $1.15 million contribution, the initiative aims to install 150 medical-grade refrigeration units at partner facilities across 17 countries. This effort supports the transportation and storage of temperature-sensitive medications, particularly insulin, ensuring they remain effective during delivery. Lilly's commitment to global health includes the broader goal of assisting 30 million people by 2030.
Read more →LLYLilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park Eli Lilly and Company (NYSE: LLY) today announced plans to invest an additional $450 million and create at least 100 new jobs to expand its...
Eli Lilly and Company has announced plans to invest an additional $450 million to expand its manufacturing facility in Research Triangle Park, North Carolina. This investment aims to enhance production capacity for incretin products that treat diabetes and is set to create at least 100 new jobs when fully operational in 2027. Lilly has committed around $4 billion to manufacturing expansions in the state since 2020, with plans to begin initial production this year. The company is focused on meeting the growing demand for its medicines and continues to prepare for potential new product launches in various therapeutic areas.
Read more →LLYUS FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) tablets, which is...
The U.S. FDA has accepted a supplemental New Drug Application for Jardiance (empagliflozin) as a treatment for chronic kidney disease (CKD). This decision is based on positive results from the EMPA-KIDNEY trial, which showed significant reductions in the risk of kidney disease progression and cardiovascular death. Jardiance is now positioned to fulfill a critical treatment gap for the approximately 37 million U.S. adults suffering from CKD. The drug was previously approved for type 2 diabetes but is now being investigated for its effects on kidney health.
Read more →LLYU.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the...
Eli Lilly announced that the FDA issued a complete response letter for the accelerated approval of donanemab, a treatment for early symptomatic Alzheimer's disease due to insufficient data on patient exposure. Despite this setback, the Phase 3 TRAILBLAZER-ALZ 2 trial remains ongoing, with data expected in Q2 2023 to support a traditional approval application. Lilly is committed to collaborating with the FDA to expedite the availability of this treatment for patients.
Read more →LLYLilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2022 financial results on Thursday, Feb. 2, 2023. Lilly will also conduct a...
Eli Lilly and Company (NYSE: LLY) has announced that it will release its fourth-quarter 2022 financial results on February 2, 2023. Alongside the announcement, the company will host a conference call at 10 a.m. Eastern time to further discuss its financial performance. Investors and the general public can access a live webcast of the call via Lilly's website, with a replay available afterward.
Read more →LLYLilly to Participate in the J.P. Morgan Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023. David A. Ricks, Lilly's...
Eli Lilly and Company (NYSE: LLY) is scheduled to participate in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023. CEO David A. Ricks will engage in a fireside chat at 6:45 p.m. Eastern time. Interested parties can access a live audio webcast on Lilly's Investor website, with a replay available for 90 days post-event.
Read more →LLYLilly and ProQR to Expand RNA Editing Collaboration Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced the expansion of their licensing and collaboration...
New agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR's Axiomer technology INDIANAPOLIS and LEIDEN, Netherlands and CAMBRIDGE, Mass. , Dec. 22, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and
Read more →LLYLilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa Eli Lilly and Company (NYSE: LLY) and EVA Pharma announced today a collaboration to deliver a sustainable supply of high-quality, affordable human...
For the first time, Lilly will supply API at a significantly reduced price along with pro-bono technical assistance, enabling EVA Pharma to manufacture and supply insulin to at least one million people in lower income countries INDIANAPOLIS and CAIRO , Dec. 14, 2022 /PRNewswire/
Read more →LLYLilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines Lilly expects to deliver strong financial and operational performance in 2023, highlighted by volume-driven revenue growth; potential launches for...
INDIANAPOLIS , Dec. 13, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its 2023 financial guidance, highlighted by expected volume-based revenue growth and increased investments to maximize future value. The company will review potential key events for th
Read more →LLYLoxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced updated clinical data from the pirtobrutinib global Phase 1/2...
Pirtobrutinib demonstrates activity across covalent BTK inhibitor pre-treated B-cell malignancies and multiple patient subgroups INDIANAPOLIS , Dec. 12, 2022 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY ), today announced updated clinical dat
Read more →LLYLilly Announces 15% Dividend Increase, First-Quarter 2023 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for the...
INDIANAPOLIS , Dec. 12, 2022 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has announced a 15% increase in its quarterly dividend and declared a dividend for the first quarter of 2023 of $1.13 per share on outstanding common stock. The dividend is
Read more →LLYPhase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes The DINAMO phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a marker of average...
INGELHEIM, Germany and RIDGEFIELD, Conn. and INDIANAPOLIS , Dec. 7, 2022 /PRNewswire/ -- The DINAMO phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a marker of average blood sugar) with Jardiance ® (empagliflozin)
Read more →LLYLilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology Eli Lilly and Company (NYSE: LLY) today announced updated results from the pivotal Phase 3 monarchE trial of adjuvant Verzenio® (abemaciclib) in...
The benefit of adjuvant Verzenio in combination with endocrine therapy continues to deepen with additional follow-up, now demonstrating an absolute improvement in invasive disease-free survival (IDFS) and distance relapse-free survival (DRFS) rates of 6.4% and 5.9% at four years,
Read more →LLYLilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ: AKUS). The acquisition...
INDIANAPOLIS , Dec. 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ: AKUS ). The acquisition expands Lilly's efforts in genetic medicines to include Akouos's portfolio of potential fir
Read more →LLYLilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease Eli Lilly and Company (NYSE: LLY) has announced that donanemab met all primary and secondary endpoints for the 6-month primary outcome analysis in...
- Brain amyloid clearance (<24.1 Centiloids) was achieved in 37.9% of donanemab-treated participants compared with 1.6% of Aduhelm ® (aducanumab-avwa)-treated patients at 6 months - Donanemab reduced brain amyloid plaque levels vs. baseline by 65.2% compared with 17.0% for Aduhe
Read more →LLYLilly and Akouos Announce Expiration of Akouos Tender Offer Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced that the tender offer to purchase all of the issued and outstanding ...
INDIANAPOLIS and BOSTON , Nov. 30, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Akouos, Inc. (NASDAQ: AKUS ) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Akouos's common stock in exchange for (a) $12.50 pe
Read more →LLYLilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2023 on Tuesday, Dec. 13, 2022. Lilly will also conduct a conference call...
INDIANAPOLIS , Nov. 29, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial guidance for 2023 on Tuesday, Dec. 13, 2022 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's
Read more →LLYLilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium Eli Lilly and Company (NYSE: LLY) today announced that study investigators will present data from its breast cancer portfolio and pipeline at the...
INDIANAPOLIS , Nov. 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that study investigators will present data from its breast cancer portfolio and pipeline at the 2022 San Antonio Breast Cancer Symposium (SABCS), to be held December 6-10, 2022 , in Sa
Read more →LLYLilly to Participate in Evercore ISI HealthCONx Conference Eli Lilly and Company (NYSE: LLY) will attend the fifth annual Evercore ISI HealthCONx Conference on Wednesday, Nov. 30, 2022. Jacob Van Naarden,...
INDIANAPOLIS , Nov. 16, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the fifth annual Evercore ISI HealthCONx Conference on Wednesday, Nov. 30 , 2022. Jacob Van Naarden, Lilly executive vice president and CEO of Loxo@Lilly, and David Hyman , M.D., chief med
Read more →LLYFDA approves Rezvoglar as second ‘interchangeable’ insulin biosimilar
The FDA has approved Eli Lilly's Rezvoglar as an interchangeable insulin biosimilar with Sanofi's Lantus, enhancing patient options and potentially lowering costs. This marks the second such approval, following Viatris and Biocon's Semglee. The move aims to address ongoing concerns about insulin pricing in the U.S.
Read more →LLYLilly to begin rollout of Tempo® Personalized Diabetes Management Platform Centralized experience supports diabetes self-management through medication reminders, education resources and insulin dose logging Data shared...
The platform consists of three key components – the Tempo Smart Button ® ; a compatible app, TempoSmart™; and a prefilled insulin pen, Tempo Pen ® – which work together to deliver personalized guidance for adults with diabetes. The Smart Button was cleared by the U.S. Food and Dr
Read more →LLYLandmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with ...
- EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice - Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any caus
Read more →LLYLoxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that study investigators will present data from the BRUIN Phase...
INDIANAPOLIS , Nov. 3, 2022 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY ), today announced that study investigators will present data from the BRUIN Phase 1/2 trial of pirtobrutinib at the American Society of Hematology (ASH) Annual Meeting t
Read more →LLYLilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress Lilly's revenue in Q3 2022 increased 2%, or 7% on a constant currency basis, primarily driven by volume growth of key growth products, partially...
INDIANAPOLIS , Nov. 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its financial results for the third quarter of 2022. "Lilly delivered another solid quarter with pipeline advancements across the portfolio, continued growth of key products, and impre
Read more →LLYLilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufacturing scholarship program and to extend research collaboration Purdue University and Eli Lilly and Company (NYSE: LLY) are establishing an innovative new pharmaceutical manufacturing scholarship program and have...
Scholarships will prioritize students from underrepresented groups, who have overcome disadvantages or are first generation to attend college Research collaboration aims to develop new methods for delivering therapies to patients INDIANAPOLIS and WEST LAFAYETTE, Ind. , Oct. 27,
Read more →LLYLilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2022 financial results on Tuesday, Nov. 1, 2022. Lilly will also conduct a...
INDIANAPOLIS , Oct. 19, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its third-quarter 2022 financial results on Tuesday, Nov. 1, 2022 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the co
Read more →LLYLilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced a definitive agreement for Lilly to acquire Akouos, a precision...
Proposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with disabling hearing loss worldwide Transaction valued at approximately $487 million plus a contingent value right for an aggregate amount up to approxima
Read more →LLYLilly Declares Fourth-Quarter 2022 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2022 of $0.98 per share on outstanding...
INDIANAPOLIS , Oct. 17, 2022 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the fourth quarter of 2022 of $0.98 per share on outstanding common stock. The dividend is payable on Dec. 9, 2022 to shareholders of record at t
Read more →LLYLilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the...
The Fast Track designation accelerates tirzepatide's path to U.S. FDA submission for the treatment of adults with obesity, or overweight with weight-related comorbidities INDIANAPOLIS , Oct. 6, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the U.S.
Read more →LLYFDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has granted approval to Retevmo® (selpercatinib, 40 mg...
Tumor-agnostic data supporting approval demonstrated an overall response rate (ORR) of 44% across multiple tumor types FDA simultaneously grants traditional approval in adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a RET gene fusion, as detec
Read more →LLYLebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials New detailed results from Eli Lilly and Company's (NYSE: LLY) Phase 3 monotherapy studies in atopic dermatitis (AD) showed investigational...
INDIANAPOLIS , Sept. 8, 2022 /PRNewswire/ -- New detailed results from Eli Lilly and Company's (NYSE: LLY ) Phase 3 monotherapy studies in atopic dermatitis (AD) showed investigational lebrikizumab provided robust and durable improvements in skin clearance and itch for patients w
Read more →LLYLilly Announces Details of Presentations at ESMO Congress 2022 Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib) and Retevmo® (selpercatinib) will be presented at ...
INDIANAPOLIS , Sept. 7, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that data from studies of Verzenio ® (abemaciclib) and Retevmo ® (selpercatinib) will be presented at the 2022 European Society for Medical Oncology (ESMO) Congress, to be held Septemb
Read more →LLYLilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, Sept. 13, 2022. Anat Ashkenazi, ...
INDIANAPOLIS , Aug. 31, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, Sept. 13 , 2022. Anat Ashkenazi, Lilly's senior vice president and chief financial officer, will participate in a fi
Read more →LLYLilly to Participate in Citi's 17th Annual BioPharma Conference Eli Lilly and Company (NYSE: LLY) will attend Citi's 17th Annual BioPharma Conference on Wednesday, Sept. 7, 2022. Daniel Skovronsky, M.D., Ph.D.,...
INDIANAPOLIS , Aug. 25, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend Citi's 17th Annual BioPharma Conference on Wednesday, Sept. 7 , 2022. Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific and medical officer, and president of Lilly Research Laborato
Read more →LLYLilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly Eli Lilly and Company (NYSE: LLY) today announced the upcoming retirement of one executive committee member, the naming of his successor, and the...
- Stephen Fry to retire at the end of 2022 - Eric Dozier named Senior Vice President, Human Resources and Diversity - Winselow Tucker to join Lilly as Senior Vice President and Chief Commercial Officer for Loxo@Lilly INDIANAPOLIS , Aug. 11, 2022 /PRNewswire/ -- Eli Lilly and C
Read more →LLYLilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience Eli Lilly and Company (NYSE: LLY) announced today the availability of a new, citrate-free formulation of Taltz® (ixekizumab) injection 80 mg/mL. The...
Since the medicine's first approval in 2016, nearly 130,000 people in the U.S. have been treated with Taltz INDIANAPOLIS , Aug. 8, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today the availability of a new, citrate-free formulation of Taltz ® (ixekizumab)
Read more →LLYLilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results Eli Lilly and Company (NYSE: LLY) will now conduct its second-quarter 2022 financial results investor conference call today at 10 a.m. Eastern time...
INDIANAPOLIS , Aug. 4, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will now conduct its second-quarter 2022 financial results investor conference call today at 10 a.m. Eastern time due to third-party technical difficulties. Investors, media and the general public can
Read more →LLYLilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements Lilly's revenue in Q2 2022 decreased 4%. On a constant currency basis, revenue decreased 1% as lower realized prices and lower Alimta revenue...
INDIANAPOLIS , Aug. 4, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its financial results for the second quarter of 2022. "We had an exciting quarter with the highly anticipated U.S. launch of Mounjaro, the first of potentially five new medicines we in
Read more →LLYLilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2022 financial results on Thursday, Aug. 4, 2022. Lilly will also conduct a...
INDIANAPOLIS , July 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its second-quarter 2022 financial results on Thursday, Aug. 4, 2022 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the
Read more →LLYLilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options Eli Lilly and Company (NYSE: LLY) today announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of...
Bebtelovimab continues to maintain neutralization against all known variants of interest and concern INDIANAPOLIS , June 29, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced a modified purchase agreement with the U.S. government to supply an additional 150
Read more →LLYLilly Declares Third-Quarter 2022 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2022 of $0.98 per share on outstanding...
INDIANAPOLIS , June 27, 2022 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the third quarter of 2022 of $0.98 per share on outstanding common stock. The dividend is payable on Sept. 9, 2022 to shareholders of record at t
Read more →LLYFDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata | Incyte
The FDA has approved OLUMIANT® (baricitinib) as the first systemic treatment for adults with severe alopecia areata. Clinical trials showed significant hair regrowth, with 32-35% of patients achieving over 80% scalp coverage. The approval marks a significant advancement for patients facing this challenging condition.
Read more →LLYEight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials Eli Lilly and Company (NYSE: LLY) today announced topline results from one-year analyses of the efficacy and safety of lebrikizumab, the company's...
80% of lebrikizumab responders maintained improvements in skin clearance and disease severity at 52 weeks; lasting improvements in itch were also observed Data supported both once every two week and once every four week maintenance dosing, with consistent and durable responses
Read more →LLYNew analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions® New data from a mechanism of action study and new analyses of the global registration program for Eli Lilly and Company's (NYSE: LLY) Mounjaro™...
Mounjaro led to significantly greater fat mass reductions compared to placebo and to injectable semaglutide 1 mg in adults with type 2 diabetes in mechanism of action study Exploratory analysis showed that Mounjaro achieved A1C and weight targets in less time than injectable sem
Read more →LLYJardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study Two analyses of the final U.S. data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study show that Jardiance®...
RIDGEFIELD, Conn. and INDIANAPOLIS , June 5, 2022 /PRNewswire/ -- Two analyses of the final U.S. data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study show that Jardiance ® (empagliflozin) was associated with a reduction in risk of hospitaliz
Read more →LLYLilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo In the phase 3 AWARD-PEDS clinical trial from Eli Lilly and Company (NYSE: LLY), Trulicity® (dulaglutide) (at 0.75 mg and 1.5 mg doses) led to...
AWARD-PEDS results presented at ADA's 82nd Scientific Sessions ® and simultaneously published in the New England Journal of Medicine demonstrate A1C reductions of up to 1.5% for Trulicity compared to placebo in this underserved population INDIANAPOLIS , June 4, 2022 /PRNewswire/
Read more →LLYLilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight Detailed results from Eli Lilly and Company's (NYSE: LLY) phase 3 SURMOUNT-1 clinical trial evaluating tirzepatide for the treatment of obesity or...
Detailed results from Lilly's first phase 3 trial in obesity or overweight presented at the American Diabetes Association's ® 82 nd Scientific Sessions ® and simultaneously published in NEJM INDIANAPOLIS , June 4, 2022 /PRNewswire/ -- Detailed results from Eli Lilly and Company'
Read more →LLYLilly to Participate in Goldman Sachs Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022. Anne White,...
INDIANAPOLIS , June 3, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14 , 2022. Anne White, senior vice president and president, Lilly Neuroscience, and Mark Mintun , senior vice pre
Read more →LLYLilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the 2022 American Society of Clinical...
INDIANAPOLIS , May 26, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that data from its oncology portfolio will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7, 2022 . The data include new analyse
Read more →LLYLilly plans to invest $2.1 billion in new manufacturing sites in Indiana Eli Lilly and Company (NYSE: LLY) plans to expand its manufacturing footprint in Indiana by investing $2.1 billion in two new manufacturing sites at...
INDIANAPOLIS , May 25, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) plans to expand its manufacturing footprint in Indiana by investing $2.1 billion in two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County . These new f
Read more →LLYFifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study In Eli Lilly and Company's (NYSE:LLY) pivotal, Phase 3 LUCENT-2 study, patients with ulcerative colitis (UC) who responded to mirikizumab at 12 weeks ...
Nearly all mirikizumab-treated patients who achieved clinical remission at one year were not taking steroids INDIANAPOLIS , May 24, 2022 /PRNewswire/ -- In Eli Lilly and Company's (NYSE: LLY ) pivotal, Phase 3 LUCENT-2 study, patients with ulcerative colitis (UC) who responded t
Read more →LLYLilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA Eli Lilly and Company (NYSE: LLY) will host a webcast on Tuesday, June 7, 2022 to discuss the company's diabetes and obesity portfolio and its...
INDIANAPOLIS , May 23, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will host a webcast on Tuesday, June 7, 2022 to discuss the company's diabetes and obesity portfolio and its presentations at the American Diabetes Association's 82nd Scientific Sessions. The webcast w
Read more →LLYLilly to Participate in UBS Global Healthcare Conference 2022 Eli Lilly and Company (NYSE: LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 24, 2022. Michael Mason, senior vice president,...
INDIANAPOLIS , May 16, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the UBS Global Healthcare Conference on Tuesday, May 24 , 2022. Michael Mason, senior vice president, president of Lilly Diabetes, will participate in a fireside chat at 8:30 a.m., Eastern
Read more →LLYFDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes The U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection, Eli Lilly and Company's (NYSE: LLY) new once-weekly GIP...
Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials While not indicated for weight loss, Mounjaro led to significantly greater weight reductions versus comparators in a key secondary endpoint Mounjaro represents the first new cla
Read more →LLYFDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today the U.S. Food and Drug Administration (FDA) has approved OLUMIANT®...
OLUMIANT is the first and only JAK inhibitor FDA-approved for the treatment of COVID-19 in certain hospitalized adults requiring various degrees of oxygen support INDIANAPOLIS , May 11, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced
Read more →LLYMary Lynne Hedley Elected to Lilly Board of Directors The Board of Directors of Eli Lilly and Company (NYSE:LLY) has elected Mary Lynne Hedley, Ph.D., as a new member, effective May 15, 2022. As a member ...
INDIANAPOLIS , May 6, 2022 /PRNewswire/ -- The Board of Directors of Eli Lilly and Company (NYSE: LLY ) has elected Mary Lynne Hedley , Ph.D., as a new member, effective May 15, 2022 . As a member of Lilly's board, she will serve on both the Science & Technology Committee and the
Read more →LLYLilly to Participate in Bank of America Securities 2022 Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Bank of America Securities 2022 Healthcare Conference, May 10-11, 2022. Daniel Skovronsky, M.D., Ph....
INDIANAPOLIS , May 3, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the Bank of America Securities 2022 Healthcare Conference, May 10-11 , 2022. Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific and medical officer, and president of Lilly Research Lab
Read more →LLYLilly Declares Second-Quarter 2022 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2022 of $0.98 per share on outstanding...
INDIANAPOLIS , May 2, 2022 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the second quarter of 2022 of $0.98 per share on outstanding common stock. The dividend is payable on June 10, 2022 to shareholders of record at th
Read more →LLYSolid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022 Lilly's revenue growth in Q1 2022 increased 15%, driven by volume growth of 20%. Excluding revenue from COVID-19 antibodies and Alimta, Q1 2022...
INDIANAPOLIS , April 28, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its financial results for the first quarter of 2022. "Lilly delivered another quarter of volume-driven revenue growth led by key products and anticipates 2022 to be an exciting year
Read more →LLYLilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1 Tirzepatide (5 mg, 10 mg, 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in topline results from Eli Lilly and...
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study 63% of participants taking tirzepatide 15 mg achieved at least 20% body weight reductions as a key secondary endpoint INDIANAPOLIS , April 28, 2022 /PRNewswire/ -- Tirzepatide (5 mg, 10 mg,
Read more →LLYTackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care Despite a similar prevalence of the chronic condition, women diagnosed with heart failure have worse outcomes compared to men. A deeper look reveals...
RIDGEFIELD, Conn. and INDIANAPOLIS , April 20, 2022 /PRNewswire/ -- Despite a similar prevalence of the chronic condition, women diagnosed with heart failure have worse outcomes compared to men. A deeper look reveals that among Black and Latina women with heart failure, negative
Read more →LLYLilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2022 financial results on Thursday, April 28, 2022. Lilly will also conduct a...
INDIANAPOLIS , April 19, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its first-quarter 2022 financial results on Thursday, April 28, 2022 . Lilly will also conduct a conference call on that day with the investment community and media to further detail th
Read more →LLYLilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined with standard-of-care topical...
Lebrikizumab significantly improved several areas of great importance to patients with atopic dermatitis, including skin and itch, in pivotal combination trial that met all primary and key secondary endpoints INDIANAPOLIS , April 11, 2022 /PRNewswire/ -- At 16 weeks, 70 percent
Read more →LLYLilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 LIBRETTO-001 trial of Retevmo® (selpercatinib 40 mg & 80 mg...
INDIANAPOLIS , April 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced updated data from the Phase 1/2 LIBRETTO-001 trial of Retevmo® (selpercatinib 40 mg & 80 mg capsules) in patients with RET fusion-positive non-small cell lung cancer (NSCLC). Retevmo (
Read more →LLYMajority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity...
Lebrikizumab rapidly improved skin and itch symptoms in four weeks INDIANAPOLIS , March 26, 2022 /PRNewswire/ -- More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75 * ) at 16 weeks
Read more →LLYNearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies Adults with severe alopecia areata (AA) who took OLUMIANT® (baricitinib) achieved significant scalp, eyelash and eyebrow hair regrowth and nearly 75% ...
New England Journal of Medicine published OLUMIANT 36-week alopecia areata data today In the pooled 52-week analysis, patients at baseline had a mean Severity of Alopecia Tool (SALT) score of 85.5 (85.5% scalp hair loss, or 14.5% scalp hair coverage); severe AA is defined as hav
Read more →LLYLilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for...
INDIANAPOLIS , March 24, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the Biologics License Application (BLA) for the investigational medicine sintilimab in
Read more →LLYJardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease The EMPA-KIDNEY trial, evaluating the effect of Jardiance® (empagliflozin) in adults with chronic kidney disease (CKD), will stop early based on a...
OXFORD, United Kingdom and RIDGEFIELD, Conn. and INDIANAPOLIS , March 16, 2022 /PRNewswire/ -- The EMPA-KIDNEY trial, evaluating the effect of Jardiance ® (empagliflozin) in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial's Indep
Read more →LLYLilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR) Eli Lilly and Company (NYSE: LLY) today announced that data from the pirtobrutinib and Verzenio® (abemaciclib) development programs will be presented ...
INDIANAPOLIS , March 8, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that data from the pirtobrutinib and Verzenio ® (abemaciclib) development programs will be presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting, April 8
Read more →LLYLilly to Participate in Barclays Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Barclays Global Healthcare Conference on Tuesday, March 15, 2022. Patrik Jonsson, Lilly...
INDIANAPOLIS , March 3, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Barclays Global Healthcare Conference on Tuesday, March 15 , 2022. Patrik Jonsson, Lilly senior vice president, president of Lilly Immunology and Lilly USA , and chief customer
Read more →LLYJardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial Adults hospitalized for acute heart failure were 36% more likely to experience a clinical benefit over 90 days if initiated on Jardiance®...
RIDGEFIELD, Conn. and INDIANAPOLIS , March 1, 2022 /PRNewswire/ -- Adults hospitalized for acute heart failure were 36% more likely to experience a clinical benefit over 90 days if initiated on Jardiance® (empagliflozin) following stabilization and prior to discharge compared wit
Read more →LLYLilly to Participate in Cowen Health Care Conference Eli Lilly and Company (NYSE: LLY) will participate in the Cowen Health Care Conference on Tuesday, March. 8, 2022. Anat Ashkenazi, Lilly senior vice...
INDIANAPOLIS , Feb. 28, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Cowen Health Care Conference on Tuesday, March. 8, 2022. Anat Ashkenazi, Lilly senior vice president and chief financial officer, will participate in a virtual fireside chat at
Read more →LLYUS FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg to reduce the risk of cardiovascular death and...
RIDGEFIELD, Conn. and INDIANAPOLIS , Feb. 24, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, Boehringer I
Read more →LLYLilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site Eli Lilly and Company (NYSE: LLY) today announced the launch of the Lilly Institute for Genetic Medicine and an investment of approximately $700...
INDIANAPOLIS , Feb. 22, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the launch of the Lilly Institute for Genetic Medicine and an investment of approximately $700 million to establish a state-of-the-art facility at a new site in the Boston Seaport. Thi
Read more →LLYNearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study Patients with moderately-to-severely active ulcerative colitis (UC) who took mirikizumab achieved statistically superior rates of clinical remission...
INDIANAPOLIS , Feb. 18, 2022 /PRNewswire/ -- Patients with moderately-to-severely active ulcerative colitis (UC) who took mirikizumab achieved statistically superior rates of clinical remission at 12 weeks compared to patients taking placebo in Eli Lilly and Company's (NYSE: LLY
Read more →LLYLilly and Breast Cancer Advocacy Organizations Collaborate to Drive Awareness of the Complexities of Early Breast Cancer and the Risk of Recurrence Breast cancer is a complex disease with many factors that influence whether the cancer will return or spread, yet few resources exist to help people...
INDIANAPOLIS , Feb. 16, 2022 /PRNewswire/ -- Breast cancer is a complex disease with many factors that influence whether the cancer will return or spread, yet few resources exist to help people diagnosed with breast cancer understand these risk factors. In recognizing the need fo
Read more →LLYLilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19 The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates...
INDIANAPOLIS , Feb. 11, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant, Eli Lilly and Company (NYSE: LLY ) announced today.
Read more →LLYLilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options Eli Lilly and Company (NYSE: LLY) today announced an agreement with the U.S. government to supply up to 600,000 doses of investigational drug...
INDIANAPOLIS , Feb. 10, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced an agreement with the U.S. government to supply up to 600,000 doses of investigational drug bebtelovimab for at least $720 million . The U.S. government will accept the doses of bebtel
Read more →LLYCynthia Cardona Elected as President of the Lilly Foundation The Eli Lilly and Company Foundation, Inc., a tax-exempt organization supported by Eli Lilly and Company (NYSE: LLY), has elected Cynthia Cardona as...
INDIANAPOLIS , Feb. 10, 2022 /PRNewswire/ -- The Eli Lilly and Company Foundation, Inc., a tax-exempt organization supported by Eli Lilly and Company (NYSE: LLY ), has elected Cynthia Cardona as its president. Additionally, Lilly has selected Cardona to serve as senior director o
Read more →LLYLilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients Eli Lilly and Company (NYSE: LLY) announced financial results for the fourth quarter and full year of 2021 today. Lilly had a remarkable year of...
INDIANAPOLIS , Feb. 3, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced financial results for the fourth quarter and full year of 2021 today. "Lilly had a remarkable year of growth and pipeline success in 2021, despite the continued hardships from the pandemic,"
Read more →LLYUNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents Eli Lilly and Company (NYSE: LLY) and UNICEF have today announced a new collaboration to help improve health outcomes for 10 million children and...
NEW YORK and INDIANAPOLIS , Feb. 2, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and UNICEF have today announced a new collaboration to help improve health outcomes for 10 million children and adolescents living with chronic, non-communicable diseases (NCDs) through 20
Read more →LLYLilly to Participate in Guggenheim Oncology Conference Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Oncology Conference on Wednesday, Feb. 9, 2022. Jake Van Naarden, CEO of Loxo...
INDIANAPOLIS , Feb. 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Guggenheim Oncology Conference on Wednesday, Feb. 9 , 2022. Jake Van Naarden, CEO of Loxo Oncology at Lilly and president, Lilly Oncology and David Hyman , M.D., chief medical o
Read more →LLYLilly announces $1 billion investment in new manufacturing facility in North Carolina Eli Lilly and Company (NYSE: LLY) plans to invest over $1 billion to create a new manufacturing site, along with nearly 600 new jobs in Concord,...
INDIANAPOLIS , Jan. 28, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) plans to invest over $1 billion to create a new manufacturing site, along with nearly 600 new jobs in Concord, North Carolina . The brand-new facility will utilize the latest technology to manufacture
Read more →LLYUpdates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) today announced updates on the Phase 3 development program for OLUMIANT® (baricitinib) in...
INDIANAPOLIS , Jan. 28, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) today announced updates on the Phase 3 development program for OLUMIANT ® (baricitinib) in adults with active systemic lupus erythematosus (also referred to as SLE and lupus
Read more →LLYLilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2021 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2021 financial results on Thursday, Feb. 3, 2022. Lilly will also...
INDIANAPOLIS , Jan. 20, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its fourth-quarter and full-year 2021 financial results on Thursday, Feb. 3, 2022 . Lilly will also conduct a conference call on that day with the investment community and media to furth
Read more →LLYLilly to Participate in the J.P. Morgan Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, Jan. 11, 2022. David A....
INDIANAPOLIS , Jan. 6, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, Jan. 11 , 2022. David A. Ricks, Lilly's chairman and CEO, will participate in a virtual fireside chat at 4:30 p
Read more →LLYLilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications Eli Lilly and Company (NYSE: LLY) has acquired exclusive rights to Entos Pharmaceuticals' Fusogenix nucleic acid delivery technology to research,...
INDIANAPOLIS and EDMONTON, AB , Jan. 6, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has acquired exclusive rights to Entos Pharmaceuticals' Fusogenix nucleic acid delivery technology to research, develop and commercialize nucleic acid products targeting the central an
Read more →LLYLilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study Lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when combined with topical corticosteroids (TCS) in people with...
INDIANAPOLIS , Dec. 21, 2021 /PRNewswire/ -- Lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when combined with topical corticosteroids (TCS) in people with moderate-to-severe atopic dermatitis (AD) in Eli Lilly and Company's (NYSE: LLY ) third pivotal P
Read more →LLY▲ +10.4%on this news
Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting Eli Lilly and Company (NYSE: LLY) is providing extensive updates across its research and development (R&D) programs to highlight the company's strong ...
INDIANAPOLIS , Dec. 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) is providing extensive updates across its research and development (R&D) programs to highlight the company's strong pipeline and potential for future growth. At an investment community meeting today,
Read more →LLYMirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022 Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary endpoint of clinical remission and all key secondary endpoints at...
INDIANAPOLIS , Dec. 14, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that mirikizumab met the primary endpoint of clinical remission and all key secondary endpoints at one year in LUCENT-2, a Phase 3 maintenance study evaluating the efficacy and safety
Read more →LLYLilly Announces 15 Percent Dividend Increase, First-Quarter 2022 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15 percent increase in its quarterly dividend and declared a dividend for ...
INDIANAPOLIS , Dec. 13, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has announced a 15 percent increase in its quarterly dividend and declared a dividend for the first quarter of 2022 of $0.98 per share on outstanding common stock. The divid
Read more →LLYLilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc. (Nasdaq: FHTX), today...
INDIANAPOLIS and CAMBRIDGE, Mass. , Dec. 13, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY ), and Foghorn Therapeutics Inc. (Nasdaq: FHTX ), today announced a strategic collaboration to create novel oncology medi
Read more →LLYLoxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced updated clinical data from the...
INDIANAPOLIS , Dec. 12, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY ), today announced updated clinical data from the pirtobrutinib global Phase 1/2 BRUIN clinical trial in patients with chronic lymphocytic leu
Read more →LLYLilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders Eli Lilly and Company (NYSE: LLY) and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to...
INDIANAPOLIS and SHANGHAI , Dec. 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders.
Read more →LLYNew Lilly Study Reveals Underappreciation of Bowel Urgency as a Symptom of Ulcerative Colitis and Highlights Communication Gap Between Healthcare Providers and Patients Eli Lilly and Company (NYSE: LLY) today announced results from the CONFIDE Study (Communicating Needs and Features of IBD Experiences) that show...
INDIANAPOLIS , Dec. 9, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced results from the CONFIDE Study (Communicating Needs and Features of IBD Experiences) that show bowel urgency – defined as the sudden or immediate need for a bowel movement – is the seco
Read more →LLYLilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12 The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab administered together...
INDIANAPOLIS , Dec. 3, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab administered together to include certain high-risk pediatric patients from birth to <12 years old, Eli Lilly
Read more →LLYLilly to Announce Initial 2022 Financial Guidance; Provide R&D Overview at Investment Community Meeting Eli Lilly and Company (NYSE: LLY) announced today that it will host a meeting for the investment community on Wednesday, Dec. 15, 2021, from 9 a.m....
INDIANAPOLIS , Dec. 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that it will host a meeting for the investment community on Wednesday, Dec. 15, 2021 , from 9 a.m. to 4 p.m., Eastern time . Earlier that day, the company will announce its initial fin
Read more →LLYEmgality® Versus Nurtec® ODT Head-to-Head Migraine Preventive Treatment Study Now Enrolling Patients Today, Eli Lilly and Company (NYSE: LLY) announced that enrollment is now open for the CHALLENGE-MIG clinical trial, the first and only head-to-head...
INDIANAPOLIS , Nov. 18, 2021 /PRNewswire/ -- Today, Eli Lilly and Company (NYSE: LLY ) announced that enrollment is now open for the CHALLENGE-MIG clinical trial, the first and only head-to-head trial comparing two anti-calcitonin gene-related peptide (CGRP) medicines for the pre
Read more →LLYLilly to Participate in Fourth Annual Evercore ISI HealthCONx Conference Eli Lilly and Company (NYSE: LLY) will participate in the fourth annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30, 2021. Daniel...
INDIANAPOLIS , Nov. 17, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the fourth annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30 , 2021. Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific and medical officer, and president of Lill
Read more →LLYUS FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Jardiance®...
RIDGEFIELD, Conn. and INDIANAPOLIS , Nov. 11 , 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Jardiance ® (empagliflozin) 10 mg, which is being investigated as a potential ne
Read more →LLYLilly announces winners of inaugural Leonard Award, a global program celebrating 100 years of innovation in diabetes care Today Eli Lilly and Company (NYSE: LLY) announced the five winners of the inaugural Leonard Award, which commemorates the 100th anniversary of the...
INDIANAPOLIS , Nov. 11, 2021 /PRNewswire/ -- Today Eli Lilly and Company (NYSE: LLY ) announced the five winners of the inaugural Leonard Award, which commemorates the 100 th anniversary of the discovery of insulin by recognizing diverse champions dedicated to advancing diabetes
Read more →LLYLilly to Participate in Wolfe Research Virtual Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Wolfe Research Virtual Healthcare Conference on Thursday, Nov. 18, 2021. Jacob Van Naarden, ...
INDIANAPOLIS , Nov. 9, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Wolfe Research Virtual Healthcare Conference on Thursday, Nov. 18 , 2021. Jacob Van Naarden, CEO of Loxo Oncology at Lilly and president, Lilly Oncology; Mark Mintun , senior vi
Read more →LLYOLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis OLUMIANT® (baricitinib) maintained a consistent safety profile in a long-term, integrated safety analysis of patients with rheumatoid arthritis (RA)...
INDIANAPOLIS , Nov. 9, 2021 /PRNewswire/ -- OLUMIANT ® (baricitinib) maintained a consistent safety profile in a long-term, integrated safety analysis of patients with rheumatoid arthritis (RA) who received OLUMIANT for 14,744 patient years of exposure, in line with previously pu
Read more →LLYJardiance® shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status Jardiance® (empagliflozin) reduced the risk for the composite primary endpoint of cardiovascular death or hospitalization for heart failure and...
RIDGEFIELD, Conn. and INDIANAPOLIS , Nov. 5, 2021 /PRNewswire/ -- Jardiance ® (empagliflozin) reduced the risk for the composite primary endpoint of cardiovascular death or hospitalization for heart failure and slowed kidney function decline in adults with heart failure with left
Read more →LLYLoxo Oncology at Lilly Announces Details of Presentations at the 2021 American Society of Hematology (ASH) Annual Meeting Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that study investigators will present...
INDIANAPOLIS , Nov. 4, 2021 /PRNewswire/ -- Loxo Oncology at Lilly , a research and development group of Eli Lilly and Company (NYSE: LLY ), today announced that study investigators will present data from the pirtobrutinib development program at the American Society of Hematology
Read more →LLYLilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the U.S. Government for the treatment or post-exposure prevention of COVID-19 Eli Lilly and Company (NYSE: LLY) today announced an additional purchase by the U.S. government for bamlanivimab with etesevimab for administration...
INDIANAPOLIS , Nov. 2, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced an additional purchase by the U.S. government for bamlanivimab with etesevimab for administration together. This neutralizing antibody therapy is authorized for emergency use for the tr
Read more →LLYLilly to Participate in Bernstein's Second Annual Operational Decisions Conference Eli Lilly and Company (NYSE: LLY) will participate in Bernstein's Second Annual Operational Decisions Conference on Thursday, Nov. 4, 2021. Jake Van...
A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations . A replay of the presentation will be available on this same website for approximately 90 days. About Eli Lilly
Read more →LLYAdditional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology Today, overall survival (OS) data from Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib) Phase 3 monarchE study were published in a Letter...
INDIANAPOLIS , Oct. 28, 2021 /PRNewswire/ -- Today, overall survival (OS) data from Eli Lilly and Company's (NYSE: LLY ) Verzenio ® (abemaciclib) Phase 3 monarchE study were published in a Letter to the Editor in the Annals of Oncology . These OS data, while immature, have been p
Read more →LLYLilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential Eli Lilly and Company (NYSE: LLY) announced financial results for the third quarter of 2021 today. Lilly demonstrated strong performance again this...
INDIANAPOLIS , Oct. 26, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced financial results for the third quarter of 2021 today. "Lilly demonstrated strong performance again this quarter. Revenue attributable to our newer medicines grew more than 35 percent and r
Read more →LLYTirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk Adults with type 2 diabetes with increased cardiovascular (CV) risk experienced superior A1C and body weight reductions from baseline across all...
INDIANAPOLIS , Oct. 19, 2021 /PRNewswire/ -- Adults with type 2 diabetes with increased cardiovascular (CV) risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared to titrated insulin glargine in detailed results from
Read more →LLYLilly Declares Fourth-Quarter 2021 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2021 of $0.85 per share on outstanding...
INDIANAPOLIS , Oct. 18, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the fourth quarter of 2021 of $0.85 per share on outstanding common stock. The dividend is payable on December 10, 2021 to shareholders of record
Read more →LLYLilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology Eli Lilly and Company (NYSE: LLY) today announced updated data from the positive Phase 3 monarchE trial evaluating the investigational use of...
INDIANAPOLIS , Oct. 14, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced updated data from the positive Phase 3 monarchE trial evaluating the investigational use of Verzenio ® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) for th
Read more →LLYFDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), in combination with endocrine...
INDIANAPOLIS , Oct. 13, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY ) Verzenio ® (abemaciclib), in combination with endocrine therapy (tamoxifen or an aromatase inhibitor), for the adjuvant treatment of adult pa
Read more →LLYLilly Confirms Date and Conference Call for Third-Quarter 2021 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2021 financial results on Tuesday, October 26, 2021. Lilly will also conduct a...
INDIANAPOLIS , Oct. 12, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its third-quarter 2021 financial results on Tuesday, October 26, 2021 . Lilly will also conduct a conference call on that day with the investment community and media to further detail th
Read more →LLYLoxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that preclinical characterization data ...
INDIANAPOLIS , Oct. 7, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY ), today announced that preclinical characterization data for two new agents, LOXO-783 and LOXO-435, will be presented at the 2021 AACR-NCI-EOR
Read more →LLYReady for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced the launch of CRMSynced™, an educational initiative that uses gamification...
RIDGEFIELD, Conn. and INDIANAPOLIS , Oct. 4, 2021 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY ) today announced the launch of CRMSynced ™ , an educational initiative that uses gamification to encourage healthcare professionals (HCPs) to prioritize a
Read more →LLYAt Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study Patients taking mirikizumab for their moderately to severely active ulcerative colitis (UC), were in symptomatic remission for up to two years as...
INDIANAPOLIS , Oct. 1, 2021 /PRNewswire/ -- Patients taking mirikizumab for their moderately to severely active ulcerative colitis (UC), were in symptomatic remission for up to two years as demonstrated in new results from Eli Lilly and Company's (NYSE: LLY ) Phase 2 study. Sympt
Read more →LLYOLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today detailed results from two pivotal Phase 3 trials (BRAVE-AA1 and...
INDIANAPOLIS , Sept. 30, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today detailed results from two pivotal Phase 3 trials (BRAVE-AA1 and BRAVE-AA2), which found once-daily OLUMIANT ® (baricitinib) 4-mg was superior to placebo in
Read more →LLYLilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study Tirzepatide led to greater improvements in liver fat content and abdominal adipose tissue compared to titrated insulin degludec in adults with type 2 ...
INDIANAPOLIS , Sept. 30, 2021 /PRNewswire/ -- Tirzepatide led to greater improvements in liver fat content and abdominal adipose tissue compared to titrated insulin degludec in adults with type 2 diabetes in an MRI sub-study of Eli Lilly and Company's (NYSE: LLY ) phase 3 SURPASS
Read more →LLYLilly's tirzepatide led to greater time in range compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 CGM sub-study All three tirzepatide doses led to more time in tight target range (71-140 mg/dL), improved glycemic variability and numerically less time in...
INDIANAPOLIS , Sept. 30, 2021 /PRNewswire/ -- All three tirzepatide doses led to more time in tight target range (71-140 mg/dL), improved glycemic variability and numerically less time in hypoglycemia compared to titrated insulin degludec in adults with type 2 diabetes in a conti
Read more →LLYLilly and Susan G. Komen® Partner to Address Disparities in Breast Cancer Outcomes Experienced By Black Women Today, Eli Lilly and Company (NYSE: LLY) and Susan G. Komen®, the world's leading breast cancer organization, launched a new multiyear program to...
INDIANAPOLIS and DALLAS , Sept. 29, 2021 /PRNewswire/ -- Today, Eli Lilly and Company (NYSE: LLY ) and Susan G. Komen ® , the world's leading breast cancer organization, launched a new multiyear program to address breast cancer health disparities experienced by Black women in the
Read more →LLYLilly again reduces list price of Insulin Lispro Injection as latest change to affordability options Eli Lilly and Company (NYSE: LLY) will lower the list price of Insulin Lispro Injection in the U.S. by an additional 40 percent effective January 1,...
INDIANAPOLIS , Sept. 28, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will lower the list price of Insulin Lispro Injection in the U.S. by an additional 40 percent effective January 1, 2022 , effectively bringing the list price down to 2008 levels. The new list price w
Read more →LLYFDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of a new indication for...
INDIANAPOLIS , Sept. 28, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of a new indication for ERBITUX ® (cetuximab injection) in combination with BRAFTOVI ® (encorafenib), marketed by
Read more →LLYNew Data from Verzenio® (abemaciclib) monarchE Study to Be Featured in ESMO Virtual Plenary New data from Eli Lilly and Company's (NYSE: LLY) monarchE study for an investigational use of Verzenio® (abemaciclib), in combination with endocrine ...
INDIANAPOLIS , Sept. 27, 2021 /PRNewswire/ -- New data from Eli Lilly and Company's (NYSE: LLY ) monarchE study for an investigational use of Verzenio ® (abemaciclib), in combination with endocrine therapy, in patients with hormone receptor-positive (HR+), human epidermal growth
Read more →LLYEli Lilly and Company Issues Voluntary Nationwide Recall of One Lot of GLUCAGON® Emergency Kit Due to Loss of Potency Eli Lilly and Company (NYSE: LLY) is voluntarily recalling lot D239382D, Expiration April 2022, of Glucagon Emergency Kit for Low Blood Sugar...
INDIANAPOLIS , Sept. 24, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) is voluntarily recalling lot D239382D, Expiration April 2022 , of Glucagon Emergency Kit for Low Blood Sugar (Glucagon for Injection, 1 mg per vial; Diluent for Glucagon, 1 mL syringe), to the consum
Read more →LLYLilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of the Note Caps for Its 3.950% Notes due 2049 and Its 4.150% Notes due 2059 Eli Lilly and Company (NYSE: LLY) announced today the early tender results of its previously announced cash tender offer for specified series of its...
INDIANAPOLIS , Sept. 21, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today the early tender results of its previously announced cash tender offer for specified series of its outstanding debt securities. Lilly also announced that it has removed the previously
Read more →LLYLilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the treatment of confirmed COVID-19 Eli Lilly and Company (NYSE: LLY) today announced a Joint Procurement Agreement with the European Commission (EC) to supply up to 220,000 doses of...
INDIANAPOLIS , Sept. 21, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced a Joint Procurement Agreement with the European Commission (EC) to supply up to 220,000 doses of bamlanivimab and etesevimab for the treatment of confirmed COVID-19 in patients aged 1
Read more →LLYLilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities Eli Lilly and Company (NYSE: LLY) announced today the pricing terms of its previously announced cash tender offer for specified series of its...
INDIANAPOLIS , Sept. 21, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today the pricing terms of its previously announced cash tender offer for specified series of its outstanding debt securities. Holders of notes subject to the tender offer who validly tend
Read more →LLYEmergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19 The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg...
INDIANAPOLIS , Sept. 16, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis (PEP) in certain individuals for
Read more →LLYLilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19 Eli Lilly and Company (NYSE: LLY) today announced an additional purchase by the U.S. government for its neutralizing antibody therapies authorized...
INDIANAPOLIS , Sept. 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced an additional purchase by the U.S. government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. As part of the agreement, Lilly will su
Read more →LLYLilly to Participate in the 2021 Cantor Virtual Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021. Patrik...
INDIANAPOLIS , Sept. 13, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28 , 2021. Patrik Jonsson, senior vice president, president of Lilly Immunology and Lilly USA , and chie
Read more →LLYLilly to Present New Data from Oncology Portfolio at ESMO Congress New data from various studies of Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), Retevmo® (selpercatinib) and CYRAMZA® (ramucirumab)...
INDIANAPOLIS , Sept. 13, 2021 /PRNewswire/ -- New data from various studies of Eli Lilly and Company's (NYSE: LLY ) Verzenio ® (abemaciclib), Retevmo ® (selpercatinib) and CYRAMZA ® (ramucirumab) will be presented at the European Society for Medical Oncology (ESMO) Congress 2021,
Read more →LLY▼ -5.8%on this newsshared move
Lilly Prices First Sustainability Bond to Advance Global ESG Strategy Eli Lilly and Company (NYSE: LLY) today announced the pricing of its first sustainability bond to advance its global environmental, social and...
INDIANAPOLIS , Sept. 9, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the pricing of its first sustainability bond to advance its global environmental, social and governance (ESG) strategy to increase access to medicines, improve lives and communities, e
Read more →LLY▼ -5.8%on this newsshared move
FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Jardiance® (empagliflozin) as an investigational treatment...
RIDGEFIELD, Conn. and INDIANAPOLIS , Sept. 9, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Jardiance ® (empagliflozin) as an investigational treatment for adults with heart failure with preserved ejection fraction (
Read more →LLYLilly Diabetes joins The Leona M. and Harry B. Helmsley Charitable Trust to pledge significant funding to Type 1 Diabetes Camps Initiative Lilly Diabetes will commit nearly $1 million over the next three years in a joint effort with The Leona M. and Harry B. Helmsley Charitable Trust to...
INDIANAPOLIS , Sept. 7, 2021 /PRNewswire/ -- Lilly Diabetes will commit nearly $1 million over the next three years in a joint effort with The Leona M. and Harry B. Helmsley Charitable Trust to promote greater access to care and resources and to inspire confidence for children li
Read more →LLYLilly Announces Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities Eli Lilly and Company (NYSE: LLY) announced today that it has commenced a cash tender offer for up to $1.5 billion combined aggregate principal...
INDIANAPOLIS , Sept. 7, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that it has commenced a cash tender offer for up to $1.5 billion combined aggregate principal amount (the " Tender Cap ") of specified series of its outstanding debt securities. Pursua
Read more →LLYLilly to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021....
INDIANAPOLIS , Sept. 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14 , 2021. Michael Mason, senior vice president, president of Lilly Diabetes, will participate in
Read more →LLYLilly to Participate in Citi's 16th Annual BioPharma Virtual Conference Eli Lilly and Company (NYSE: LLY) will participate in Citi's 16th Annual BioPharma Virtual Conference on September 8 and 9, 2021. Anat Ashkenazi,...
INDIANAPOLIS , Aug. 31, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in Citi's 16th Annual BioPharma Virtual Conference on September 8 and 9, 2021. Anat Ashkenazi, senior vice president and chief financial officer, will participate in a virtual firesid
Read more →LLYLandmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction Full results from the landmark EMPEROR-Preserved phase III trial demonstrated that Jardiance® (empagliflozin) showed an impressive 21% relative risk...
RIDGEFIELD, Conn. and INDIANAPOLIS , Aug. 27, 2021 /PRNewswire/ -- Full results from the landmark EMPEROR-Preserved phase III trial demonstrated that Jardiance ® (empagliflozin) showed an impressive 21% relative risk reduction for the composite primary endpoint of cardiovascular
Read more →LLYLilly Announces that Professor Carolyn Bertozzi has Resigned from its Board of Directors The board of directors of Eli Lilly and Company (NYSE: LLY) announced today that Carolyn R. Bertozzi, Ph.D., has resigned from her role as an...
INDIANAPOLIS , Aug. 25, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) announced today that Carolyn R. Bertozzi , Ph.D., has resigned from her role as an independent director of Lilly's board. Her resignation is in connection with Lilly's entry
Read more →LLYLilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on ...
INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif. , Aug. 25, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of
Read more →LLYUS FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction Jardiance® (empagliflozin) 10 mg has been approved by the U.S. Food and Drug Administration to reduce the risk of cardiovascular death plus...
RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 18, 2021 /PRNewswire/ -- Jardiance ® (empagliflozin) 10 mg has been approved by the U.S. Food and Drug Administration to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduc
Read more →LLYLilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units Eli Lilly and Company (NYSE: LLY) today announced executive leadership changes and the creation of neuroscience and immunology business units. These...
INDIANAPOLIS , Aug. 17, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced executive leadership changes and the creation of neuroscience and immunology business units. These changes will increase Lilly's focus on introducing breakthrough new medicines to mill
Read more →LLYFDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps The U.S. Food and Drug Administration (FDA) has approved an expanded label for Eli Lilly and Company's (NYSE: LLY) rapid-acting insulin, Lyumjev®...
INDIANAPOLIS , Aug. 16, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved an expanded label for Eli Lilly and Company's (NYSE: LLY ) rapid-acting insulin, Lyumjev ® (insulin lispro-aabc injection) 100 units/mL indicated to improve glycemic control in a
Read more →LLYLilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials Lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic...
INDIANAPOLIS , Aug. 16, 2021 /PRNewswire/ -- Lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), as measured by EASI, in Eli Lilly and Company's (NYSE: LLY ) ADvocate 1 an
Read more →LLYLilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2021. We delivered strong performance this quarter,...
INDIANAPOLIS , Aug. 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the second quarter of 2021. "We delivered strong performance this quarter, with volume-driven growth across our core business and most major geographies. We accel
Read more →LLYLilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results from an additional cohort of 101 adult patients from the...
INDIANAPOLIS , Aug. 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today results from an additional cohort of 101 adult patients from the COV-BARRIER trial. In this sub-study, patients with COVID-19 on mechanical ventilation or ext
Read more →LLYLilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline Today at the Alzheimer's Association International Conference© (AAIC© 2021), Eli Lilly and Company (NYSE: LLY) presented two new exploratory analyses ...
INDIANAPOLIS , July 29, 2021 /PRNewswire/ -- Today at the Alzheimer's Association International Conference © (AAIC © 2021), Eli Lilly and Company (NYSE: LLY ) presented two new exploratory analyses of data from the Phase 2 TRAILBLAZER-ALZ study. In the first, greater amyloid plaq
Read more →LLYFDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today the U.S. Food and Drug Administration (FDA) has broadened the Emergency...
INDIANAPOLIS , July 29, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today the U.S. Food and Drug Administration (FDA) has broadened the Emergency Use Authorization (EUA) for baricitinib to allow for treatment with or without remdes
Read more →LLYLilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive...
INDIANAPOLIS and SAN DIEGO , July 29, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY ), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development and commercializatio
Read more →LLYLilly Confirms Date and Conference Call for Second-Quarter 2021 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2021 financial results on Tuesday, August 3, 2021. Lilly will also conduct a...
INDIANAPOLIS , July 22, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its second-quarter 2021 financial results on Tuesday, August 3, 2021 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the
Read more →LLYLilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) will not meet the...
INDIANAPOLIS , July 16, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today that the U.S. Food and Drug Administration (FDA) will not meet the Prescription Drug User Fee Act (PDUFA) action date for the supplemental new drug applicati
Read more →LLYLilly and Banner Alzheimer's Institute collaborate on planned Phase 3 prevention trial of donanemab Eli Lilly and Company (NYSE: LLY) and Banner Alzheimer's Institute today announced a strategic research collaboration as part of the planned Phase 3, ...
INDIANAPOLIS and PHOENIX , July 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Banner Alzheimer's Institute today announced a strategic research collaboration as part of the planned Phase 3, randomized, placebo-controlled study evaluating donanemab in participant
Read more →LLYLilly Announces Acquisition of Protomer Technologies Eli Lilly and Company (NYSE: LLY) today announced the acquisition of Protomer Technologies ( Protomer ), a private biotech company. Protomer's...
INDIANAPOLIS , July 14, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the acquisition of Protomer Technologies ("Protomer"), a private biotech company. Protomer's proprietary peptide- and protein-engineering platform is used to identify and synthesize mo
Read more →LLYBreakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction The EMPEROR-Preserved phase III trial met its primary endpoint, establishing Jardiance® (empagliflozin) as the first and only therapy to...
RIDGEFIELD, Conn. and INDIANAPOLIS , July 6, 2021 /PRNewswire/ -- The EMPEROR-Preserved phase III trial met its primary endpoint, establishing Jardiance ® (empagliflozin) as the first and only therapy to significantly reduce the risk of the composite of cardiovascular death or ho
Read more →LLYLilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes after 40 weeks of...
INDIANAPOLIS , June 26, 2021 /PRNewswire/ -- Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes after 40 weeks of treatment in Eli Lilly and Company's (NYSE: LLY ) SURPASS-1 monotherapy clinical trial eva
Read more →LLYLilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's (NYSE: LLY)...
INDIANAPOLIS , June 24, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's (NYSE: LLY ) investigational antibody therapy for Alzheimer's disease (AD). The Breakthrough Therapy designatio
Read more →LLYLilly announces call for Leonard Award nominations as part of global initiative celebrating 100 years of insulin In honor of the 100th anniversary of the discovery of insulin, Eli Lilly and Company (NYSE: LLY) today launched the Leonard Award to recognize...
INDIANAPOLIS , June 24, 2021 /PRNewswire/ -- In honor of the 100th anniversary of the discovery of insulin, Eli Lilly and Company (NYSE: LLY ) today launched the Leonard Award to recognize diverse champions dedicated to advancing diabetes management through innovative thinking an
Read more →LLYLilly Launches Think Talk Treat Migraine™ to Help Improve Diagnosis and Treatment of Migraine Based on results from a large population-based survey, it is estimated that approximately half of people with migraine hesitate to seek care for a...
INDIANAPOLIS , June 17, 2021 /PRNewswire/ -- Based on results from a large population-based survey, it is estimated that approximately half of people with migraine hesitate to seek care for a variety of reasons, and even fewer receive a diagnosis and take the treatment they need.
Read more →LLYLilly Announces Head-to-Head Study Comparing Once-Monthly Emgality® with Every-Other-Day Nurtec® ODT for the Preventive Treatment of Migraine To advance the science of migraine treatment and aid the understanding of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs)...
The study, which is the first head-to-head clinical trial comparing two medications targeting CGRP, is a multi-site, randomized, double-blind, double-dummy, parallel-group Phase 4 study in patients who meet the International Classification of Headache Disorders (ICHD) criteria fo
Read more →LLYLilly to Participate in Guggenheim Biopharma Strategy Series Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Biopharma Strategy Series – Biopharma's Next Decade: Views from the Top on...
INDIANAPOLIS , June 14, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Guggenheim Biopharma Strategy Series – Biopharma's Next Decade: Views from the Top on Global Strategy and Innovation – on Friday, June 18, 2021 . Daniel Skovronsky , M.D., Ph.D
Read more →LLYLilly Announces Webcast to Provide Diabetes Portfolio Update at ADA Eli Lilly and Company (NYSE: LLY) will host a webcast on Thursday, July 1, 2021 to discuss the company's diabetes portfolio and its presentations at...
INDIANAPOLIS , June 11, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will host a webcast on Thursday, July 1, 2021 to discuss the company's diabetes portfolio and its presentations at the American Diabetes Association's Virtual 81st Scientific Sessions. The webcast wil
Read more →LLYLilly Announces New Clinical Data from Verzenio and Oral SERD Programs at the American Society of Clinical Oncology Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced new data for the investigational use of Verzenio® (abemaciclib) in high risk early breast cancer,...
INDIANAPOLIS , June 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced new data for the investigational use of Verzenio® (abemaciclib) in high risk early breast cancer, and for its oral selective estrogen receptor degrader (SERD) LY3484356 at the 57 th Ann
Read more →LLYLilly to Participate in Goldman Sachs Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs Healthcare Conference on June 9 and 10, 2021. Anne White, senior vice...
INDIANAPOLIS , June 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Goldman Sachs Healthcare Conference on June 9 and 10, 2021. Anne White , senior vice president and president, Lilly Oncology and Jake Van Naarden , CEO, Loxo Oncology at Lilly,
Read more →LLYLilly Reveals Critical Barriers to Optimal Migraine Care and Insights From Novel Clinical and Patient-Centric Real-World Evidence, Supporting Lilly's Preventive and Acute Treatment Portfolio at AHS 2021 To improve the understanding and advance the treatment of migraine, Eli Lilly and Company (NYSE: LLY) presented data on unmet needs in migraine from...
INDIANAPOLIS , June 3, 2021 /PRNewswire/ -- To improve the understanding and advance the treatment of migraine, Eli Lilly and Company (NYSE: LLY ) presented data on unmet needs in migraine from the OVERCOME (U.S.) study and on its portfolio of migraine medicines during the Americ
Read more →LLYTaltz® Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study Eli Lilly and Company (NYSE: LLY) will present new data from Phase 3 studies that further demonstrated the long-term efficacy and safety profile of...
INDIANAPOLIS , June 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present new data from Phase 3 studies that further demonstrated the long-term efficacy and safety profile of Taltz ® (ixekizumab) among patients with axial spondyloarthritis (axSpA). These results
Read more →LLYLilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting New data from across Eli Lilly and Company's (NYSE: LLY) oncology portfolio will be presented at the 2021 American Society of Clinical Oncology...
INDIANAPOLIS , May 19, 2021 /PRNewswire/ -- New data from across Eli Lilly and Company's (NYSE: LLY ) oncology portfolio will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 4-8, 2021 . The data include new analyses of Verzenio ® (a
Read more →LLYLilly to Participate in UBS Global Healthcare Virtual Conference Eli Lilly and Company (NYSE: LLY) will participate in the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021. Anat Ashkenazi, senior ...
INDIANAPOLIS , May 13, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021 . Anat Ashkenazi, senior vice president and chief financial officer, will participate in a virtual fireside c
Read more →LLYLilly and MiNA Therapeutics Announce saRNA Research Collaboration Eli Lilly and Company (NYSE: LLY) and MiNA Therapeutics Limited, a pioneer in RNA activation therapeutics, today announced a global research...
INDIANAPOLIS and LONDON , May 11, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and MiNA Therapeutics Limited, a pioneer in RNA activation therapeutics, today announced a global research collaboration to develop novel drug candidates using MiNA's proprietary small activ
Read more →LLYLilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes With a goal of integrating data and technology to help streamline diabetes management, Eli Lilly and Company (NYSE: LLY) signed strategic...
INDIANAPOLIS , May 6, 2021 /PRNewswire/ -- With a goal of integrating data and technology to help streamline diabetes management, Eli Lilly and Company (NYSE: LLY ) signed strategic international agreements with four companies – DexCom, Inc., Glooko Inc., myDiabby Healthcare and
Read more →LLYLilly to Participate in Bank of America Securities 2021 Health Care Conference Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Securities 2021 Health Care Conference on Tuesday, May 11, 2021. Michael...
INDIANAPOLIS , May 5, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Bank of America Securities 2021 Health Care Conference on Tuesday, May 11, 2021 . Michael Mason , senior vice president, president of Lilly Diabetes, will participate in a virtua
Read more →LLYLilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries Eli Lilly and Company (NYSE: LLY) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19...
INDIANAPOLIS , May 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pa
Read more →LLYLilly Outlines Robust Plans to Strengthen ESG Commitments Across the Globe Eli Lilly and Company (NYSE: LLY) will outline its newly updated Environmental, Social and Governance (ESG) strategy, highlighting its commitments in ...
INDIANAPOLIS , May 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will outline its newly updated Environmental, Social and Governance (ESG) strategy, highlighting its commitments in key areas during the company's Sustainability Webcast today at 10:30 am ET . In additi
Read more →LLYLilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements Eli Lilly and Company (NYSE: LLY) announces new initiatives to help COVID-19 patients in India as part of its commitment to bring the full force of...
INDIANAPOLIS , May 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announces new initiatives to help COVID-19 patients in India as part of its commitment to bring the full force of its scientific and medical expertise to attack the coronavirus pandemic around the world
Read more →LLYLilly Declares Second-Quarter 2021 Dividend and Announces Additional Share Repurchase Authorization The board of directors of Eli Lilly and Company (NYSE: LLY) (the Board ) has declared a dividend for the second quarter of 2021 of $0.85 per share...
INDIANAPOLIS , May 3, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) (the "Board") has declared a dividend for the second quarter of 2021 of $0.85 per share on outstanding common stock. The dividend is payable on June 10, 2021 to shareholders of
Read more →LLYLilly to Commit $5 Million to Direct Relief's Fund for Health Equity Eli Lilly and Company (NYSE: LLY) today announced its support of Direct Relief's Fund for Health Equity (the Fund) with a $5 million commitment over...
INDIANAPOLIS , May 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its support of Direct Relief's Fund for Health Equity (the Fund) with a $5 million commitment over the next five years. The Fund launched in March 2020 with $75 million raised against a
Read more →LLYLilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2021. $ in millions, except per share data First Quarter ...
INDIANAPOLIS , April 27, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the first quarter of 2021. Certain financial information for 2021 and 2020 is presented on both a reported and a non-GAAP basis. Some numbers in this press rele
Read more →LLYOLUMIANT® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company (NYSE:...
INDIANAPOLIS , April 23, 2021 /PRNewswire/ -- Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company (NYSE: LLY ) and Incyte's (NASDAQ: INCY ) OLUMIANT ® (baricitinib) 2-mg tablet taken once dai
Read more →LLYTaltz® Delivers More Cumulative Days with Completely Clear Skin for Adults with Psoriasis Compared to Seven Other Biologics in Novel Network Meta-Analysis Through clinical trial meta-analysis and real-world evidence, Eli Lilly and Company's (NYSE: LLY) Taltz® (ixekizumab) demonstrated greater success in ...
INDIANAPOLIS , April 23, 2021 /PRNewswire/ -- Through clinical trial meta-analysis and real-world evidence, Eli Lilly and Company's (NYSE: LLY ) Taltz ® (ixekizumab) demonstrated greater success in key measured treatment outcomes compared to other biologics in adults with moderat
Read more →LLYLilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today results from a second Phase 3 trial (BRAVE-AA1) evaluating the efficacy...
INDIANAPOLIS , April 20, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today results from a second Phase 3 trial (BRAVE-AA1) evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia ar
Read more →LLYLilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S. Eli Lilly and Company (NYSE: LLY) has requested the U.S. Food and Drug Administration (FDA) revoke the Emergency Use Authorization (EUA) for...
INDIANAPOLIS , April 16, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has requested the U.S. Food and Drug Administration (FDA) revoke the Emergency Use Authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg alone. Lilly made this request due to the evolving variant l
Read more →LLYDiogo Rau to join Lilly as Senior Vice-President and Chief Information and Digital Officer Eli Lilly and Company (NYSE: LLY) announced today that Diogo Rau will join the company on May 17, 2021 as senior vice-president and chief information ...
INDIANAPOLIS , April 12, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that Diogo Rau will join the company on May 17, 2021 as senior vice-president and chief information and digital officer. Rau succeeds Aarti Shah , whose planned retirement was announc
Read more →LLYLilly modified COVID-19 purchase agreement for bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together Eli Lilly and Company (NYSE: LLY) today announced changes to the purchase agreements with the U.S. government for its neutralizing antibody therapies ...
INDIANAPOLIS , April 12, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced changes to the purchase agreements with the U.S. government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. As part of Lilly's planne
Read more →LLYLilly Presents New Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced for the first time data from the Phase 1/2 LIBRETTO-001 trial showing treatment with Retevmo®...
INDIANAPOLIS , April 11, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced for the first time data from the Phase 1/2 LIBRETTO-001 trial showing treatment with Retevmo ® (selpercatinib) demonstrated encouraging antitumor activity and safety across RET fusion
Read more →LLYLilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once...
INDIANAPOLIS , April 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet st
Read more →LLYLilly Confirms Date and Conference Call for First-Quarter 2021 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2021 financial results on Tuesday, April 27, 2021. Lilly will also conduct a...
INDIANAPOLIS , April 6, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its first-quarter 2021 financial results on Tuesday, April 27, 2021 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the
Read more →LLYLilly to Host Sustainability Webcast to Provide Overview of Environmental, Social and Governance (ESG) Efforts Eli Lilly and Company (NYSE: LLY) will host a webcast for the investment community, media and the general public on May 4, 2021 to provide an...
INDIANAPOLIS , April 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will host a webcast for the investment community, media and the general public on May 4, 2021 to provide an overview of the company's strong commitment to sustainability efforts in the areas of Enviro
Read more →LLYSurvey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care Approximately 9 in 10 specialists agree that people with type 2 diabetes whose healthcare professionals (HCPs) collaborate tend to have better...
RIDGEFIELD, Conn. and INDIANAPOLIS, March 31, 2021 /PRNewswire/ -- Approximately 9 in 10 specialists agree that people with type 2 diabetes whose healthcare professionals (HCPs) collaborate tend to have better outcomes than those whose HCPs do not, while the top barrier to more c
Read more →LLYLilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19 Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced topline data from...
INDIANAPOLIS and SAN FRANCISCO and LONDON , March 29, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ), Vir Biotechnology, Inc. (NASDAQ: VIR ) and GlaxoSmithKline plc (LSE/NYSE: GSK ) today announced topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk ad
Read more →LLYLilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021 Eli Lilly and Company (NYSE: LLY) today announced patient-reported outcomes (PRO) for the investigational use of Verzenio® (abemaciclib) in...
INDIANAPOLIS , March 17, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced patient-reported outcomes (PRO) for the investigational use of Verzenio ® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) for the treatment of hormone recep
Read more →LLYLilly's Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase 3...
INDIANAPOLIS , March 16, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase 3 induction study evaluating the efficacy and safety of mirikizumab for the treatment of
Read more →LLYLilly's donanemab slowed Alzheimer's disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM Phase 2 TRAILBLAZER-ALZ results presented today by Eli Lilly and Company (NYSE: LLY) at the 15th International Conference on Alzheimer's & Parkinson...
INDIANAPOLIS , March 13, 2021 /PRNewswire/ -- Phase 2 TRAILBLAZER-ALZ results presented today by Eli Lilly and Company (NYSE: LLY ) at the 15th International Conference on Alzheimer's & Parkinson Diseases™ 2021 ( AD/PD™ 2021 ) held virtually March 9-14, 2021 and published simulta
Read more →LLYLilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR) Eli Lilly and Company (NYSE: LLY) today announced that data from programs across its oncology portfolio and pipeline will be presented at the 2021...
INDIANAPOLIS , March 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that data from programs across its oncology portfolio and pipeline will be presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, to be held virtually A
Read more →LLYLilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19 Eli Lilly and Company (NYSE: LLY) today announced new data from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 3 study, demonstrating ...
INDIANAPOLIS , March 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced new data from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 3 study, demonstrating bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together signifi
Read more →LLYLilly Announces Leadership Transitions in Manufacturing and Ethics and Compliance Organizations Eli Lilly and Company (NYSE: LLY) today announced the upcoming retirement of two executive committee members and the naming of their successors in...
INDIANAPOLIS , March 9, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the upcoming retirement of two executive committee members and the naming of their successors in the company's manufacturing operations and ethics and compliance organizations. Myles
Read more →LLYData from Lilly at International Conference on Alzheimer's & Parkinson Diseases 2021™ (AD/PD™ 2021) to Showcase Clinical Advances in Alzheimer's Disease Research New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer's &...
INDIANAPOLIS , March 9, 2021 /PRNewswire/ -- New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY ) at the upcoming virtual International Conference on Alzheimer's & Parkinson Diseases ™ 2021 (AD/PD ™ 2021), March 9-14, 2021 . Lilly will present detailed
Read more →LLYLilly to Participate in Barclays Global Healthcare Conference Eli Lilly and Company (NYSE:LLY) will participate in the Barclays Global Healthcare Conference on Tuesday, March 9, 2021. Patrik Jonsson, senior vice ...
INDIANAPOLIS , March 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Barclays Global Healthcare Conference on Tuesday, March 9, 2021 . Patrik Jonsson , senior vice president, president of Lilly USA and chief customer officer, will participate in
Read more →LLYLilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes Eli Lilly and Company (NYSE: LLY) and Biolojic Design Ltd. ( Biolojic ), a biotechnology company that computationally designs functional antibodies,...
INDIANAPOLIS and TEL AVIV , March 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Biolojic Design Ltd. ("Biolojic"), a biotechnology company that computationally designs functional antibodies, today announced a research collaboration and license agreement that will
Read more →LLYEMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP)...
"Today's CHMP recommendation is another important milestone in our efforts to extend access to antibody therapies for patients with COVID-19 around the world, providing a pathway for more EU countries to enable use of potentially life-saving treatments for COVID-19. In addition,
Read more →LLYLoxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that The Lancet has published data...
INDIANAPOLIS , March 5, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY ), today announced that The Lancet has published data from the pirtobrutinib (previously referred to as LOXO-305) global Phase 1/2 BRUIN clini
Read more →LLYTirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses compared to injectable semaglutide 1 mg in adults...
INDIANAPOLIS , March 4, 2021 /PRNewswire/ -- Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses compared to injectable semaglutide 1 mg in adults with type 2 diabetes in Eli Lilly and Company's (NYSE: LLY ) 40-week SURPASS-2 clinical t
Read more →LLYLilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19 The U.S. government has agreed to purchase a minimum of 100,000 doses of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, ...
INDIANAPOLIS , Feb. 26, 2021 /PRNewswire/ -- The U.S. government has agreed to purchase a minimum of 100,000 doses of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli Lilly and Company (NYSE: LLY ) announced. Bamlanivimab and etesevimab together re
Read more →LLYWelldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly's connected insulin solutions Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc's software into...
COLUMBIA, Md. and INDIANAPOLIS , Feb. 25, 2021 /PRNewswire/ -- Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY ) announced today a collaboration and licensing agreement to integrate Welldoc's software into Lilly's connected insulin solutions, currently in development. Under t
Read more →LLYLilly to Participate in Cowen Health Care Conference Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 41st Annual Health Care Conference on Thursday, March 4, 2021. Daniel...
INDIANAPOLIS , Feb. 24, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Cowen and Company 41 st Annual Health Care Conference on Thursday, March 4, 2021 . Daniel Skovronsky , M.D., Ph.D., Lilly's Chief Scientific Officer and President of Lilly Rese
Read more →LLYTirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program Tirzepatide led to significant A1C and body weight reductions from baseline in adults with type 2 diabetes in Eli Lilly and Company's (NYSE: LLY)...
INDIANAPOLIS , Feb. 17, 2021 /PRNewswire/ -- Tirzepatide led to significant A1C and body weight reductions from baseline in adults with type 2 diabetes in Eli Lilly and Company's (NYSE: LLY ) SURPASS-3 and SURPASS-5 phase 3 clinical trials after 52 weeks and 40 weeks, respectivel
Read more →LLYKimberly H. Johnson Elected to Lilly Board of Directors The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Kimberly H. Johnson as a new member, effective February 16, 2021. As a member ...
INDIANAPOLIS , Feb. 17, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has elected Kimberly H. Johnson as a new member, effective February 16, 2021 . As a member of Lilly's board, she will serve on both the Compensation Committee and the Ethics
Read more →LLYLilly To Participate in SVB Leerink Global Healthcare Conference Eli Lilly and Company (NYSE:LLY) will participate in the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021. Ilya...
INDIANAPOLIS , Feb. 11, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 . Ilya Yuffa , Lilly senior vice president and president of Lilly Bio-Medicines, will parti
Read more →LLYLilly Appoints Anat Ashkenazi Chief Financial Officer Eli Lilly and Company (NYSE: LLY) today announced the appointment of Anat Ashkenazi as senior vice president and chief financial officer. Ms....
INDIANAPOLIS , Feb. 9, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the appointment of Anat Ashkenazi as senior vice president and chief financial officer. Ms. Ashkenazi, who most recently served in the role of senior vice president, controller and chie
Read more →LLYLilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19 The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for investigational bamlanivimab (LY-CoV555) 700 mg and...
INDIANAPOLIS , Feb. 9, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for investigational bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli Lilly and Company (NYSE: LLY ) announced today. T
Read more →LLYLilly Announces Webcast to Provide Alzheimer's Disease Update at AD/PD Conference Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, March 15, 2021 to provide an update on its Alzheimer's disease program and...
INDIANAPOLIS , Feb. 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will conduct a webcast on Monday, March 15, 2021 to provide an update on its Alzheimer's disease program and discuss results from the Phase 2 TRAILBLAZER-ALZ study for donanemab being presented at the
Read more →LLYLilly to Participate in Guggenheim Healthcare Talks 2021 Oncology Day Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021. Anne White,...
INDIANAPOLIS , Feb. 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021 . Anne White , senior vice president and president, Lilly Oncology, and Jacob Van Naarden , chief exec
Read more →LLYLilly Partners with Area Health Systems to Help Enable Access to Important Antibody Infusion Therapies for COVID-19 Patients Eli Lilly and Company (NYSE: LLY) has partnered with local health systems to launch dedicated infusion center locations serving central, northern,...
INDIANAPOLIS , Feb. 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has partnered with local health systems to launch dedicated infusion center locations serving central, northern, and now southern Indiana that are intended to provide Hoosiers with access to important
Read more →LLYLilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2020. $ in millions, except per share...
INDIANAPOLIS , Jan. 29, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the fourth quarter and full year of 2020. Certain financial information for 2020 and 2019 is presented on both a reported and a non-GAAP basis. Some numbers in t
Read more →LLYLilly, Life for a Child and Beyond Type 1 advance partnership to improve diabetes care in resource-limited countries To address inequity in access to quality diabetes care for many children and young adults around the world, Eli Lilly and Company (NYSE: LLY) and...
INDIANAPOLIS and SAN FRANCISCO and SYDNEY , Jan. 28, 2021 /PRNewswire/ -- To address inequity in access to quality diabetes care for many children and young adults around the world, Eli Lilly and Company (NYSE: LLY ) and Life for a Child (LFAC) are significantly expanding their l
Read more →LLYLilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate Eli Lilly and Company (NYSE: LLY) and Asahi Kasei Pharma Corporation today announced a license agreement whereby Lilly will acquire the exclusive...
INDIANAPOLIS and TOKYO , Jan. 28, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Asahi Kasei Pharma Corporation today announced a license agreement whereby Lilly will acquire the exclusive rights for AK1780 from Asahi Kasei Pharma. AK1780 is an orally bioavailable P2
Read more →LLYLilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19 Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to...
INDIANAPOLIS and SAN FRANCISCO and LONDON , Jan. 27, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ), Vir Biotechnology, Inc. (NASDAQ: VIR ) and GlaxoSmithKline plc (LSE/NYSE: GSK ) today announced a collaboration to evaluate a combination of two COVID-19 therapies in low
Read more →LLYNew data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent Bamlanivimab (LY-CoV555) 2800 mg and etesevimab (LY-CoV016) 2800 mg together significantly reduced COVID-19-related hospitalizations and deaths...
INDIANAPOLIS , Jan. 26, 2021 /PRNewswire/ -- Bamlanivimab (LY-CoV555) 2800 mg and etesevimab (LY-CoV016) 2800 mg together significantly reduced COVID-19-related hospitalizations and deaths (collectively, "events") in high-risk patients recently diagnosed with COVID-19, meeting th
Read more →LLYLilly Completes Acquisition of Prevail Therapeutics Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The...
INDIANAPOLIS , Jan. 22, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL ). The acquisition establishes a new modality for drug discovery and development at Lilly, exten
Read more →LLYLilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities,...
INDIANAPOLIS , Jan. 21, 2021 /PRNewswire/ -- Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY ) announced. The Phase 3 BLAZE-2 COVID-19 prevention t
Read more →LLYLilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage...
INDIANAPOLIS and UTRECHT, The Netherlands , Jan. 19, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY ), and Merus N.V. (NASDAQ: MRUS ), a clinical-stage oncology company developing multi-specific antibodies, today
Read more →LLYLilly Confirms Date and Conference Call for Fourth-Quarter 2020 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2020 financial results on Friday, January 29, 2021. Lilly will also...
INDIANAPOLIS , Jan. 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its fourth-quarter and full-year 2020 financial results on Friday, January 29, 2021 . Lilly will also conduct a conference call on that day with the investment community and media to fur
Read more →LLYLilly Announces $30 Million Limited Partner Investment in Unseen Capital Health Fund Eli Lilly and Company (NYSE: LLY) today announced a $30 million limited partner investment in Unseen Capital Health Fund LP, a newly-formed venture...
INDIANAPOLIS , Jan. 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced a $30 million limited partner investment in Unseen Capital Health Fund LP, a newly-formed venture fund created by racially diverse and historically underrepresented business leaders th
Read more →LLYGabrielle Sulzberger Elected to Lilly Board of Directors The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Gabrielle Sulzberger as a new member, effective January 25, 2021. As a member ...
INDIANAPOLIS , Jan. 14, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has elected Gabrielle Sulzberger as a new member, effective January 25, 2021 . As a member of Lilly's board, she will serve on both the Audit Committee and the Ethics and Com
Read more →LLYUS FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) which is being...
RIDGEFIELD, Conn. and INDIANAPOLIS, Jan. 11, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance ® (empagliflozin) which is being investigated as a potential new treatment to reduce the risk of car
Read more →LLYLilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial Donanemab, an investigational antibody that targets a modified form of beta amyloid called N3pG, showed significant slowing of decline in a composite ...
INDIANAPOLIS , Jan. 11, 2021 /PRNewswire/ -- Donanemab, an investigational antibody that targets a modified form of beta amyloid called N3pG, showed significant slowing of decline in a composite measure of cognition and daily function in patients with early symptomatic Alzheimer'
Read more →LLYLilly to Participate in J.P. Morgan Healthcare Conference Eli Lilly and Company (NYSE:LLY) will participate in the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. David A. Ricks,...
INDIANAPOLIS , Jan. 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 . David A. Ricks , Lilly's chairman and chief executive officer, will participate in a virtual firesi
Read more →LLYLilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico Eli Lilly and Company (NYSE: LLY) today announced plans to begin a new pragmatic study of bamlanivimab (LY-CoV555) in high-risk patients with...
INDIANAPOLIS , Dec. 18, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced plans to begin a new pragmatic study of bamlanivimab (LY-CoV555) in high-risk patients with COVID-19, in collaboration with major local institutions in the state of New Mexico . Conduc
Read more →LLYLilly Announces Agreement to Acquire Prevail Therapeutics Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acquire Prevail...
INDIANAPOLIS and NEW YORK , Dec. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Prevail Therapeutics Inc. (NASDAQ: PRVL ) today announced a definitive agreement for Lilly to acquire Prevail for $22.50 per share in cash (or an aggregate of approximately $880 milli
Read more →LLYLilly Announces 2021 Financial Guidance, Updates 2020 Guidance Eli Lilly and Company (NYSE: LLY) today announced its 2021 financial guidance, highlighted by volume-based revenue growth, increased investment in...
INDIANAPOLIS , Dec. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its 2021 financial guidance, highlighted by volume-based revenue growth, increased investment in research and development, operating margin expansion and strong earnings performance. T
Read more →LLYLilly Announces 15 Percent Dividend Increase The board of directors of Eli Lilly and Company (NYSE: LLY) today announced a 15 percent increase in its quarterly dividend. The dividend for the...
INDIANAPOLIS , Dec. 14, 2020 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) today announced a 15 percent increase in its quarterly dividend. The dividend for the first quarter of 2021 will be $0.85 per share on outstanding common stock. This raises t
Read more →LLYLilly announces opening of patient enrollment for New IDEAS: Imaging Dementia - Evidence for Amyloid Scanning study Eli Lilly and Company (NYSE: LLY) today announced that qualified physicians may now enroll patients in the study New IDEAS: Imaging Dementia—Evidence ...
INDIANAPOLIS , Dec. 14, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that qualified physicians may now enroll patients in the study New IDEAS: Imaging Dementia—Evidence for Amyloid Scanning at New IDEAS-Study.org . New IDEAS builds off the historic IDEA
Read more →LLYData from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that The New England Journal of Medicine has published peer-reviewed...
INDIANAPOLIS , Dec. 11, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today that The New England Journal of Medicine has published peer-reviewed results from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National In
Read more →LLYLilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio® Eli Lilly and Company (NYSE: LLY) today announced additional data from a pre-planned primary outcome analysis from the Phase 3 monarchE trial that...
INDIANAPOLIS , Dec. 9, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced additional data from a pre-planned primary outcome analysis from the Phase 3 monarchE trial that showed Verzenio ® (abemaciclib) in combination with standard adjuvant endocrine therapy
Read more →LLYLilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes Tirzepatide led to superior A1C and body weight reductions from baseline in adults with type 2 diabetes after 40 weeks of treatment in topline...
INDIANAPOLIS , Dec. 9, 2020 /PRNewswire/ -- Tirzepatide led to superior A1C and body weight reductions from baseline in adults with type 2 diabetes after 40 weeks of treatment in topline results from Eli Lilly and Company's (NYSE: LLY ) SURPASS-1 monotherapy clinical trial evalua
Read more →LLYLilly Confirms Date and Conference Call for 2021 Financial Guidance Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2021 on Tuesday, December 15, 2020. Lilly will also conduct a conference...
INDIANAPOLIS , Dec. 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial guidance for 2021 on Tuesday, December 15, 2020 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the company
Read more →LLYLoxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology Annual Meeting Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced clinical data from the LOXO-305 global ...
INDIANAPOLIS , Dec. 7, 2020 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY ), today announced clinical data from the LOXO-305 global Phase 1/2 BRUIN clinical trial in chronic lymphocytic leukemia (CLL) and small lympho
Read more →LLYLoxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Mantle Cell Lymphoma and Non-Hodgkin Lymphomas at the American Society of Hematology (ASH) Annual Meeting Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced clinical data from the LOXO-305 global ...
INDIANAPOLIS , Dec. 5, 2020 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY ), today announced clinical data from the LOXO-305 global Phase 1/2 BRUIN clinical trial in mantle cell lymphoma (MCL) and other non-Hodgkin ly
Read more →LLYLilly and UnitedHealth Group partner on pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 Eli Lilly and Company (NYSE: LLY) and UnitedHealth Group (NYSE: UNH) today announced a partnership to conduct a pragmatic study of bamlanivimab...
INDIANAPOLIS and MINNETONKA, Minn. , Dec. 4, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and UnitedHealth Group (NYSE: UNH ) today announced a partnership to conduct a pragmatic study of bamlanivimab (LY-CoV555) in high-risk, COVID-19 infected individuals. Bamlanivim
Read more →LLYLilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19 The U.S. government has purchased 650,000 additional doses of Eli Lilly and Company's (NYSE: LLY) neutralizing antibody bamlanivimab (LY-CoV555) 700...
INDIANAPOLIS , Dec. 2, 2020 /PRNewswire/ -- The U.S. government has purchased 650,000 additional doses of Eli Lilly and Company's (NYSE: LLY ) neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. The purchase agreement is for $812.5 million and the doses will be delivered throu
Read more →LLYLilly to Participate in Evercore ISI 3rd Annual HealthCONx Conference Eli Lilly and Company (NYSE: LLY) will participate in the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1, 2020. Michael Mason,...
INDIANAPOLIS , Nov. 24, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Evercore ISI 3 rd Annual HealthCONx Conference on Tuesday, December 1, 2020 . Michael Mason , Lilly senior vice president and president of Lilly Diabetes and Connected Care, wi
Read more →LLYLilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19 Health Canada today granted authorization under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to...
INDIANAPOLIS , Nov. 20, 2020 /PRNewswire/ -- Health Canada today granted authorization under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the use of bamlanivimab (LY-CoV555) as a treatment for adults and pediatric
Read more →LLYLilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement Eli Lilly and Company (NYSE: LLY) and Precision BioSciences, Inc. (Nasdaq: DTIL) today announced a research collaboration and exclusive license...
Genome editing technologies enable precise editing of the DNA of a living organism, opening up the possibility of correcting genetic problems at their source. ARCUS is a unique, proprietary, and versatile genome editing platform with attributes including specificity, ability to m
Read more →LLYBaricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19 Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) issued an Emergency Use...
INDIANAPOLIS , Nov. 19, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today that the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the distribution and emergency use of baricitinib to be used
Read more →LLYLilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes Eli Lilly and Company (NYSE: LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery...
BURGDORF, Switzerland and INDIANAPOLIS , Nov. 19, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly's connected diabetes solutions. Und
Read more →LLYJardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial Jardiance® (empagliflozin) reduced the risk of total (first plus recurrent) cardiovascular events compared with placebo, when both were given on top...
RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 18, 2020 /PRNewswire/ -- Jardiance ® (empagliflozin) reduced the risk of total (first plus recurrent) cardiovascular events compared with placebo, when both were given on top of standard of care, in adults with type 2 diabetes and establis
Read more →LLYLilly to Participate in Wolfe Research Virtual Healthcare Conference Eli Lilly and Company (NYSE:LLY) will participate in the Wolfe Research Virtual Healthcare Conference on Wednesday, November 18, 2020. Joshua Smiley, ...
INDIANAPOLIS , Nov. 12, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Wolfe Research Virtual Healthcare Conference on Wednesday, November 18, 2020 . Joshua Smiley , senior vice president and Lilly's chief financial officer, will participate in a
Read more →LLYLilly to Participate in Bernstein Operational Decisions Conference Eli Lilly and Company (NYSE:LLY) will participate in the Bernstein Operational Decisions Conference on Monday, November 16, 2020. Andrew Adams,...
A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations . A replay of the presentation will be available on this same website for approximately 90 days. About Eli Lilly
Read more →LLYLilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Friday, November 20, 2020 to provide an overview of the tirzepatide Phase 3 type 2...
INDIANAPOLIS , Nov. 11, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will conduct a webcast on Friday, November 20, 2020 to provide an overview of the tirzepatide Phase 3 type 2 diabetes clinical trial program in preparation for five future Phase 3 top-line data disclo
Read more →LLYLilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19 The U.S. Food and Drug Administration (FDA) today granted Emergency Use Authorization (EUA) for Eli Lilly and Company's (NYSE: LLY) investigational...
INDIANAPOLIS , Nov. 9 , 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today granted Emergency Use Authorization (EUA) for Eli Lilly and Company's (NYSE: LLY ) investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. Bamlanivimab is authorized for
Read more →LLYAarti Shah to Retire as Lilly Chief Information and Digital Officer Eli Lilly and Company (NYSE: LLY) announced today that Aarti Shah, Ph.D., senior vice president and chief information and digital officer, will...
INDIANAPOLIS , Nov. 5, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that Aarti Shah , Ph.D., senior vice president and chief information and digital officer, will retire in the first half of 2021 after 27 years of service with the company. A search is n
Read more →LLYLoxo Oncology at Lilly Announces Details of LOXO-305 Presentations at the 2020 American Society of Hematology (ASH) Annual Meeting Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that study investigators will present...
INDIANAPOLIS , Nov. 5, 2020 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY ), today announced that study investigators will present data from the LOXO-305 development program at the American Society of Hematology (ASH)
Read more →LLYACR 2020: Lilly and Incyte Highlight Positive Data for Olumiant® in Rheumatoid Arthritis Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today positive data for Olumiant® (baricitinib) will be presented at ACR...
INDIANAPOLIS , Nov. 2, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today positive data for Olumiant ® (baricitinib) will be presented at ACR Convergence 2020, the American College of Rheumatology's virtual annual meeting taking pla
Read more →LLYEADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib will be presented at the 29th annual European...
INDIANAPOLIS , Oct. 31, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today new data for baricitinib will be presented at the 29 th annual European Academy of Dermatology and Venereology (EADV) Congress taking place virtually October
Read more →LLYFall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT®) will be presented at the ...
INDIANAPOLIS , Oct. 30, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-Novemb
Read more →LLYNew Data at EADV 2020 Confirm Taltz® (ixekizumab) Demonstrates Sustained Long-Term Efficacy in Patients with Psoriasis and Psoriatic Arthritis Eli Lilly and Company (NYSE: LLY) announced today it will share new Taltz® (ixekizumab) data from multiple long-term and post-hoc analyses that...
INDIANAPOLIS , Oct. 29, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today it will share new Taltz ® (ixekizumab) data from multiple long-term and post-hoc analyses that indicate sustained efficacy in patients with psoriasis and psoriatic arthritis. Notably,
Read more →LLYData for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine The New England Journal of Medicine has published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of Eli ...
INDIANAPOLIS , Oct. 28, 2020 /PRNewswire/ -- The New England Journal of Medicine has published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of Eli Lilly and Company's (NYSE: LLY ) bamlanivimab (LY-CoV555) – a neutralizing antibody –
Read more →LLYLilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19 Eli Lilly and Company (NYSE: LLY) announced today an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab (LY-CoV555)...
INDIANAPOLIS , Oct. 28, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab (LY-CoV555) 700 mg, an investigational neutralizing antibody, for $375 million . The U.S. governme
Read more →LLYLilly Reports Third-Quarter Financial Results, Updates Guidance Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2020. $ in millions, except per share data Third Quarter ...
INDIANAPOLIS , Oct. 27, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the third quarter of 2020. Certain financial information for 2020 and 2019 is presented on both a reported and a non-GAAP basis. Some numbers in this press relea
Read more →LLYNew Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status Findings from a new exploratory sub-analysis of the EMPEROR-Reduced phase III trial showed that Jardiance® (empagliflozin) reduced the risk of...
RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 23, 2020 /PRNewswire/ -- Findings from a new exploratory sub-analysis of the EMPEROR-Reduced phase III trial showed that Jardiance ® (empagliflozin) reduced the risk of adverse cardiovascular and kidney events in adults with heart failure
Read more →LLYLilly Declares Fourth-Quarter 2020 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2020 of $0.74 per share on outstanding...
INDIANAPOLIS , Oct. 19, 2020 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the fourth quarter of 2020 of $0.74 per share on outstanding common stock. The dividend is payable December 10, 2020 , to shareholders of record
Read more →LLYLilly Announces Agreement to Acquire Disarm Therapeutics Eli Lilly and Company (NYSE: LLY) today announced a definitive agreement to acquire Disarm Therapeutics, a privately-held biotechnology company...
INDIANAPOLIS and CAMBRIDGE, Mass. , Oct. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced a definitive agreement to acquire Disarm Therapeutics, a privately-held biotechnology company creating a new class of disease-modifying therapeutics for patients w
Read more →LLYMirikizumab Shows Continued Symptom Improvement and Reduction of Intestinal Inflammation in Patients with Crohn's Disease in 52-Week Phase 2 Trial Eli Lilly and Company (NYSE:LLY) announced today new efficacy and safety data from the Phase 2 SERENITY study evaluating mirikizumab in patients with ...
INDIANAPOLIS , Oct. 12, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today new efficacy and safety data from the Phase 2 SERENITY study evaluating mirikizumab in patients with moderately to severely active Crohn's disease, a form of inflammatory bowel disease
Read more →LLYLilly's OVERCOME Study Reveals Nearly 80% of People Reported Improvement in Their Migraine Since Starting a CGRP Monoclonal Antibody for Preventive Treatment Nearly 80% of people taking calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) for the preventive treatment of migraine reported their ...
INDIANAPOLIS , Oct. 9, 2020 /PRNewswire/ -- Nearly 80% of people taking calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) for the preventive treatment of migraine reported their migraine as "better" overall since starting their medication, according to a web-based
Read more →LLYLilly Confirms Date and Conference Call for Third-Quarter 2020 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2020 financial results on Tuesday, October 27, 2020. Lilly will also conduct a...
INDIANAPOLIS , Oct. 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its third-quarter 2020 financial results on Tuesday, October 27, 2020 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the
Read more →LLYBaricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) are sharing additional data showing baricitinib in combination with remdesivir reduced...
INDIANAPOLIS , Oct. 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) are sharing additional data showing baricitinib in combination with remdesivir reduced time to recovery and improved clinical outcomes for patients with COVID-19 infection co
Read more →LLYIndy Racial Equity Pledge Launches to Drive Accountability, Action and Progress on Racial Equity A local coalition of corporate and civic organizations has launched the Indy Racial Equity Pledge to hold their organizations accountable for driving ...
INDIANAPOLIS , Oct. 8, 2020 /PRNewswire/ -- A local coalition of corporate and civic organizations has launched the Indy Racial Equity Pledge to hold their organizations accountable for driving measurable progress in advancing racial equity for African Americans in Central Indian
Read more →LLYLilly Announces Arrangement for Supply of Potential COVID-19 Antibody Therapy for Low- and Middle-Income Countries Eli Lilly and Company (NYSE: LLY) and the Bill & Melinda Gates Foundation, as part of the COVID-19 Therapeutics Accelerator, have entered into an...
INDIANAPOLIS , Oct. 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and the Bill & Melinda Gates Foundation, as part of the COVID-19 Therapeutics Accelerator, have entered into an agreement to facilitate access to future Lilly therapeutic antibodies under development f
Read more →LLYLilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs Eli Lilly and Company (NYSE: LLY) today announced additional details on its SARS-CoV-2 neutralizing antibody programs – including interim data on...
INDIANAPOLIS , Oct. 7, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced additional details on its SARS-CoV-2 neutralizing antibody programs – including interim data on combination therapy in recently diagnosed patients with mild-to-moderate COVID-19 – and p
Read more →LLYLilly and Dexcom team up on new program to help improve diabetes management Eli Lilly and Company (NYSE: LLY) and DexCom, Inc. (NASDAQ: DXCM) announced today a joint program for U.S. healthcare providers (HCPs) about Lilly's...
INDIANAPOLIS and SAN DIEGO , Oct. 7, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and DexCom, Inc. (NASDAQ: DXCM ) announced today a joint program for U.S. healthcare providers (HCPs) about Lilly's new rapid-acting mealtime insulin Lyumjev ™ (insulin lispro-aabc inject
Read more →LLYREYVOW® (lasmiditan) C-V Demonstrated Superior Pain Freedom At 2 Hours in At Least 2 of 3 Migraine Attacks in New Phase 3 Consistency of Effect Study Adults who took REYVOW® (lasmiditan) C-V for their migraine attacks at doses of 100 mg or 200 mg had 3.8 and 7.2 times greater odds, respectively, of ...
INDIANAPOLIS , Oct. 6, 2020 /PRNewswire/ -- Adults who took REYVOW ® (lasmiditan) C-V for their migraine attacks at doses of 100 mg or 200 mg had 3.8 and 7.2 times greater odds, respectively, of achieving superior pain freedom at 2 hours post treatment compared to those taking pl
Read more →LLYVerzenio® Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer Eli Lilly and Company (NYSE: LLY) today announced Verzenio® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) significantly...
INDIANAPOLIS , Sept. 20, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced Verzenio ® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) significantly decreased the risk of breast cancer recurrence by 25 percent compared to standard a
Read more →LLYCHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products ...
INDIANAPOLIS , Sept. 18, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for baricitinib for the treat
Read more →LLYLilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the...
INDIANAPOLIS and THOUSAND OAKS, Calif. , Sept. 17, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Amgen (NASDAQ: AMGN ) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly's potential COVID-1
Read more →LLYLilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting Eli Lilly and Company (NYSE: LLY) today announced proof of concept data from an interim analysis of the BLAZE-1 clinical trial, showing a reduced...
INDIANAPOLIS , Sept. 16, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced proof of concept data from an interim analysis of the BLAZE-1 clinical trial, showing a reduced rate of hospitalization for patients treated with LY-CoV555. The randomized, double-bli
Read more →LLYLilly Launches Digital Health Open Innovation Challenge to Help Transform Atopic Dermatitis Care Eli Lilly and Company (NYSE: LLY) has launched an open innovation challenge for individuals and teams across the United States to submit inspiring...
INDIANAPOLIS , Sept. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has launched an open innovation challenge for individuals and teams across the United States to submit inspiring digital health solutions that can help make life better for people living with atopic
Read more →LLYUS FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of Jardiance® (empagliflozin) to prevent...
RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 15, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of Jardiance® (empagliflozin) to prevent hospitalization for heart failure and reduce the risk of mortality in pat
Read more →LLYBaricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) ...
INDIANAPOLIS , Sept. 14, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), pa
Read more →LLYLilly to Participate in Cantor Fitzgerald Virtual Global Healthcare Conference Eli Lilly and Company (NYSE:LLY) will participate in the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020....
INDIANAPOLIS , Sept. 11, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020 . Joshua Smiley , senior vice president and Lilly's chief financial officer, will partic
Read more →LLYLilly to Participate in Morgan Stanley Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, September 16, 2020. Joshua...
INDIANAPOLIS , Sept. 11, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, September 16, 2020 . Joshua Smiley , senior vice president and Lilly's chief financial officer, will participate in a
Read more →LLYREYVOW® (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study Adults who took REYVOW® (lasmiditan) C-V for their migraine attacks at doses of 100 mg or 200 mg had 3.8 and 4.6 times greater odds, respectively, of ...
INDIANAPOLIS , Sept. 11, 2020 /PRNewswire/ -- Adults who took REYVOW® (lasmiditan) C-V for their migraine attacks at doses of 100 mg or 200 mg had 3.8 and 4.6 times greater odds, respectively, of achieving pain freedom at 2 hours compared to those taking placebo (co-primary endpo
Read more →LLYLilly commits Insulin Value Program, featuring $35 copay card, to suite of affordability solutions for people with diabetes Eli Lilly and Company (NYSE: LLY), which introduced the Lilly Insulin Value Program $35 copay card in April 2020 to help people struggling...
INDIANAPOLIS , Sept. 10, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ), which introduced the Lilly Insulin Value Program $35 copay card in April 2020 to help people struggling financially during the COVID-19 crisis, today announced the program has been added to the comp
Read more →LLYLilly Oncology to Showcase New Data from Robust Cancer Research Pipeline at ESMO Virtual Congress 2020 Data from 20 studies across Eli Lilly and Company's (NYSE: LLY) oncology product portfolio will be presented at the European Society for Medical...
INDIANAPOLIS , Sept. 10, 2020 /PRNewswire/ -- Data from 20 studies across Eli Lilly and Company's (NYSE: LLY ) oncology product portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress, September 19-21, 2020 . The data include positive resu
Read more →LLYLilly Announces Webcast to Discuss ESMO 2020 Presentations Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, September 21, 2020 to discuss the company's presentations at the 2020 European...
INDIANAPOLIS , Sept. 10, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will conduct a webcast on Monday, September 21, 2020 to discuss the company's presentations at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress. The webcast will begin at 3:00 p
Read more →LLYLilly Announces Leadership Changes Eli Lilly and Company (NYSE: LLY) announced today that Patrik Jonsson, senior vice president and president of Lilly Bio-Medicines, is being named to...
INDIANAPOLIS , Sept. 9, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that Patrik Jonsson , senior vice president and president of Lilly Bio-Medicines, is being named to the new role of senior vice president, president of Lilly USA , and Chief Customer O
Read more →LLYFDA approves additional doses of Trulicity® (dulaglutide) for the treatment of type 2 diabetes The U.S. Food and Drug Administration (FDA) today approved two additional doses of Eli Lilly and Company's (NYSE: LLY) Trulicity® (dulaglutide). The...
INDIANAPOLIS , Sept. 3, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today approved two additional doses of Eli Lilly and Company's (NYSE: LLY ) Trulicity ® (dulaglutide). The approval expands the label of once-weekly Trulicity to include 3.0 mg and 4.5 mg dos
Read more →LLYJardiance® reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure with reduced ejection fraction Full results from the EMPEROR-Reduced phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, showed...
RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 29, 2020 /PRNewswire/ -- Full results from the EMPEROR-Reduced phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, showed that Jardiance ® (empagliflozin) was associated with a significan
Read more →LLYNew England Journal of Medicine Publishes Phase 1/2 Data for Retevmo™ (selpercatinib) in Advanced RET-Driven Lung and Thyroid Cancers Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine (NEJM) published Phase 1/2 study results of the...
INDIANAPOLIS , Aug. 27, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the New England Journal of Medicine ( NEJM ) published Phase 1/2 study results of the registrational trial for Retevmo™ (selpercatinib), the first and only therapy specifically in
Read more →LLYLilly and Innovent Announce Global Expansion of TYVYT Licensing Agreement Eli Lilly and Company (NYSE: LLY) and Innovent Biologics, Inc. (HKEX: 01801) today announced a global expansion of their strategic alliance for...
INDIANAPOLIS and SUZHOU, China , Aug. 18, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Innovent Biologics, Inc. (HKEX: 01801) today announced a global expansion of their strategic alliance for TYVYT ® (sintilimab injection), an anti-PD-1 monoclonal antibody immuno-
Read more →LLYLilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID) Eli Lilly and Company (NYSE: LLY) today announced the initiation of BLAZE-2, a Phase 3 trial studying LY-CoV555 for the prevention of SARS-CoV-2...
INDIANAPOLIS , Aug. 3, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the initiation of BLAZE-2, a Phase 3 trial studying LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19 in residents and staff at long-term care facilities in the U.S. (sk
Read more →LLYLilly Reports Second-Quarter Financial Results, Raises EPS Guidance Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2020. $ in millions, except per share data Second...
INDIANAPOLIS , July 30, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the second quarter of 2020. Certain financial information for 2020 and 2019 is presented on both a reported and a non-GAAP basis. Some numbers in this press rele
Read more →LLYJardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes Positive top-line results from the EMPEROR-Reduced phase III trial in adults with heart failure with reduced ejection fraction, with and without...
RIDGEFIELD, Conn. and INDIANAPOLIS, July 30, 2020 /PRNewswire/ -- Positive top-line results from the EMPEROR-Reduced phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, were announced today by Boehringer Ingelheim and Eli Lilly
Read more →LLYLilly's P-tau217 Blood Test Shows High Accuracy in Diagnosis of Alzheimer's Disease in Data Published in JAMA A new study on Lilly's blood test for Alzheimer's disease (AD), P-tau217 (phosphorylated tau at threonine-217), was published today in JAMA. The...
INDIANAPOLIS , July 28, 2020 /PRNewswire/ -- A new study on Lilly's blood test for Alzheimer's disease (AD), P-tau217 (phosphorylated tau at threonine-217), was published today in JAMA . The results showed that P-tau217 distinguished AD from other neurodegenerative diseases signi
Read more →LLYData from Lilly at Alzheimer's Association International Conference 2020® (AAIC® 2020) to Showcase Clinical Advances in Alzheimer's Research Eli Lilly and Company (NYSE: LLY) today announced that new results from 17 research studies will be presented at the upcoming Alzheimer's Association ...
INDIANAPOLIS , July 21, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that new results from 17 research studies will be presented at the upcoming Alzheimer's Association International Conference ® 2020 (AAIC ® 2020) which will be held virtually July 27-3
Read more →LLYLilly's Mirikizumab Superior to Cosentyx® (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis Eli Lilly and Company (NYSE:LLY) announced today that mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of IL23, met...
INDIANAPOLIS , July 17, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of IL23, met the primary and all key secondary endpoints versus placebo at Week 16 (superiority)
Read more →LLYLilly Confirms Date and Conference Call for Second-Quarter 2020 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2020 financial results on Thursday, July 30, 2020. Lilly will also conduct a...
INDIANAPOLIS , July 17, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its second-quarter 2020 financial results on Thursday, July 30, 2020 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the
Read more →LLYLilly Declares Third-Quarter 2020 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2020 of $0.74 per share on outstanding...
INDIANAPOLIS , July 15, 2020 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the third quarter of 2020 of $0.74 per share on outstanding common stock. The dividend is payable September 10, 2020 , to shareholders of record
Read more →LLYCentral Indiana Racial Equity Fund Launches with more than $2.2 Million in Initial Commitments A coalition of local stakeholders has established the Central Indiana Racial Equity Fund with an initial investment of more than $2.2 million to...
INDIANAPOLIS , June 25, 2020 /PRNewswire/ -- A coalition of local stakeholders has established the Central Indiana Racial Equity Fund with an initial investment of more than $2.2 million to advance effective solutions to racial inequality in Indianapolis and its surrounding count
Read more →LLYLilly launches program about what people with diabetes should Know Before the Low™ About 34 million Americans live with diabetes, and some are at risk of low blood sugar and very low blood sugar emergencies (severe hypoglycemia).1...
INDIANAPOLIS , June 24, 2020 /PRNewswire/ -- About 34 million Americans live with diabetes, and some are at risk of low blood sugar and very low blood sugar emergencies (severe hypoglycemia). 1 That is why Eli Lilly and Company (NYSE: LLY ) launched a new initiative today, to rai
Read more →LLYFull results from EMPERIAL exercise ability trials presented Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced full results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials...
RIDGEFIELD, Conn. and INDIANAPOLIS, June 19, 2020 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY ) today announced full results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to exercise ability and symptom improvement with Jardiance ®
Read more →LLYEmgality® Demonstrates Reduction in Frequency, Duration, and Pain Severity in Patients with Episodic and Chronic Migraine Emgality® (galcanezumab-gnlm) reduces total pain burden in a recent analysis of patients with episodic and chronic migraine. Total pain burden is a...
INDIANAPOLIS , June 17, 2020 /PRNewswire/ -- Emgality ® (galcanezumab-gnlm) reduces total pain burden in a recent analysis of patients with episodic and chronic migraine. Total pain burden is a patient-centric measure that combines the monthly frequency, duration, and pain severi
Read more →LLYLilly's OVERCOME Study Reveals Less than 30 Percent of People Living with Migraine Take Recommended Prescription Medications Eli Lilly and Company (NYSE: LLY) announced today that less than 30 percent of people with migraine are taking a recommended prescription medication, ...
INDIANAPOLIS , June 16, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that less than 30 percent of people with migraine are taking a recommended prescription medication, highlighting the need for improvement in migraine care. These data are from the init
Read more →LLYVerzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer Eli Lilly and Company (NYSE: LLY) today announced Verzenio® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) has met the...
INDIANAPOLIS , June 16, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced Verzenio ® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) has met the primary endpoint of invasive disease-free survival (IDFS), significantly decreasing th
Read more →LLYLilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients Eli Lilly and Company (NYSE: LLY) announced today that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo–controlled...
INDIANAPOLIS , June 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo–controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor
Read more →LLYFDA approves Lyumjev™ (insulin lispro-aabc injection), Lilly's new rapid-acting insulin The U.S. Food and Drug Administration (FDA) has approved Lyumjev™ (insulin lispro-aabc injection, 100 units/mL and 200 units/mL), Eli Lilly and...
INDIANAPOLIS , June 15, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Lyumjev ™ (insulin lispro-aabc injection, 100 units/mL and 200 units/mL), Eli Lilly and Company's (NYSE: LLY ) new rapid-acting insulin indicated to improve glycemic control in a
Read more →LLYOnce-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections New real-world data showed Trulicity® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of...
INDIANAPOLIS , June 13, 2020 /PRNewswire/ -- New real-world data showed Trulicity ® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of semaglutide or exenatide (BCise pen) in people with type 2 diabetes new to GLP-1 receptor a
Read more →LLYEli Lilly and Company Foundation Pledges $25 Million to Combat Racial Injustice Eli Lilly and Company (NYSE: LLY) and the Lilly Foundation announced today a pledge of $25 million and 25,000 volunteer hours over five years to...
INDIANAPOLIS , June 13, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and the Lilly Foundation announced today a pledge of $25 million and 25,000 volunteer hours over five years to decrease the burden of racial injustice and its effects on local and national communities
Read more →LLYLilly Highlights the Evolution of Its Dermatology Portfolio at Annual American Academy of Dermatology Meeting (AAD) Eli Lilly and Company (NYSE: LLY) announced today that it will present new data from Taltz® (ixekizumab), Olumiant® (baricitinib), mirikizumab and...
INDIANAPOLIS , June 12, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that it will present new data from Taltz ® (ixekizumab), Olumiant ® (baricitinib), mirikizumab and lebrikizumab at the virtual American Academy of Dermatology (AAD) meeting. The data b
Read more →LLYLilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life Eli Lilly and Company (NYSE: LLY) and Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company, presented new data from the Phase 2b...
INDIANAPOLIS , June 12, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company, presented new data from the Phase 2b clinical trial of lebrikizumab in patients with moderate-to-severe atopic dermatitis. Data f
Read more →LLYLilly Partners with Indianapolis Recorder Newspaper, Radio One and WISH-TV for a Day of Solidarity Virtual Event What: Eli Lilly and Company, Indianapolis Recorder Newspaper, Radio One and WISH-TV invite people and organizations to come together to acknowledge...
INDIANAPOLIS , June 12, 2020 /PRNewswire/ -- What: Eli Lilly and Company, Indianapolis Recorder Newspaper, Radio One and WISH-TV invite people and organizations to come together to acknowledge the trauma of racial injustice, understand its many forms, and create a call to action
Read more →LLYFirst patient dose delivered for Lilly's tirzepatide cardiovascular outcomes trial The first patient dose has been delivered in SURPASS-CVOT, the phase 3 cardiovascular outcomes trial for tirzepatide, Eli Lilly and Company's (NYSE:...
INDIANAPOLIS , June 9, 2020 /PRNewswire/ -- The first patient dose has been delivered in SURPASS-CVOT, the phase 3 cardiovascular outcomes trial for tirzepatide, Eli Lilly and Company's (NYSE: LLY ) investigational dual GIP and GLP-1 receptor agonist. The study will assess both n
Read more →LLYLilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment Eli Lilly and Company (NYSE: LLY) announced today its partner Junshi Biosciences (HKEX: 1877) has dosed the first healthy volunteer in a study of a...
INDIANAPOLIS , June 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today its partner Junshi Biosciences (HKEX: 1877) has dosed the first healthy volunteer in a study of a potential neutralizing antibody treatment designed to fight COVID-19. The investigatio
Read more →LLYLilly to Participate in Goldman Sachs Global Healthcare Conference Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020. Joshua...
INDIANAPOLIS , June 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Goldman Sachs 41 st Annual Global Healthcare Conference on Wednesday, June 10, 2020 . Joshua Smiley , senior vice president and Lilly's chief financial officer, will participate
Read more →LLYEULAR 2020: Lilly's Taltz® (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis Taltz® (ixekizumab) demonstrated consistent efficacy and long-term potential to help patients with psoriatic arthritis (PsA) in new data to be...
INDIANAPOLIS , June 3, 2020 /PRNewswire/ -- Taltz ® (ixekizumab) demonstrated consistent efficacy and long-term potential to help patients with psoriatic arthritis (PsA) in new data to be presented virtually on June 5 at the European Congress of Rheumatology 2020 (EULAR). Eli Li
Read more →LLYEULAR 2020: Lilly Shares New Data for Olumiant® in Rheumatoid Arthritis and Systemic Lupus Erythematosus Eli Lilly and Company (NYSE: LLY) will present new data for Olumiant® (baricitinib) at the virtual European Congress of Rheumatology (EULAR 2020)...
INDIANAPOLIS , June 3, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present new data for Olumiant ® (baricitinib) at the virtual European Congress of Rheumatology (EULAR 2020) taking place June 3-6, 2020 . Highlights from Olumiant data being presented at the virtu
Read more →LLYLilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA) Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License...
INDIANAPOLIS , June 1, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Taltz ® (ixekizumab) injection 80 mg/mL for the treatment of active non-
Read more →LLYLilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans Eli Lilly and Company (NYSE: LLY) today announced patients have been dosed in the world's first study of a potential antibody treatment designed to...
INDIANAPOLIS , June 1, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19. This investigational medicine, referred to as LY-CoV555, is the first
Read more →LLYLilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab injection, 10...
INDIANAPOLIS , May 29, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA ® (ramucirumab injection, 10 mg/mL solution), in combination with erlotinib, for the first-line treatment of people
Read more →LLYLilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease TAUVID™, a radioactive diagnostic agent, has been approved by the FDA for positron emission tomography (PET) imaging of the brain to estimate the...
INDIANAPOLIS , May 28, 2020 /PRNewswire/ -- TAUVID ™ , a radioactive diagnostic agent, has been approved by the FDA for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patie
Read more →LLYStatement from Lilly Chairman and CEO Dave Ricks on New Part D Senior Savings Model President Donald J. Trump and Seema Verma, Administrator for the Centers for Medicare & Medicaid Services, today announced details of the new Part D...
INDIANAPOLIS , May 26, 2020 /PRNewswire/ -- President Donald J. Trump and Seema Verma , Administrator for the Centers for Medicare & Medicaid Services, today announced details of the new Part D Senior Savings Model that will allow people in the Medicare Part D program to buy thei
Read more →LLYEmgality® Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine and a History of Preventive Treatment Failure Emgality® (galcanezumab-gnlm) significantly improved work productivity and reduced interictal burden, defined as health and well-being between...
INDIANAPOLIS , May 26, 2020 /PRNewswire/ -- Emgality ® (galcanezumab-gnlm) significantly improved work productivity and reduced interictal burden, defined as health and well-being between migraine attacks, in an analysis of the 3-month double-blind period of the CONQUER study, wh
Read more →LLYBoehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance's® effects following an acute myocardial infarction Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced an academic research collaboration with the Duke Clinical Research...
RIDGEFIELD, Conn. and INDIANAPOLIS, May 26, 2020 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY ) today announced an academic research collaboration with the Duke Clinical Research Institute (DCRI) on a new trial, EMPACT-MI (EMPAgliflozin for the preven
Read more →LLYResults of GERAS-US Study Demonstrate Societal Cost Burden for Patients and Caregivers During Early Stages of Alzheimer's Disease Eli Lilly and Company (NYSE: LLY) announced baseline results from the GERAS-US Study examining the societal costs associated with mild cognitive...
INDIANAPOLIS , May 19, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced baseline results from the GERAS-US Study examining the societal costs associated with mild cognitive impairment (MCI), mild dementia (MILD), and caring for someone with Alzheimer's disease (A
Read more →LLYLilly Oncology Showcases Innovation in Cancer Research at ASCO 2020 Data from 23 studies across Eli Lilly and Company's (NYSE: LLY) oncology product portfolio will be presented at the 56th Annual Meeting of the...
"We're excited to present data at this year's ASCO that highlight our commitment to developing new targeted treatments for people living with cancer. We are especially looking forward to sharing data from our LIBRETTO-001 trial examining Retevmo, which recently received FDA appro
Read more →LLYHigher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A1C and body weight in people with type 2 diabetes New 36-week data showed higher investigational doses of Trulicity (3 mg and 4.5 mg) were well-tolerated and led to A1C reductions up to 1.9 percent...
INDIANAPOLIS , May 8, 2020 /PRNewswire/ -- New 36-week data showed higher investigational doses of Trulicity (3 mg and 4.5 mg) were well-tolerated and led to A1C reductions up to 1.9 percent and weight reductions up to 10.4 pounds in people with type 2 diabetes. The results from
Read more →LLYLilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved Retevmo™ (selpercatinib, 40 mg & 80 mg...
INDIANAPOLIS , May 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the U.S. Food and Drug Administration (FDA) approved Retevmo™ (selpercatinib, 40 mg & 80 mg capsules), the first therapy specifically indicated for the treatment of adult patients w
Read more →LLYLilly to Participate in UBS Virtual Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020. Michael Mason, Lilly...
INDIANAPOLIS , May 5, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020 . Michael Mason , Lilly senior vice president and president of Lilly Diabetes and Connected Care, will participa
Read more →LLYLilly and Junshi Biosciences to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19 Junshi Biosciences (HKEX: 1877) and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop therapeutic...
SHANGHAI and INDIANAPOLIS , May 4, 2020 /PRNewswire/ -- Junshi Biosciences (HKEX: 1877) and Eli Lilly and Company (NYSE: LLY ) announced today they have entered into an agreement to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the dise
Read more →LLYLilly Declares Second-Quarter 2020 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2020 of $0.74 per share on outstanding...
INDIANAPOLIS , May 4, 2020 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the second quarter of 2020 of $0.74 per share on outstanding common stock. The dividend is payable June 10, 2020 , to shareholders of record at the
Read more →LLYLilly to Participate in Bank of America Securities Health Care Conference Eli Lilly and Company (NYSE:LLY) will participate in the Bank of America Securities 2020 Health Care Conference on Wednesday, May 13, 2020. Patrik...
INDIANAPOLIS , April 30, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Bank of America Securities 2020 Health Care Conference on Wednesday, May 13, 2020 . Patrik Jonsson , Lilly senior vice president and president of Lilly Bio-Medicines, will par
Read more →LLYLilly Reports Strong First-Quarter Financial Results, Adjusts EPS Guidance Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2020. $ in millions, except per share data First Quarter ...
INDIANAPOLIS , April 23, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the first quarter of 2020. Certain financial information for 2020 and 2019 is presented on both a reported and a non-GAAP basis. Some numbers in this press rele
Read more →LLYLower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® now available Non-branded versions of Humalog® Mix75/25™ KwikPen® (insulin lispro protamine and insulin lispro injectable suspension, 100 units/mL) and Humalog®...
INDIANAPOLIS , April 16, 2020 /PRNewswire/ -- Non-branded versions of Humalog ® Mix75/25 ™ KwikPen ® (insulin lispro protamine and insulin lispro injectable suspension, 100 units/mL) and Humalog ® Junior KwikPen ® (insulin lispro injection, 100 units/mL) are now available for ord
Read more →LLYLilly Begins Clinical Testing of Therapies for COVID-19 Eli Lilly and Company (NYSE: LLY) announced today it has entered into an agreement with the National Institute of Allergy and Infectious Diseases...
INDIANAPOLIS , April 10, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to study baricitinib as an ar
Read more →LLYLilly Confirms Date and Conference Call for First-Quarter 2020 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2020 financial results on Thursday, April 23, 2020. Lilly will also conduct a...
INDIANAPOLIS , April 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its first-quarter 2020 financial results on Thursday, April 23, 2020 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the
Read more →LLYEli Lilly and Company to Hold 2020 Annual Meeting of Shareholders Virtually Eli Lilly and Company (NYSE: LLY) announced today that due to the public health impact of the coronavirus outbreak, and to support the health and...
INDIANAPOLIS , April 7, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that due to the public health impact of the coronavirus outbreak, and to support the health and well-being of its employees, shareholders, and other meeting participants, the Board of
Read more →LLYNew $35 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-19 Crisis in U.S. In response to the crisis caused by COVID-19, Eli Lilly and Company (NYSE: LLY) is introducing the Lilly Insulin Value Program, allowing anyone with...
INDIANAPOLIS , April 7, 2020 /PRNewswire/ -- In response to the crisis caused by COVID-19, Eli Lilly and Company (NYSE: LLY ) is introducing the Lilly Insulin Value Program, allowing anyone with commercial insurance and those without insurance at all to fill their monthly prescri
Read more →LLYLilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines Eli Lilly and Company (NYSE: LLY) today announced an exclusive global licensing and research collaboration with Sitryx, a biopharmaceutical company...
INDIANAPOLIS and OXFORD, England , March 31, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced an exclusive global licensing and research collaboration with Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifyin
Read more →LLYLilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License...
INDIANAPOLIS , March 30, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Taltz ® (ixekizumab) injection, 80 mg/mL for the treatment of pediatri
Read more →LLYUpdates from Lilly about insulin supply and affordability To keep the diabetes community informed about important developments from the COVID-19 crisis, Eli Lilly and Company (NYSE: LLY) today is providing...
INDIANAPOLIS , March 24, 2020 /PRNewswire/ -- To keep the diabetes community informed about important developments from the COVID-19 crisis, Eli Lilly and Company (NYSE: LLY ) today is providing updates related to insulin supply and affordability: "COVID-19 is an unprecedented c
Read more →LLYLilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic Eli Lilly and Company (NYSE: LLY) today provided an update on the company's clinical trial activities in light of the COVID-19 pandemic. The company...
INDIANAPOLIS , March 23, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today provided an update on the company's clinical trial activities in light of the COVID-19 pandemic. The company will delay most new study starts and pause enrollment in most ongoing studies. Lilly
Read more →LLYLilly to Provide Drive-Through COVID-19 Testing for Indianapolis Health Care Workers Eli Lilly and Company (NYSE:LLY) will offer drive-through testing for SARS-CoV-2, the virus that causes COVID-19, to Indianapolis area health care...
INDIANAPOLIS , March 22, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will offer drive-through testing for SARS-CoV-2, the virus that causes COVID-19, to Indianapolis area health care workers beginning Monday, March 23 , as a service to the community and in an effort t
Read more →LLYKathryn Beiser to join Lilly as Vice President, Global Communications Eli Lilly and Company (NYSE: LLY) announced today that Kathryn Beiser will join the company on April 6, 2020 as vice president, global communications....
INDIANAPOLIS , March 20, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that Kathryn Beiser will join the company on April 6, 2020 as vice president, global communications. In this role, Beiser will oversee all aspects of the company's corporate communica
Read more →LLYUS FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes The U.S. Food and Drug Administration (FDA) has issued a complete response letter for the supplemental New Drug Application (sNDA) of the...
RIDGEFIELD, Conn. and INDIANAPOLIS, March 20, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has issued a complete response letter for the supplemental New Drug Application (sNDA) of the investigational medicine empagliflozin 2.5 mg as an adjunct to insulin for
Read more →LLYLilly, Indiana State Department of Health Partner to Accelerate COVID-19 Testing Using Lilly Research Laboratories Eli Lilly and Company (NYSE:LLY) announced today its scientists are partnering with the Indiana State Department of Health (ISDH), with support from...
INDIANAPOLIS , March 18, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today its scientists are partnering with the Indiana State Department of Health (ISDH), with support from the Food and Drug Administration (FDA), to accelerate testing in Indiana for SARS-C
Read more →LLYLilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has granted...
INDIANAPOLIS , March 16, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to baricitinib for the treatment of alopecia areat
Read more →LLYAbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19 AbCellera and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop antibody products for the treatment ...
VANCOUVER, British Columbia and INDIANAPOLIS , March 12, 2020 /PRNewswire/ -- AbCellera and Eli Lilly and Company (NYSE: LLY ) announced today they have entered into an agreement to co-develop antibody products for the treatment and prevention of COVID-19, the disease caused by t
Read more →LLYUS FDA grants Fast Track designation to Jardiance® for the treatment of chronic kidney disease The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of Jardiance® (empagliflozin) to reduce the risk ...
RIDGEFIELD, Conn. and INDIANAPOLIS, March 12, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of Jardiance ® (empagliflozin) to reduce the risk of kidney disease progression and cardiovascular death in adul
Read more →LLYLilly to Participate in New Model Designed to Make Insulins More Affordable for Seniors in Medicare Part D Eli Lilly and Company (NYSE: LLY) is proud to announce its planned participation in the new Part D Senior Savings Model, announced today by the...
INDIANAPOLIS , March 11, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) is proud to announce its planned participation in the new Part D Senior Savings Model, announced today by the Centers for Medicare & Medicaid Services (CMS), that aims to improve the affordability of
Read more →LLYLilly to Participate in Barclays Global Healthcare Conference Eli Lilly and Company (NYSE:LLY) will participate in the Barclays Global Healthcare Conference on Tuesday, March 10, 2020. Ilya Yuffa, vice...
INDIANAPOLIS , March 9, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Barclays Global Healthcare Conference on Tuesday, March 10, 2020 . Ilya Yuffa , vice president, U.S. Diabetes, and Jeffrey Emmick , M.D., Ph.D., vice president, diabetes produc
Read more →LLYLilly Statement on Novel Coronavirus and the Reliable Supply of the Company's Medicines Eli Lilly and Company (NYSE: LLY) issued the following statement today regarding the novel coronavirus: Among the concerns raised due to the impact...
INDIANAPOLIS , March 3, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) issued the following statement today regarding the novel coronavirus: Among the concerns raised due to the impact of the novel coronavirus is whether patients can count on a reliable supply of medici
Read more →LLYU.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a...
NEW YORK and INDIANAPOLIS , March 2, 2020 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE ) and Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for tanezumab 2.5 mg administered s
Read more →LLYFDA Advisory Committee Votes in Favor of Lilly's CYRAMZA® (ramucirumab) as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Eli Lilly and Company (NYSE: LLY) today announced that a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 6-5...
About the RELAY Trial RELAY is a global randomized, double-blind, placebo-controlled Phase 3 study of CYRAMZA in combination with erlotinib, compared to placebo in combination with erlotinib, as a first-line treatment in previously untreated patients with metastatic NSCLC whose t
Read more →LLYTrulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease The U.S. Food and Drug Administration (FDA) has approved Trulicity® (dulaglutide) for the reduction of major adverse cardiovascular events (MACE) in...
The new indication reflects the differentiated patient population of REWIND, the Trulicity cardiovascular outcomes trial. While all participants had CV risk factors, the study consisted primarily of people without established CV disease. REWIND showed a significant risk reduction
Read more →LLYLilly To Participate in SVB Leerink Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the 9th Annual SVB Leerink Global Healthcare Conference on Thursday, February 27, 2020. Patrik...
INDIANAPOLIS , Feb. 21, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the 9th Annual SVB Leerink Global Healthcare Conference on Thursday, February 27, 2020 . Patrik Jonsson , Lilly senior vice president and president of Lilly Bio-Medicines, will par
Read more →LLYLilly to Participate in Cowen Health Care Conference Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 40th Annual Health Care Conference on Tuesday, March 3, 2020. Joshua...
INDIANAPOLIS , Feb. 21, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Cowen and Company 40 th Annual Health Care Conference on Tuesday, March 3, 2020 . Joshua Smiley , senior vice president and Lilly's chief financial officer, will participate in
Read more →LLYLilly Completes Acquisition of Dermira Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Dermira, Inc. (NASDAQ: DERM). The acquisition...
INDIANAPOLIS , Feb. 20, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the successful completion of its acquisition of Dermira, Inc. (NASDAQ: DERM ). The acquisition expands Lilly's immunology pipeline with the addition of lebrikizumab, a novel, investiga
Read more →LLYLilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study Eli Lilly and Company (NYSE: LLY) today announced that the analysis performed by Washington University School of Medicine in the Dominantly Inherited ...
INDIANAPOLIS , Feb. 10, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the analysis performed by Washington University School of Medicine in the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study showed that solanezumab did not meet t
Read more →LLYLilly to Participate in Guggenheim Healthcare Talks Idea Forum Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Healthcare Talks Idea Forum on Thursday, February 13, 2020. Jacob Van Naarden,...
INDIANAPOLIS , Feb. 7, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Guggenheim Healthcare Talks Idea Forum on Thursday, February 13, 2020 . Jacob Van Naarden , chief operating officer for Loxo Oncology at Lilly; Eric Dozier , vice president, Lil
Read more →LLYCHMP Recommends Approval of Lilly's New Fast-Acting Mealtime Insulin to Improve Glycemic Control in Adults with Diabetes Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP)...
INDIANAPOLIS , Jan. 31, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Lilly's new mealtime insulin for the treatment of adu
Read more →LLYLilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase 3 Study of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate to Severe Atopic Dermatitis Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD5, an...
INDIANAPOLIS , Jan. 30, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today that baricitinib met the primary endpoint in BREEZE-AD5, an investigational Phase 3, randomized, placebo-controlled study evaluating the safety and efficacy
Read more →LLYLilly Reports Strong Fourth-Quarter and Full-Year 2019 Financial Results, Updates 2020 Guidance for Pending Dermira Acquisition Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2019. $ in millions, except per share...
INDIANAPOLIS , Jan. 30, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the fourth quarter and full year of 2019. Certain financial information for 2019 and 2018 is presented on both a reported and a non-GAAP basis. Some numbers in t
Read more →LLYLilly Receives FDA Priority Review for the Selpercatinib New Drug Application Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted priority review for the New Drug...
INDIANAPOLIS , Jan. 29, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the U.S. Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) for selpercatinib (LOXO-292), for the treatment of patients with advance
Read more →LLYLilly plans donation of 200,000 insulin KwikPens over next three years to support lower-income communities Starting this month, Eli Lilly and Company (NYSE: LLY) will donate at least 200,000 KwikPens® to three relief organizations – Americares, Direct...
INDIANAPOLIS , Jan. 28, 2020 /PRNewswire/ -- Starting this month, Eli Lilly and Company (NYSE: LLY ) will donate at least 200,000 KwikPens ® to three relief organizations – Americares, Direct Relief and Dispensary of Hope – to stock insulin at nearly 200 U.S. free clinics through
Read more →LLYLilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD4, an...
INDIANAPOLIS , Jan. 27, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announced today that baricitinib met the primary endpoint in BREEZE-AD4, an investigational Phase 3, randomized, placebo-controlled study evaluating the safety and efficacy
Read more →LLYUS FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes The U.S. Food and Drug Administration (FDA) has approved Trijardy™ XR (empagliflozin/linagliptin/metformin hydrochloride extended release tablets) to ...
RIDGEFIELD, Conn. , and INDIANAPOLIS , Jan. 27, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Trijardy™ XR (empagliflozin/linagliptin/metformin hydrochloride extended release tablets) to lower blood sugar in adults with type 2 diabetes, along with
Read more →LLYAnat Hakim to join Lilly as General Counsel Eli Lilly and Company (NYSE: LLY) announced today that Anat Hakim will join the company on February 3, 2020 as senior vice-president and general...
INDIANAPOLIS , Jan. 24, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that Anat Hakim will join the company on February 3, 2020 as senior vice-president and general counsel. Hakim succeeds Michael J. Harrington who will retire on January 31 , 2020. "I a
Read more →LLYGovernor Cooper Announces over 460 Jobs in Durham as Eli Lilly and Company Selects North Carolina for Major Pharmaceutical Plant Eli Lilly and Company (NYSE: LLY), a global healthcare and biopharmaceutical company, will invest over $470 million and create more than 460 new jobs ...
RALEIGH, N.C. , Jan. 21, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ), a global healthcare and biopharmaceutical company, will invest over $470 million and create more than 460 new jobs in Durham , Governor Roy Cooper announced today. The project will bring a new state
Read more →LLYLilly Confirms Date and Conference Call for Fourth-Quarter 2019 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2019 financial results on Thursday, January 30, 2020. Lilly will...
INDIANAPOLIS , Jan. 16, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its fourth-quarter and full-year 2019 financial results on Thursday, January 30, 2020 . Lilly will also conduct a conference call on that day with the investment community and media to f
Read more →LLYLilly, Anna Kaiser Launch '30-Day Thriver Challenge' to Increase Awareness of Daily Stress of Living with Metastatic Breast Cancer, Elevate Support for Women and Men Living with the Disease - An estimated 113 people die every day in the U.S. from metastatic breast cancer (MBC).1 This devastating statistic adds to the emotional and mental ...
INDIANAPOLIS , Jan. 15, 2020 /PRNewswire/ -- - An estimated 113 people die every day in the U.S. from metastatic breast cancer (MBC). 1 This devastating statistic adds to the emotional and mental weight of living with incurable cancer. - The busy holiday season and pressure of
Read more →LLYLilly expands insulin affordability options with lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® Eli Lilly and Company (NYSE: LLY) today announced plans to add two more cost-saving options to its suite of solutions for people who use Lilly...
INDIANAPOLIS , Jan. 14, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced plans to add two more cost-saving options to its suite of solutions for people who use Lilly insulin by introducing lower-priced versions of Humalog ® Mix75/25 ™ KwikPen ® (insulin lis
Read more →LLYTyvyt® (Sintilimab Injection) Combined with ALIMTA® (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC Today, Eli Lilly and Company (NYSE: LLY) jointly announced with Innovent Biologics, Inc. the results of a Phase 3 study in China; the ORIENT-11 trial ...
INDIANAPOLIS , Jan. 13, 2020 /PRNewswire/ -- Today, Eli Lilly and Company (NYSE: LLY ) jointly announced with Innovent Biologics, Inc. the results of a Phase 3 study in China ; the ORIENT-11 trial of Tyvyt ® (sintilimab injection) in combination with ALIMTA ® (pemetrexed) and pla
Read more →LLYLilly Announces Agreement to Acquire Dermira Eli Lilly and Company (NYSE: LLY) and Dermira, Inc. (NASDAQ: DERM) today announced a definitive agreement for Lilly to acquire Dermira for $18.75 per ...
INDIANAPOLIS and MENLO PARK, Calif. , Jan. 10, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Dermira, Inc. (NASDAQ: DERM ) today announced a definitive agreement for Lilly to acquire Dermira for $18.75 per share, or approximately $1.1 billion , in an all-cash transa
Read more →LLYEli Lilly and Company in Collaboration with Strateos, Inc. Launch Remote-Controlled Robotic Cloud Lab Eli Lilly and Company (NYSE: LLY) and Strateos, Inc. today unveiled a new robotic laboratory in San Diego, California designed to accelerate the drug ...
INDIANAPOLIS , Jan. 9, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Strateos, Inc. today unveiled a new robotic laboratory in San Diego, California designed to accelerate the drug discovery process. The Lilly Life Sciences Studio lab was conceptualized and designed
Read more →LLYLilly to Participate in J.P. Morgan Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020. David A. Ricks, ...
INDIANAPOLIS , Jan. 2, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the 38 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 . David A. Ricks , Lilly's chairman and chief executive officer, will participate in a fireside chat
Read more →LLYLilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer Eli Lilly and Company (NYSE: LLY) today announced the opening of the LIBRETTO-531 clinical trial [NCT04211337] for selpercatinib, also known as...
INDIANAPOLIS , Dec. 30, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the opening of the LIBRETTO-531 clinical trial [NCT04211337] for selpercatinib, also known as LOXO-292, for treatment-naïve RET -mutant medullary thyroid cancer (MTC) patients. This is
Read more →LLYU.S. District Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of Indiana ruled in favor of Lilly that the...
INDIANAPOLIS , Dec. 30, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. District Court for the Southern District of Indiana ruled in favor of Lilly that the Alimta ® (pemetrexed for injection) vitamin regimen patent would be infringed by a co
Read more →LLYLilly Launches Campaign to Increase Awareness of Insulin Cost-Saving Options In an open letter published today in several top U.S. newspapers, Eli Lilly and Company (NYSE: LLY) Chairman and CEO Dave Ricks encouraged anyone who ...
INDIANAPOLIS , Dec. 19, 2019 /PRNewswire/ -- In an open letter published today in several top U.S. newspapers, Eli Lilly and Company (NYSE: LLY ) Chairman and CEO Dave Ricks encouraged anyone who needs help affording their monthly prescription of Lilly insulin to call the Lilly D
Read more →LLYLilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm) Eli Lilly and Company (NYSE: LLY) announced today the launch of TRIUMPH, a long-term, real-world evidence study of Emgality® (galcanezumab-gnlm). The ...
INDIANAPOLIS , Dec. 18, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today the launch of TRIUMPH, a long-term, real-world evidence study of Emgality ® (galcanezumab-gnlm). The objective of the TRIUMPH study (Preventive Tr eatment of M i graine: O u tco m es f
Read more →LLYLilly Announces 2020 Financial Guidance, Updates 2019 Guidance Eli Lilly and Company (NYSE: LLY) today announced its 2020 financial guidance, highlighted by volume-based revenue growth and improving productivity, ...
INDIANAPOLIS , Dec. 17, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its 2020 financial guidance, highlighted by volume-based revenue growth and improving productivity, which are expected to result in operating margin expansion and strong earnings perfo
Read more →LLYLilly to Integrate Dexcom CGM into Personalized Diabetes Management System Eli Lilly and Company (NYSE: LLY) has announced a global commercialization agreement to integrate DexCom, Inc. (NASDAQ: DXCM) products into Lilly's...
INDIANAPOLIS , Dec. 16, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has announced a global commercialization agreement to integrate DexCom, Inc. (NASDAQ: DXCM ) products into Lilly's personalized diabetes management system, currently in development to advance the trea
Read more →LLYCHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP)...
INDIANAPOLIS , Dec. 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending a new indication and associated label update for
Read more →LLYBoehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to ...
RIDGEFIELD , Conn. and INDIANAPOLIS , Dec. 13, 2019 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY ) announced today results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to functional endpoints with Jardiance® (empagliflozin) in adult
Read more →LLYLilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer Eli Lilly and Company (NYSE: LLY) today announced the opening of the LIBRETTO-431 clinical trial [NCT04194944] for selpercatinib, also known as...
INDIANAPOLIS , Dec. 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the opening of the LIBRETTO-431 clinical trial [NCT04194944] for selpercatinib, also known as LOXO-292, for treatment-naïve RET fusion-positive non-small cell lung cancer (NSCLC) patie
Read more →LLYLilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced interim clinical data from the LOXO-305 global Phase 1/2 BRUIN dose escalation trial. LOXO-305 is...
INDIANAPOLIS , Dec. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced interim clinical data from the LOXO-305 global Phase 1/2 BRUIN dose escalation trial. LOXO-305 is an investigational, highly selective, non-covalent Bruton's tyrosine kinase (BTK) inhib
Read more →LLYLilly Announces New Leadership and Strategy in Oncology Research and Development Eli Lilly and Company (NYSE: LLY) today announced new leadership and strategic direction in oncology R&D, combining the Lilly Research Laboratories...
INDIANAPOLIS , Dec. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced new leadership and strategic direction in oncology R&D, combining the Lilly Research Laboratories (LRL) oncology organization and Loxo Oncology, which was acquired by Lilly in early 201
Read more →LLYLilly to Participate in Evercore ISI 2nd Annual HealthCONx Conference Eli Lilly and Company (NYSE: LLY) will participate in the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019. Daniel...
INDIANAPOLIS , Dec. 2, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Evercore ISI 2 nd Annual HealthCONx Conference on Wednesday, December 4, 2019 . Daniel Skovronsky , M.D., Ph.D., Lilly's Chief Scientific Officer and President of Lilly Research
Read more →LLYLilly Names HealthVoyager as Winner of Digital Health Innovation Challenge for Inflammatory Bowel Disease (IBD) Eli Lilly and Company's (NYSE: LLY) first digital health open innovation challenge, Transforming IBD Care: Better Disease Monitoring, Management,...
INDIANAPOLIS , Dec. 2, 2019 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY ) first digital health open innovation challenge, "Transforming IBD Care: Better Disease Monitoring, Management, and Care for People with Inflammatory Bowel Disease," has concluded, with HealthVoyager
Read more →LLYEli Lilly and Company Unveils Shared Innovation Laboratory in South San Francisco Eli Lilly and Company (NYSE: LLY) today unveiled its first shared innovation lab, located in South San Francisco, designed to speed the discovery of...
INDIANAPOLIS , Dec. 2, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today unveiled its first shared innovation lab, located in South San Francisco , designed to speed the discovery of innovative medicines through collaboration with local biotech companies. Lilly Gatewa
Read more →LLYLilly announces $400 million capital investment in manufacturing facilities in Indianapolis Eli Lilly and Company (NYSE: LLY) today announced plans to invest $400 million in its manufacturing facilities at its Lilly Technology Center campus...
INDIANAPOLIS , Nov. 20, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced plans to invest $400 million in its manufacturing facilities at its Lilly Technology Center campus in Indianapolis . The plans are driven by increasing demand for Lilly's current medic
Read more →LLYLilly Confirms Date and Conference Call for 2020 Financial Guidance Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2020 on Tuesday, December 17, 2019. Lilly will also conduct a conference...
INDIANAPOLIS , Nov. 19, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial guidance for 2020 on Tuesday, December 17, 2019 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the compan
Read more →LLYInterim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness...
RIDGEFIELD , Conn. and INDIANAPOLIS , Nov. 17, 2019 /PRNewswire/ -- A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows that Jardiance® (empagliflozin) was associated with a decrea
Read more →LLYBoehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 14 to 2 that the benefits of...
RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 13, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 14 to 2 that the benefits of empagliflozin 2.5 mg do not outweigh the risks to support approval as an
Read more →LLYACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz® (ixekizumab) Versus Humira® (adalimumab) Trial in Psoriatic Arthritis Eli Lilly and Company (NYSE: LLY) announced today the 52-week results from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study of Taltz® (ixekizumab)...
INDIANAPOLIS , Nov. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today the 52-week results from the Phase 3b /4 SPIRIT-Head-to-Head (H2H) study of Taltz ® (ixekizumab) versus Humira ® (adalimumab) in biologic-naïve patients with active psoriatic arthritis
Read more →LLYBoehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people hospitalized for acute heart failure who have been stabilized Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth phase III study in the Jardiance®...
RIDGEFIELD , Conn. and INDIANAPOLIS , Nov. 12, 2019 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY ) today announced the initiation of EMPULSE, the sixth phase III study in the Jardiance® (empagliflozin) heart failure program. The study will assess whet
Read more →LLYACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis Eli Lilly and Company (NYSE: LLY) presented detailed results today demonstrating Taltz® (ixekizumab) met the primary and all major secondary...
INDIANAPOLIS , Nov. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) presented detailed results today demonstrating Taltz ® (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a 52-week placebo-controlled Phase 3 study evaluating the safety and e
Read more →LLYLilly Reinforces its Commitment to Rheumatology through Data Showcased at the ACR/ARP Annual Meeting Eli Lilly and Company (NYSE: LLY) announced today that it will present new data from Taltz® (ixekizumab) and Olumiant® (baricitinib) at the American...
INDIANAPOLIS , Nov. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that it will present new data from Taltz ® (ixekizumab) and Olumiant ® (baricitinib) at the American College of Rheumatology (ACR)/Association of Rheumatology Professionals (ARP) annual
Read more →LLYLilly Announces the Early Tender Results and Upsizing of Its Pending Cash Tender Offer to Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities Eli Lilly and Company (NYSE: LLY) announced today the early tender results for its previously announced cash tender offer of its outstanding debt...
INDIANAPOLIS , Nov. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today the early tender results for its previously announced cash tender offer of its outstanding debt securities. Lilly also announced that it had increased the previously announced tender ca
Read more →LLYLilly Announces the Pricing Terms of its Cash Tender Offer for Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities Eli Lilly and Company (NYSE: LLY) announced today the pricing terms of its previously announced cash tender offer for up to $2,000,006,000 aggregate...
INDIANAPOLIS , Nov. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today the pricing terms of its previously announced cash tender offer for up to $2,000,006,000 aggregate principal amount of its outstanding debt securities. Holders of notes who tendered, a
Read more →LLYEli Lilly and Company to Present Multiple Abstracts for LOXO-305 at ASH 2019 Eli Lilly and Company (NYSE: LLY) today announced that multiple abstracts from its LOXO-305 program have been accepted for presentation at the 61st...
INDIANAPOLIS , Nov. 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that multiple abstracts from its LOXO-305 program have been accepted for presentation at the 61st American Society of Hematology Annual Meeting and Exposition to be held December 7-10,
Read more →LLYLilly to Participate in Credit Suisse 28th Annual Healthcare Conference Eli Lilly and Company (NYSE:LLY) will participate in the Credit Suisse 28th Annual Healthcare Conference on Wednesday, November 13, 2019. Anne White, ...
INDIANAPOLIS , Nov. 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Credit Suisse 28 th Annual Healthcare Conference on Wednesday, November 13, 2019 . Anne White , president of Lilly Oncology, Kimberly Blackwell , M.D., vice president, early pha
Read more →LLYBoehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance® In a move to better serve people living with and without diabetes, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will modernise their...
- Alliance to focus combined expertise and investment to maximise Jardiance® for people with type 2 diabetes, heart failure, and chronic kidney disease - Alliance to continue to include three product families – empagliflozin, linagliptin and insulin glargine INGELHEIM, Germany
Read more →LLYLilly Announces Cash Tender Offer for Up to $2.0 Billion Aggregate Principal Amount of Its Outstanding Debt Securities Eli Lilly and Company (NYSE: LLY) announced today that it has commenced a cash tender offer for up to $2.0 billion aggregate principal amount (the...
INDIANAPOLIS , Oct. 24, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that it has commenced a cash tender offer for up to $2.0 billion aggregate principal amount (the "tender cap") of specified series of its outstanding debt. Pursuant to the tender offer
Read more →LLYEnrique Conterno, Senior Vice President and President of Lilly Diabetes and Lilly USA, to Retire at End of Year; Mike Mason to Succeed Conterno Eli Lilly and Company (NYSE: LLY) announced today that Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes and Lilly...
INDIANAPOLIS , Oct. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that Enrique Conterno , senior vice president of Lilly and president of Lilly Diabetes and Lilly USA , will retire at the end of the year after 27 years of service with the company. Mi
Read more →LLYLilly Reports Strong Third-Quarter 2019 Financial Results, Raises 2019 EPS Guidance Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2019. $ in millions, except per share data Third Quarter ...
INDIANAPOLIS , Oct. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the third quarter of 2019. Certain financial information for 2019 and 2018 is presented on both a reported and a non-GAAP basis. Some numbers in this press relea
Read more →LLYLilly Declares Fourth-Quarter 2019 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2019 of $0.645 per share on outstanding ...
INDIANAPOLIS , Oct. 21, 2019 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the fourth quarter of 2019 of $0.645 per share on outstanding common stock. The dividend is payable December 10, 2019 , to shareholders of record
Read more →LLYLilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survival Eli Lilly and Company (NYSE: LLY) today announced top-line results from its Phase 3 SEQUOIA trial evaluating pegilodecakin plus FOLFOX (folinic acid, ...
INDIANAPOLIS , Oct. 16, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced top-line results from its Phase 3 SEQUOIA trial evaluating pegilodecakin plus FOLFOX (folinic acid, 5-FU, oxaliplatin) compared to FOLFOX alone in patients with metastatic pancreatic c
Read more →LLYLilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress Eli Lilly and Company (NYSE: LLY) announced today that Taltz met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in...
INDIANAPOLIS , Oct. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that Taltz met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with moderate to severe plaque psoriasis, demonstrating that 89 pe
Read more →LLYLilly's REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved REYVOW™ (lasmiditan) an oral...
INDIANAPOLIS , Oct. 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the U.S. Food and Drug Administration (FDA) has approved REYVOW™ (lasmiditan) an oral medication for the acute treatment of migraine, with or without aura, in adults. REYVOW has a
Read more →LLYLilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress Eli Lilly and Company (NYSE: LLY) announced today that it will present new data for Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab at...
INDIANAPOLIS , Oct. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that it will present new data for Taltz ® (ixekizumab), Olumiant ® (baricitinib) and mirikizumab at the 28 th annual European Academy of Dermatology and Venereology (EADV) Congress taki
Read more →LLYLilly's CYRAMZA® (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology Eli Lilly and Company (NYSE: LLY) today announced that results from the global Phase 3 RELAY trial of CYRAMZA® (ramucirumab) in previously untreated...
INDIANAPOLIS , Oct. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that results from the global Phase 3 RELAY trial of CYRAMZA ® (ramucirumab) in previously untreated patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC) were publish
Read more →LLYNew Head-to-Head Data Show Taltz® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis Eli Lilly and Company (NYSE: LLY) today presented detailed data at the 5th Annual Maui Derm NP+PA Fall meeting from the Phase 4 IXORA-R study, the...
INDIANAPOLIS , Oct. 3, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today presented detailed data at the 5 th Annual Maui Derm NP+PA Fall meeting from the Phase 4 IXORA-R study, the first head-to-head (H2H) study between an IL-17A inhibitor and an IL-23/p19 inhibitor u
Read more →LLYLilly Announces Voluntary Delisting from Euronext Paris Eli Lilly and Company (NYSE: LLY) announced today that it has requested the delisting of its shares (ISIN US5324571083) ( Lilly Shares ) from...
INDIANAPOLIS , Oct. 3, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that it has requested the delisting of its shares (ISIN US5324571083) ("Lilly Shares") from Euronext Paris due to the very low trading volume, costs and administrative requirements rela
Read more →LLYLilly Confirms Date and Conference Call for Third-Quarter 2019 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2019 financial results on Wednesday, October 23, 2019. Lilly will also conduct a...
INDIANAPOLIS , Oct. 2, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its third-quarter 2019 financial results on Wednesday, October 23, 2019 . Lilly will also conduct a conference call on that day with the investment community and media to further detail t
Read more →LLYVerzenio® (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study Eli Lilly and Company (NYSE: LLY) today announced Verzenio® (abemaciclib) in combination with fulvestrant significantly extended life by a median of...
INDIANAPOLIS , Sept. 29, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced Verzenio® (abemaciclib) in combination with fulvestrant significantly extended life by a median of 9.4 months in women with hormone receptor-positive (HR+), human epidermal growth fac
Read more →LLYLilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated RET-Altered Thyroid Cancers Eli Lilly and Company (NYSE: LLY) today presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral...
INDIANAPOLIS , Sept. 29, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral selpercatinib 1 monotherapy, also known as LOXO-292, for the treatment of RET -altered thyroid c
Read more →LLYLilly Oncology to Present Robust Data across Its Growing Portfolio at ESMO 2019 Eli Lilly and Company (NYSE: LLY) today announced data from a number of studies across the company's oncology product portfolio will be presented at...
INDIANAPOLIS , Sept. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced data from a number of studies across the company's oncology product portfolio will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain ,
Read more →LLYCHMP Issues Positive Opinion to Expand Trulicity® (dulaglutide) Label to Include Results from REWIND Cardiovascular Outcomes Trial Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a ...
INDIANAPOLIS , Sept. 20, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending an update to the Trulicity® (dulaglutide) label and i
Read more →LLYLilly Announces Webcast to Discuss ESMO 2019 Presentations Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Wednesday, October 2, 2019 to discuss the company's presentations at the 2019 European...
INDIANAPOLIS , Sept. 19, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will conduct a webcast on Wednesday, October 2, 2019 to discuss the company's presentations at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain . Remarks will focus
Read more →LLYLilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer Eli Lilly and Company (NYSE: LLY) today presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral...
INDIANAPOLIS , Sept. 9, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral selpercatinib [1] monotherapy, also known as LOXO-292, for the treatment of RET fusion-positive n
Read more →LLYLilly's Pain Clinical Trial Protocol Selected for FDA Complex Innovative Trial Designs Pilot Meeting Program Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has accepted its application to enter the Complex...
INDIANAPOLIS , Sept. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the U.S. Food and Drug Administration (FDA) has accepted its application to enter the Complex Innovative Trial Designs (CID) Pilot Meeting Program, an initiative which aims to further
Read more →LLYLilly to Participate in Morgan Stanley Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019. Daniel Skovronsky,...
INDIANAPOLIS , Sept. 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019 . Daniel Skovronsky , M.D., Ph.D., Lilly's Chief Scientific Officer and President of Lilly Research Laborat
Read more →LLYLilly Receives U.S. FDA Approval for Taltz® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Eli Lilly's Taltz (ixekizumab) has received FDA approval for treating active ankylosing spondylitis, marking its third indication. Clinical trials showed significant improvements in patient symptoms, providing a new treatment option for those affected by this challenging disease.
Read more →LLYLilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD7, the...
INDIANAPOLIS , Aug. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) announced today that baricitinib met the primary endpoint in BREEZE-AD7, the third pivotal Phase 3 trial in the BREEZE-AD program to be completed in 2019. BREEZ
Read more →LLYArbitration panel rules in favor of Lilly in complaint filed by Adocia A Chicago-based arbitration panel has ruled in favor of Eli Lilly and Company (NYSE: LLY) in a claim filed by Adocia S.A. over the companies' prior...
INDIANAPOLIS , Aug. 22, 2019 /PRNewswire/ -- A Chicago-based arbitration panel has ruled in favor of Eli Lilly and Company (NYSE: LLY ) in a claim filed by Adocia S.A. over the companies' prior collaboration on a rapid-acting insulin. The panel of three arbitrators ruled that Lil
Read more →LLYLilly Announces Webcast to Discuss World Conference on Lung Cancer Presentation Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, September 9, 2019 to discuss data presented for its RET-Inhibitor, LOXO-292, at...
INDIANAPOLIS , Aug. 19, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will conduct a webcast on Monday, September 9, 2019 to discuss data presented for its RET-Inhibitor, LOXO-292, at the 20 th meeting of the International Association for the Study of Lung Cancer (IASLC
Read more →LLYLilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health Eli Lilly and Company (NYSE: LLY) is launching an open innovation challenge to encourage individuals and teams across the U.S. to identify and submit ...
INDIANAPOLIS , Aug. 14, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) is launching an open innovation challenge to encourage individuals and teams across the U.S. to identify and submit pioneering digital health solutions aimed at transforming inflammatory bowel disease
Read more →LLYLilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis Eli Lilly and Company (NYSE: LLY) announced today Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4...
INDIANAPOLIS , Aug. 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today Taltz ® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA ® (gu
Read more →LLYU.S. Court of Appeals Rules in Favor of Lilly in Alimta Alternate Salt Form Patent Lawsuit Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit ruled in favor of Lilly, confirming that the ...
INDIANAPOLIS , Aug. 9, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Court of Appeals for the Federal Circuit ruled in favor of Lilly, confirming that the Alimta ® (pemetrexed for injection) vitamin regimen patent would be infringed by comp
Read more →LLYLilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia Initial results from a feasibility study conducted by Eli Lilly and Company (NYSE: LLY), Evidation Health, and Apple Inc. (NASDAQ: AAPL) showed that...
INDIANAPOLIS , Aug. 8, 2019 /PRNewswire/ -- Initial results from a feasibility study conducted by Eli Lilly and Company (NYSE: LLY ), Evidation Health, and Apple Inc. (NASDAQ: AAPL ) showed that an iPhone, Apple Watch, iPad and the Beddit sleep monitoring device, in combination w
Read more →LLYLilly Announces Leadership Changes in Corporate Business Development, Oncology R&D, and Managed Healthcare Services Eli Lilly and Company (NYSE: LLY) today announced several leadership changes in the company's corporate business development, oncology R&D, and...
INDIANAPOLIS , Aug. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced several leadership changes in the company's corporate business development, oncology R&D, and managed healthcare services organizations. Darren Carroll , senior vice president of corpo
Read more →LLYLilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments Eli Lilly and Company (NYSE: LLY) announced today that Emgality® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a...
INDIANAPOLIS , Aug. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that Emgality ® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 study evaluating the efficacy and safety of Emgality in the preventive treatment
Read more →LLYLilly Reports Second-Quarter 2019 Financial Results, Raises 2019 EPS Guidance Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2019. $ in millions, except per share data Second...
INDIANAPOLIS , July 30, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the second quarter of 2019. Certain financial information for 2019 and 2018 is presented on both a reported and a non-GAAP basis. Some numbers in this press rele
Read more →LLYLilly's Verzenio® (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Eli Lilly and Company (NYSE: LLY) today announced that Verzenio (abemaciclib) demonstrated a statistically significant improvement in overall...
INDIANAPOLIS , July 30, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that Verzenio (abemaciclib) demonstrated a statistically significant improvement in overall survival in the Phase 3 MONARCH 2 clinical trial. These results were from a pre-planned inte
Read more →LLYBAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA The U.S. Food and Drug Administration (FDA) has approved BAQSIMI™ (glucagon) nasal powder 3 mg for the treatment of severe hypoglycemia in people...
INDIANAPOLIS , July 24, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved BAQSIMI™ (glucagon) nasal powder 3 mg for the treatment of severe hypoglycemia in people with diabetes ages four years and above, Eli Lilly and Company (NYSE: LLY ) announced tod
Read more →LLYLilly's OVERCOME Observational Study Reveals Inconsistent and Sub-Optimal Treatment Landscape for Migraine Eli Lilly and Company (NYSE: LLY) announced the upcoming presentation of data highlighting inconsistent and sub-optimal treatment patterns that...
INDIANAPOLIS , July 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced the upcoming presentation of data highlighting inconsistent and sub-optimal treatment patterns that people living with migraine experience across the U.S. healthcare landscape, specifically
Read more →LLYNew England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine published positive Phase 3 study results of Emgality®...
INDIANAPOLIS , July 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the New England Journal of Medicine published positive Phase 3 study results of Emgality ® (galcanezumab-gnlm) for the treatment of episodic cluster headache. 1 In this study, Emg
Read more →LLYLilly Announces Changes in Senior Leadership Eli Lilly and Company (NYSE: LLY) today announced several changes to the company's executive committee. Mike Harrington, senior vice president and...
INDIANAPOLIS , July 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced several changes to the company's executive committee. Harrington has been a member of Lilly's executive committee for seven years—a period of strong growth and change for the company.
Read more →LLYLilly Announces Upcoming Presentation of New Data Indicating Rise in Opioid Use for Migraine Treatment Eli Lilly and Company (NYSE: LLY) today announced the upcoming presentation of data indicating rising rates of opioid use for the treatment of...
INDIANAPOLIS , July 10, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the upcoming presentation of data indicating rising rates of opioid use for the treatment of migraine based on results from the OVERCOME ( O bser v ational Survey of the E pidemiology,
Read more →LLYLilly Confirms Date and Conference Call for Second-Quarter 2019 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2019 financial results on Tuesday, July 30, 2019. Lilly will also conduct a...
INDIANAPOLIS , July 9, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its second-quarter 2019 financial results on Tuesday, July 30, 2019 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the c
Read more →LLYLilly's AWARD-11 trial studying higher investigational doses of Trulicity® (dulaglutide) demonstrated superiority in A1C reduction in people with type 2 diabetes Eli Lilly and Company's (NYSE: LLY) trial studying higher investigational doses of Trulicity® (dulaglutide) met its primary efficacy endpoint of...
INDIANAPOLIS , June 26, 2019 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY ) trial studying higher investigational doses of Trulicity ® (dulaglutide) met its primary efficacy endpoint of superiority, significantly reducing A1C from baseline in people with type 2 diabetes, co
Read more →LLYU.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to empagliflozin for the reduction of the risk of cardiovascular death ...
RIDGEFIELD, Conn. and INDIANAPOLIS , June 26, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to empagliflozin for the reduction of the risk of cardiovascular death and hospitalization for heart failure in people with chronic he
Read more →LLYLilly Declares Third-Quarter 2019 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2019 of $0.645 per share on outstanding...
INDIANAPOLIS , June 19, 2019 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the third quarter of 2019 of $0.645 per share on outstanding common stock. The dividend is payable September 10, 2019 , to shareholders of record
Read more →LLYLilly Presents Positive Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology Eli Lilly and Company (NYSE: LLY) announced today that the company will present positive findings from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study ...
INDIANAPOLIS , June 14, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the company will present positive findings from the Phase 3b /4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriatic arthritis (PsA) as a late-breaking abstract at th
Read more →LLYLilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology Eli Lilly and Company (NYSE: LLY) announced today the company will present positive, five-year Phase 3 data for Taltz® (ixekizumab). Patients with...
INDIANAPOLIS , June 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today the company will present positive, five-year Phase 3 data for Taltz ® (ixekizumab). Patients with moderate- to severe plaque psoriasis who continued to receive Taltz maintained high le
Read more →LLYDetailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta® Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced detailed findings from the CAROLINA® trial demonstrating that Tradjenta®...
RIDGEFIELD, Conn. and INDIANAPOLIS , June 10, 2019 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY ) announced detailed findings from the CAROLINA ® trial demonstrating that Tradjenta ® (linagliptin) did not increase cardiovascular risk compared with gli
Read more →LLYNew analysis shows cardiorenal risk reductions of Jardiance® are consistent in adults with type 2 diabetes, cardiovascular disease and kidney disease without overt proteinuria A new post-hoc analysis of data from the EMPA-REG OUTCOME® trial indicates a consistent effect of Jardiance® (empagliflozin) on reducing...
RIDGEFIELD , Conn. and INDIANAPOLIS , June 10, 2019 /PRNewswire/ -- A new post-hoc analysis of data from the EMPA-REG OUTCOME ® trial indicates a consistent effect of Jardiance ® (empagliflozin) on reducing cardiovascular and renal risk in adults with type 2 diabetes and known ca
Read more →LLYTrulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes Detailed results from REWIND, the Trulicity® (dulaglutide) cardiovascular outcome trial, showed a significant 12 percent reduction in major...
INDIANAPOLIS , June 9, 2019 /PRNewswire/ -- Detailed results from REWIND, the Trulicity ® (dulaglutide) cardiovascular outcome trial, showed a significant 12 percent reduction in major cardiovascular events (MACE), a composite endpoint of non-fatal myocardial infarction (heart at
Read more →LLYLilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions Two phase 3 studies show that Eli Lilly and Company's (NYSE: LLY) ultra rapid lispro (URLi) provided non-inferior A1C reductions compared to Humalog® ...
INDIANAPOLIS , June 9, 2019 /PRNewswire/ -- Two phase 3 studies show that Eli Lilly and Company's (NYSE: LLY ) ultra rapid lispro (URLi) provided non-inferior A1C reductions compared to Humalog ® (insulin lispro) at 26 weeks in people with type 1 and type 2 diabetes. The data fro
Read more →LLYLilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Association's® 79ᵗʰ Scientific Sessions® Results from several studies of Eli Lilly and Company's (NYSE: LLY) investigational dual GIP and GLP-1 receptor agonist (RA), tirzepatide, reinforce...
INDIANAPOLIS , June 8, 2019 /PRNewswire/ -- Results from several studies of Eli Lilly and Company's (NYSE: LLY ) investigational dual GIP and GLP-1 receptor agonist (RA), tirzepatide, reinforce its potential in lowering A1C and body weight in people with type 2 diabetes. Early re
Read more →LLYLilly to Present New Data and Commitment to Patient-Centered Solutions at the Annual European Congress of Rheumatology Eli Lilly and Company (NYSE: LLY) will present data for Taltz® (ixekizumab) and Olumiant® (baricitinib) at the Annual European Congress of...
INDIANAPOLIS , June 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present data for Taltz ® (ixekizumab) and Olumiant ® (baricitinib) at the Annual European Congress of Rheumatology (EULAR 2019) in Madrid from June 12-15, 2019 . The data include clinical studies
Read more →LLYLilly to Showcase Scientific Innovation within Dermatology Portfolio at 24th World Congress of Dermatology Eli Lilly and Company (NYSE: LLY) will present data for Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab at the 24th World Congress of...
INDIANAPOLIS , June 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present data for Taltz ® (ixekizumab), Olumiant ® (baricitinib) and mirikizumab at the 24th World Congress of Dermatology (WCD) taking place June 10-15, 2019 in Milan , Italy. The data include 11
Read more →LLYFDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality® (galcanezumab-gnlm)...
INDIANAPOLIS , June 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality ® (galcanezumab-gnlm) injection (300 mg) for the treatment of episodic cluster headache in adults. 1 Emgality is a
Read more →LLYU.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the investigational fixed-dose combination tablet of...
RIDGEFIELD , Conn. and INDIANAPOLIS , June 4, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the investigational fixed-dose combination tablet of empagliflozin, linagliptin and metformin extended release (XR) for t
Read more →LLYHurricane Season is Almost Here. Are You Ready? The 2019 Atlantic hurricane season begins June 1. With natural disasters and extreme weather on the rise, it's critical to be prepared and ready to...
INDIANAPOLIS , May 31, 2019 /PRNewswire/ -- The 2019 Atlantic hurricane season begins June 1 . With natural disasters and extreme weather on the rise, it's critical to be prepared and ready to respond. That's why Eli Lilly and Company (NYSE: LLY ) and two leading disaster relief
Read more →LLYLilly to Participate in Goldman Sachs Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 40th Annual Global Healthcare Conference on Wednesday, June 12, 2019. Joshua...
INDIANAPOLIS , May 30, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Goldman Sachs 40 th Annual Global Healthcare Conference on Wednesday, June 12, 2019 . Joshua Smiley , senior vice president and Lilly's chief financial officer, will participate
Read more →LLYLilly Announces Webcast to Discuss ADA Presentations and Diabetes Portfolio Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, June 10, 2019 to discuss the company's diabetes portfolio and its presentations...
INDIANAPOLIS , May 29, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will conduct a webcast on Monday, June 10, 2019 to discuss the company's diabetes portfolio and its presentations at the American Diabetes Association's 79th Scientific Sessions in San Francisco, Calif
Read more →LLYLilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics Eli Lilly and Company (NYSE: LLY) today announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion...
INDIANAPOLIS , May 28, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeut
Read more →LLYLilly's Lower-Priced Insulin Now Available Eli Lilly and Company's (NYSE: LLY) Insulin Lispro Injection is now available for order in pharmacies for people who use Lilly's rapid-acting insulin ...
INDIANAPOLIS , May 22, 2019 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY ) Insulin Lispro Injection is now available for order in pharmacies for people who use Lilly's rapid-acting insulin and need a lower-cost option. Lilly's Insulin Lispro Injection has a 50 percent lower
Read more →LLYLilly to Participate in UBS Global Healthcare Conference Eli Lilly and Company (NYSE:LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 21, 2019. Christi Shaw, president of Lilly...
INDIANAPOLIS , May 16, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the UBS Global Healthcare Conference on Tuesday, May 21, 2019 . Christi Shaw , president of Lilly Bio-Medicines, will participate in a fireside chat at 9:30 a.m., Eastern Time. A live audi
Read more →LLYData Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer Eli Lilly and Company (NYSE: LLY) today announced that data from a number of studies across the company's oncology product portfolio will be...
INDIANAPOLIS , May 15, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that data from a number of studies across the company's oncology product portfolio will be presented at the 55 th Annual Meeting of the American Society of Clinical Oncology (ASCO) in C
Read more →LLYLilly to Participate in Bank of America Merrill Lynch Health Care Conference Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15, 2019....
INDIANAPOLIS , May 15, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15, 2019 . Enrique Conterno , senior vice president of Lilly and president of Lilly Diabetes and Lill
Read more →LLYLilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab injection, 10...
INDIANAPOLIS , May 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA ® (ramucirumab injection, 10 mg/mL solution), as a single agent, for the treatment of patients with hepatocellular
Read more →LLYLilly Declares Second-Quarter 2019 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2019 of $0.645 per share on outstanding ...
INDIANAPOLIS , May 6, 2019 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the second quarter of 2019 of $0.645 per share on outstanding common stock. The dividend is payable June 10, 2019 , to shareholders of record at th
Read more →LLYAAN 2019: Pooled Analyses of Two Emgality® (galcanezumab-gnlm) Phase 3 Studies Show Reduction in Monthly Migraine Headache Days in Low- and High-Frequency Episodic Migraine Subgroups Eli Lilly and Company (NYSE: LLY) today announced the upcoming presentation of results from pooled subgroup analyses of efficacy data from the Phase...
INDIANAPOLIS , May 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the upcoming presentation of results from pooled subgroup analyses of efficacy data from the Phase 3 EVOLVE-1 and EVOLVE-2 studies. These analyses demonstrate a reduction in monthly migr
Read more →LLYLilly to Present New Data at AAN 2019 on Emgality® (galcanezumab-gnlm) and Lasmiditan Reinforcing Breadth of Headache Disorders Portfolio Eli Lilly and Company (NYSE: LLY) announced today it will present 19 scientific abstracts for Emgality® (galcanezumab-gnlm) and lasmiditan at the...
INDIANAPOLIS , May 2, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today it will present 19 scientific abstracts for Emgality ® (galcanezumab-gnlm) and lasmiditan at the 71 st Annual Meeting of the American Academy of Neurology (AAN) taking place in Philadelp
Read more →LLYLilly Reports Solid First-Quarter 2019 Financial Results, Updates 2019 Guidance to Reflect Disposition of Elanco Animal Health Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2019. $ in millions, except per share data First Quarter ...
INDIANAPOLIS , April 30, 2019 PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the first quarter of 2019. Certain financial information for 2019 and 2018 is presented on both a reported and a non-GAAP basis. Some numbers in this press relea
Read more →LLYU.S. Court of Appeals Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has ruled in the company's favor regarding...
In the inter partes review (IPR) proceedings initiated by Neptune Generics, LLC and Sandoz Inc., the U.S. PTO found on October 5, 2017 that the claims of the vitamin regimen patent are valid. Neptune, Fresenius Kabi and Mylan filed an appeal, which was decided today. If the pate
Read more →LLYLilly to Establish an Access Program for Patients as it Prepares to Withdraw Lartruvo from the Global Market Eli Lilly and Company (NYSE: LLY) today announced that the company has been working to facilitate the withdrawal of Lartruvo® (olaratumab) from the...
INDIANAPOLIS , April 25, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the company has been working to facilitate the withdrawal of Lartruvo® (olaratumab) from the market for the treatment of advanced soft tissue sarcoma (STS). Lilly's actions to wi
Read more →LLYLilly Announces Sale of Legacy Antibiotics Brands and Manufacturing Facility in China Eli Lilly and Company (NYSE: LLY) today announced that it has entered into an agreement to sell the rights in China for two legacy Lilly antibiotic...
INDIANAPOLIS , April 22, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that it has entered into an agreement to sell the rights in China for two legacy Lilly antibiotic medicines, Ceclor ® and Vancocin ® , as well as a manufacturing facility in Suzhou, C
Read more →LLYLilly Announces Positive Top-Line Results for COAST-X, a 52-Week Placebo-Controlled Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis Eli Lilly and Company (NYSE: LLY) announced today that Taltz® (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a Phase 3...
INDIANAPOLIS , April 22, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that Taltz ® (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of non-radiograph
Read more →LLYLilly and Avidity Biosciences Announce Licensing and Research Collaboration Eli Lilly and Company (NYSE: LLY) and Avidity Biosciences, Inc. today announced a global licensing and research collaboration focused on the...
INDIANAPOLIS and LA JOLLA, Calif. , April 22, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Avidity Biosciences, Inc. today announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines
Read more →LLYLilly Confirms Date and Conference Call for First-Quarter 2019 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2019 financial results on Tuesday, April 30, 2019. Lilly will also conduct a...
INDIANAPOLIS , April 10, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its first-quarter 2019 financial results on Tuesday, April 30, 2019 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the
Read more →LLYLilly and ImmuNext Announce Licensing and Research Collaboration Eli Lilly and Company (NYSE: LLY) and ImmuNext, Inc. today announced a global licensing and research collaboration focused on the study of a...
INDIANAPOLIS and LEBANON, N.H. , March 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and ImmuNext, Inc. today announced a global licensing and research collaboration focused on the study of a preclinical novel target that could lead to potential new medicines for au
Read more →LLYLilly Announces Final Results of Elanco Exchange Offer Eli Lilly and Company (NYSE: LLY) today announced the final results of its offer for shareholders to exchange their shares of Lilly common stock for...
INDIANAPOLIS , March 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the final results of its offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (NYSE: ELAN ) previously owned by Lilly,
Read more →LLYLilly's CYRAMZA® (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 RELAY study of CYRAMZA® (ramucirumab) met its primary endpoint of progression-free ...
INDIANAPOLIS , March 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that its Phase 3 RELAY study of CYRAMZA ® (ramucirumab) met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement in the time
Read more →LLYLilly Announces Preliminary Results of Elanco Exchange Offer Eli Lilly and Company (NYSE: LLY) today announced that, based on preliminary results, its previously-announced offer for shareholders to exchange...
INDIANAPOLIS , March 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that, based on preliminary results, its previously-announced offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (NYS
Read more →LLYLilly to Participate in Barclays Global Healthcare Conference Eli Lilly and Company (NYSE:LLY) will participate in the Barclays Global Healthcare Conference on Wednesday, March 13, 2019. Daniel Skovronsky, M.D., ...
INDIANAPOLIS , March 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Barclays Global Healthcare Conference on Wednesday, March 13, 2019 . Daniel Skovronsky , M.D., Ph.D., Lilly's Chief Scientific Officer and President of Lilly Research Laborator
Read more →LLYLilly to Participate in Cowen Health Care Conference Eli Lilly and Company (NYSE:LLY) will participate in the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019. Joshua...
INDIANAPOLIS , March 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Cowen and Company 39 th Annual Health Care Conference on Monday, March 11, 2019 . Joshua Smiley , senior vice president and Lilly's chief financial officer, will participate in
Read more →LLYLilly Announces Final Exchange Ratio of 4.5121 for Elanco Exchange Offer Eli Lilly and Company (NYSE: LLY) today announced the final exchange ratio for its previously-announced offer for shareholders to exchange their...
INDIANAPOLIS , March 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the final exchange ratio for its previously-announced offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (NYSE: ELAN
Read more →LLYLilly Receives FDA Priority Review Designation for Emgality® (galcanezumab-gnlm) Injection for the Preventive Treatment of Episodic Cluster Headache in Adults Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its supplemental...
INDIANAPOLIS , March 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its supplemental Biologics License Application (sBLA) for Emgality ® (galcanezumab-gnlm) injection for
Read more →LLYLilly to Introduce Lower-Priced Insulin Reinforcing our commitment to lower out-of-pocket costs for people who need insulin, Eli Lilly and Company (NYSE: LLY) today announced we will...
INDIANAPOLIS , March 4, 2019 /PRNewswire/ -- Reinforcing our commitment to lower out-of-pocket costs for people who need insulin, Eli Lilly and Company (NYSE: LLY ) today announced we will introduce a lower-priced version of Humalog ® (insulin lispro injection 100 units/mL) in th
Read more →LLYLilly to Present Data Demonstrating Continued Scientific Advancements in Broad Dermatology Portfolio at AAD Annual Meeting Eli Lilly and Company (NYSE: LLY) announced that it will present data for Taltz® (ixekizumab) and mirikizumab at the American Academy of Dermatology...
INDIANAPOLIS , March 1, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced that it will present data for Taltz ® (ixekizumab) and mirikizumab at the American Academy of Dermatology (AAD) annual meeting taking place March 1-5, 2019 in Washington , DC. The data incl
Read more →LLYPfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain Pfizer Inc. (NYSE: PFE) and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab in...
NEW YORK and INDIANAPOLIS , Feb. 19, 2019 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE ) and Eli Lilly and Company (NYSE: LLY ) today announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low back pain (CLBP). In the s
Read more →LLYLilly Completes Acquisition of Loxo Oncology Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Loxo Oncology, Inc. (NASDAQ:LOXO). The acquisition...
Lilly's tender offer for all outstanding shares of common stock of Loxo Oncology, at a price of $235.00 per share in cash, expired as scheduled at one minute past 11:59 p.m., Eastern time , on Thursday, February 14, 2019 . As of the expiration of the tender offer, 26,043,820 shar
Read more →LLYLilly To Participate in Leerink Partners Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019. Christi...
INDIANAPOLIS , Feb. 14, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019 . Christi Shaw , president of Lilly Bio-Medicines, will participate in a fireside chat at 1:00 p.m
Read more →LLYBoehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced CAROLINA® (CARdiovascular Outcome study of LINAgliptin versus glimepiride in...
RIDGEFIELD, Conn. and INDIANAPOLIS , Feb. 14, 2019 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY ) announced CAROLINA ® (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its primary endpoint, defined
Read more →LLYLilly to Participate in Guggenheim Healthcare Talks Idea Forum Eli Lilly and Company (NYSE:LLY) will participate in the Guggenheim Healthcare Talks Idea Forum on Thursday, February 14, 2019. Anne White, president ...
INDIANAPOLIS , Feb. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Guggenheim Healthcare Talks Idea Forum on Thursday, February 14, 2019 . Anne White , president of Lilly Oncology, and Levi Garraway , M.D., Ph.D., senior vice president, oncolog
Read more →LLYLilly Will Initiate Divestiture of its Remaining Interest in Elanco Animal Health Eli Lilly and Company (NYSE: LLY) announced it will initiate an exchange offer today to divest its remaining interest in Elanco Animal Health (NYSE:...
INDIANAPOLIS , Feb. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced it will initiate an exchange offer today to divest its remaining interest in Elanco Animal Health (NYSE: ELAN ). Elanco completed its initial public offering (IPO) in September 2018 , with L
Read more →LLYLilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2018. $ in millions, except per share...
INDIANAPOLIS , Feb. 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the fourth quarter and full year of 2018. Certain financial information for 2018 and 2017 is presented on both a reported and a non-GAAP basis. Some numbers in th
Read more →LLYLilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction Eli Lilly and Company (NYSE: LLY) ( Lilly ) and Loxo Oncology, Inc. (NASDAQ: LOXO) ( Loxo Oncology ) today announced the expiration of the waiting...
INDIANAPOLIS and STAMFORD, Conn. , Feb. 1, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) ("Lilly") and Loxo Oncology, Inc. (NASDAQ: LOXO ) ("Loxo Oncology") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 19
Read more →LLYFDA Expands Lilly's ALIMTA® (pemetrexed) Label with Combination of KEYTRUDA® (pembrolizumab) and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new indication for...
INDIANAPOLIS , Jan. 31, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new indication for ALIMTA ® (pemetrexed for injection) in combination with KEYTRUDA ® (pembrolizumab), devel
Read more →LLYLilly Revises Date for Fourth-Quarter 2018 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) has revised the date for its fourth-quarter and full-year 2018 financial results announcement. The company will now ...
INDIANAPOLIS , Jan. 30, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has revised the date for its fourth-quarter and full-year 2018 financial results announcement. The company will now announce results on Wednesday, February 6, 2019 , one week earlier than previously s
Read more →LLYGovernment Employees Affected by Federal Shutdown Encouraged to Contact Lilly Diabetes Solution Center to Access Insulin Eli Lilly and Company (NYSE: LLY) is encouraging government employees affected by the partial government shutdown to call the Lilly Diabetes Solution ...
INDIANAPOLIS , Jan. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) is encouraging government employees affected by the partial government shutdown to call the Lilly Diabetes Solution Center and check whether they are receiving all eligible discounts to lower the out-
Read more →LLYLilly Confirms Date and Conference Call for Fourth-Quarter 2018 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2018 financial results on Wednesday, February 13, 2019. Lilly will...
INDIANAPOLIS , Jan. 21, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its fourth-quarter and full-year 2018 financial results on Wednesday, February 13, 2019 . Lilly will also conduct a conference call on that day with the investment community and media to
Read more →LLYLilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA® (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients Eli Lilly and Company (NYSE: LLY) announced that results from the global Phase 3 REACH-2 study of CYRAMZA® (ramucirumab) as a single agent in the...
INDIANAPOLIS , Jan. 18, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced that results from the global Phase 3 REACH-2 study of CYRAMZA ® (ramucirumab) as a single agent in the second-line treatment of people with AFP-High (alpha-fetoprotein ≥400 ng/mL) hepatocell
Read more →LLYLilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO® Eli Lilly and Company (NYSE: LLY) today reported that the results of ANNOUNCE, the Phase 3 study of LARTRUVO® (olaratumab), in combination with...
INDIANAPOLIS , Jan. 18, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today reported that the results of ANNOUNCE, the Phase 3 study of LARTRUVO ® (olaratumab), in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma (STS), did not co
Read more →LLYLilly Announces Agreement To Acquire Loxo Oncology Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines through the addition of a marketed therapy and a pipeline...
INDIANAPOLIS and STAMFORD, Conn. , Jan. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Loxo Oncology, Inc. (NASDAQ: LOXO ) today announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion . Lox
Read more →LLYLilly to Participate in J.P. Morgan Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019. David A. Ricks,...
INDIANAPOLIS , Jan. 3, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the 37 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 . David A. Ricks , Lilly's chairman and chief executive officer, will participate in a fireside chat f
Read more →LLYLilly Announces Financial Guidance, Reviews Commercial Performance, and Highlights Promising Pipeline Opportunities at Investment Community Meeting 2019 revenue is expected to be between $25.3 billion and $25.8 billion, representing mid-single-digit growth driven by volume from newer medicines,...
INDIANAPOLIS , Dec. 19, 2018 /PRNewswire/ -- At a meeting today with the investment community, Eli Lilly and Company (NYSE: LLY ) announced its 2019 financial guidance, updated certain elements of its 2018 guidance and 2020 minimum financial expectations, reviewed the performanc
Read more →LLYLilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies Eli Lilly and Company (NYSE: LLY) and Aduro Biotech, Inc. (NASDAQ: ADRO) today announced a research collaboration and exclusive license agreement for ...
INDIANAPOLIS and BERKLEY, Calif., Dec. 18, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Aduro Biotech, Inc. (NASDAQ: ADRO ) today announced a research collaboration and exclusive license agreement for Aduro's cGAS-STING Pathway Inhibitor program for the research an
Read more →LLYLilly announces publication of analyses showing benefit of the addition of Verzenio® (abemaciclib) in multiple subgroups of patients with advanced breast cancer identified as having a more concerning prognosis Eli Lilly and Company (NYSE: LLY) today announced npj Breast Cancer published results from exploratory subgroup analyses of the MONARCH 2 and MONARCH ...
INDIANAPOLIS , Dec. 18, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced npj Breast Cancer published results from exploratory subgroup analyses of the MONARCH 2 and MONARCH 3 trials reinforcing the clinical benefit of Verzenio ® (abemaciclib) plus endocrine
Read more →LLYLilly Announces Positive Top-Line Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis Eli Lilly and Company (NYSE: LLY) announced today Taltz® (ixekizumab) met the primary and all major secondary endpoints in the Phase 3b/4 SPIRIT-H2H...
INDIANAPOLIS , Dec. 17, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today Taltz ® (ixekizumab) met the primary and all major secondary endpoints in the Phase 3b /4 SPIRIT-H2H study, which evaluated the efficacy and safety of Taltz versus Humira ® (adalimumab
Read more →LLYLilly to Acquire Pre-Clinical Pain Program from Hydra Biosciences Eli Lilly and Company (NYSE: LLY) today announced an agreement with Hydra Biosciences to acquire all assets related to Hydra's pre-clinical program...
INDIANAPOLIS , Dec. 14, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced an agreement with Hydra Biosciences to acquire all assets related to Hydra's pre-clinical program of TRPA1 antagonists, part of the Transient Receptor Potential (TRP) family of ion cha
Read more →LLYLilly and Evidation Health Expand Collaboration to Analyze Data from Smartphones and Connected Sensors Eli Lilly and Company (NYSE: LLY) and Evidation Health, a health and measurement company that helps innovative life sciences and health care...
INDIANAPOLIS and SAN MATEO, Calif. , Dec. 14, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Evidation Health, a health and measurement company that helps innovative life sciences and health care companies understand how everyday behavior and health interact, announc
Read more →LLYBoehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease The Duke Clinical Research Institute (DCRI) is leading a new clinical study to optimize care for people with type 2 diabetes and cardiovascular...
RIDGEFIELD, Conn. and INDIANAPOLIS , Dec. 13, 2018 /PRNewswire/ -- The Duke Clinical Research Institute (DCRI) is leading a new clinical study to optimize care for people with type 2 diabetes and cardiovascular disease through evaluation of a multidisciplinary approach at cardiol
Read more →LLYLilly and AC Immune Announce License and Collaboration Agreement Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative...
INDIANAPOLIS and LAUSANNE, Switzerland , Dec. 12, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and AC Immune SA (NASDAQ: ACIU ) today announced that the two companies have signed a license and collaboration agreement to research and develop tau aggregation inhibitor s
Read more →LLYLilly to Present Clinical Data for Verzenio® (abemaciclib) and Real-World Evidence across HR+, HER2- Metastatic Breast Cancer at 2018 SABCS Eli Lilly and Company (NYSE: LLY) today announced the upcoming presentation of clinical data at the 2018 San Antonio Breast Cancer Symposium (SABCS)...
INDIANAPOLIS , Nov. 29, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the upcoming presentation of clinical data at the 2018 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas , December 4-8, 2018 on the safety and efficacy of Verzenio ® (
Read more →LLYLilly to Announce 2019 Financial Guidance, Highlight Late-Stage Pipeline Opportunities and Discuss Commercial Performance at Upcoming Investment Community Meeting Eli Lilly and Company (NYSE:LLY) today announced that it will host a meeting for the investment community on Wednesday, December 19, 2018, from 9:00...
INDIANAPOLIS , Nov. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that it will host a meeting for the investment community on Wednesday, December 19, 2018 , from 9:00 a.m. (EST) until approximately 12:00 p.m. Earlier that day, the company will annou
Read more →LLYJardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends Jardiance® (empagliflozin) as the preferred...
The 2018 ACC Expert Consensus statement emphasizes the need for a collaborative treatment approach by healthcare providers to reduce cardiovascular risk and improve survival in people with type 2 diabetes, a growing public health epidemic. People with diabetes are up to four time
Read more →LLYLilly to Participate in Credit Suisse 27th Annual Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Credit Suisse 27th Annual Healthcare Conference on Tuesday, November 13, 2018. Enrique...
INDIANAPOLIS , Nov. 8, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Credit Suisse 27 th Annual Healthcare Conference on Tuesday, November 13, 2018 . Enrique Conterno , senior vice president of Lilly and president of Lilly Diabetes and Lilly USA
Read more →LLYLilly Delivers Solid Third-Quarter 2018 Results, Revises EPS Guidance Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2018. $ in millions, except per share data Third Quarter ...
INDIANAPOLIS , Nov. 6, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the third quarter of 2018. Certain financial information for 2018 and 2017 is presented on both a reported and a non-GAAP basis. Some numbers in this press releas
Read more →LLYLilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines Eli Lilly and Company (NYSE: LLY) and NextCure, Inc. today announced a multi-year collaboration focused on the discovery and development of...
INDIANAPOLIS and BELTSVILLE, Md. , Nov. 5, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and NextCure, Inc. today announced a multi-year collaboration focused on the discovery and development of immuno-oncology therapies. The collaboration seeks to discover novel cancer
Read more →LLYTrulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes Trulicity® (dulaglutide) significantly reduced major adverse cardiovascular events (MACE), a composite endpoint of cardiovascular (CV) death,...
INDIANAPOLIS , Nov. 5, 2018 /PRNewswire/ -- Trulicity ® (dulaglutide) significantly reduced major adverse cardiovascular events (MACE), a composite endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke, meeting the primary effic
Read more →LLYInitial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study showed Jardiance® was associated with a 44...
RIDGEFIELD, Conn. and INDIANAPOLIS , Nov. 5, 2018 /PRNewswire/ -- Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study showed Jardiance ® was associated with a 44 percent relative risk reduction in hospitalization for heart failur
Read more →LLYLilly and Dicerna Announce RNAi Licensing and Research Collaboration Eli Lilly and Company (NYSE: LLY) and Dicerna Pharmaceuticals (NASDAQ: DRNA) today announced a global licensing and research collaboration focused on ...
INDIANAPOLIS and CAMBRIDGE, Mass. , Oct. 29, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Dicerna Pharmaceuticals (NASDAQ: DRNA ) today announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential
Read more →LLYACR 2018: Lilly Announces Positive Results for Two Phase 3 Studies of Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) Eli Lilly and Company (NYSE: LLY) announced today that the company will present positive findings from two Phase 3 studies, COAST-V and COAST-W, in...
INDIANAPOLIS , Oct. 22, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the company will present positive findings from two Phase 3 studies, COAST-V and COAST-W, in adults with ankylosing spondylitis (AS), also referred to as radiographic axial spondy
Read more →LLYACR 2018: Lilly Shares Updated Safety Analysis of OLUMIANT® (baricitinib) in Patients with Moderately-to-Severely Active Rheumatoid Arthritis Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today findings from an updated integrated safety analysis of...
INDIANAPOLIS , Oct. 21, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) announced today findings from an updated integrated safety analysis of OLUMIANT ® (baricitinib) based on an ongoing long-term extension (LTE) study of rheumatoid
Read more →LLYKaren Walker Elected to Lilly Board of Directors The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Karen Walker as a new member, effective December 1, 2018. As a member of...
INDIANAPOLIS , Oct. 16, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has elected Karen Walker as a new member, effective December 1, 2018 . As a member of Lilly's board, she will serve on both the Audit Committee and the Public Policy and Comp
Read more →LLYLilly Declares Fourth-Quarter 2018 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2018 of $0.5625 per share on...
INDIANAPOLIS , Oct. 15, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the fourth quarter of 2018 of $0.5625 per share on outstanding common stock. The dividend is payable December 10, 2018 , to shareholders of recor
Read more →LLYNew Data Showcasing Lilly's Growing Commitment in Rheumatology to be Featured at the ACR/ARHP Annual Meeting Eli Lilly and Company (NYSE: LLY) announced that it will present new data for Taltz® (ixekizumab) and Olumiant® (baricitinib) at the American College ...
INDIANAPOLIS , Oct. 15, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced that it will present new data for Taltz ® (ixekizumab) and Olumiant ® (baricitinib) at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annu
Read more →LLYLilly and Metastatic Breast Cancer Advocates Launch Thriver Movement to Elevate Understanding of the Daily Impact of the Disease, Encourage Public to do More for MBC Results from a new national, multi-stakeholder survey commissioned by Eli Lilly and Company (NYSE: LLY) reveal that metastatic breast cancer (MBC)...
INDIANAPOLIS , Oct. 12, 2018 /PRNewswire/ -- Results from a new national, multi-stakeholder survey commissioned by Eli Lilly and Company (NYSE: LLY ) reveal that metastatic breast cancer (MBC) places a significant daily strain on those living with the incurable disease. People wi
Read more →LLYNew analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease Novel results based on data from the landmark EMPA-REG OUTCOME® trial were published in the journal Circulation which suggest that treatment with...
RIDGEFIELD, Conn. and INDIANAPOLIS , Oct. 10, 2018 /PRNewswire/ -- Novel results based on data from the landmark EMPA-REG OUTCOME® trial were published in the journal Circulation which suggest that treatment with Jardiance ® positively impacts life expectancy in adults with type
Read more →LLYLilly to Present New Data From Oncology Portfolio at ESMO 2018 Congress, Showcasing Patient-Centric Advances in Cancer Care Eli Lilly and Company (NYSE: LLY) will present new data from its clinical development program at the European Society for Medical Oncology (ESMO)...
INDIANAPOLIS , Oct. 8, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present new data from its clinical development program at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany , October 19-23 . Data presented showcase how Lilly is t
Read more →LLYLilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes Results from a phase 2b clinical trial of Eli Lilly and Company's (NYSE: LLY) dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA, LY3298176) showed...
INDIANAPOLIS , Oct. 4, 2018 /PRNewswire/ -- Results from a phase 2b clinical trial of Eli Lilly and Company's (NYSE: LLY ) dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA, LY3298176) showed strong and clinically meaningful blood sugar reduction and weight loss in people with ty
Read more →LLYLilly Confirms Date and Conference Call for Third-Quarter 2018 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2018 on Tuesday, November 6, 2018. Lilly will also...
INDIANAPOLIS , Oct. 3, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the third quarter of 2018 on Tuesday, November 6, 2018 . Lilly will also conduct a conference call on that day with the investment community and media to further
Read more →LLYResults from Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint in People with Type 1 and Type 2 Diabetes Readouts from two phase 3 clinical trials demonstrated that Eli Lilly and Company's (NYSE: LLY) Ultra Rapid Lispro (URLi) met the primary efficacy...
INDIANAPOLIS , Oct. 2, 2018 /PRNewswire/ -- Readouts from two phase 3 clinical trials demonstrated that Eli Lilly and Company's (NYSE: LLY ) Ultra Rapid Lispro (URLi) met the primary efficacy endpoint of non-inferior A1C reduction from baseline compared to Humalog ® (insulin lisp
Read more →LLYLilly's Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg...
INDIANAPOLIS , Sept. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality ™ (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults. 1 Emgality offers a o
Read more →LLYLilly Receives Positive CHMP Opinion for Emgality™ (galcanezumab) for the Prophylaxis of Migraine in Adults Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...
INDIANAPOLIS , Sept. 21, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality ™ (galcanezumab) for the prophylaxis of mig
Read more →LLYNew Lilly Diabetes Center of Excellence Established at the Indiana Bioscience Research Institute Eli Lilly and Company (NYSE: LLY) and the Indiana Bioscience Research Institute (IBRI), in collaboration with Indiana University School of Medicine,...
INDIANAPOLIS , Sept. 13, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and the Indiana Bioscience Research Institute (IBRI), in collaboration with Indiana University School of Medicine , have created the Lilly Diabetes Center of Excellence (LDCE), which aims to establis
Read more →LLYLilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz® and Tremfya® in Patients with Moderate-to-Severe Plaque Psoriasis Eli Lilly and Company (NYSE: LLY) announced today the initiation of the IXORA-R head-to-head (H2H) clinical trial, designed to evaluate superiority...
INDIANAPOLIS , Sept. 10, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today the initiation of the IXORA-R head-to-head (H2H) clinical trial, designed to evaluate superiority between Taltz ® (ixekizumab) and Tremfya ® (guselkumab) in adult patients with modera
Read more →LLYLilly Announces Webcast to Discuss EASD Presentations Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Thursday, October 4, 2018 to discuss the company's presentations at the 54th annual...
INDIANAPOLIS , Sept. 6, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will conduct a webcast on Thursday, October 4, 2018 to discuss the company's presentations at the 54 th annual meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany .
Read more →LLYLilly Announces Positive Phase 3 Results in Study of Flortaucipir PET Imaging Agent Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced that a Phase 3 study of...
INDIANAPOLIS , Sept. 5, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced that a Phase 3 study of flortaucipir F 18, a Positron Emission Tomography (PET) imaging agent, met its two prim
Read more →LLYAnne White Promoted to President of Lilly Oncology Eli Lilly and Company (NYSE: LLY) today announced that Anne White has been promoted to senior vice president of Lilly and president of Lilly Oncology ...
INDIANAPOLIS , Aug. 30, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that Anne White has been promoted to senior vice president of Lilly and president of Lilly Oncology effective September 1, 2018 . She will become a member of Lilly's executive committe
Read more →LLYLilly to Participate in Morgan Stanley Global Healthcare Conference Eli Lilly and Company (NYSE:LLY) will attend the Morgan Stanley Global Healthcare Conference on Wednesday, September 12, 2018. Joshua Smiley, senior...
INDIANAPOLIS , Aug. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the Morgan Stanley Global Healthcare Conference on Wednesday, September 12, 2018 . Joshua Smiley , senior vice president and Lilly's chief financial officer, will participate in a fireside
Read more →LLYElanco Animal Health Announces Pricing of $2.0 Billion of Senior Notes Eli Lilly and Company (NYSE: LLY) today announced that its subsidiary, Elanco Animal Health Incorporated, has priced a private offering of $2.0...
INDIANAPOLIS , Aug. 14, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that its subsidiary, Elanco Animal Health Incorporated, has priced a private offering of $2.0 billion of senior notes (the "Offering"), consisting of $500 million aggregate principal a
Read more →LLYElanco Animal Health Files IPO Registration Statement Eli Lilly and Company (NYSE: LLY) today announced that its subsidiary, Elanco Animal Health, has filed a registration statement with the U.S....
INDIANAPOLIS , Aug. 2, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that its subsidiary, Elanco Animal Health, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO) of common stock
Read more →LLYLilly Diabetes Solution Center Now Open to Help People with Insulin Affordability The Lilly Diabetes Solution Center, a new patient-focused helpline with representatives who will identify personalized solutions to address insulin...
INDIANAPOLIS , Aug. 1, 2018 /PRNewswire/ -- The Lilly Diabetes Solution Center, a new patient-focused helpline with representatives who will identify personalized solutions to address insulin affordability, is now available to residents in the U.S. and all U.S. territories. Begin
Read more →LLYLilly Announces Extension of Cancer Research Collaboration with Dana-Farber Cancer Institute Eli Lilly and Company (NYSE: LLY) today announced a three-year extension of its cancer research collaboration with Dana-Farber Cancer Institute....
INDIANAPOLIS , July 30, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced a three-year extension of its cancer research collaboration with Dana-Farber Cancer Institute. Since 2015, scientists from Lilly and Dana -Farber have been working together on pre-clin
Read more →LLYLilly Delivers Strong Second-Quarter 2018 Results, Revises EPS Guidance Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2018. $ in millions, except per share data Second...
INDIANAPOLIS , July 24, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the second quarter of 2018. Certain financial information for 2018 and 2017 is presented on both a reported and a non-GAAP basis. Some numbers in this press rele
Read more →LLYLilly to Separate Elanco Animal Health with Initial Public Offering Eli Lilly and Company (NYSE: LLY) today announced that the company has completed its strategic review of Elanco Animal Health, and will file a...
INDIANAPOLIS , July 24, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the company has completed its strategic review of Elanco Animal Health, and will file a registration statement in the coming weeks with the U.S. Securities and Exchange Commission
Read more →LLYHighlights from Lilly's Alzheimer's Disease Pipeline at the Alzheimer's Association International Conference® 2018 (AAIC® 2018) Eli Lilly and Company (NYSE: LLY) today announced that new results from a number of studies across the company's Alzheimer's disease pipeline will be ...
INDIANAPOLIS , July 20, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that new results from a number of studies across the company's Alzheimer's disease pipeline will be presented at the Alzheimer's Association International Conference (AAIC) in Chicago
Read more →LLYStudy Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE) Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that results of a global systemic lupus erythematosus (SLE)...
INDIANAPOLIS , July 19, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) announced today that results of a global systemic lupus erythematosus (SLE) Phase 2 study for baricitinib were published by The Lancet . The study, the first com
Read more →LLYBoehringer Ingelheim and Lilly announce Tradjenta's CARMELINA® cardiovascular outcome trial meets primary endpoint CARMELINA® (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) met its...
RIDGEFIELD, Conn. and INDIANAPOLIS , July 19, 2018 /PRNewswire/ -- CARMELINA ® (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) met its primary endpoint, defined as time to first occurrence of cardiova
Read more →LLYLilly's Once-Weekly Trulicity® (dulaglutide) Label Updated to Include Data Showing Benefits for Adults with Type 2 Diabetes and Chronic Kidney Disease The U.S. label for Eli Lilly and Company's (NYSE: LLY) once-weekly Trulicity® (dulaglutide) is updated to show the medicine's safety and efficacy in...
INDIANAPOLIS , July 19, 2018 /PRNewswire/ -- The U.S. label for Eli Lilly and Company's (NYSE: LLY ) once-weekly Trulicity ® (dulaglutide) is updated to show the medicine's safety and efficacy in people with type 2 diabetes who have moderate to severe chronic kidney disease (CKD)
Read more →LLYNew Lilly Diabetes helpline to Assist People Seeking Solutions to Insulin Affordability Starting August 1, a new dedicated helpline called the Lilly Diabetes Solution Center will assist people who need help paying for their insulin –...
INDIANAPOLIS , July 12, 2018 /PRNewswire/ -- Starting August 1 , a new dedicated helpline called the Lilly Diabetes Solution Center will assist people who need help paying for their insulin – such as those with lower incomes, the uninsured, and people in the deductible phase of t
Read more →LLYLilly Announces Initiation of the Observational Survey of the Epidemiology, Treatment and Care of Migraine (OVERCOME) to Advance Understanding of Burden, Impact and Epidemiology of Migraine Eli Lilly and Company (NYSE: LLY) announced today initiation of the ObserVational Survey of the Epidemiology, tReatment and Care Of MigrainE...
INDIANAPOLIS , June 29, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today initiation of the O bser V ational Survey of the E pidemiology, t R eatment and C are O f M igrain E (OVERCOME) study, which aims to be the largest study of its kind in the field of mi
Read more →LLYLilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients Eli Lilly and Company (NYSE: LLY) announced today that Taltz® (ixekizumab) met the primary and major secondary endpoints in COAST-W, a Phase 3 study...
INDIANAPOLIS , June 28, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that Taltz ® (ixekizumab) met the primary and major secondary endpoints in COAST-W, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of Ankylosing Spondyli
Read more →LLYLilly Confirms Date and Conference Call for Second-Quarter 2018 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2018 on Tuesday, July 24, 2018. Lilly will also...
INDIANAPOLIS , June 28, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the second quarter of 2018 on Tuesday, July 24, 2018 . Lilly will also conduct a conference call on that day with the investment community and media to further
Read more →LLYAHS 2018: Lilly's Emgality™ (galcanezumab-gnlm) Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed BOTOX®* (onabotulinumtoxinA) Eli Lilly and Company (NYSE: LLY) announced today results from a post-hoc analysis which demonstrated efficacy of Emgality™ (galcanezumab-gnlm) in...
INDIANAPOLIS , June 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today results from a post-hoc analysis which demonstrated efficacy of Emgality ™ (galcanezumab-gnlm) in patients with episodic and chronic migraine who had previously failed preventive treat
Read more →LLYAHS 2018: Lilly Highlights Positive Phase 3 Results from the Largest Controlled Preventive Trial in Episodic Cluster Headache Eli Lilly and Company (NYSE:LLY) announced today full results from a positive Phase 3 study of patients with episodic cluster headache treated with...
INDIANAPOLIS , June 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today full results from a positive Phase 3 study of patients with episodic cluster headache treated with Emgality ™ (galcanezumab-gnlm). Detailed primary and secondary results will be presen
Read more →LLYFirst-ever Study of Lilly's Humulin® R U-500 Administered in an Insulin Pump Shows Improved A1C in People with Type 2 Diabetes Eli Lilly and Company's (NYSE: LLY) Humulin® R U-500 administered via an investigational insulin pump (Omnipod® U-500™ Insulin Management System)...
INDIANAPOLIS , June 25, 2018 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY ) Humulin ® R U-500 administered via an investigational insulin pump (Omnipod ® U-500™ Insulin Management System) provided greater A1C reduction with less daily insulin needed compared to multiple dai
Read more →LLYBoehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomized controlled trials in the EASE Phase III program,...
RIDGEFIELD, Conn. and INDIANAPOLIS , June 25, 2018 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY ) today announced that both randomized controlled trials in the EASE Phase III program, investigating the use of empagliflozin in combination with insulin
Read more →LLYLilly to Present Phase 3 Data at AHS 2018 Highlighting Innovative Potential Treatments for Migraine and Cluster Headache Eli Lilly and Company (NYSE: LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational, non-opioid...
INDIANAPOLIS , June 25, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational, non-opioid treatments for migraine and cluster headache, at the American Headache Society (AHS) annua
Read more →LLYReal-World Data Show Advantages in People Treated with Lilly's Once-Weekly Trulicity® (dulaglutide) Compared to Those Treated with Liraglutide and Exenatide QW People with type 2 diabetes new to treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist (RA) had better blood sugar control, were more...
INDIANAPOLIS , June 24, 2018 /PRNewswire/ -- People with type 2 diabetes new to treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist (RA) had better blood sugar control, were more likely to adhere to treatment and stayed on treatment longer with once-weekly Trulicity
Read more →LLYNew Data Presented at the American Diabetes Association 78th Scientific Sessions® Reinforce Potential of Lilly's Ultra Rapid Lispro in People with Type 1 and Type 2 Diabetes Eli Lilly and Company's (NYSE: LLY) ultra rapid lispro (URLi) led to improved and sustained blood sugar control after meals in people with type 1 and ...
INDIANAPOLIS , June 23, 2018 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY ) ultra rapid lispro (URLi) led to improved and sustained blood sugar control after meals in people with type 1 and type 2 diabetes, according to results from three phase 1b studies evaluating URLi co
Read more →LLYJardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced findings from two new analyses of the landmark EMPA-REG OUTCOME® trial,...
RIDGEFIELD , Conn. and INDIANAPOLIS , June 23, 2018 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY ) today announced findings from two new analyses of the landmark EMPA-REG OUTCOME ® trial, presented at the 78 th American Diabetes Association (ADA) Scie
Read more →LLYInvestigational Doses of Lilly's Once-Weekly Trulicity® (dulaglutide) Show Promise in Delivering Powerful Efficacy in People with Type 2 Diabetes Two investigational doses of Lilly's dulaglutide (4.5 mg and 3.0 mg), as well as Trulicity® (dulaglutide) 1.5 mg, provided significantly better blood ...
INDIANAPOLIS , June 23, 2018 /PRNewswire/ -- Two investigational doses of Lilly's dulaglutide (4.5 mg and 3.0 mg), as well as Trulicity ® (dulaglutide) 1.5 mg, provided significantly better blood sugar control with weight benefits compared to placebo in adults with type 2 diabete
Read more →LLYLilly Completes Acquisition of ARMO BioSciences Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of ARMO BioSciences, Inc. (NASDAQ: ARMO). Lilly's...
INDIANAPOLIS , June 22, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the successful completion of its acquisition of ARMO BioSciences, Inc. (NASDAQ: ARMO ). Lilly's tender offer for all outstanding shares of common stock of ARMO, at a price of $50.00 p
Read more →LLYLilly Declares Third-Quarter 2018 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2018 of $0.5625 per share on outstanding ...
INDIANAPOLIS , June 18, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the third quarter of 2018 of $0.5625 per share on outstanding common stock. The dividend is payable September 10, 2018 , to shareholders of recor
Read more →LLYUpdate on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease Eli Lilly and Company (NYSE: LLY) and AstraZeneca are discontinuing the global Phase 3 clinical trials of lanabecestat, an oral beta secretase...
"The complexity of Alzheimer's disease poses one of the most difficult medical challenges of our time, and we are deeply disappointed for the millions suffering from this devastating disease," said Daniel Skovronsky , M.D., Ph.D., president of Lilly Research Labs. "We are gratefu
Read more →LLYLilly to Unveil New Data at the Annual European Congress of Rheumatology, Furthering Commitment to Scientific Discovery in Immunology Eli Lilly and Company (NYSE: LLY) announced today it will present new data from its immunology portfolio, including cornerstone treatments OLUMIANT®...
INDIANAPOLIS , June 11, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today it will present new data from its immunology portfolio, including cornerstone treatments OLUMIANT ® (baricitinib) and Taltz ® (ixekizumab), at the Annual European Congress of Rheumatol
Read more →LLYFDA Expands Lilly's ALIMTA® (pemetrexed) Label to Include Combination with KEYTRUDA® (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new indication for...
INDIANAPOLIS , June 5, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new indication for ALIMTA ® (pemetrexed for injection) in combination with carboplatin and KEYTRUDA ® (pembro
Read more →LLYDDW 2018: Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial Eli Lilly and Company (NYSE: LLY) announced today new safety and efficacy data from a Phase 2 study evaluating mirikizumab in patients with...
INDIANAPOLIS , June 5, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today new safety and efficacy data from a Phase 2 study evaluating mirikizumab in patients with moderate-to-severe ulcerative colitis (UC). The results showed that patients treated with mirik
Read more →LLYFDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved ...
INDIANAPOLIS , June 1, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) announced today that the U.S. Food and Drug Administration (FDA) has approved the 2-mg dose of OLUMIANT ® (baricitinib), a once-daily oral medication for the trea
Read more →LLYLilly to Participate in Goldman Sachs Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018. David A....
INDIANAPOLIS , May 31, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018 . David A. Ricks , Lilly's chairman and chief executive officer, will participate in a firesi
Read more →LLYLilly to Participate in Jefferies Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Jefferies Global Healthcare Conference on Wednesday, June 6, 2018. Joshua Smiley, senior vice...
INDIANAPOLIS , May 30, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the Jefferies Global Healthcare Conference on Wednesday, June 6, 2018 . Joshua Smiley , senior vice president and Lilly's chief financial officer, will participate in a fireside chat at 11:
Read more →LLYSue Mahony to Retire as President of Lilly Oncology Eli Lilly and Company (NYSE: LLY) announced today that Sue Mahony, Ph.D., senior vice president of Lilly and president of Lilly Oncology, will retire ...
INDIANAPOLIS , May 23, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that Sue Mahony , Ph.D., senior vice president of Lilly and president of Lilly Oncology, will retire at the end of August after 18 years of service with the company. Mahony is also a me
Read more →LLYLilly's Taltz® (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz®...
INDIANAPOLIS , May 22, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz ® (ixekizumab) injection 80 mg/mL to include data in psoriasis involving the genital area. 1 Taltz
Read more →LLYLilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care Eli Lilly and Company (NYSE: LLY) today announced that new results from a number of studies across the company's oncology product and pipeline...
INDIANAPOLIS , May 16, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that new results from a number of studies across the company's oncology product and pipeline portfolio will be presented at the 54 th Annual Meeting of the American Society of Clinical
Read more →LLYLilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache Eli Lilly and Company (NYSE: LLY) announced today that galcanezumab met its primary endpoint in a Phase 3 study of patients with episodic cluster...
INDIANAPOLIS , May 15, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that galcanezumab met its primary endpoint in a Phase 3 study of patients with episodic cluster headache, demonstrating statistically significant differences in the reduction of weekly
Read more →LLYLilly to Acquire AurKa Pharma Eli Lilly and Company (NYSE: LLY) today announced an agreement to acquire AurKa Pharma, Inc., a company established by TVM Capital Life Science to...
INDIANAPOLIS , May 14, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced an agreement to acquire AurKa Pharma, Inc., a company established by TVM Capital Life Science to develop oncology compound AK-01, an Aurora kinase A inhibitor that was originally discov
Read more →LLYLilly to Participate in UBS Global Healthcare Conference Eli Lilly and Company (NYSE:LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 22, 2018. Enrique Conterno, senior vice president...
INDIANAPOLIS , May 11, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the UBS Global Healthcare Conference on Tuesday, May 22, 2018 . Enrique Conterno , senior vice president of Lilly and president of Lilly Diabetes and Lilly USA , will participate in a fires
Read more →LLYLilly Announces Agreement To Acquire ARMO BioSciences Eli Lilly and Company (NYSE: LLY) and ARMO BioSciences, Inc. (NASDAQ: ARMO) today announced a definitive agreement for Lilly to acquire ARMO for $50...
INDIANAPOLIS and REDWOOD CITY, Calif. , May 10, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and ARMO BioSciences, Inc. (NASDAQ: ARMO ) today announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion , in an all-cash tr
Read more →LLYLilly Declares Second-Quarter 2018 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2018 of $0.5625 per share on...
INDIANAPOLIS , May 7, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the second quarter of 2018 of $0.5625 per share on outstanding common stock. The dividend is payable June 8, 2018 , to shareholders of record at th
Read more →LLYLilly and Local Partners Launch Diabetes Prevention and Management Pilot in Three Underserved Neighborhoods in Indianapolis Eli Lilly and Company (NYSE: LLY) and Indiana University's Richard M. Fairbanks School of Public Health at IUPUI announced today the launch of a new...
INDIANAPOLIS , May 1, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Indiana University's Richard M. Fairbanks School of Public Health at IUPUI announced today the launch of a new neighborhood-based, data-driven pilot in Indianapolis to help address the high incidenc
Read more →LLYLilly to Participate in Bank of America Merrill Lynch Health Care Conference Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018....
INDIANAPOLIS , April 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018 . Christi Shaw , senior vice president and president of Lilly Bio-Medicines will participa
Read more →LLYLilly Reports Strong First-Quarter 2018 Results, Raises EPS Guidance Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2018. $ in millions, except per share data First Quarter ...
INDIANAPOLIS , April 24, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the first quarter of 2018. Certain financial information for 2018 and 2017 is presented on both a reported and a non-GAAP basis. Some numbers in this press rele
Read more →LLYFDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration's (FDA) Arthritis...
INDIANAPOLIS , April 23, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) announced today that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee recommended approval of the 2-mg dose of baricitinib, a once-dai
Read more →LLYLilly to Present Phase 3 Data at AAN 2018 Reinforcing Commitment to New, Innovative Therapies in Migraine Eli Lilly and Company (NYSE: LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational treatments for...
INDIANAPOLIS , April 20, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational treatments for migraine, at the American Academy of Neurology (AAN) annual meeting taking place April
Read more →LLYLilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer Eli Lilly and Company (NYSE: LLY) today announced additional results from its global, randomized, double-blind, placebo-controlled Phase 3 RANGE...
INDIANAPOLIS , April 20, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced additional results from its global, randomized, double-blind, placebo-controlled Phase 3 RANGE trial evaluating CYRAMZA ® (ramucirumab) in combination with docetaxel in patients with
Read more →LLYBoehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced an academic collaboration with the University of Oxford to investigate the ...
RIDGEFIELD, Conn. and INDIANAPOLIS , April 16, 2018 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY ) today announced an academic collaboration with the University of Oxford to investigate the effects of Jardiance ® on the progression of kidney disease a
Read more →LLYLilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics today announced a global collaboration to develop encapsulated cell therapies for the...
INDIANAPOLIS and CAMBRIDGE, Mass. , April 4, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Sigilon Therapeutics today announced a global collaboration to develop encapsulated cell therapies for the potential treatment of type 1 diabetes. Sigilon is a privately-held
Read more →LLYLilly Announces CYRAMZA® (ramucirumab) Phase 3 REACH-2 Study in Second-Line Hepatocellular Carcinoma Patients Met Overall Survival Endpoint Eli Lilly and Company (NYSE: LLY) today announced top-line results from its Phase 3 REACH-2 study of CYRAMZA® (ramucirumab) as a single agent in the...
INDIANAPOLIS , April 4, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced top-line results from its Phase 3 REACH-2 study of CYRAMZA ® (ramucirumab) as a single agent in the second-line treatment of people with hepatocellular carcinoma (HCC), also known as l
Read more →LLYLilly Confirms Date and Conference Call for First-Quarter 2018 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the first quarter of 2018 on Tuesday, April 24, 2018. Lilly will also...
INDIANAPOLIS , April 4, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the first quarter of 2018 on Tuesday, April 24, 2018 . Lilly will also conduct a conference call on that day with the investment community and media to further
Read more →LLYMaura Dickler, M.D., to become Vice President of Late Phase Development at Lilly Oncology Eli Lilly and Company (NYSE: LLY) today announced that Maura Dickler, M.D., a prestigious breast cancer researcher, will join Lilly Oncology as Vice...
INDIANAPOLIS , March 9, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that Maura Dickler , M.D., a prestigious breast cancer researcher, will join Lilly Oncology as Vice President of Late Phase Development on May 7 , 2018. Dr. Dickler is currently the S
Read more →LLYEFSD, JDRF and Lilly Extend Collaboration Supporting Type 1 Diabetes Research The European Foundation for the Study of Diabetes (EFSD), JDRF and Eli Lilly and Company (NYSE: LLY) have agreed to extend their collaboration for...
INDIANAPOLIS , March 8, 2018 /PRNewswire/ -- The European Foundation for the Study of Diabetes (EFSD), JDRF and Eli Lilly and Company (NYSE: LLY ) have agreed to extend their collaboration for the European Programme in Type 1 Diabetes Research through 2020. The programme, which b
Read more →LLYLilly Receives Additional FDA Approval for Verzenio™ (abemaciclib), as Initial Treatment for Advanced Breast Cancer Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved VerzenioTM (abemaciclib) in...
INDIANAPOLIS , Feb. 26, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Food and Drug Administration (FDA) has approved Verzenio TM (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treat
Read more →LLYLilly to Participate in Barclays Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Barclays Global Healthcare Conference on Wednesday, March 14, 2018. Joshua Smiley, senior...
INDIANAPOLIS , Feb. 21, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Barclays Global Healthcare Conference on Wednesday, March 14, 2018 . Joshua Smiley , senior vice president and Lilly's chief financial officer, will participate in a fireside c
Read more →LLYSurvey Reveals Many People with Migraine Live with Pain Nearly Half of Every Month li Lilly and Company (NYSE: LLY) announced today findings from a Lilly-sponsored, quantitative opinion survey, which found among those surveyed,...
INDIANAPOLIS , Feb. 20, 2018 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY ) announced today findings from a Lilly-sponsored, quantitative opinion survey, which found among those surveyed, people diagnosed with migraine experienced on average 15.4 completely pain-free days over
Read more →LLYLilly to Participate in Cowen Health Care Conference Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018. Sue...
INDIANAPOLIS , Feb. 20, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Cowen and Company 38 th Annual Health Care Conference on Tuesday, March 13, 2018 . Sue Mahony , Ph.D., senior vice president and president of Lilly Oncology and Levi Garraway ,
Read more →LLYAAD 2018: Treatment with Lilly's Taltz® (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity Eli Lilly and Company (NYSE: LLY) announced today that patients with moderate-to-severe genital psoriasis treated with Taltz® (ixekizumab) reported a ...
INDIANAPOLIS , Feb. 19, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that patients with moderate-to-severe genital psoriasis treated with Taltz ® (ixekizumab) reported a greater decrease in the impact of their condition on sexual activity compared to pl
Read more →LLYLilly to Showcase New Data for Taltz® (ixekizumab) and Other Products Across Immunology Pipeline at AAD Annual Meeting Eli Lilly and Company (NYSE: LLY) announced that it will present new data for Taltz® (ixekizumab), baricitinib and mirikizumab at the American...
INDIANAPOLIS , Feb. 14, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced that it will present new data for Taltz ® (ixekizumab), baricitinib and mirikizumab at the American Academy of Dermatology (AAD) annual meeting taking place Feb. 16-20, 2018 , in San Diego,
Read more →LLYLilly Announces Positive Top-Line Phase 3 Results for Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) Eli Lilly and Company (NYSE: LLY) announced today that Taltz® (ixekizumab) met the primary and all key secondary endpoints in COAST-V, a Phase 3...
INDIANAPOLIS , Feb. 13, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that Taltz ® (ixekizumab) met the primary and all key secondary endpoints in COAST-V, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of Ankylosing Spondy
Read more →LLYLilly Reports Strong Fourth-Quarter and Full-Year 2017 Revenue Growth, Increases 2018 EPS Guidance Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2017. $ in millions, except per share...
INDIANAPOLIS , Jan. 31, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the fourth quarter and full year of 2017. Certain financial information for 2017 and 2016 is presented on both a reported and a non-GAAP basis. Some numbers in t
Read more →LLYLilly To Present At Leerink Partners Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will present at the Leerink Partners Global Healthcare Conference on Thursday, February 15, 2018. Jan Lundberg,...
INDIANAPOLIS , Jan. 26, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present at the Leerink Partners Global Healthcare Conference on Thursday, February 15, 2018 . Jan Lundberg , Ph.D., executive vice president for science and technology and president of Lilly Rese
Read more →LLYLilly Confirms Date and Conference Call for Fourth-Quarter 2017 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2017 financial results on Wednesday, January 31, 2018. Lilly will...
INDIANAPOLIS , Jan. 5, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its fourth-quarter and full-year 2017 financial results on Wednesday, January 31, 2018 . Lilly will also conduct a conference call on that day with the investment community and media to f
Read more →LLYLilly to Present at J.P. Morgan Healthcare Conference Eli Lilly and Company (NYSE: LLY) will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018. David A. Ricks,...
INDIANAPOLIS , Jan. 2, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present at the 36 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 . David A. Ricks , Lilly's chairman and chief executive officer, will speak from 7:00 p.m. to 7:25 p.m. Ea
Read more →LLYLilly to Participate in Goldman Sachs Healthcare CEOs Unscripted Conference Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs Healthcare CEOs Unscripted Conference on Thursday, January 4, 2018. David A....
INDIANAPOLIS , Dec. 18, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Goldman Sachs Healthcare CEOs Unscripted Conference on Thursday, January 4, 2018 . David A. Ricks , Lilly's chairman and chief executive officer, will participate in a fireside
Read more →LLYLilly Announces 2018 Financial Guidance and Enhances Outlook Through 2020 Eli Lilly and Company (NYSE: LLY) today announced its 2018 financial guidance, including low-single-digit revenue growth driven by volume from...
INDIANAPOLIS , Dec. 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its 2018 financial guidance, including low-single-digit revenue growth driven by volume from recently launched pharmaceutical products. The company also highlighted key events for the
Read more →LLYLilly Announces 8 Percent Dividend Increase The board of directors of Eli Lilly and Company (NYSE: LLY) today announced an 8 percent increase in its quarterly dividend. The dividend for the...
INDIANAPOLIS , Dec. 11, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) today announced an 8 percent increase in its quarterly dividend. The dividend for the first quarter of 2018 will be $0.5625 per share on outstanding common stock. This raises
Read more →LLYFDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) ...
INDIANAPOLIS , Dec. 11, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) to review galcanezumab for the prevention of migraine in adults. Galcanezumab has be
Read more →LLYKimberly Blackwell, M.D., to become Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology Eli Lilly and Company (NYSE: LLY) today announced that Kimberly Blackwell, M.D., one of the nation's leading breast cancer researchers, will join...
INDIANAPOLIS , Dec. 11, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that Kimberly Blackwell , M.D., one of the nation's leading breast cancer researchers, will join Lilly Oncology as vice president of early phase development and immuno-oncology on Marc
Read more →LLYLilly Reports Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer Eli Lilly and Company (NYSE: LLY) today announced top-line results from its Phase 3 RAINFALL study of CYRAMZA® (ramucirumab) in combination with...
INDIANAPOLIS , Dec. 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced top-line results from its Phase 3 RAINFALL study of CYRAMZA ® (ramucirumab) in combination with cisplatin and capecitabine or 5-FU (5-fluorouracil) in the first-line treatment of patien
Read more →LLYLilly Initiates Clinical Trial to Evaluate the Functionality and Safety of its Automated Insulin Delivery System Yesterday marked dosing of the first patient with type 1 diabetes in a feasibility study to evaluate the functionality and safety of an automated...
INDIANAPOLIS , Dec. 5, 2017 /PRNewswire/ -- Yesterday marked dosing of the first patient with type 1 diabetes in a feasibility study to evaluate the functionality and safety of an automated insulin delivery (AID) system in development by Eli Lilly and Company (NYSE: LLY ). The AI
Read more →LLYLilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80...
INDIANAPOLIS , Dec. 1, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz ® (ixekizumab) injection 80 mg/mL for the treatment of adults with active psoriatic arthritis (PsA). 1 Taltz was firs
Read more →LLYLilly Confirms Date and Conference Call for 2018 Financial Guidance Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2018 on Wednesday, December 13, 2017. Lilly will also conduct a conference ...
INDIANAPOLIS , Nov. 20, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial guidance for 2018 on Wednesday, December 13, 2017 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the comp
Read more →LLYLilly to Participate in Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference Eli Lilly and Company (NYSE:LLY) will participate in the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference on Thursday, November 30, 2017....
INDIANAPOLIS , Nov. 17, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference on Thursday, November 30, 2017 . Dan Skovronsky , M.D., Ph.D., senior vice president of Clinical and Product Developme
Read more →LLYLilly Appoints Philip Johnson to Senior Vice President and Treasurer Eli Lilly and Company (NYSE: LLY) today announced Philip Johnson has been appointed to senior vice president, Finance, and treasurer effective...
INDIANAPOLIS , Nov. 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced Philip Johnson has been appointed to senior vice president, Finance, and treasurer effective January 1, 2018 . Johnson currently serves as vice president for Investor Relations at Lill
Read more →LLYNew Data on FORTEO® (teriparatide [rDNA origin] injection) Showed Reduced Risk for New Vertebral and Clinical Fractures in Postmenopausal Women with Severe Osteoporosis Eli Lilly and Company (NYSE: LLY) today announced new data showing that treatment with FORTEO® for 24 months was associated with significantly fewer...
INDIANAPOLIS , Nov. 9, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced new data showing that treatment with FORTEO ® for 24 months was associated with significantly fewer vertebral and clinical fractures (a composite of painful vertebral and non-vertebral
Read more →LLYACR/ARHP 2017: Long-Term Use of Lilly's Taltz® (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors Eli Lilly and Company (NYSE: LLY) announced today patients with active psoriatic arthritis (PsA) treated with Taltz® (ixekizumab), who were...
INDIANAPOLIS , Nov. 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today patients with active psoriatic arthritis (PsA) treated with Taltz ® (ixekizumab), who were previously intolerant or had inadequate responses to TNF inhibitors, showed improvements in th
Read more →LLYACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that patients with moderate-to-severe rheumatoid arthritis...
INDIANAPOLIS , Nov. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) announced today that patients with moderate-to-severe rheumatoid arthritis (RA) treated with baricitinib reported greater improvements in pain control when compar
Read more →LLYLilly To Participate In Credit Suisse 26th Annual Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Credit Suisse 26th Annual Healthcare Conference on Tuesday, November 7, 2017. Jan Lundberg, ...
INDIANAPOLIS , Oct. 25, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Credit Suisse 26 th Annual Healthcare Conference on Tuesday, November 7, 2017 . Jan Lundberg , Ph.D., executive vice president for science and technology and president of Lilly
Read more →LLYLilly Reports Third-Quarter Results, Announces Strategic Review of Elanco Animal Health Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2017. $ in millions, except per share data Third Quarter ...
INDIANAPOLIS , Oct. 24, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the third quarter of 2017. Certain financial information for 2017 and 2016 is presented on both a reported and a non-GAAP basis. Some numbers in this press relea
Read more →LLYLilly announces $72 million investment in diabetes manufacturing in Indianapolis Eli Lilly and Company (NYSE: LLY) today announced plans to invest $72 million in an insulin manufacturing project at one of its Indianapolis...
INDIANAPOLIS , Oct. 23, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced plans to invest $72 million in an insulin manufacturing project at one of its Indianapolis facilities. The investment will be used to replace an existing insulin vial filling line and
Read more →LLYLilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines Eli Lilly and Company (NYSE: LLY) and CureVac AG have announced a global immuno-oncology collaboration focused on the development and...
INDIANAPOLIS and TÜBINGEN, Germany , Oct. 18, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on Cur
Read more →LLYLilly Declares Fourth-Quarter 2017 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2017 of $0.52 per share on outstanding...
INDIANAPOLIS , Oct. 16, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the fourth quarter of 2017 of $0.52 per share on outstanding common stock. The dividend is payable December 8, 2017 , to shareholders of record a
Read more →LLYRapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA® (ramucirumab) Phase 3 Subgroup Analysis New subgroup analysis from Eli Lilly and Company's (NYSE: LLY) Phase 3 REVEL trial of CYRAMZA® (ramucirumab) in advanced non-small cell lung cancer...
INDIANAPOLIS , Oct. 16, 2017 /PRNewswire/ -- New subgroup analysis from Eli Lilly and Company's (NYSE: LLY ) Phase 3 REVEL trial of CYRAMZA ® (ramucirumab) in advanced non-small cell lung cancer (NSCLC) was presented today at the 18 th World Conference on Lung Cancer (WCLC), host
Read more →LLYFDA Grants Priority Review for Potential New Indication for Lilly's Verzenio™ (abemaciclib) as Initial Treatment of Advanced Breast Cancer Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for its...
INDIANAPOLIS , Oct. 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for its New Drug Application (NDA) for Verzenio ™ (abemaciclib), a cyclin-dependent kinase (CDK
Read more →LLYLilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 JUNIPER study evaluating Verzenio™ (abemaciclib), a cyclin-dependent kinase (CDK)4 ...
INDIANAPOLIS , Oct. 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that its Phase 3 JUNIPER study evaluating Verzenio™ (abemaciclib), a cyclin-dependent kinase (CDK)4 and CDK6 inhibitor, as monotherapy in KRAS-mutated, advanced non-small lung cancer (
Read more →LLYLilly MONARCH 3 Study Published in Journal of Clinical Oncology Demonstrates Benefit of Verzenio™ (abemaciclib) Plus NSAI in Advanced Breast Cancer Eli Lilly and Company (NYSE: LLY) today announced that interim results from the double-blind, placebo-controlled Phase 3 MONARCH 3 study evaluating...
INDIANAPOLIS , Oct. 6, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that interim results from the double-blind, placebo-controlled Phase 3 MONARCH 3 study evaluating Verzenio TM (abemaciclib), a cyclin-dependent kinase (CDK)4 & 6 inhibitor, in combinati
Read more →LLYU.S. Patent and Trademark Office Rules In Lilly's Favor On Alimta Vitamin Regimen Patent Eli Lilly and Company (NYSE: LLY) today announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (PTO) has ruled in...
INDIANAPOLIS , Oct. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (PTO) has ruled in the company's favor regarding patentability of the vitamin regimen for Alimta ® (pemetr
Read more →LLYAdditional Delivery of Insulin Ready for Distribution in Puerto Rico Today, a new shipment of commercial medicines, including more than 36,000 vials and pens of insulin, arrived in Puerto Rico. The delivery by Eli...
INDIANAPOLIS , Oct. 5, 2017 /PRNewswire/ -- Today, a new shipment of commercial medicines, including more than 36,000 vials and pens of insulin, arrived in Puerto Rico . The delivery by Eli Lilly and Company (NYSE: LLY ) includes 3,000 vials for humanitarian distribution and enou
Read more →LLYHumalog® Junior KwikPen® Now Available in the U.S. for People with Diabetes Humalog® Junior KwikPen® [insulin lispro injection 100 units/mL] is now available by prescription for the treatment of diabetes in the U.S. This...
INDIANAPOLIS , Oct. 4, 2017 /PRNewswire/ -- Humalog ® Junior KwikPen ® [insulin lispro injection 100 units/mL] is now available by prescription for the treatment of diabetes in the U.S. This innovation is the latest in the treatment and delivery options Eli Lilly and Company (NYS
Read more →LLYLilly Confirms Date and Conference Call for Third-Quarter 2017 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2017 on Tuesday, October 24, 2017. Lilly will also...
INDIANAPOLIS , Oct. 2, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the third quarter of 2017 on Tuesday, October 24, 2017 . Lilly will also conduct a conference call on that day with the investment community and media to further
Read more →LLYLilly Announces Senior Leadership Appointments for Finance, Research & Development and Manufacturing Eli Lilly and Company (NYSE: LLY) today announced a number of leadership changes, promoting several experienced Lilly leaders to executive roles,...
INDIANAPOLIS , Sept. 29, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced a number of leadership changes, promoting several experienced Lilly leaders to executive roles, effective in 2018. "Joining our executive team are individuals who have the experience
Read more →LLYLilly Receives U.S. FDA Approval of Verzenio™ (abemaciclib) | Eli Lilly and Company
Eli Lilly's Verzenio™ (abemaciclib) has received FDA approval for treating HR+, HER2- advanced breast cancer, both in combination with fulvestrant and as monotherapy. The approval is based on positive results from clinical trials, marking a significant advancement in treatment options for patients.
Read more →LLYGeisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death In an effort to improve health outcomes of people with type 2 diabetes, Geisinger and Boehringer Ingelheim, on behalf of its diabetes alliance with...
DANVILLE, Pa. , RIDGEFIELD, Conn. and INDIANAPOLIS , Sept. 25, 2017 /PRNewswire/ -- In an effort to improve health outcomes of people with type 2 diabetes, Geisinger and Boehringer Ingelheim, on behalf of its diabetes alliance with Eli Lilly and Company (NYSE: LLY ), today announ
Read more →LLYLilly to Present New Data for Olumiant® (baricitinib) and Taltz® (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress Eli Lilly and Company (NYSE: LLY) announced that data across its immunology portfolio will be presented at the annual European Academy of Dermatology ...
INDIANAPOLIS , Sept. 11, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced that data across its immunology portfolio will be presented at the annual European Academy of Dermatology and Venereology Congress (EADV), including Phase 2 safety and efficacy data evaluat
Read more →LLYLilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer At the European Society for Medical Oncology (ESMO) 2017 Congress today, Phase 3 RANGE data from Eli Lilly and Company (NYSE: LLY) were presented in...
INDIANAPOLIS , Sept. 10, 2017 /PRNewswire/ -- At the European Society for Medical Oncology (ESMO) 2017 Congress today, Phase 3 RANGE data from Eli Lilly and Company (NYSE: LLY ) were presented in the Presidential Symposium (abstract#: LBA4_PR). These are the first detailed result
Read more →LLYIHC 2017: Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine Eli Lilly and Company (NYSE: LLY) will present key primary and secondary endpoint data for lasmiditan, an investigational, oral, first-in-class...
INDIANAPOLIS , Sept. 9, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present key primary and secondary endpoint data for lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, which demonstrated statistically significant
Read more →LLYIHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results for up to 12 Months in Patients with Migraine Eli Lilly and Company (NYSE: LLY) announced today that treatment with self-administered galcanezumab for up to 12 months demonstrated a positive...
INDIANAPOLIS , Sept. 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that treatment with self-administered galcanezumab for up to 12 months demonstrated a positive safety and tolerability profile in patients with migraine, consistent with previous studi
Read more →LLYLilly Takes Steps to Streamline Business, Invest in New Medicines and Drive Growth Eli Lilly and Company (NYSE: LLY) today announced actions to streamline operations to more efficiently focus resources on developing new medicines...
INDIANAPOLIS , Sept. 7, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced actions to streamline operations to more efficiently focus resources on developing new medicines and to improve its cost structure. Global workforce reductions, including those from a
Read more →LLYLilly to Present New Data for Galcanezumab and Lasmiditan at the 18th Congress of the International Headache Society (IHC) Eli Lilly and Company (NYSE: LLY) announced today it will present new data for galcanezumab and lasmiditan, two investigational treatments for...
INDIANAPOLIS , Sept. 6, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today it will present new data for galcanezumab and lasmiditan, two investigational treatments for migraine, at the 18th Congress of the International Headache Society (IHC) taking place Sep
Read more →LLYLilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018 Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that, after discussions with the U.S. Food and Drug...
INDIANAPOLIS , Aug. 30, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) announced today that, after discussions with the U.S. Food and Drug Administration (FDA) in late August, Lilly will resubmit the New Drug Application (NDA) for b
Read more →LLYNew Phase 3 Data for Abemaciclib and Ramucirumab Presented at ESMO 2017 Congress Eli Lilly and Company (NYSE: LLY) will showcase new data across six different tumor types at the European Society for Medical Oncology (ESMO) 2017...
INDIANAPOLIS , Aug. 29, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will showcase new data across six different tumor types at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain , September 8-12, 2017 . Notably, results from Phase 3 studie
Read more →LLYLilly to Participate in Morgan Stanley Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2017. Derica Rice, Lilly's...
INDIANAPOLIS , Aug. 28, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2017 . Derica Rice , Lilly's executive vice president for global services and chief financial officer, will partic
Read more →LLYLilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of Migraine Eli Lilly and Company (NYSE: LLY) announced today that lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of...
INDIANAPOLIS , Aug. 4, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, met its primary endpoint in SPARTAN, a second Phase 3 study. At two hours followi
Read more →LLYBoehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight the increasingly important role of cardiologists in reducing cardiovascular risk and cardiovascular death in people with type 2 diabetes Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the companies will support an American College of Cardiology (ACC)...
RIDGEFIELD, Conn. and INDIANAPOLIS , July 31, 2017 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY ) today announced that the companies will support an American College of Cardiology (ACC) program focused on driving quality improvement in cardiology and
Read more →LLYLilly Reports Second-Quarter Results Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2017. $ in millions, except per share data Second...
INDIANAPOLIS , July 25, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the second quarter of 2017. Certain financial information for 2017 and 2016 is presented on both a reported and a non-GAAP basis. Some numbers in this press rele
Read more →LLYLilly and Incyte Provide Update on Baricitinib Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that a resubmission to the U.S. Food and Drug Administration...
INDIANAPOLIS , July 25, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) announced today that a resubmission to the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for baricitinib, a once-daily oral medicati
Read more →LLYLilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation Eli Lilly and Company (NYSE: LLY) has entered into a settlement agreement with generic companies to resolve pending patent litigation in the U.S....
INDIANAPOLIS , July 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has entered into a settlement agreement with generic companies to resolve pending patent litigation in the U.S. District Court for the Eastern District of Virginia regarding the Cialis ® (tadalafil) u
Read more →LLYEli Lilly and Company to Present More Than 40 Abstracts at the Alzheimer's Association International Conference® 2017 (AAIC® 2017) Eli Lilly and Company (NYSE: LLY) today announced it will present findings from more than 40 research studies at the upcoming Alzheimer's Association ...
Data highlights include important health outcomes data emphasizing the need for timely detection and management of Alzheimer's disease INDIANAPOLIS , July 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced it will present findings from more than 40 resea
Read more →LLYRenowned Television Personality Don Francisco Introduces New Initiative to Help Dispel Myths About Diabetes and Insulin Treatment Popular television host and legendary entertainer, Don Francisco, is joining Lilly and Boehringer Ingelheim to launch a new awareness initiative,...
INDIANAPOLIS and RIDGEFIELD, Conn. , July 10, 2017 /PRNewswire/ -- Popular television host and legendary entertainer, Don Francisco , is joining Lilly and Boehringer Ingelheim to launch a new awareness initiative, Basado en Hechos , to help address common misconceptions about typ
Read more →LLYLa popular estrella de televisión Don Francisco presenta una nueva iniciativa para ayudar a disipar los mitos sobre la diabetes y el tratamiento con insulina El popular presentador de televisión y legendario animador, Don Francisco, se une a Lilly y Boehringer Ingelheim para lanzar una nueva iniciativa de...
INDIANAPOLIS y RIDGEFIELD, Connecticut , 10 de julio de 2017 /PRNewswire-HISPANIC PR WIRE/ -- El popular presentador de televisión y legendario animador, Don Francisco , se une a Lilly y Boehringer Ingelheim para lanzar una nueva iniciativa de concientización, Basado en Hechos ,
Read more →LLYFDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed its New Drug Application...
INDIANAPOLIS , July 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed its New Drug Application (NDA) for abemaciclib, a cyclin-dependent kinase (CDK)4 & 6 inhibitor, and given the ND
Read more →LLYUK Supreme Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents Eli Lilly and Company (NYSE: LLY) today announced that the UK Supreme Court has decided in the litigation relating to alternative salt forms of...
INDIANAPOLIS , July 7, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the UK Supreme Court has decided in the litigation relating to alternative salt forms of Alimta ® (pemetrexed disodium) that Actavis's products directly infringe Lilly's vitamin re
Read more →LLYLilly Confirms Date and Conference Call for Second-Quarter 2017 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2017 on Tuesday, July 25, 2017. Lilly will also...
INDIANAPOLIS , July 6, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the second quarter of 2017 on Tuesday, July 25, 2017 . Lilly will also conduct a conference call on that day with the investment community and media to further d
Read more →LLYLilly and Purdue University Announce Strategic Research Collaboration Eli Lilly and Company (NYSE: LLY) and Purdue University today announced a strategic collaboration to conduct life science research. The five-year...
INDIANAPOLIS and WEST LAFAYETTE, Ind. , July 6, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Purdue University today announced a strategic collaboration to conduct life science research. The five-year agreement, where Lilly will provide up to $52 million , marks Pu
Read more →LLYJapan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant® (baricitinib) for the Treatment of Rheumatoid Arthritis Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that Japan's Ministry of Health, Labor and Welfare (MHLW)...
INDIANAPOLIS , July 3, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) announced today that Japan's Ministry of Health, Labor and Welfare (MHLW) granted marketing approval for Olumiant ® (baricitinib) 2-mg and 4-mg tablets for the tr
Read more →LLYLilly Diabetes Brings an Extra Splash of Summertime Fun and Inspiration to Diabetes Camps with Launch of Annual Camp Care Package Speaker Tour For the 22,000 children who attend diabetes camp each year, feelings of isolation that may accompany type 1 diabetes can be overcome by fun...
INDIANAPOLIS , June 27, 2017 /PRNewswire/ -- For the 22,000 children who attend diabetes camp each year, feelings of isolation that may accompany type 1 diabetes can be overcome by fun experiences and new friends who say, "you are not alone." Lilly Diabetes understands the import
Read more →LLYEli Lilly and Company Unveils Expanded Biotechnology Center in San Diego Eli Lilly and Company (NYSE: LLY) today announced completion of a $90 million expansion of its Biotechnology Center in San Diego, California. Lilly's ...
INDIANAPOLIS , June 21, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced completion of a $90 million expansion of its Biotechnology Center in San Diego, California . Lilly's new space will help foster and accelerate the discovery of medicines within the com
Read more →LLYLilly Declares Third-Quarter 2017 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2017 of $0.52 per share on outstanding...
INDIANAPOLIS , June 19, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the third quarter of 2017 of $0.52 per share on outstanding common stock. The dividend is payable September 8, 2017 , to shareholders of record a
Read more →LLYEULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks Eli Lilly and Company (NYSE: LLY) announced today that the majority of patients with active psoriatic arthritis (PsA) treated with Taltz®...
INDIANAPOLIS , June 16, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the majority of patients with active psoriatic arthritis (PsA) treated with Taltz ® (ixekizumab) exhibited either no progression or minimal progression of radiographic structural
Read more →LLYNew Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017 Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced a new pooled analysis of data from eight Olumiant®...
INDIANAPOLIS , June 16, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) today announced a new pooled analysis of data from eight Olumiant ® (baricitinib) clinical trials, showing that baricitinib-treated and placebo-treated patients
Read more →LLYEULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate Response or Intolerance to TNF Inhibitors Eli Lilly and Company (NYSE: LLY) announced today that patients with active psoriatic arthritis (PsA) who had inadequate response to one or two TNF...
Taltz also demonstrated significant improvements in key secondary measures at 24 weeks INDIANAPOLIS , June 15, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that patients with active psoriatic arthritis (PsA) who had inadequate response to one or two TN
Read more →LLYLilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017) Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that new data on safety and long-term efficacy from the...
INDIANAPOLIS , June 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) announced today that new data on safety and long-term efficacy from the Olumiant ® (baricitinib) clinical trials will be presented in 21 abstracts, including one
Read more →LLYJardiance® (empagliflozin) tablets to be studied in chronic kidney disease Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced plans to conduct a new, large clinical outcomes trial investigating...
RIDGEFIELD, Conn. and INDIANAPOLIS , June 12, 2017 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY ) today announced plans to conduct a new, large clinical outcomes trial investigating Jardiance ® (empagliflozin) tablets for the treatment of people with
Read more →LLYLilly's Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine: New Results Presented at AHS Eli Lilly and Company (NYSE: LLY) announced today positive results from three Phase 3 studies of galcanezumab, an investigational treatment for the...
INDIANAPOLIS , June 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today positive results from three Phase 3 studies of galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, including late-breaking data on several k
Read more →LLYIDF, in partnership with Lilly, announces second phase of BRIDGES programme funding for translational research in diabetes with focus on secondary prevention More than 400 million people are living with diabetes. In a further effort to help spread lessons learned from clinical research to benefit people...
BRUSSELS and INDIANAPOLIS , June 9, 2017 /PRNewswire/ -- More than 400 million people are living with diabetes. In a further effort to help spread lessons learned from clinical research to benefit people affected by this condition, the International Diabetes Federation (IDF) and
Read more →LLYLilly to Present Late-Breaking Data for Galcanezumab and Lasmiditan at the American Headache Society Annual Scientific Meeting Eli Lilly and Company (NYSE: LLY) will present data from 14 abstracts, including late-breaking Phase 3 data for two investigational treatments for...
INDIANAPOLIS , June 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present data from 14 abstracts, including late-breaking Phase 3 data for two investigational treatments for migraine, at the American Headache Society (AHS) annual scientific meeting, taking place
Read more →LLYLilly Announces Webcast to Discuss Pain Management Portfolio Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, June 19, 2017, to discuss the company's pain management portfolio, including data ...
INDIANAPOLIS , June 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will conduct a webcast on Monday, June 19, 2017 , to discuss the company's pain management portfolio, including data from three Phase 3 studies of galcanezumab, an investigational treatment for the pre
Read more →LLYLilly Announces Strategic Collaboration with KeyBioscience AG Eli Lilly and Company (NYSE: LLY) and KeyBioscience AG have agreed to a new collaboration focused on the development of Dual Amylin Calcitonin...
STANS, Switzerland and INDIANAPOLIS , June 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and KeyBioscience AG have agreed to a new collaboration focused on the development of Dual Amylin Calcitonin Receptor Agonists (DACRAs), a potential new class of treatments for m
Read more →LLYLilly Builds Upon Body of Data for Abemaciclib with Phase 3 MONARCH 2 Data Demonstrating Superior Progression-Free Survival in Advanced Breast Cancer Eli Lilly and Company (NYSE: LLY) today announced that results from the Phase 3 MONARCH 2 study showed that abemaciclib, a cyclin-dependent kinase...
INDIANAPOLIS , June 3, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that results from the Phase 3 MONARCH 2 study showed that abemaciclib, a cyclin-dependent kinase (CDK)4 & 6 inhibitor, in combination with fulvestrant, significantly improved progressio
Read more →LLYBoehringer Ingelheim and Lilly Diabetes Alliance to Present 33 Abstracts at the American Diabetes Association's 77th Scientific Sessions® Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will present 33 abstracts highlighting the companies' wide range of diabetes treatment...
RIDGEFIELD, Conn. and INDIANAPOLIS , June 1, 2017 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY ) will present 33 abstracts highlighting the companies' wide range of diabetes treatment options at the 77 th American Diabetes Association's (ADA) Scientif
Read more →LLYDerica Rice to Retire as Lilly Chief Financial Officer Eli Lilly and Company (NYSE: LLY) announced today that Derica Rice, executive vice president global services and chief financial officer, will retire ...
INDIANAPOLIS , June 1, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that Derica Rice , executive vice president global services and chief financial officer, will retire at the end of December 2017 after 27 years of service with the company. Rice is also
Read more →LLYLilly to Participate in Goldman Sachs Global Healthcare Conference Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 38th Annual Global Healthcare Conference on Wednesday, June 14, 2017. Sue...
INDIANAPOLIS , May 31, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Goldman Sachs 38 th Annual Global Healthcare Conference on Wednesday, June 14, 2017 . Sue Mahony , Ph.D., senior vice president and president of Lilly Oncology and Levi Garraway
Read more →LLYLilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA® (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 RANGE study of CYRAMZA® (ramucirumab) met its primary endpoint of progression-free ...
INDIANAPOLIS , May 31, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that its Phase 3 RANGE study of CYRAMZA ® (ramucirumab) met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement. The Phase 3 g
Read more →LLYLilly to Present Results from Pivotal Breast Cancer Study of Abemaciclib and New Portfolio Data at ASCO 2017 Eli Lilly and Company (NYSE: LLY) today announced that new research demonstrating advances in the Company's oncology pipeline and product portfolio...
INDIANAPOLIS , May 17, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that new research demonstrating advances in the Company's oncology pipeline and product portfolio will be presented at the 53rd Annual Meeting of the American Society of Clinical Oncolo
Read more →LLYLilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine Eli Lilly and Company (NYSE: LLY) announced today that galcanezumab, an investigational treatment for the prevention of episodic and chronic...
INDIANAPOLIS , May 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, met its primary endpoint in three Phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) de
Read more →LLYLilly to Participate in Bernstein Strategic Decisions Conference Eli Lilly and Company (NYSE:LLY) will attend the Bernstein Strategic Decisions Conference on Wednesday, May 31, 2017. David A. Ricks, Lilly's...
A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at http://investor.lilly.com/events.cfm . A replay of the presentation will be available on this same website for approximately 90 days. About Eli Lilly and Company Lilly
Read more →LLYLeigh Ann Pusey Joins Lilly as Senior Vice President of Corporate Affairs and Communications Eli Lilly and Company (NYSE: LLY) announced today that Leigh Ann Pusey will be joining Lilly as senior vice president of corporate affairs and...
INDIANAPOLIS , May 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that Leigh Ann Pusey will be joining Lilly as senior vice president of corporate affairs and communications, effective June 12, 2017 . She will be a member of Lilly's executive committe
Read more →LLYLilly to Participate in UBS Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 23, 2017. Derica Rice, Lilly's executive vice...
INDIANAPOLIS , May 3, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the UBS Global Healthcare Conference on Tuesday, May 23, 2017 . Derica Rice , Lilly's executive vice president for global services and chief financial officer, will participate in a fireside
Read more →LLYLilly Announces Webcast to Discuss Oncology Pipeline Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Saturday, June 3, 2017, to discuss the company's oncology pipeline, including data from...
INDIANAPOLIS , May 2, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will conduct a webcast on Saturday, June 3, 2017 , to discuss the company's oncology pipeline, including data from the MONARCH 2 study of abemaciclib in patients with hormone-receptor-positive (HR+), hu
Read more →LLYLilly Declares Second-Quarter 2017 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2017 of $0.52 per share on outstanding...
INDIANAPOLIS , May 1, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the second quarter of 2017 of $0.52 per share on outstanding common stock. The dividend is payable June 9, 2017 , to shareholders of record at the
Read more →LLYLilly Reports First-Quarter 2017 Results Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2017. $ in millions, except per share data First Quarter ...
INDIANAPOLIS , April 25, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the first quarter of 2017. Certain financial information for 2017 and 2016 is presented on both a reported and a non-GAAP basis. Some numbers in this press rele
Read more →LLYLilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis Eli Lilly and Company (NYSE: LLY) today announced that following a pre-planned interim analysis for MONARCH 3, the trial met its primary endpoint of...
INDIANAPOLIS , April 24, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that following a pre-planned interim analysis for MONARCH 3, the trial met its primary endpoint of demonstrating statistically significant improvement in progression-free survival (PF
Read more →LLYLilly to Present Data for Galcanezumab for the Prevention of Migraine at the American Academy of Neurology (AAN) Annual Meeting Eli Lilly and Company (NYSE: LLY) will highlight Phase 2 data evaluating galcanezumab for the prevention of migraine at the American Academy of...
INDIANAPOLIS , April 20, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will highlight Phase 2 data evaluating galcanezumab for the prevention of migraine at the American Academy of Neurology (AAN) annual meeting, which will take place April 22-28, 2017 , in Boston . Li
Read more →LLYU.S. FDA Issues Complete Response Letter for Baricitinib Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has issued a ...
INDIANAPOLIS , April 14, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the New Drug Application (NDA) of the investigational
Read more →LLYLilly Confirms Date and Conference Call for First-Quarter 2017 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the first quarter of 2017 on Tuesday, April 25, 2017. Lilly will also...
INDIANAPOLIS , April 11, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the first quarter of 2017 on Tuesday, April 25, 2017 . Lilly will also conduct a conference call on that day with the investment community and media to further
Read more →LLYLife with Type 1 Diabetes Made a Little Easier through Lilly Diabetes Scholarship Donations for Camps, College and Conferences Living with type 1 diabetes comes with many unique challenges in all stages of life. For parents of children with the condition, financial, medical...
INDIANAPOLIS , ARLINGTON, Va. and ROLLING MEADOWS, Ill. , April 7, 2017 /PRNewswire/ -- Living with type 1 diabetes comes with many unique challenges in all stages of life. For parents of children with the condition, financial, medical and emotional worries can be overwhelming. T
Read more →LLYLilly and Ohio University Heritage College of Osteopathic Medicine Partner on Rotation Program for Medical Students Students from Ohio University's Heritage College of Osteopathic Medicine will soon join Eli Lilly and Company's (NYSE: LLY) innovative rotation...
INDIANAPOLIS , April 4, 2017 /PRNewswire/ -- Students from Ohio University's Heritage College of Osteopathic Medicine will soon join Eli Lilly and Company's (NYSE: LLY ) innovative rotation program for aspiring physicians. Launched in early 2014, the program provides students wit
Read more →LLYLilly Announces $850 Million Investment in U.S. Capital Projects in 2017 Eli Lilly and Company (NYSE: LLY) today announced plans to invest $850 million in its U.S. operations in 2017. The company's investments span...
INDIANAPOLIS , March 24, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced plans to invest $850 million in its U.S. operations in 2017. The company's investments span facilities across its U.S. enterprise, including research laboratories, manufacturing sites
Read more →LLYLilly and the William Sansum Diabetes Center announce a five-year research collaboration Eli Lilly and Company (NYSE: LLY) and the William Sansum Diabetes Center have established a research collaboration to improve the lives of Latino...
SANTA BARBARA, Calif. and INDIANAPOLIS , March 23, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and the William Sansum Diabetes Center have established a research collaboration to improve the lives of Latino people affected by diabetes through enhanced research, educat
Read more →LLYLilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival Eli Lilly and Company (NYSE: LLY) today announced that its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival (PFS)....
INDIANAPOLIS , March 20, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival (PFS). The Phase 3 study evaluated abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK
Read more →LLYNew Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis Eli Lilly and Company (NYSE: LLY) announced today that patients with moderate-to-severe plaque psoriasis treated with Taltz® (ixekizumab)...
Lilly to present head-to-head 24-week data comparing the efficacy and safety of Taltz and Stelara for the treatment of moderate-to-severe plaque psoriasis INDIANAPOLIS , March 4, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that patients with moderate-
Read more →LLYLilly Diabetes Becomes 'Official Diabetes Health Partner of NASCAR®' NASCAR® and Lilly Diabetes announced today that Lilly is expanding its involvement in NASCAR with a multi-year official partnership with the...
DAYTONA BEACH, Fla. , March 3, 2017 /PRNewswire/ -- NASCAR ® and Lilly Diabetes announced today that Lilly is expanding its involvement in NASCAR with a multi-year official partnership with the sanctioning body. The new collaboration designates Lilly Diabetes as the "Official Dia
Read more →LLYLilly Announces Changes in Senior Management Eli Lilly and Company (NYSE: LLY) today announced changes in its executive committee. Johna Norton will be promoted to senior vice president of...
INDIANAPOLIS , March 2, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced changes in its executive committee. "Fionnuala and Bart have been invaluable members of our executive committee as our business has gone through tremendous transformation during the l
Read more →LLYLilly Completes Acquisition of CoLucid Pharmaceuticals Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of CoLucid Pharmaceuticals, Inc. (NASD:CLCD). The...
INDIANAPOLIS , March 1, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the successful completion of its acquisition of CoLucid Pharmaceuticals, Inc. (NASD:CLCD). The tender offer for all outstanding shares of common stock of CoLucid, at a price of $46.50
Read more →LLYLilly to Present New Data for Taltz® (ixekizumab) in Psoriasis and Psoriatic Arthritis at the American Academy of Dermatology (AAD) Annual Meeting Eli Lilly and Company (NYSE: LLY) will highlight new Phase 3 data evaluating Taltz® (ixekizumab) for the treatment of moderate-to-severe plaque...
INDIANAPOLIS , Feb. 28, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will highlight new Phase 3 data evaluating Taltz ® (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis at the 75 th annual meeting of the American Acad
Read more →LLYAdditional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today additional detailed results from RA-BEAM – a pivotal phase 3...
INDIANAPOLIS , Feb. 15, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) announced today additional detailed results from RA-BEAM – a pivotal phase 3 study of baricitinib in the treatment of moderate-to-severe rheumatoid arthritis (RA
Read more →LLYLilly To Present At Leerink Partners Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will present at the Leerink Partners Global Healthcare Conference on Thursday, February 16, 2017. Enrique Conterno, ...
INDIANAPOLIS , Feb. 9, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present at the Leerink Partners Global Healthcare Conference on Thursday, February 16, 2017 . Enrique Conterno , senior vice president of Lilly and president of Lilly Diabetes and Lilly USA , will
Read more →LLYCarolyn R. Bertozzi, Ph.D., Elected to Lilly Board of Directors The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Carolyn R. Bertozzi, Ph.D., as a new member, effective Feb. 10, 2017. As a...
INDIANAPOLIS , Feb. 9, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has elected Carolyn R. Bertozzi , Ph.D., as a new member, effective Feb. 10, 2017 . As a member of Lilly's board, she will serve on the Science and Technology and Public Polic
Read more →LLYLilly to Present at Cowen Health Care Conference Eli Lilly and Company (NYSE: LLY) will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017. David A. Ricks, ...
INDIANAPOLIS , Feb. 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present at the Cowen and Company 37 th Annual Health Care Conference on Tuesday, March 7, 2017 . David A. Ricks , Lilly's president and chief executive officer, will speak at 8:40 a.m., Eastern Ti
Read more →LLYLilly's Trulicity® (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes The label for Eli Lilly and Company's (NYSE: LLY) once-weekly Trulicity® (dulaglutide) is now updated to include use in combination with basal...
INDIANAPOLIS , Feb. 8, 2017 /PRNewswire/ -- The label for Eli Lilly and Company's (NYSE: LLY ) once-weekly Trulicity ® (dulaglutide) is now updated to include use in combination with basal insulin for adults with type 2 diabetes. The U.S. Food and Drug Administration (FDA) includ
Read more →LLYJapan IP High Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents Eli Lilly and Company (NYSE: LLY) today announced that the Japan IP High Court confirmed the decisions of the Japan Patent Office and ruled in...
If the patents are ultimately upheld through all challenges, they could provide intellectual property protection for Alimta in Japan until June 2021 . Lilly will take necessary actions to defend and enforce the patents. Harrington continued, "We continue to emphasize that protec
Read more →LLYLilly Reports Fourth-Quarter and Full-Year 2016 Results Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2016. $ in millions, except per share...
INDIANAPOLIS , Jan. 31, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the fourth quarter and full year of 2016. Certain financial information for 2016 and 2015 is presented on both a reported and a non-GAAP basis. Some numbers in t
Read more →LLYLilly Revises Time for Conference Call for Fourth-Quarter 2016 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will host a call for investors, media and the general public at 11:30 a.m. Eastern Time on January 31, 2017 to...
INDIANAPOLIS , Jan. 30, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will host a call for investors, media and the general public at 11:30 a.m. Eastern Time on January 31, 2017 to discuss the company's fourth-quarter and full-year 2016 financial results. Originally, th
Read more →LLYLilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid Eli Lilly and Company (NYSE: LLY) and CoLucid Pharmaceuticals, Inc. (NASD: CLCD) today announced an agreement for Lilly to acquire CoLucid for $46.50 ...
INDIANAPOLIS and CAMBRIDGE, Mass. , Jan. 18, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and CoLucid Pharmaceuticals, Inc. (NASD: CLCD) today announced an agreement for Lilly to acquire CoLucid for $46.50 per share or approximately $960 million . This all-cash transac
Read more →LLYU.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended ...
INDIANAPOLIS , Jan. 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the new drug application (NDA) for investigational baricitini
Read more →LLYU.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the district court's decision and ...
In the case of Eli Lilly and Company v. Teva Parenteral Medicines, Inc., et al. , the court affirmed the earlier district court's rulings that the vitamin regimen patent is valid and would be infringed by the generic challengers' proposed products. If the patent is ultimately uph
Read more →LLYLilly and Merck Expand Immuno-Oncology Collaboration Eli Lilly and Company (NYSE: LLY) today announced the expansion of an existing immuno-oncology collaboration with Merck, known as MSD outside the U.S....
INDIANAPOLIS , Jan. 11, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the expansion of an existing immuno-oncology collaboration with Merck, known as MSD outside the U.S. and Canada , through a subsidiary, to add a new study of Lilly's LARTRUVO™ (olaratu
Read more →LLYLilly to Adjust Organization and Leadership Structure to Better Align with Growth Opportunities Eli Lilly and Company (NYSE: LLY) today announced a series of changes to its organization and leadership structure to better align them with the...
INDIANAPOLIS , Jan. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced a series of changes to its organization and leadership structure to better align them with the company's growth opportunities. Explaining the need for these changes, David A. Ricks , L
Read more →LLYLilly Confirms Date and Conference Call for Fourth-Quarter 2016 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2016 financial results on Tuesday, January 31, 2017. Lilly will also ...
INDIANAPOLIS , Jan. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its fourth-quarter and full-year 2016 financial results on Tuesday, January 31, 2017 . Lilly will also conduct a conference call on that day with the investment community and media to fur
Read more →LLYU.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linagliptin) tablets The U.S. Food and Drug Administration (FDA) approved supplemental New Drug Applications for three type 2 diabetes medicines within the empagliflozin...
RIDGEFIELD, Conn. and INDIANAPOLIS , Jan. 4, 2017 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved supplemental New Drug Applications for three type 2 diabetes medicines within the empagliflozin family to include data from the landmark EMPA-REG OUTCOME ® trial
Read more →LLYLilly to Present at J.P. Morgan Healthcare Conference Eli Lilly and Company (NYSE: LLY) will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017. David A. Ricks,...
INDIANAPOLIS , Jan. 3, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present at the 35 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 . David A. Ricks , Lilly's president and chief executive officer, will make a formal presentation from 7:
Read more →LLYCHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA) Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the European Medicines Agency's (EMA) Committee for...
INDIANAPOLIS , Dec. 16, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending the
Read more →LLYBoehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) Tablets in Updated American Diabetes Association's 2017 Standards The American Diabetes Association's (ADA) 2017 Standards of Medical Care in Diabetes specifically include a new recommendation to consider the use of ...
RIDGEFIELD, Conn. and INDIANAPOLIS , Dec. 16, 2016 /PRNewswire/ -- The American Diabetes Association's (ADA) 2017 Standards of Medical Care in Diabetes specifically include a new recommendation to consider the use of Jardiance ® (empagliflozin) tablets in people with type 2 diabe
Read more →LLYLilly Provides 2017 Financial Guidance and 2016 Update, Reaffirms Financial Expectations Through the Remainder of the Decade Eli Lilly and Company (NYSE: LLY) today announced its 2017 financial guidance and highlighted key events for the upcoming year. The company...
INDIANAPOLIS , Dec. 15, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its 2017 financial guidance and highlighted key events for the upcoming year. The company reaffirmed its financial expectations through the remainder of the decade, including at least
Read more →LLYLilly Announces Program to Provide Insulin at Discounted Prices Eli Lilly and Company (NYSE: LLY) today announced that people who use Lilly insulin will be able to access discounted prices for their purchases...
INDIANAPOLIS , Dec. 13, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that people who use Lilly insulin will be able to access discounted prices for their purchases starting January 1, 2017 via mobile and web platforms hosted by Blink Health. The discoun
Read more →LLYLilly Announces Dividend Increase The board of directors of Eli Lilly and Company (NYSE: LLY) today announced a 2 percent increase in its quarterly dividend. The dividend for the...
INDIANAPOLIS , Dec. 12, 2016 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) today announced a 2 percent increase in its quarterly dividend. The dividend for the first quarter of 2017 will be $0.52 per share on outstanding common stock. This raises th
Read more →LLYU.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes The U.S. Food and Drug Administration (FDA) has approved Synjardy® XR (empagliflozin and metformin hydrochloride extended-release) tablets for adults ...
RIDGEFIELD, Conn. and INDIANAPOLIS , Dec. 12, 2016 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Synjardy ® XR (empagliflozin and metformin hydrochloride extended-release) tablets for adults with type 2 diabetes. When used along with diet and exercise,
Read more →LLYLilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease Eli Lilly and Company (NYSE: LLY) and AstraZeneca announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42...
INDIANAPOLIS , Dec. 9, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and AstraZeneca announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase 1 trials as a potential disease-modifying treatment
Read more →LLYLilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at the Clinical Trials on Alzheimer's Disease (CTAD) 2016 Meeting Eli Lilly and Company (NYSE:LLY) today presented detailed results of its phase 3 EXPEDITION3 trial at the 9th Clinical Trials on Alzheimer's Disease...
INDIANAPOLIS , Dec. 8, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today presented detailed results of its phase 3 EXPEDITION3 trial at the 9 th Clinical Trials on Alzheimer's Disease (CTAD) meeting. As previously disclosed, solanezumab did not meet the primary endpoi
Read more →LLYLilly Presents neoMONARCH Phase 2 Data on Abemaciclib in Early-Stage Breast Cancer Eli Lilly and Company (NYSE: LLY) today announced that the neoMONARCH study of abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor,...
SAN ANTONIO , Dec. 8, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the neoMONARCH study of abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, met its primary endpoint of reducing expression of Ki67, a biomarker of cell proliferatio
Read more →LLYLilly Introduces Scholars Programs for Florida A&M University's and Howard University's Business Students Eli Lilly and Company (NYSE:LLY) will deepen its partnership with Florida Agricultural and Mechanical University (FAMU) and Howard University with...
INDIANAPOLIS , Nov. 30, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will deepen its partnership with Florida Agricultural and Mechanical University (FAMU) and Howard University with the inaugural Sybil C. Mobley Scholars Program and the inaugural H. Naylor Fitzhugh Sc
Read more →LLYLilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial Eli Lilly and Company (NYSE: LLY) today announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3...
INDIANAPOLIS , Nov. 23, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD). Pati
Read more →LLYNew Analyses of Phase 3 Trials Show Improvements in Rheumatoid Arthritis Symptoms Following Treatment with Baricitinib Across Diverse Population of Patients Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced new data analyses of two phase 3 trials, RA-BUILD and...
Three post-hoc analyses of two phase 3 studies showed improvements in rheumatoid arthritis symptoms in patients irrespective of age, BMI and number of previously used conventional synthetic DMARDs INDIANAPOLIS , Nov. 14, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) an
Read more →LLYBaricitinib Demonstrates Early Response Compared to Placebo and Significant Improvement Compared to Adalimumab in Patient-Reported Outcomes Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that in two phase 3 trials, RA-BEAM and RA-BUILD, patients...
- Significant improvement in joint pain, severity of morning joint stiffness and tiredness with baricitinib compared to placebo, were seen as early as day 3 - Post-hoc analysis of two phase 3 studies shows significantly improved joint pain, severity of morning joint stiffness an
Read more →LLYJardiance® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline New data presented today at the American Heart Association Scientific Sessions 2016 showed that Jardiance® (empagliflozin) tablets consistently...
RIDGEFIELD, Conn. , and INDIANAPOLIS , Nov. 13, 2016 /PRNewswire/ -- New data presented today at the American Heart Association Scientific Sessions 2016 showed that Jardiance ® (empagliflozin) tablets consistently reduced the risk for cardiovascular death, regardless of the type
Read more →LLYLilly Presents Clinical Efficacy, Safety and Patient-Reported Outcomes Data of Baricitinib in Patients with Rheumatoid Arthritis at 2016 American College of Rheumatology Annual Meeting Eli Lilly and Company (NYSE: LLY) announced that new post-hoc analyses of pooled efficacy and safety data from baricitinib phase 3 studies, along...
INDIANAPOLIS , Nov. 3, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced that new post-hoc analyses of pooled efficacy and safety data from baricitinib phase 3 studies, along with findings from a real-world assessment of medication use among rheumatoid arthritis (
Read more →LLYNew data from pivotal RA-BEACON study show significant improvement in patient-reported outcomes in rheumatoid arthritis patients treated with baricitinib compared to placebo Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that new data from RA-BEACON – a pivotal phase 3 study of...
INDIANAPOLIS , Nov. 2, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) announced today that new data from RA-BEACON – a pivotal phase 3 study of baricitinib in the treatment of moderate-to-severe rheumatoid arthritis (RA) – showed ba
Read more →LLYNew Edition of Online Tool to Measure Cancer Progress to Launch at World Cancer Congress The 2016 World Cancer Congress (WCC) in Paris – a global gathering of more than 3,500 cancer experts – will be the setting for the introduction of a...
PARIS , Oct. 31, 2016 /PRNewswire/ -- The 2016 World Cancer Congress (WCC) in Paris – a global gathering of more than 3,500 cancer experts – will be the setting for the introduction of a new, enhanced version of the PACE Continuous Innovation Indicators™ (CII) by PACE (Patient Ac
Read more →LLYLilly Reports Third-Quarter 2016 Results Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2016. $ in millions, except per share data Third Quarter ...
INDIANAPOLIS , Oct. 25, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the third quarter of 2016. Certain financial information for 2016 and 2015 is presented on both a reported and a non-GAAP basis. Some numbers in this press relea
Read more →LLYFDA Approves Lilly's LARTRUVO™ (olaratumab) in Combination with Doxorubicin for Soft Tissue Sarcoma Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of LARTRUVO™ (olaratumab...
INDIANAPOLIS , Oct. 19, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of LARTRUVO ™ (olaratumab injection, 10 mg/mL), in combination with doxorubicin, for the treatment of adults with
Read more →LLYLilly Partners with the National Cancer Institute to Accelerate Cancer Research through New Program under Cancer Moonshot Initiative With the global prevalence of new cancer cases expected to rise by 70 percent during the next two decades, representatives from government, academic, ...
INDIANAPOLIS , Oct. 17, 2016 /PRNewswire/ -- With the global prevalence of new cancer cases expected to rise by 70 percent during the next two decades, representatives from government, academic, pharmaceutical and diagnostic companies are pooling their knowledge to accelerate tre
Read more →LLYLilly Declares Fourth-Quarter 2016 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2016 of $0.51 per share on outstanding...
INDIANAPOLIS , Oct. 17, 2016 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the fourth quarter of 2016 of $0.51 per share on outstanding common stock. The dividend is payable December 9, 2016 , to shareholders of record a
Read more →LLYEli Lilly and Company Sponsors Arthritis Foundation 'Living Your Yes With RA,' an Initiative to Provide Resources for the Rheumatoid Arthritis Community Supported by Eli Lilly and Company (NYSE: LLY), the Arthritis Foundation is launching 'Living Your Yes With RA,' a new initiative designed to empower ...
INDIANAPOLIS , Oct. 12, 2016 /PRNewswire/ -- Supported by Eli Lilly and Company ( NYSE: LLY ), the Arthritis Foundation is launching 'Living Your Yes With RA,' a new initiative designed to empower people living with rheumatoid arthritis (RA) by giving them tools, education and re
Read more →LLYLilly to Participate in Credit Suisse 2016 Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Credit Suisse 2016 Healthcare Conference on Monday, November 7, 2016. The following Lilly...
INDIANAPOLIS , Oct. 11, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Credit Suisse 2016 Healthcare Conference on Monday, November 7, 2016 . The following Lilly executives will participate in a fireside chat at 6:00 p.m., Eastern Time : A live a
Read more →LLYLeading Experts Warn Global Goal to Cure or Treat Alzheimer's Disease By 2025 is at Risk, Offer Solutions to Adjust Course Alzheimer's disease (AD) has an enormous impact on the lives of patients and caregivers, in addition to placing a significant burden on health care...
INDIANAPOLIS , Oct. 11, 2016 /PRNewswire/ -- Alzheimer's disease (AD) has an enormous impact on the lives of patients and caregivers, in addition to placing a significant burden on health care systems around the world. According to a paper published in Alzheimer's Research & Ther
Read more →LLYNew Data on the Combination of Lilly's ALIMTA® (pemetrexed) and Merck's KEYTRUDA® (pembrolizumab) Show a Near-Doubling of Objective Response Rate Compared to Standard of Care Alone in First-Line Metastatic Non-Small Cell Lung Cancer Important clinical study results from one of Eli Lilly and Company's (NYSE: LLY) ongoing immuno-oncology collaborations with Merck (known as MSD...
INDIANAPOLIS , Oct. 9, 2016 /PRNewswire/ -- Important clinical study results from one of Eli Lilly and Company's (NYSE: LLY ) ongoing immuno-oncology collaborations with Merck (known as MSD outside the U.S. and Canada ) were announced today at the ESMO 2016 Congress, the annual m
Read more →LLYLilly Highlights Advancements in its Oncology Portfolio with New Data at ESMO 2016 Eli Lilly and Company (NYSE: LLY) will present data from several studies which further reinforce the advancement of its diverse clinical cancer...
INDIANAPOLIS , Oct. 5, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present data from several studies which further reinforce the advancement of its diverse clinical cancer portfolio during the European Society of Medical Oncology's (ESMO) 2016 Congress in Copenha
Read more →LLYElanco Animal Health Enters Agreement to Acquire Boehringer Ingelheim Vetmedica's U.S. Feline, Canine and Rabies Vaccines Portfolio Eight new product lines and a fully integrated manufacturing and R&D site to transfer to Elanco, adding to its growing companion animal business;...
GREENFIELD, Ind., Oct. 5, 2016 /PRNewswire/ -- Today Elanco U.S., Inc., a subsidiary of Eli Lilly and Company (NYSE: LLY ), announced an agreement to acquire Boehringer Ingelheim Vetmedica, Inc.'s (BIVI) U.S. feline, canine and rabies vaccines portfolio – as well as a fully inte
Read more →LLYLilly Confirms Date And Conference Call For Third-Quarter 2016 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2016 on Tuesday, October 25, 2016. Lilly will also...
INDIANAPOLIS , Oct. 4, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the third quarter of 2016 on Tuesday, October 25, 2016 . Lilly will also conduct a conference call on that day with the investment community and media to further
Read more →LLYLilly to Present Latest Data for Taltz® (ixekizumab) in Psoriasis at the European Academy of Dermatology and Venereology (EADV) Annual Congress Eli Lilly and Company (NYSE: LLY) will highlight clinical and patient-related health outcomes data evaluating Taltz® (ixekizumab) for the treatment...
17 abstracts, including eight oral abstracts with one late-breaker presentation, will feature new sub-analyses for Taltz in moderate-to-severe plaque psoriasis INDIANAPOLIS , Sept. 27, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will highlight clinical and patient-re
Read more →LLYCHMP Recommends Approval of Lilly's Olaratumab, in Combination with Doxorubicin, for Advanced Soft Tissue Sarcoma Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP)...
INDIANAPOLIS , Sept. 16, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the granting of a conditional marketing aut
Read more →LLYBoston Mayor Walsh and the Alzheimer's Association, Massachusetts/New Hampshire Chapter, Receive Alzheimer's Readiness Award Boston Mayor Martin J. Walsh and the Alzheimer's Association, Massachusetts/New Hampshire Chapter were recognized today for their efforts to ensure...
BOSTON , Sept. 15, 2016 /PRNewswire/ -- Boston Mayor Martin J. Walsh and the Alzheimer's Association, Massachusetts /New Hampshire Chapter were recognized today for their efforts to ensure the city of Boston is prepared for the fiscal and social impact of Alzheimer's disease. Th
Read more →LLYLevi Garraway, M.D., Ph.D., to become Senior Vice President of Global Oncology at Lilly, Succeeding Richard Gaynor, M.D., Who is Retiring after a Distinguished Career Eli Lilly and Company (NYSE: LLY) today announced that Levi Garraway, M.D., Ph.D., a world leader in the analysis of cancer genomics and resistance...
INDIANAPOLIS , Sept. 14, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that Levi Garraway , M.D., Ph.D., a world leader in the analysis of cancer genomics and resistance to targeted therapies, will join Lilly as senior vice president, Global Development
Read more →LLYJamere Jackson Elected to Lilly Board of Directors The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Jamere Jackson as a new member, effective October 1, 2016. As a member of...
INDIANAPOLIS , Aug. 31, 2016 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has elected Jamere Jackson as a new member, effective October 1, 2016 . As a member of Lilly's board, he will serve on the Audit and Finance committees. Jackson is currently
Read more →LLYLilly to Participate in Morgan Stanley Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016. Jeffrey Simmons, senior ...
INDIANAPOLIS , Aug. 24, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 . Jeffrey Simmons , senior vice president and president, Elanco Animal Health, will participate in a fireside
Read more →LLYLilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293, an Investigational Treatment for Early Alzheimer's Disease Eli Lilly and Company (NYSE: LLY) and AstraZeneca today announced they have received U.S. Food and Drug Administration (FDA) Fast Track designation...
INDIANAPOLIS , Aug. 22, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and AstraZeneca today announced they have received U.S. Food and Drug Administration (FDA) Fast Track designation for the development program in Alzheimer's disease for AZD3293, an oral beta secretase
Read more →LLYLilly announces Joshua Smiley, Anat Ashkenazi appointed to new roles, Thomas Grein retires Eli Lilly and Company (NYSE: LLY) today announced Joshua Smiley will be appointed to senior vice president, Finance, and treasurer effective October...
INDIANAPOLIS , Aug. 10, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced Joshua Smiley will be appointed to senior vice president, Finance, and treasurer effective October 1 . Smiley will replace Thomas Grein , who will retire in September after a 41-year c
Read more →LLYLilly Provides Update on MONARCH 2 Phase 3 Trial of Abemaciclib Eli Lilly and Company (NYSE: LLY) today announced that following a pre-planned interim analysis for MONARCH 2, an independent Data Monitoring...
INDIANAPOLIS , Aug. 10, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that following a pre-planned interim analysis for MONARCH 2, an independent Data Monitoring Committee (DMC) provided the recommendation to continue the study without modification as th
Read more →LLYJohn C. Lechleiter to Retire as Lilly CEO; Board Elects David A. Ricks as Successor Eli Lilly and Company (NYSE: LLY) today announced that John C. Lechleiter, Ph.D., chairman, president and chief executive officer, will retire as...
INDIANAPOLIS , July 27, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that John C. Lechleiter , Ph.D., chairman, president and chief executive officer, will retire as president and CEO and from the company effective December 31 , 2016. Lechleiter will co
Read more →LLYNew Studies Suggest Relationship between Tau Pathology and Progression of Alzheimer's Disease Eli Lilly and Company (NYSE: LLY) today announced results from two distinct analyses of a phase 2 study using the tau imaging agent flortaucipir...
INDIANAPOLIS , July 27, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced results from two distinct analyses of a phase 2 study using the tau imaging agent flortaucipir ([18F] AV-1451) that evaluated the relationship between tau tangles and the progression o
Read more →LLYLilly Reports Second-Quarter 2016 Results, Provides Financial Expectations Through the Remainder of the Decade Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2016. $ in millions, except per share data Second...
INDIANAPOLIS , July 26, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the second quarter of 2016. Certain financial information for 2016 and 2015 is presented on both a reported and a non-GAAP basis. Some numbers in this press rele
Read more →LLYDiversity of Lilly's Alzheimer's Disease Pipeline Showcased at the Alzheimer's Association International Conference® 2016 (AAIC® 2016) Eli Lilly and Company (NYSE:LLY) today announced it will present findings from more than 25 research studies at the upcoming Alzheimer's Association...
INDIANAPOLIS , July 21, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced it will present findings from more than 25 research studies at the upcoming Alzheimer's Association International Conference ® 2016 (AAIC ® 2016) in Toronto, Canada , July 24 – 28. The
Read more →LLYLilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced a new collaboration on a Phase 1b study that will evaluate the safety and...
INDIANAPOLIS , July 13, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Boehringer Ingelheim today announced a new collaboration on a Phase 1b study that will evaluate the safety and tolerability of abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and
Read more →LLYLilly and Howard University partner on summer Medical Scientific Fellowship Lilly USA, LLC will partner with Howard University this summer on an inaugural Minority Fellowship program for post-graduate minority professionals...
INDIANAPOLIS , July 12, 2016 /PRNewswire/ -- Lilly USA , LLC will partner with Howard University this summer on an inaugural Minority Fellowship program for post-graduate minority professionals embarking on careers in science or medicine. The fellowship aims to increase collabora
Read more →LLYLilly Diabetes Welcomes Acclaimed Singer/Songwriter Crystal Bowersox as Newest Spokesperson Crystal Bowersox understands how crucial it is to properly manage diabetes and find a healthy balance on and off the stage. Diagnosed with type 1...
INDIANAPOLIS , July 6, 2016 /PRNewswire/ -- Crystal Bowersox understands how crucial it is to properly manage diabetes and find a healthy balance on and off the stage. Diagnosed with type 1 diabetes at age 6, Crystal – now 30 – rose from humble beginnings in northwestern Ohio to
Read more →LLYLilly Confirms Date And Conference Call For Second-Quarter 2016 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2016 on Tuesday, July 26, 2016. Lilly will also...
INDIANAPOLIS , June 28, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the second quarter of 2016 on Tuesday, July 26, 2016 . Lilly will also conduct a conference call on that day with the investment community and media to further
Read more →LLYLilly Convenes Leaders at National Mayor's Conference to Address Impact of Alzheimer's Disease on Local Communities With the prevalence of Alzheimer's disease expected to triple by 2050, there is an urgent need for greater awareness of the economic and social...
INDIANAPOLIS , June 27, 2016 /PRNewswire/ -- With the prevalence of Alzheimer's disease expected to triple by 2050, there is an urgent need for greater awareness of the economic and social impact of the disease on families, communities and health systems. In an effort to educate
Read more →LLYDiabetes Scholars Foundation Announces 2016 Scholarship Recipients If the caliber of students receiving a Lilly Diabetes Tomorrow's Leaders Scholarship is any indication, the future is in good hands. The 2016...
PARK RIDGE, Ill. and INDIANAPOLIS , June 23, 2016 /PRNewswire/ -- If the caliber of students receiving a Lilly Diabetes Tomorrow's Leaders Scholarship is any indication, the future is in good hands. The 2016 scholarship winners, announced today online at www.diabetesscholars.org
Read more →LLYLilly Declares Third-Quarter 2016 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2016 of $0.51 per share on outstanding...
INDIANAPOLIS , June 20, 2016 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the third quarter of 2016 of $0.51 per share on outstanding common stock. The dividend is payable September 9, 2016 , to shareholders of record a
Read more →LLYGerman Supreme Court Grants Lilly Appeal in Alimta® Vitamin Regimen Patent Lawsuit The German Federal Supreme Court has granted the appeal by Eli Lilly and Company (NYSE: LLY) in the case of Eli Lilly and Company v. Actavis,...
"We are pleased with the ruling by the German Federal Supreme Court granting our appeal regarding infringement of Alimta's vitamin regimen patent in Germany ," said Michael J. Harrington , senior vice president and general counsel for Lilly. "This ruling supports our continuing b
Read more →LLYAarti Shah named chief information officer Eli Lilly and Company (NYSE: LLY) today announced the promotion of Aarti Shah, Ph.D., to senior vice president and chief information officer...
INDIANAPOLIS , June 13, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the promotion of Aarti Shah , Ph.D., to senior vice president and chief information officer effective July 1 . She has been the global brand development leader for immunology since 201
Read more →LLYNew Data Show Lilly's Once-Weekly Trulicity® (dulaglutide) in Combination with Insulin Glargine Improves Glycemic Control in People with Type 2 Diabetes New data from a completed Phase 3 trial show Trulicity® (dulaglutide) 1.5 mg significantly reduced hemoglobin A1c (A1C) and body weight as an add-on...
INDIANAPOLIS , June 12, 2016 /PRNewswire/ -- New data from a completed Phase 3 trial show Trulicity ® (dulaglutide) 1.5 mg significantly reduced hemoglobin A1c (A1C) and body weight as an add-on to insulin glargine without increasing the risk of low blood sugar after 28 weeks com
Read more →LLYNew Study Findings Underscore Importance of Physician/Patient Communication on Insulin Adherence and Outcomes New data from a study funded by Eli Lilly and Company (NYSE: LLY) show that how healthcare professionals and people with diabetes communicate - as...
INDIANAPOLIS , June 11, 2016 /PRNewswire/ -- New data from a study funded by Eli Lilly and Company (NYSE: LLY ) show that how healthcare professionals and people with diabetes communicate - as well as the perceived quality of the personal relationship between the parties - direct
Read more →LLYLilly and American Migraine Foundation Announce $1 Million Grant for Launch of First Patient Registry to Advance Research and Development in Migraine Eli Lilly and Company (NYSE: LLY) and the American Migraine Foundation announced today that Lilly will provide a $1 million grant to the American...
INDIANAPOLIS AND MOUNT ROYAL, N.J. , June 9, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and the American Migraine Foundation announced today that Lilly will provide a $1 million grant to the American Migraine Foundation to sponsor the development of the American Regi
Read more →LLYBaricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that data from a pivotal long-term extension study,...
INDIANAPOLIS , June 9, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) today announced that data from a pivotal long-term extension study, RA-BEYOND, was presented at the Annual European Congress of Rheumatology (EULAR 2016) in Londo
Read more →LLYPatient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA) Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that in two phase 3 trials patients with rheumatoid arthritis ...
Pivotal trials show treatment with baricitinib resulted in significant improvements in pain, fatigue and ability to perform daily activities compared to methotrexate – the current standard of care – and adalimumab (Humira ® )* INDIANAPOLIS , June 9, 2016 /PRNewswire/ -- Eli Lill
Read more →LLYData in The Lancet Show Olaratumab Plus Doxorubicin Offered 11.8-Month Increase in Overall Survival in Patients with Advanced Soft Tissue Sarcoma, as Reported by Lilly and Memorial Sloan Kettering Researchers Eli Lilly and Company (NYSE: LLY) announced that The Lancet published detailed results from a Phase 2 study evaluating the efficacy and safety of...
INDIANAPOLIS , June 9, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced that The Lancet published detailed results from a Phase 2 study evaluating the efficacy and safety of olaratumab, an investigational compound, in combination with doxorubicin chemotherapy in
Read more →LLYStudies Demonstrate Lilly's Taltz® (ixekizumab) Maintained or Achieved High Levels of Skin Clearance for Patients with Moderate-to-Severe Plaque Psoriasis through 60 Weeks: Results Published in the New England Journal of Medicine Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine has published detailed results from three pivotal Phase 3...
INDIANAPOLIS , June 8, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the New England Journal of Medicine has published detailed results from three pivotal Phase 3 studies—UNCOVER-1, UNCOVER-2 and UNCOVER-3—that demonstrated the efficacy and safety o
Read more →LLYResults of Clinical and Patient-Reported Outcomes Data for Baricitinib in Patients with Rheumatoid Arthritis to be Presented at Annual European Congress of Rheumatology (EULAR 2016) Eli Lilly and Company (NYSE: LLY) announced that radiographic results from a long-term extension study of baricitinib, RA-BEYOND, and...
Lilly immunology portfolio to be featured in 16 presentations INDIANAPOLIS , June 7, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced that radiographic results from a long-term extension study of baricitinib, RA-BEYOND, and patient-reported outcomes data from ba
Read more →LLYEarly-Phase Immuno-Oncology Studies of Lilly's ALIMTA® (pemetrexed) and CYRAMZA® (ramucirumab) with Merck's KEYTRUDA® (pembrolizumab) Show Encouraging Results in Non-Small Cell Lung Cancer Eli Lilly and Company (NYSE: LLY) today announced that clinical study data from two of its ongoing immuno-oncology clinical collaborations with Merck ...
CHICAGO , June 5, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that clinical study data from two of its ongoing immuno-oncology clinical collaborations with Merck (known as MSD outside the U.S. and Canada ) were presented this weekend at the 52 nd Annua
Read more →LLYLilly Announces Results from MONARCH 1 Trial of Abemaciclib Monotherapy Eli Lilly and Company (NYSE: LLY) today announced results from the MONARCH 1 Phase 2 study of abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK...
INDIANAPOLIS , June 3, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced results from the MONARCH 1 Phase 2 study of abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, in patients with hormone-receptor-positive (HR+), human epidermal growth
Read more →LLYLilly Announces Diabetes Commercial Update Investor Call Eli Lilly and Company (NYSE: LLY) will conduct a call on June 17 to update the investment community and media on the key commercial aspects of the...
INDIANAPOLIS , June 1, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will conduct a call on June 17 to update the investment community and media on the key commercial aspects of the company's diabetes business. The webcast will begin at 9 a.m. EDT . Investors, media an
Read more →LLYU.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes The U.S. Food and Drug Administration (FDA) has approved Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) tablets for the...
RIDGEFIELD, Conn. and INDIANAPOLIS , May 31, 2016 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) tablets for the treatment of type 2 diabetes (T2D) in adults. JENTADUETO XR, which
Read more →LLYLilly Announces Webcast to Discuss Abemaciclib Data Eli Lilly and Company (NYSE: LLY) will conduct a webcast on June 9 to discuss the abemaciclib data presented at the American Society of Clinical...
INDIANAPOLIS , May 31, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will conduct a webcast on June 9 to discuss the abemaciclib data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. The webcast will begin at 10 a.m. EDT . Investors, media
Read more →LLYLilly to Participate in Goldman Sachs 37th Annual Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 37th Annual Healthcare Conference on June 8, 2016. Enrique Conterno, Lilly senior...
INDIANAPOLIS , May 25, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the Goldman Sachs 37 th Annual Healthcare Conference on June 8, 2016 . Enrique Conterno , Lilly senior vice president and president of Lilly Diabetes, will participate in a fireside chat at
Read more →LLYLilly Details Robust R&D Pipeline to Investment Community In a presentation to the investment community today, Eli Lilly and Company (NYSE: LLY) stated it has the potential to launch 20 new products in the...
INDIANAPOLIS , May 24, 2016 /PRNewswire/ -- In a presentation to the investment community today, Eli Lilly and Company (NYSE: LLY ) stated it has the potential to launch 20 new products in the 10 years beginning in 2014 and extending through 2023. In addition, Lilly could launch
Read more →LLYLilly to Participate in Bernstein Strategic Decisions Conference Eli Lilly and Company (NYSE: LLY) will attend the Bernstein Strategic Decisions Conference on June 2, 2016. John C. Lechleiter, Ph.D., Lilly's...
A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at http://investor.lilly.com/events.cfm . A replay of the fireside chat will be available for approximately 90 days. About Eli Lilly and Company Lilly is a global healthc
Read more →LLYLilly's First Volunteer Teams of 2016 Depart in May for Thailand and Ghana A team of Eli Lilly and Company (NYSE: LLY) volunteers from its operations worldwide is on the ground in Thailand, working with a local hospital and...
INDIANAPOLIS , May 19, 2016 /PRNewswire/ -- A team of Eli Lilly and Company (NYSE: LLY ) volunteers from its operations worldwide is on the ground in Thailand , working with a local hospital and health volunteers as part of Lilly's Connecting Hearts Abroad global employee volunte
Read more →LLYASCO Data Underscore Lilly's Diverse Oncology Pipeline and Portfolio Several studies will underscore the strength of Eli Lilly and Company's (NYSE: LLY) diverse clinical cancer pipeline and portfolio during the 52nd...
INDIANAPOLIS , May 18, 2016 /PRNewswire/ -- Several studies will underscore the strength of Eli Lilly and Company's (NYSE: LLY ) diverse clinical cancer pipeline and portfolio during the 52 nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago , June 3
Read more →LLYLilly partners with Washington University School of Medicine and Meharry Medical College on unique summer research program Lilly USA, LLC will partner with Washington University School of Medicine and Meharry Medical College on a unique summer research program designed to ...
INDIANAPOLIS , May 18, 2016 /PRNewswire/ -- Lilly USA , LLC will partner with Washington University School of Medicine and Meharry Medical College on a unique summer research program designed to expand diversity in research to reduce minority health disparities and fuel innovativ
Read more →LLYEli Lilly and Company marks 140 years of caring and discovery Eli Lilly and Company (NYSE: LLY) will commemorate its 140th anniversary today with activities at Lilly locations worldwide, including a ceremony to...
INDIANAPOLIS , May 10, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will commemorate its 140th anniversary today with activities at Lilly locations worldwide, including a ceremony to unveil a statue dedicated to founder Colonel Eli Lilly at global headquarters in India
Read more →LLYFDA Grants Priority Review for Lilly's Olaratumab, an Investigational Medicine for Advanced Soft Tissue Sarcoma Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the biologics...
INDIANAPOLIS , May 4, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the biologics license application (BLA) for olaratumab, a PDGFRα antagonist, in combination with doxorubi
Read more →LLYLilly Releases First-Ever Integrated Report Eli Lilly and Company (NYSE: LLY) today released its first-ever integrated report, combining two of the company's traditional documents: its annual...
INDIANAPOLIS , May 2, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today released its first-ever integrated report, combining two of the company's traditional documents: its annual report and its corporate responsibility report. Lilly's 2015 Integrated Report covers th
Read more →LLYLilly Declares Second-Quarter 2016 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2016 of $0.51 per share on outstanding...
INDIANAPOLIS , May 2, 2016 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the second quarter of 2016 of $0.51 per share on outstanding common stock. The dividend is payable June 10, 2016 , to shareholders of record at the
Read more →LLYLilly's Taltz® (ixekizumab) Now Available in the U.S. for the Treatment of Moderate-to-Severe Plaque Psoriasis Eli Lilly and Company (NYSE: LLY) announced today that Taltz® (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque...
INDIANAPOLIS , May 2, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that Taltz ® (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis is now available by prescription order through a contracted network of specialty pha
Read more →LLYLilly to Participate in Bank of America Merrill Lynch 2016 Health Care Conference Eli Lilly and Company (NYSE: LLY) will attend the Bank of America Merrill Lynch 2016 Health Care Conference on May 11, 2016. David Ricks, Lilly...
INDIANAPOLIS , April 28, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the Bank of America Merrill Lynch 2016 Health Care Conference on May 11, 2016 . David Ricks , Lilly senior vice president and president of Lilly Bio-Medicines, will participate in a fires
Read more →LLYLilly Reports First-Quarter 2016 Results, Revises 2016 Financial Guidance Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2016. $ in millions, except per share data First Quarter ...
INDIANAPOLIS , April 26, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the first quarter of 2016. Certain financial information for 2016 and 2015 is presented on both a reported and a non-GAAP basis. Some numbers in this press rele
Read more →LLYLilly to Provide Detailed Update of Pipeline and R&D Strategy at Upcoming Investment Community Meeting Eli Lilly and Company (NYSE: LLY) today announced it will host a meeting for the investment community, including institutional investors, sell-side...
INDIANAPOLIS , April 12, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced it will host a meeting for the investment community, including institutional investors, sell-side analysts, ratings agency representatives, and financial and business media. The meet
Read more →LLYEli Lilly and Company and AstraZeneca Announce Continuation of Pivotal Clinical Trial for People with Early Alzheimer's Disease Eli Lilly and Company (NYSE: LLY) and AstraZeneca today announced that AMARANTH, a Phase 2/3 study of AZD3293, an oral beta secretase cleaving enzyme ...
Phase 2/3 trial of AZD3293, an oral potent small molecule BACE inhibitor, will continue to Phase 3 after positive interim safety data INDIANAPOLIS , April 8, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and AstraZeneca today announced that AMARANTH, a Phase 2/3 study
Read more →LLYLilly Confirms Date and Conference Call for First-Quarter 2016 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the first quarter of 2016 on Tuesday, April 26, 2016. Lilly will also...
INDIANAPOLIS , April 4, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the first quarter of 2016 on Tuesday, April 26, 2016 . Lilly will also conduct a conference call on that day with the investment community and media to further
Read more →LLYNew 2016 ACC/AHA Guideline Focused Update States that it is Reasonable to Choose Effient® (prasugrel) Over Clopidogrel for Certain ACS-PCI Patients with ST-Elevation Myocardial Infarction and NSTE-ACS A new guideline focused update provided oral antiplatelet therapy Effient® (prasugrel) with a Class IIa recommendation, meaning that it is reasonable ...
PARSIPPANY, N.J. and INDIANAPOLIS , March 31, 2016 /PRNewswire/ -- A new guideline focused update provided oral antiplatelet therapy Effient ® (prasugrel) with a Class IIa recommendation, meaning that it is reasonable to choose Effient over clopidogrel for the maintenance therapy
Read more →LLYLilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80...
INDIANAPOLIS , March 22, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz ® (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis in adult patients who ar
Read more →LLYLilly Announces Change to Primary Endpoint of EXPEDITION3 Study Eli Lilly and Company (NYSE: LLY) today announced a change to the primary endpoint for the EXPEDITION3 clinical trial, a Phase 3 study of solanezumab ...
INDIANAPOLIS , March 15, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced a change to the primary endpoint for the EXPEDITION3 clinical trial, a Phase 3 study of solanezumab in people with mild Alzheimer's dementia. The original study design included co-pr
Read more →LLYIxekizumab Demonstrates High Levels of Skin Clearance among Patients with Moderate-to-Severe Plaque Psoriasis Who Did Not Respond to Treatment with Etanercept Eli Lilly and Company (NYSE: LLY) announced today that patients with moderate-to-severe plaque psoriasis who did not respond to treatment with...
INDIANAPOLIS , March 7, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that patients with moderate-to-severe plaque psoriasis who did not respond to treatment with etanercept achieved significant improvement in their psoriasis plaques when treated with ix
Read more →LLYStudies Show Ixekizumab Improved Work Productivity for Patients with Moderate-to-Severe Plaque Psoriasis: Results Published in JAMA Dermatology Eli Lilly and Company (NYSE: LLY) announced today that JAMA Dermatology has published detailed results from three pivotal Phase 3 trials that...
INDIANAPOLIS , March 7, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that JAMA Dermatology has published detailed results from three pivotal Phase 3 trials that evaluated the effect of ixekizumab on work productivity in patients with moderate-to-severe
Read more →LLYIxekizumab Demonstrates Rapid, Clinically Meaningful Improvements as Early as One Week among Patients with Moderate-to-Severe Plaque Psoriasis Eli Lilly and Company (NYSE: LLY) announced today that treatment for moderate-to-severe plaque psoriasis with ixekizumab resulted in clinically...
INDIANAPOLIS , March 4, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that treatment for moderate-to-severe plaque psoriasis with ixekizumab resulted in clinically meaningful improvements as early as one week, compared to patients treated with etanercept
Read more →LLYLilly to Participate in Barclays Global Healthcare Conference Eli Lilly and Company (NYSE:LLY) will attend the Barclays Global Healthcare Conference on Wednesday, March 16, 2016. Derica Rice, Lilly's executive...
INDIANAPOLIS , March 2, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the Barclays Global Healthcare Conference on Wednesday, March 16, 2016 . Derica Rice , Lilly's executive vice president for global services and chief financial officer, will participate in
Read more →LLYLilly to Present Phase 3 Data at the American Academy of Dermatology (AAD) Annual Meeting for Ixekizumab in Psoriasis and Psoriatic Arthritis Eli Lilly and Company (NYSE: LLY) will showcase results from pivotal Phase 3 data investigating ixekizumab for the treatment of moderate-to-severe...
INDIANAPOLIS , March 1, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will showcase results from pivotal Phase 3 data investigating ixekizumab for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis at the 74 th annual meeting of the Amer
Read more →LLYLilly Receives Positive CHMP Opinion for Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP)...
INDIANAPOLIS , Feb. 26, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for ixekizumab for the treatment of moderate-to-severe pl
Read more →LLYLilly to Present at Cowen Health Care Conference Eli Lilly and Company (NYSE: LLY) will present at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8, 2016. Jan Lundberg,...
INDIANAPOLIS , Feb. 25, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present at the Cowen and Company 36 th Annual Health Care Conference on Tuesday, March 8, 2016 . Jan Lundberg , Ph.D., executive vice president of science and technology and president of Lilly Re
Read more →LLYUK Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit Eli Lilly and Company (NYSE: LLY) today announced that the UK High Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would not...
INDIANAPOLIS , Feb. 12, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the UK High Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would not presently be infringed by Actavis marketing pemetrexed trometamol in the UK, France ,
Read more →LLYLilly Diabetes Helps Inspiring Students with Type 1 Diabetes Attend College Through Scholarship Donation Attending college is a major milestone for many young people, but for those with type 1 diabetes, the journey can be extra demanding. Not only do...
ROLLING MEADOWS , Ill. and INDIANAPOLIS , Feb. 11, 2016 /PRNewswire/ -- Attending college is a major milestone for many young people, but for those with type 1 diabetes, the journey can be extra demanding. Not only do these students juggle class schedules, assignments and campus
Read more →LLYAmerican Diabetes Association® Survey Shows Summer Camp Can Positively Impact Children's Disease Management Skills, Confidence and Stress A three-year survey by the American Diabetes Association (Association) shows attending summer camp can do much more than lift the spirits of children ...
INDIANAPOLIS and ALEXANDRIA, Va. , Feb. 3, 2016 /PRNewswire/ -- A three-year survey by the American Diabetes Association (Association) shows attending summer camp can do much more than lift the spirits of children with type 1 diabetes. Surveys conducted with caregivers before and
Read more →LLYLilly Reports Fourth-Quarter and Full-Year 2015 Results Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2015. $ in millions, except per share...
INDIANAPOLIS , Jan. 28, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the fourth quarter and full year of 2015. Certain financial information for 2015 and 2014 is presented on both a reported and a non-GAAP basis. Some numbers in t
Read more →LLYLilly and Roche Diagnostics to Collaborate on Alzheimer's Disease Adjunct Diagnostic Tool Eli Lilly and Company (NYSE: LLY) today announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially...
INDIANAPOLIS , Jan. 27, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal fluid assay for amyloid-beta 1-42. Together with tau tangles, the
Read more →LLYLilly To Present At Leerink Partners Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will present at the Leerink Partners Global Healthcare Conference on Wednesday, February 10, 2016. Derica Rice,...
INDIANAPOLIS , Jan. 27, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present at the Leerink Partners Global Healthcare Conference on Wednesday, February 10, 2016 . Derica Rice , Lilly's executive vice president for global services and chief financial officer, will
Read more →LLYU.S. Food and Drug Administration Approves Humulin® R U-500 KwikPen® The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY) Humulin® R U-500 KwikPen®(insulin human injection) 500...
INDIANAPOLIS , Jan. 21, 2016 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY ) Humulin ® R U-500 KwikPen ® (insulin human injection) 500 units/mL, a pre-filled device containing Humulin R U-500, a highly concentrated for
Read more →LLYLilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that Lilly has submitted a new drug application (NDA) to the...
INDIANAPOLIS , Jan. 19, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) today announced that Lilly has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of oral once-daily bariciti
Read more →LLYLilly Announces 2016 Financial Guidance, Updates 2015 Expectations Eli Lilly and Company (NYSE: LLY) today announced its 2016 financial guidance and highlighted key events for the upcoming year. The company also...
INDIANAPOLIS , Jan. 5, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its 2016 financial guidance and highlighted key events for the upcoming year. The company also reaffirmed its commitment to grow revenue and expand margins through the balance of the de
Read more →LLYLilly to Present at J.P. Morgan Healthcare Conference Eli Lilly and Company (NYSE: LLY) will present at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016. John C. Lechleiter, ...
INDIANAPOLIS , Jan. 4, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present at the 34 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016 . John C. Lechleiter , Ph.D., Lilly's chairman, president and chief executive officer, will make a formal
Read more →LLYFDA Approves Basaglar® (insulin glargine injection), a Long-Acting Insulin Treatment Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration...
INDIANAPOLIS and RIDGEFIELD, Conn. , Dec. 16, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Basaglar ® (insulin glargine injection
Read more →LLYJuan R. Luciano elected to Lilly board of directors The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Juan R. Luciano as a new member, effective February 1, 2016. Luciano is chief ...
INDIANAPOLIS , Dec. 15, 2015 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has elected Juan R. Luciano as a new member, effective February 1, 2016 . Luciano is chief executive officer and president of Archer Daniels Midland Company (ADM), and a mem
Read more →LLYLilly Sets Dates and Conference Calls for 2016 Financial Guidance and Fourth-Quarter 2015 Financial Results Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2016 on Tuesday, January 5, 2016 and, separately, will announce its...
INDIANAPOLIS , Dec. 15, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial guidance for 2016 on Tuesday, January 5, 2016 and, separately, will announce its fourth-quarter and full-year 2015 financial results on Thursday, January 28, 2016 . On each
Read more →LLYLilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA® Combination Trial Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced another immuno-oncology...
INDIANAPOLIS and KENILWORTH, N.J. , Dec. 10, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Merck (NYSE: MRK ), known as MSD outside the United States and Canada , today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly
Read more →LLYLilly Ends Basal Insulin Peglispro Development Program Eli Lilly and Company (NYSE: LLY) today announced that it will cease development of basal insulin peglispro (BIL), a potential treatment for type 1...
INDIANAPOLIS , Dec. 4, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that it will cease development of basal insulin peglispro (BIL), a potential treatment for type 1 and type 2 diabetes, in order to focus research and development efforts on other assets
Read more →LLYNew Data Show Lilly's Once-Weekly Trulicity® (dulaglutide) is Effective as Add-on Treatment to Sulfonylurea New data from a completed Phase 3 trial show Trulicity® (dulaglutide) 1.5 mg plus a sulfonylurea was significantly more effective than a sulfonylurea ...
INDIANAPOLIS , Dec. 1, 2015 /PRNewswire/ -- New data from a completed Phase 3 trial show Trulicity ® (dulaglutide) 1.5 mg plus a sulfonylurea was significantly more effective than a sulfonylurea alone in lowering hemoglobin A1c (A1C) from baseline after 24 weeks of treatment. 1 T
Read more →LLYFDA Approves Portrazza™ (necitumumab) for Specific Type of Lung Cancer Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Portrazza™ (necitumumab injection for ...
INDIANAPOLIS , Nov. 24, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the U.S. Food and Drug Administration (FDA) has approved Portrazza™ (necitumumab injection for intravenous use, 800 mg/50 mL), in combination with gemcitabine and cisplatin, as th
Read more →LLYLilly to Provide Detailed Review of Elanco Animal Health and Alzheimer's R&D Strategy at Investment Community Meeting Eli Lilly and Company (NYSE: LLY) today announced it will host a meeting for the investment community, including institutional investors, sell-side...
INDIANAPOLIS , Nov. 20, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced it will host a meeting for the investment community, including institutional investors, sell-side analysts, ratings agency representatives, and financial and business media. The meeti
Read more →LLYLilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the extension of an...
INDIANAPOLIS and KENILWORTH, N.J. , Nov. 19, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Merck (NYSE: MRK ), known as MSD outside the United States and Canada , today announced the extension of an existing collaboration to evaluate the safety and efficacy of the c
Read more →LLYPatients Show Significant Improvement in Signs and Symptoms of Psoriatic Arthritis, Less Progression of Structural Joint Damage When Treated with Ixekizumab for 24 Weeks Eli Lilly and Company (NYSE: LLY) announced today that psoriatic arthritis (PsA) patients treated with ixekizumab for 24 weeks achieved significant...
INDIANAPOLIS , Nov. 8, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that psoriatic arthritis (PsA) patients treated with ixekizumab for 24 weeks achieved significant improvements in signs and symptoms of their disease when compared to placebo, while als
Read more →LLYDetailed Results Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced detailed data from pivotal phase 3 study RA-BEAM, the fourth...
-- Once-daily oral baricitinib significantly improved all seven components of ACR response versus injectable adalimumab -- Patient-reported pain, joint stiffness, fatigue and physical function scores significantly improved with baricitinib compared to adalimumab -- Detailed res
Read more →LLYLilly and Incyte Announce Patients Treated with Baricitinib Demonstrated Significant Improvement in Signs and Symptoms of Rheumatoid Arthritis Compared with Methotrexate - Compared to methotrexate, baricitinib as monotherapy or in combination with methotrexate demonstrated improvements in all ACR components as early...
- Compared to methotrexate, baricitinib as monotherapy or in combination with methotrexate demonstrated improvements in all ACR components as early as week 1 and maintained through 52 weeks - Both baricitinib regimens were superior to methotrexate monotherapy in inducing clinica
Read more →LLYLilly and United Way Celebrate Deepening Partnership, Community Impact Representatives from Eli Lilly and Company (NYSE: LLY) and United Way and its partner agencies gathered today to celebrate the early success of a new ...
INDIANAPOLIS , Nov. 5, 2015 /PRNewswire/ -- Representatives from Eli Lilly and Company (NYSE: LLY ) and United Way and its partner agencies gathered today to celebrate the early success of a new partnership approach that includes pairing Lilly teams with United Way agencies and a
Read more →LLYLilly to Participate in Credit Suisse 2015 Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Credit Suisse 2015 Healthcare Conference on Tuesday, November 10, 2015. Enrique Conterno,...
INDIANAPOLIS , Nov. 4, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Credit Suisse 2015 Healthcare Conference on Tuesday, November 10, 2015 . Enrique Conterno , president, Lilly Diabetes, will participate in a fireside chat at 1:00 p.m., Eastern
Read more →LLYResults of Two Pivotal Baricitinib Trials to be Presented at 2015 American College of Rheumatology Annual Meeting Eli Lilly and Company (NYSE: LLY) announces that detailed data for two phase 3 pivotal trials of the investigational medicine baricitinib in...
INDIANAPOLIS , Nov. 4, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announces that detailed data for two phase 3 pivotal trials of the investigational medicine baricitinib in rheumatoid arthritis, RA-BEGIN and RA-BEAM, will be presented at the American College of Rheum
Read more →LLYLilly Diabetes and NASCAR XFINITY Series Driver Ryan Reed Announce Winners of the My Diabetes Pit Crew Sweepstakes NASCAR XFINITY Series driver Ryan Reed's pit crew will have a different look during American Diabetes Month in November. Each pit crew member's fire...
INDIANAPOLIS , Nov. 3, 2015 /PRNewswire/ -- NASCAR XFINITY Series driver Ryan Reed's pit crew will have a different look during American Diabetes Month in November. Each pit crew member's fire suit will feature the name of a winner of the My Diabetes Pit Crew Sweepstakes, a progr
Read more →LLYEli Lilly and Company Announces Expansion of Indianapolis R&D Headquarters Eli Lilly and Company (NYSE: LLY) today revealed plans to expand its global research and development (R&D) headquarters in Indianapolis, Indiana....
INDIANAPOLIS , Nov. 2, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today revealed plans to expand its global research and development (R&D) headquarters in Indianapolis, Indiana . Adding 130,000 square feet to Lilly's existing complex, the new $70 million building wil
Read more →LLYLilly and Incyte Announce Webcast to Discuss Baricitinib Phase 3 Data Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) will host a webcast on November 11 to discuss detailed data from the final...
INDIANAPOLIS , Oct. 27, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (Nasdaq: INCY ) will host a webcast on November 11 to discuss detailed data from the final two of four pivotal Phase 3 studies of baricitinib in rheumatoid arthritis. Data from
Read more →LLYLilly Reports Third-Quarter 2015 Results, Revises 2015 Financial Guidance Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2015. $ in millions, except per share data Third Quarter ...
INDIANAPOLIS , Oct. 22, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the third quarter of 2015. Certain financial information for 2015 and 2014 is presented on both a reported and a non-GAAP basis. Some numbers in this press relea
Read more →LLYLilly and AstraZeneca Expand Immuno-Oncology Research Collaboration with New Combinations Eli Lilly and Company (NYSE: LLY) and AstraZeneca (NYSE: AZN) today announced an extension to their existing immuno-oncology collaboration exploring...
INDIANAPOLIS , Oct. 22, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and AstraZeneca (NYSE: AZN ) today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumors. Under
Read more →LLYLilly supports global Dementia Discovery Fund Eli Lilly and Company (NYSE: LLY) announced it will be a key collaborator in the $100 million Dementia Discovery Fund (DDF), which aims to accelerate ...
INDIANAPOLIS , Oct. 21, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced it will be a key collaborator in the $100 million Dementia Discovery Fund (DDF), which aims to accelerate the discovery and development of new treatments for dementia. This first-ever global
Read more →LLYLilly Declares Fourth-Quarter 2015 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2015 of $0.50 per share on outstanding...
INDIANAPOLIS , Oct. 19, 2015 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the fourth quarter of 2015 of $0.50 per share on outstanding common stock. The dividend is payable December 10, 2015 , to shareholders of record
Read more →LLYBaricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced positive topline results of RA-BEAM, the fourth successful...
INDIANAPOLIS , Oct. 14, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) today announced positive topline results of RA-BEAM, the fourth successful Phase 3 study of baricitinib, an investigational medicine for patients with moderately
Read more →LLYLilly brings drug development to the classroom with new college course offering Graduate students across the country, with an interest in health care and medical research, will soon have the opportunity to learn about a...
INDIANAPOLIS , Oct. 13, 2015 /PRNewswire/ -- Graduate students across the country, with an interest in health care and medical research, will soon have the opportunity to learn about a lesser-known area of patient care – the drug discovery and development process. Eli Lilly and C
Read more →LLYLilly and ImaginAb Announce Preclinical Immuno-Oncology Collaboration Eli Lilly and Company (NYSE: LLY) and ImaginAb Inc. are pleased to announce a preclinical research collaboration to study potential novel...
LOS ANGELES and INDIANAPOLIS , Oct. 13, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and ImaginAb Inc. are pleased to announce a preclinical research collaboration to study potential novel T-cell-based immuno-oncology therapies. Per the agreement, ImaginAb will conduc
Read more →LLYLilly to Discontinue Development of Evacetrapib for High-Risk Atherosclerotic Cardiovascular Disease Eli Lilly and Company (NYSE: LLY) and the ACCELERATE study's academic leadership have accepted the recommendation of the independent data monitoring...
INDIANAPOLIS , Oct. 12, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and the ACCELERATE study's academic leadership have accepted the recommendation of the independent data monitoring committee to terminate the Phase 3 trial of the investigational medicine evacetrapib,
Read more →LLYLilly and Innovent Biologics Expand Their Strategic Alliance to Include Immuno-Oncology Bispecific Antibodies in China and Globally Eli Lilly and Company (NYSE:LLY) and Innovent Biologics, Inc. (Innovent) today announced an expansion of their drug development collaboration,...
INDIANAPOLIS and SHANGHAI , Oct. 11, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Innovent Biologics, Inc. (Innovent) today announced an expansion of their drug development collaboration, already one of the largest in China between a multi-national and domestic bio
Read more →LLYEli Lilly and Company Expands New York City Research and Development Site Eli Lilly and Company (NYSE: LLY) today announced plans to add 30,000 square feet and approximately 50 new jobs to its research and development...
INDIANAPOLIS , Oct. 9, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced plans to add 30,000 square feet and approximately 50 new jobs to its research and development presence at the Alexandria Center for Life Science in New York, New York . Upon completion
Read more →LLYLilly Acquires Phase III Intranasal Glucagon from Locemia Solutions Eli Lilly and Company (NYSE:LLY) and Locemia Solutions today announced Lilly has acquired worldwide rights to Locemia's intranasal glucagon, a...
INDIANAPOLIS , Oct. 9, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Locemia Solutions today announced Lilly has acquired worldwide rights to Locemia's intranasal glucagon, a potential treatment for severe hypoglycemia in people with diabetes treated with insulin. I
Read more →LLYLilly Receives FDA Breakthrough Therapy Designation for Abemaciclib - a CDK 4 and 6 Inhibitor - in Advanced Breast Cancer Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to...
INDIANAPOLIS , Oct. 8, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refrac
Read more →LLYLilly Joins the Imaging Dementia - Evidence for Amyloid Scanning (IDEAS) Study Eli Lilly and Company (NYSE:LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced financial commitment and...
INDIANAPOLIS , Oct. 7, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced financial commitment and continued scientific partnership to support the recently established Imaging Dementia –
Read more →LLYLilly Confirms Date and Conference Call for Third-Quarter 2015 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2015 on Thursday, October 22, 2015. Lilly will also...
INDIANAPOLIS , Oct. 7, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the third quarter of 2015 on Thursday, October 22, 2015 . Lilly will also conduct a conference call on that day with the investment community and media to furthe
Read more →LLYLilly to Showcase Data for Investigational Psoriasis Treatment at 24th European Academy of Dermatology and Venereology Congress Eli Lilly and Company (NYSE: LLY) will showcase results from the ixekizumab clinical development program during the 24th European Academy of...
INDIANAPOLIS , Oct. 6, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will showcase results from the ixekizumab clinical development program during the 24 th European Academy of Dermatology and Venereology Congress in Copenhagen, Denmark , Oct. 7-11. Ixekizumab is the co
Read more →LLYLilly and Sanofi Reach Settlement Agreement in U.S. Insulin Glargine Litigation Eli Lilly and Company (NYSE: LLY) has entered into a settlement agreement to resolve patent litigation with Sanofi regarding its insulin glargine...
INDIANAPOLIS , Sept. 28, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has entered into a settlement agreement to resolve patent litigation with Sanofi regarding its insulin glargine product, Basaglar®. As a part of the agreement, Lilly and its alliance partner, Boehrin
Read more →LLYLilly's CYRAMZA® (ramucirumab) Significantly Improves Progression-Free Survival in Phase II Bladder Cancer Trial A Phase II study of Eli Lilly and Company's (NYSE: LLY) CYRAMZA® (ramucirumab) in combination with docetaxel met its primary endpoint, demonstrating...
INDIANAPOLIS , Sept. 28, 2015 /PRNewswire/ -- A Phase II study of Eli Lilly and Company's (NYSE: LLY ) CYRAMZA ® (ramucirumab) in combination with docetaxel met its primary endpoint, demonstrating a statistically significant increase in progression-free survival (PFS) for patient
Read more →LLYLilly Announces Webcast to Discuss EMPA-REG OUTCOME® Data Eli Lilly and Company (NYSE: LLY) will host a webcast on September 24 to discuss data from EMPA-REG OUTCOME®, a long-term clinical trial...
INDIANAPOLIS , Sept. 15, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will host a webcast on September 24 to discuss data from EMPA-REG OUTCOME ® , a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance ® (empagliflozin) in more than 7,000
Read more →LLYLilly to Participate in Morgan Stanley Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2015. Sue Mahony, Ph.D.,...
INDIANAPOLIS , Aug. 27, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2015 . Sue Mahony , Ph.D., senior vice president and president of Lilly Oncology and Richard Gaynor , M.D., senio
Read more →LLYLilly, AACE Mark 10th Anniversary of Hurricane Katrina with Reminder of My Diabetes Emergency Plan Checklist For Sherry Martin, M.D., starting her new job at Eli Lilly and Company (NYSE: LLY) in August 2005 was stressful enough. She was in the process of...
INDIANAPOLIS , Aug. 25, 2015 /PRNewswire/ -- For Sherry Martin , M.D., starting her new job at Eli Lilly and Company (NYSE: LLY ) in August 2005 was stressful enough. She was in the process of leaving her 15-year clinical practice and moving her family from Mississippi to Indiana
Read more →LLYU.S. District Court Rules in Lilly's Favor on Alimta Vitamin Regimen Patent Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of Indiana has ruled in the company's favor...
INDIANAPOLIS , Aug. 25, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. District Court for the Southern District of Indiana has ruled in the company's favor regarding infringement of the vitamin regimen patent for Alimta ® (pemetrexed for inj
Read more →LLYLilly's Humalog® 200 units/mL KwikPen® Now Available in U.S. Pharmacies Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), the first and only concentrated mealtime insulin analog in the U.S., is now...
INDIANAPOLIS , Aug. 18, 2015 /PRNewswire/ -- Humalog ® 200 units/mL KwikPen ® (insulin lispro 200 units/mL; U-200), the first and only concentrated mealtime insulin analog in the U.S., is now available in pharmacies, Eli Lilly and Company (NYSE: LLY ) announced today. Humalog U-2
Read more →LLYLilly Provides Update on Evacetrapib Phase 3 Trial Eli Lilly and Company (NYSE: LLY) has accepted the recommendation of the ACCELERATE study data monitoring committee to continue the Phase 3 trial of...
INDIANAPOLIS , July 27, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has accepted the recommendation of the ACCELERATE study data monitoring committee to continue the Phase 3 trial of the investigational medicine evacetrapib, based on data from an interim futility anal
Read more →LLYLilly Diabetes and NASCAR XFINITY Series Driver Ryan Reed Want You to Think About Your Diabetes Pit Crew To emphasize the importance of a support system in diabetes management, Lilly Diabetes and NASCAR XFINITY Series driver Ryan Reed will kick off the...
INDIANAPOLIS , July 23, 2015 /PRNewswire/ -- To emphasize the importance of a support system in diabetes management, Lilly Diabetes and NASCAR XFINITY Series driver Ryan Reed will kick off the My Diabetes Pit Crew Sweepstakes today in association with the Lilly Diabetes 250, the
Read more →LLYEli Lilly and Company Announces Expansion of San Diego Biotechnology Center Eli Lilly and Company (NYSE: LLY) today revealed plans to expand the Lilly Biotechnology Center located in San Diego, Calif. The expansion will...
INDIANAPOLIS , July 23, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today revealed plans to expand the Lilly Biotechnology Center located in San Diego, Calif. The expansion will effectively double Lilly's research presence in San Diego as the company seeks to develop
Read more →LLYLilly Reports Second-Quarter 2015 Results, Revises 2015 Financial Guidance Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2015. $ in millions, except per share data Second...
INDIANAPOLIS , July 23, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the second quarter of 2015. Certain financial information for 2015 and 2014 is presented on both a reported and a non-GAAP basis. Some numbers in this press rele
Read more →LLYNew Study Shows Florbetapir F 18 Injection Scans Led to Change in Diagnosis and Management of Patients Being Evaluated for Cognitive Decline Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced new data showing that...
INDIANAPOLIS , July 22, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced new data showing that knowledge of amyloid status as determined by Florbetapir F 18 Injection imaging altered d
Read more →LLYData Using New Delayed-Start Methodology Suggested Benefit of Early Treatment with Solanezumab in Patients with Mild Alzheimer's Disease Eli Lilly and Company (NYSE: LLY) today announced results suggesting the treatment effect of solanezumab was preserved within a pre-specified amount...
INDIANAPOLIS , July 22, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced results suggesting the treatment effect of solanezumab was preserved within a pre-specified amount in patients with mild Alzheimer's disease who received solanezumab earlier in the dis
Read more →LLYLilly Diabetes Launches Android Version of Glucagon Mobile Application for Those Who Support People with Diabetes News Highlights Now for Android: Lilly Diabetes' Glucagon Mobile App to support #diabetes caregivers Leverage the power of Android or iPhone...
INDIANAPOLIS , July 14, 2015 /PRNewswire/ -- News Highlights Lilly Diabetes has released an Android version of its mobile application designed for caregivers and healthcare providers who support people with diabetes. Through an injection tutorial and emergency instructions, the
Read more →LLYLilly Statement on FDA Advisory Committee Review of Necitumumab The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) met today to discuss the data supporting Eli Lilly and...
INDIANAPOLIS , July 9, 2015 /PRNewswire/ -- The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) met today to discuss the data supporting Eli Lilly and Company's (NYSE: LLY ) necitumumab in combination with gemcitabine and cisplatin for use in f
Read more →LLYLilly Confirms Date and Conference Call for Second-Quarter 2015 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2015 on Thursday, July 23, 2015. Lilly will also...
INDIANAPOLIS , July 1, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the second quarter of 2015 on Thursday, July 23, 2015 . Lilly will also conduct a conference call on that day with the investment community and media to further
Read more →LLYLilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma Eli Lilly and Company (NYSE: LLY) and Immunocore Limited today announced that they have entered into an immunotherapy-based clinical trial...
INDIANAPOLIS and OXFORD, England , June 29, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Immunocore Limited today announced that they have entered into an immunotherapy-based clinical trial collaboration to explore the utility of Immunocore's lead T cell receptor-b
Read more →LLYDiabetes Scholars Foundation Announces 2015 Scholarship Recipients Attending college is a critical milestone in the lives of many young people. But balancing college life and a full course load while keeping a...
ROLLING MEADOWS , Ill. and INDIANAPOLIS , June 25, 2015 /PRNewswire/ -- Attending college is a critical milestone in the lives of many young people. But balancing college life and a full course load while keeping a chronic disease such as diabetes in check can make an exciting ti
Read more →LLYUK Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit Eli Lilly and Company (NYSE: LLY) today announced that the Court of Appeal has ruled that the Alimta® (pemetrexed disodium) vitamin regimen patent...
INDIANAPOLIS , June 25, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the Court of Appeal has ruled that the Alimta® (pemetrexed disodium) vitamin regimen patent would be indirectly infringed by a generic competitor that had stated its intent to mar
Read more →LLYCYRAMZA® (ramucirumab) Hepatocellular Carcinoma Data Published by The Lancet Oncology Eli Lilly and Company (NYSE: LLY) announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA®...
INDIANAPOLIS , June 19, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA ® (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC),
Read more →LLYLilly's investigational medicine for prevention of migraine met primary endpoint in a Phase 2b study Eli Lilly and Company (NYSE: LLY) announced today that its investigational medicine for prevention of migraine (LY2951742, a CGRP neutralizing...
INDIANAPOLIS , June 17, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that its investigational medicine for prevention of migraine (LY2951742, a CGRP neutralizing antibody) met the primary endpoint in a Phase 2b study in episodic migraine. The randomize
Read more →LLYEli Lilly and Company Enters Into Strategic Partnership with Sarah Cannon Research Institute to Develop Investigational Oncology Therapy Eli Lilly and Company (NYSE: LLY) and Sarah Cannon Research Institute (SCRI) today announced a strategic partnership to co‑develop an investigational ...
INDIANAPOLIS and NASHVILLE, Tenn., June 17, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Sarah Cannon Research Institute (SCRI) today announced a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. Under
Read more →LLYLilly and Dana-Farber Cancer Institute Announce Research Collaboration Eli Lilly and Company (NYSE: LLY) and Dana-Farber Cancer Institute today announced a multiyear collaboration to research new medicines under...
INDIANAPOLIS and BOSTON , June 17, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Dana-Farber Cancer Institute today announced a multiyear collaboration to research new medicines under development to fight cancer. "Working together is the most powerful approach in f
Read more →LLYLilly Declares Third-Quarter 2015 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2015 of $0.50 per share on outstanding...
INDIANAPOLIS , June 15, 2015 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the third quarter of 2015 of $0.50 per share on outstanding common stock. The dividend is payable September 10, 2015 , to shareholders of record
Read more →LLYLilly Announces Webcast to Discuss Ixekizumab Phase III Data Eli Lilly and Company (NYSE: LLY) will host a webcast on June 23 to discuss three pivotal Phase III studies investigating ixekizumab for the...
INDIANAPOLIS , June 11, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will host a webcast on June 23 to discuss three pivotal Phase III studies investigating ixekizumab for the treatment of moderate-to-severe plaque psoriasis. Data from the UNCOVER-1, -2 and -3 clinical
Read more →LLYStudies Show Psoriasis Patients Achieved Significant Levels of Skin Clearance and Improved Quality of Life after 12 Weeks of Ixekizumab Treatment Eli Lilly and Company (NYSE: LLY) announced today that detailed results of two pivotal Phase III studies for ixekizumab were published by The Lancet. ...
INDIANAPOLIS , June 10, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that detailed results of two pivotal Phase III studies for ixekizumab were published by The Lancet. The UNCOVER-2 and UNCOVER-3 clinical studies of more than 2,500 patients found ixeki
Read more →LLYLilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that five abstracts featuring data from three clinical...
INDIANAPOLIS , June 10, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) today announced that five abstracts featuring data from three clinical studies and separate pharmacology studies for its investigational rheumatoid arthritis dru
Read more →LLYNew Data Show Superiority of Lilly's Once-Weekly Trulicity™ (dulaglutide) to Lantus® (insulin glargine) in Patients with Type 2 Diabetes Trulicity™ 1.5 mg and 0.75 mg provided superior hemoglobin A1c (A1C) reduction compared to Lantus® in a study of patients with type 2 diabetes and...
INDIANAPOLIS , June 8, 2015 /PRNewswire/ -- Trulicity ™ 1.5 mg and 0.75 mg provided superior hemoglobin A1c (A1C) reduction compared to Lantus ® in a study of patients with type 2 diabetes and primarily enrolled from East Asia , according to new data presented by Eli Lilly and Co
Read more →LLYOlympian Kris Freeman and NASCAR Driver Ryan Reed to Share Their Courageous Stories with Children Who Have Type 1 Diabetes Olympic cross-country skier Kris Freeman and NASCAR XFINITY Series driver Ryan Reed will travel across the U.S. this summer to share their stories of ...
INDIANAPOLIS , June 8, 2015 /PRNewswire/ -- Olympic cross-country skier Kris Freeman and NASCAR XFINITY Series driver Ryan Reed will travel across the U.S. this summer to share their stories of perseverance and triumph as part of the Lilly Camp Care Package (LCCP) program. Kris a
Read more →LLYStudy: Once-Weekly Trulicity™ (dulaglutide) Provides Greater Blood Sugar Reduction Compared to Once-Daily Victoza® (liraglutide) in Japanese Patients after 52 weeks Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity™ 0.75 mg provided greater hemoglobin A1c (A1C)...
INDIANAPOLIS , June 6, 2015 /PRNewswire/ -- Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity ™ 0.75 mg provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza ® 0.9 mg after 52 weeks of treatment. Eli Lilly and
Read more →LLYBasal Insulin Peglispro Studies Demonstrate Superiority to Insulin Glargine Across Multiple Measures in People with Type 1 Diabetes In newly released Phase III trial data, Eli Lilly and Company's (NYSE: LLY) basal insulin peglispro (BIL) demonstrated statistically significantly...
INDIANAPOLIS , June 6, 2015 /PRNewswire/ -- In newly released Phase III trial data, Eli Lilly and Company's (NYSE: LLY ) basal insulin peglispro (BIL) demonstrated statistically significantly lower hemoglobin A1c (HbA1c) compared to insulin glargine at 26 and 52 weeks in people w
Read more →LLYLilly's Basal Insulin Peglispro Shows Superiority to Insulin Glargine in Reducing HbA1c in People with Type 2 Diabetes Eli Lilly and Company's (NYSE: LLY) basal insulin peglispro (BIL) consistently demonstrated superior hemoglobin A1c (HbA1c) reduction in people with...
INDIANAPOLIS , June 6, 2015 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY ) basal insulin peglispro (BIL) consistently demonstrated superior hemoglobin A1c (HbA1c) reduction in people with type 2 diabetes compared to insulin glargine across three Phase III trials. The result
Read more →LLYLilly to Present Pivotal Phase 3 Study Results for Investigational Psoriasis Treatment at 23rd World Congress of Dermatology Eli Lilly and Company (NYSE: LLY) will showcase results from three pivotal Phase 3 studies investigating ixekizumab for the treatment of...
INDIANAPOLIS , June 4, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will showcase results from three pivotal Phase 3 studies investigating ixekizumab for the treatment of moderate-to-severe plaque psoriasis at the 23 rd World Congress of Dermatology in Vancouver, Briti
Read more →LLYLilly commits 780,000 additional vials of insulin to Life for a Child Eli Lilly and Company (NYSE:LLY) has committed another 780,000 vials of insulin to the International Diabetes Federation's Life for a Child program....
INDIANAPOLIS , June 4, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has committed another 780,000 vials of insulin to the International Diabetes Federation's Life for a Child program. Life for a Child provides free, life-saving medicine to children living in impoverish
Read more →LLYLilly to Participate in Goldman Sachs Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 36th Annual Global Healthcare Conference on Tuesday, June 9, 2015. Jeffrey Simmons,...
INDIANAPOLIS , May 29, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the Goldman Sachs 36th Annual Global Healthcare Conference on Tuesday, June 9, 2015 . Jeffrey Simmons , senior vice president and president, Elanco Animal Health, will participate in a fire
Read more →LLYLilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors Eli Lilly and Company (NYSE: LLY) and AstraZeneca (NYSE: AZN) today announced that they have entered into a clinical trial collaboration to evaluate...
INDIANAPOLIS , May 29, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and AstraZeneca (NYSE: AZN ) today announced that they have entered into a clinical trial collaboration to evaluate the safety and preliminary efficacy of AstraZeneca's investigational anti-PD-L1 immun
Read more →LLYPROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting Eli Lilly and Company (NYSE: LLY) announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the...
INDIANAPOLIS , May 28, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago . PROCLAIM was
Read more →LLYLilly Announces the Early Results of Its Cash Tender Offer Eli Lilly and Company (NYSE: LLY) announced today that pursuant to its previously announced cash tender offer for up to $1.6 billion aggregate...
INDIANAPOLIS , May 28, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that pursuant to its previously announced cash tender offer for up to $1.6 billion aggregate principal amount (the "tender cap") of specified series of its outstanding debt, approximate
Read more →LLYLilly to Present CYRAMZA® (ramucirumab) Data at 2015 ASCO Annual Meeting Eli Lilly and Company (NYSE: LLY) announced that data from several trials of CYRAMZA® (ramucirumab) will be presented at the American Society of...
INDIANAPOLIS , May 28, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced that data from several trials of CYRAMZA ® (ramucirumab) will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago , including a Phase II study of non-sm
Read more →LLYLilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities Eli Lilly and Company (NYSE: LLY) announced today the pricing terms of its previously announced cash tender offer for up to $1.6 billion aggregate...
INDIANAPOLIS , May 28, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today the pricing terms of its previously announced cash tender offer for up to $1.6 billion aggregate principal amount of certain of its outstanding debt securities. Holders of notes who te
Read more →LLYLilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) will host a webcast on June 11 to discuss data from the first two pivotal...
INDIANAPOLIS , May 28, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte Corporation (Nasdaq: INCY ) will host a webcast on June 11 to discuss data from the first two pivotal Phase III studies of baricitinib in rheumatoid arthritis. Data from these two trials, RA
Read more →LLYLilly Sends Employees to Serve in Vulnerable Communities around the World Marcio Donatelli, a senior marketing associate with the animal health division of Eli Lilly and Company (NYSE: LLY), believes his volunteer work in a ...
INDIANAPOLIS , May 27, 2015 /PRNewswire/ -- Marcio Donatelli, a senior marketing associate with the animal health division of Eli Lilly and Company (NYSE: LLY ), believes his volunteer work in a healthcare setting in Bangkok, Thailand , will be among the most humbling experiences
Read more →LLYU.S. Food and Drug Administration Approves Humalog® 200 units/mL KwikPen® The U.S. Food and Drug Administration (FDA) has approved Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), a pre-filled pen...
INDIANAPOLIS , May 27, 2015 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Humalog ® 200 units/mL KwikPen ® (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog ® (insulin li
Read more →LLYLilly to Present New Clinical Data at 75th American Diabetes Association® Scientific Sessions New clinical data demonstrating the range of treatment options represented in Lilly's (NYSE: LLY) diabetes portfolio will be presented in 79...
INDIANAPOLIS , May 27, 2015 /PRNewswire/ -- New clinical data demonstrating the range of treatment options represented in Lilly's (NYSE: LLY ) diabetes portfolio will be presented in 79 abstracts on June 5-9 , at the 75 th American Diabetes Association (ADA) ® Scientific Sessions
Read more →LLYLilly Announces Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities and the Redemption of Its 6.57% Notes due 2016 Eli Lilly and Company (NYSE: LLY) announced today that it has commenced a cash tender offer for up to $1.6 billion aggregate principal amount (the...
INDIANAPOLIS , May 12, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that it has commenced a cash tender offer for up to $1.6 billion aggregate principal amount (the "tender cap") of specified series of its outstanding debt. Pursuant to the tender offer,
Read more →LLYLilly and BioNTech Announce Research Collaboration on Novel Cancer Immunotherapies Eli Lilly and Company (NYSE:LLY) and BioNTech AG today announced they have entered into a research collaboration to discover novel cancer...
INDIANAPOLIS and MAINZ, Germany , May 11, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and BioNTech AG today announced they have entered into a research collaboration to discover novel cancer immunotherapies. The companies will seek to use the power of the body's own i
Read more →LLYEli Lilly and Company Reveals Plan for Innovation Center in Cambridge, Massachusetts Eli Lilly and Company (NYSE: LLY) today announced plans to establish a new drug delivery and device innovation center in Cambridge, Massachusetts – a ...
INDIANAPOLIS , May 6, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced plans to establish a new drug delivery and device innovation center in Cambridge, Massachusetts – a strategic location that will help attract top scientists and bioengineers, as well as
Read more →LLYLilly Releases Corporate Responsibility, Global Health Reports Eli Lilly and Company (NYSE: LLY) today released two new reports that provide a comprehensive overview of the company's corporate responsibility...
INDIANAPOLIS , May 4, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today released two new reports that provide a comprehensive overview of the company's corporate responsibility efforts. The reports highlight how Lilly is evolving its approach to corporate responsibili
Read more →LLYLilly Declares Second-Quarter 2015 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2015 of $0.50 per share on outstanding...
INDIANAPOLIS , May 4, 2015 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the second quarter of 2015 of $0.50 per share on outstanding common stock. The dividend is payable June 10, 2015 , to shareholders of record at the
Read more →LLYLilly to Participate in Bank of America Merrill Lynch Health Care Conference Eli Lilly and Company (NYSE: LLY) will attend the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13, 2015. Derica Rice,...
INDIANAPOLIS , May 1, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13, 2015 . Derica Rice , Lilly's executive vice president for global services and chief financial officer will
Read more →LLYSurvey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP)...
PARSIPPANY, N.J. and INDIANAPOLIS , April 28, 2015 /PRNewswire/ -- People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP) therapy and aspirin to help prevent a heart attack, a blood clot i
Read more →LLYLilly's CYRAMZA® (ramucirumab) Receives Fourth FDA Approval Eli Lilly and Company (NYSE: LLY) has received its fourth U.S. Food and Drug Administration (FDA) approval for CYRAMZA® (ramucirumab). CYRAMZA...
INDIANAPOLIS , April 24, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has received its fourth U.S. Food and Drug Administration (FDA) approval for CYRAMZA ® (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFI
Read more →LLYLilly Reports First-Quarter 2015 Results Revenue declined 1 percent due to the unfavorable impact of foreign exchange rates and the continuing impact of Cymbalta and Evista patent...
INDIANAPOLIS , April 23, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the first quarter of 2015. Certain financial information for 2015 and 2014 is presented on both a reported and a non-GAAP basis. Some numbers in this press rel
Read more →LLYLilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 Eli Lilly and Company (NYSE: LLY) will present early stage data from several targeted cancer therapies, reflecting Lilly's diverse oncology pipeline, ...
INDIANAPOLIS , April 20, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present early stage data from several targeted cancer therapies, reflecting Lilly's diverse oncology pipeline, during the American Association for Cancer Research (AACR) Annual Meeting 2015, hel
Read more →LLYLilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis Eli Lilly and Company (NYSE: LLY) announced today that the investigational medicine ixekizumab was statistically superior to placebo in the treatment ...
INDIANAPOLIS , April 20, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the investigational medicine ixekizumab was statistically superior to placebo in the treatment of patients with active psoriatic arthritis (PsA), as demonstrated by the proportio
Read more →LLYLilly Confirms Date and Conference Call for First-Quarter 2015 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the first quarter of 2015 on Thursday, April 23, 2015. Lilly will also...
INDIANAPOLIS , April 1, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the first quarter of 2015 on Thursday, April 23 , 2015. Lilly will also conduct a conference call on that day with the investment community and media to further
Read more →LLYLilly Announces Date for Diabetes Investor Meeting Eli Lilly and Company (NYSE: LLY) will conduct a meeting on June 7 to update the investment community and media on the company's diabetes business....
INDIANAPOLIS , March 30, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will conduct a meeting on June 7 to update the investment community and media on the company's diabetes business. The discussion, being held in conjunction with the 75th American Diabetes Association
Read more →LLYPreparation Is Personal for Those with Chronic Illnesses News Highlights: .@TheAACE and @LillyDiabetes highlight the My Diabetes Emergency Plan at the 2015 @NatHurricaneCon .@TheAACE and @LillyDiabetes at...
AUSTIN, Texas , March 30, 2015 /PRNewswire/ -- News Highlights: The American College of Endocrinology (ACE) – the charitable, educational and scientific arm of the American Association of Clinical Endocrinologists (AACE) – has joined forces with Lilly Diabetes to share the My D
Read more →LLYLilly and Innovent Biologics Announce a Strategic Alliance to Bring Potential Oncology Therapies to Patients in China and Around the World Eli Lilly and Company (NYSE:LLY) and Innovent Biologics, Inc. (Innovent) today announced one of the largest biotech drug development collaborations...
BEIJING , March 20, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Innovent Biologics, Inc. (Innovent) today announced one of the largest biotech drug development collaborations in China to date between a multi-national and domestic company. Under terms of the agreem
Read more →LLYGerman Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit The German Court of Appeal has ruled that Eli Lilly and Company's (NYSE: LLY) vitamin regimen patent for Alimta® (pemetrexed disodium) would not be...
INDIANAPOLIS , March 6, 2015 /PRNewswire/ -- The German Court of Appeal has ruled that Eli Lilly and Company's (NYSE: LLY ) vitamin regimen patent for Alimta® (pemetrexed disodium) would not be infringed by a generic competitor that intends to market a dipotassium salt form of pe
Read more →LLYLilly and IU School of Medicine Partner on Rotation Program for Medical Students Students from Indiana University School of Medicine are getting a first-hand look at how new medicines are discovered. Through a partnership with...
INDIANAPOLIS , March 4, 2015 /PRNewswire/ -- Students from Indiana University School of Medicine are getting a first-hand look at how new medicines are discovered. Through a partnership with Lilly USA , third- and fourth-year medical students from IU School of Medicine are learni
Read more →LLYLilly to Participate in Barclays Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Barclays Global Healthcare Conference on Wednesday, March 11, 2015. Jan M. Lundberg, Ph.D.,...
INDIANAPOLIS , March 3, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the Barclays Global Healthcare Conference on Wednesday, March 11, 2015 . Jan M. Lundberg , Ph.D., executive vice president of science and technology and president of Lilly Research Laborat
Read more →LLYLilly to Present at Cowen Health Care Conference Eli Lilly and Company (NYSE: LLY) will present at the 35th Annual Cowen and Company Health Care Conference on Tuesday, March 3, 2015. Mr. David...
INDIANAPOLIS , Feb. 24, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present at the 35 th Annual Cowen and Company Health Care Conference on Tuesday, March 3, 2015 . Mr. David Ricks, Sr. Vice President and President, Lilly Bio-Medicines will speak at 10:40 a.m. ES
Read more →LLYLilly Announces Update on Regulatory Submission Timing for Basal Insulin Peglispro Eli Lilly and Company (NYSE: LLY) today announced a delay in the submission of basal insulin peglispro (BIL) to regulatory agencies beyond the first...
INDIANAPOLIS , Feb. 23, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced a delay in the submission of basal insulin peglispro (BIL) to regulatory agencies beyond the first quarter of 2015. The delay includes filings with the U.S. Food and Drug Administratio
Read more →LLYNASCAR Driver Ryan Reed Takes First Place At Daytona International Speedway News Highlights: Lilly Diabetes ambassador @driverRyanReed wins in Daytona! Congratulations! #Daytona500 Victory for Lilly Diabetes ambassador and...
INDIANAPOLIS and ALEXANDRIA, Va. , Feb. 21, 2015 /PRNewswire/ -- News Highlights: On Saturday, February 21 , NASCAR Xfinity Series driver and Lilly Diabetes ambassador Ryan Reed won the Alert Today Florida 300 at Daytona International Speedway. This is his first win as a NASCAR
Read more →LLYLilly Provides Update on Evacetrapib Phase 3 Trial Eli Lilly and Company (NYSE: LLY) has accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging science in...
Last patient visit in ACCELERATE – which is evaluating evacetrapib in approximately 12,000 people with high-risk atherosclerotic cardiovascular disease (ASCVD) -- is now expected in July 2016 . The academic executive committee based its recommendation on analysis of recent resul
Read more →LLYLilly to Present at Leerink Global Healthcare Conference Eli Lilly and Company (NYSE:LLY) will present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11, 2015. Alfonso Zulueta, Sr....
INDIANAPOLIS , Feb. 6, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11, 2015 . Alfonso Zulueta, Sr. Vice President and President, Emerging Markets will participate in a fireside chat a
Read more →LLYThe Lilly Foundation Commits $1 Million to Support AMPATH Oncology Institute in Kenya In conjunction with World Cancer Day, Eli Lilly and Company (NYSE: LLY) announced a commitment of $1 million to AMPATH in Eldoret, Kenya. The...
INDIANAPOLIS , Feb. 4, 2015 /PRNewswire/ -- In conjunction with World Cancer Day, Eli Lilly and Company (NYSE: LLY ) announced a commitment of $1 million to AMPATH in Eldoret, Kenya . The funding, provided by the Lilly Foundation, will help equip a new oncology center, hire addit
Read more →LLYLilly Diabetes Donates $92,000 in Camp Scholarships to the American Diabetes Association News Highlights: Diabetes camping can change lives for kids with #T1D. @LillyDiabetes works to help; supports @AmDiabetesAssn-led program for 10+...
INDIANAPOLIS and ALEXANDRIA, Va. , Feb. 3, 2015 /PRNewswire/ -- News Highlights: Today Lilly Diabetes announced its support of the American Diabetes Association (Association) summer camp program by donating $92,000 for camp scholarships – $1,000 for each year Lilly has helped t
Read more →LLYLilly Reports Fourth-Quarter and Full-Year 2014 Results, Updates 2015 Guidance Fourth-quarter 2014 revenue declined 12 percent driven by the impact of U.S. patent expirations for Cymbalta and Evista and the unfavorable impact of ...
INDIANAPOLIS , Jan. 30, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the fourth quarter and full year of 2014. Certain financial information for 2014 and 2013 is presented on both a reported and a non-GAAP basis. Some numbers in
Read more →LLYScoring Progress Against Cancer: New Tool Measures Cancer Progress to Help Inform Research and Policy Decisions On the eve of World Cancer Day 2015, amidst the ongoing cost-of-cancer-care debate, PACE (Patient Access to Cancer care Excellence), a Lilly Oncology ...
WASHINGTON , Jan. 29, 2015 /PRNewswire/ -- On the eve of World Cancer Day 2015, amidst the ongoing cost-of-cancer-care debate, PACE (Patient Access to Cancer care Excellence), a Lilly Oncology initiative, is launching the PACE Continuous Innovation Indicators™ (CII). CII is the f
Read more →LLYLilly Provides Update on Strategy and Announces 2015 Financial Guidance Eli Lilly and Company (NYSE: LLY) today announced its 2015 financial guidance and outlined plans to grow revenue and expand margins through the...
INDIANAPOLIS , Jan. 7, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its 2015 financial guidance and outlined plans to grow revenue and expand margins through the balance of the decade. The company's refined strategy will provide greater focus for resear
Read more →LLYLilly Announces Promotion of Darren J. Carroll to Senior Vice President of Corporate Business Development Eli Lilly and Company (NYSE: LLY) today announced the promotion of Darren J. Carroll to Senior Vice President of Corporate Business Development...
INDIANAPOLIS , Jan. 5, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the promotion of Darren J. Carroll to Senior Vice President of Corporate Business Development effective Jan. 1, 2015 . He has been the Vice President of Corporate Business Development s
Read more →LLYLilly to Present at J.P. Morgan Healthcare Conference Eli Lilly and Company (NYSE:LLY) will present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015. John C. Lechleiter,...
INDIANAPOLIS , Jan. 5, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015 . John C. Lechleiter , Ph.D., Lilly's chairman, president and chief executive officer will make a formal p
Read more →LLYLilly Finalizes Novartis Animal Health Acquisition Eli Lilly and Company (NYSE: LLY) today announced that it has completed the acquisition of Novartis Animal Health, which will further position...
INDIANAPOLIS , Jan. 1, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that it has completed the acquisition of Novartis Animal Health, which will further position Lilly's Elanco as a global leader in the animal health industry. The transaction, first anno
Read more →LLYLilly Announces Diabetes Research Partnership with University of Surrey Eli Lilly and Company (NYSE: LLY) today announced a five-year research partnership with the University of Surrey to study health outcomes, focusing...
INDIANAPOLIS , Dec. 22, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced a five-year research partnership with the University of Surrey to study health outcomes, focusing on the effects of treatment in people with type 2 diabetes, which affects about 95 per
Read more →LLYLilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology Eli Lilly and Company (NYSE: LLY) and Adocia (Euronext Paris: FR0011184241 – ADOC) today announced a worldwide licensing collaboration focused on...
INDIANAPOLIS and LYON, France , Dec. 19, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Adocia (Euronext Paris: FR0011184241 – ADOC) today announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, for tr
Read more →LLYLilly's CYRAMZA® (ramucirumab) Receives Third FDA Approval Eli Lilly and Company (NYSE: LLY) has received its third U.S. Food and Drug Administration (FDA) approval for CYRAMZA® (ramucirumab). Specifically,...
INDIANAPOLIS , Dec. 16, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has received its third U.S. Food and Drug Administration (FDA) approval for CYRAMZA ® (ramucirumab). Specifically, CYRAMZA is now also indicated in combination with docetaxel, for the treatment of pa
Read more →LLYLilly Announces Dividend Increase The board of directors of Eli Lilly and Company (NYSE: LLY) today announced a 2 percent increase in its quarterly dividend. The board has declared a...
INDIANAPOLIS , Dec. 15, 2014 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) today announced a 2 percent increase in its quarterly dividend. The board has declared a dividend for the first quarter of 2015 of $0.50 per share on outstanding common stock
Read more →LLYEli Lilly and Company and AstraZeneca Initiate Pivotal Clinical Trial for Patients with Early Alzheimer's Disease Eli Lilly and Company (NYSE: LLY) and AstraZeneca today announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta ...
INDIANAPOLIS , Dec. 1, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and AstraZeneca today announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential tr
Read more →LLYNational Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes As part of American Diabetes Month, the National Alliance for Hispanic Health (the Alliance) announced results of a survey of Hispanic adults and...
WASHINGTON and RIDGEFIELD, Conn. and INDIANAPOLIS , Nov. 19, 2014 /PRNewswire/ -- As part of American Diabetes Month, the National Alliance for Hispanic Health (the Alliance) announced results of a survey of Hispanic adults and their attitudes toward diabetes. The results showed
Read more →LLYEncuesta de la National Alliance for Hispanic Health brinda percepciones sobre las actitudes de los hispanos respecto a la diabetes Como parte del Mes Americano de la Diabetes, la National Alliance for Hispanic Health (Alianza Nacional por la Salud de los Hispanos, la Alianza)...
WASHINGTON y RIDGEFIELD, Connecticut e INDIANAPOLIS , 19 de noviembre de 2014 /PRNewswire-HISPANIC PR WIRE/ -- Como parte del Mes Americano de la Diabetes, la National Alliance for Hispanic Health (Alianza Nacional por la Salud de los Hispanos, la Alianza) anunció los resultados
Read more →LLYLilly's Trulicity™ (dulaglutide) Now Available in U.S. Pharmacies The newest GLP-1 receptor agonist treatment option to help improve glycemic control type 2 diabetes in adults is now available in U.S. pharmacies....
INDIANAPOLIS , Nov. 10, 2014 /PRNewswire/ -- The newest GLP-1 receptor agonist treatment option to help improve glycemic control type 2 diabetes in adults is now available in U.S. pharmacies. Eli Lilly and Company's (NYSE: LLY ) Trulicity™ (dulaglutide) is a once-weekly glucagon-
Read more →LLYLilly's CYRAMZA® (ramucirumab) in Combination with Paclitaxel Granted FDA Approval for Advanced Gastric Cancer After Prior Chemotherapy Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab) in combination ...
INDIANAPOLIS , Nov. 5, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA ® (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or
Read more →LLYLilly Shares Insights from Decade-Long Technology Transfer Experience Today Eli Lilly and Company (NYSE: LLY) published details of its long-standing technology transfer program to increase the global supply of medicines ...
INDIANAPOLIS , Oct. 30, 2014 /PRNewswire/ -- Today Eli Lilly and Company (NYSE: LLY ) published details of its long-standing technology transfer program to increase the global supply of medicines for multidrug-resistant tuberculosis (MDR-TB). Begun in 2003, the effort included Li
Read more →LLYLilly to Present Record-Breaking $12.7 Million Gift to United Way Eli Lilly and Company (NYSE: LLY) today will present a record-breaking gift of $12.7 million to United Way. As the company's largest United Way...
INDIANAPOLIS , Oct. 29, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today will present a record-breaking gift of $12.7 million to United Way. As the company's largest United Way contribution ever, the donation represents the giving of Lilly and Elanco Animal Health em
Read more →LLYBoehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance in Certain Countries In a move that will strengthen their alliance by enhancing efficiencies and enabling greater focus on product launches, Boehringer Ingelheim and Eli...
INDIANAPOLIS and INGELHEIM, Germany , Oct. 29, 2014 /PRNewswire/ -- In a move that will strengthen their alliance by enhancing efficiencies and enabling greater focus on product launches, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY ) are changing the operational and
Read more →LLYLilly to Participate in Credit Suisse 2014 Healthcare Conference Eli Lilly and Company (NYSE:LLY) will participate in the Credit Suisse 2014 Healthcare Conference at the Arizona Biltmore in Phoenix, AZ, on...
INDIANAPOLIS , Oct. 28, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Credit Suisse 2014 Healthcare Conference at the Arizona Biltmore in Phoenix, AZ , on Wednesday, November 12, 2014 . Jeffrey Simmons, Senior Vice President and President, Elanco
Read more →LLYLilly Responds to Decision in Case of Terrence Allen, et al. v. Takeda Eli Lilly and Company (NYSE: LLY) issued the following statement today in response to a judge's ruling that the punitive damages awarded in the case...
INDIANAPOLIS , Oct. 27, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) issued the following statement today in response to a judge's ruling that the punitive damages awarded in the case of Terrence Allen , et al. v. Takeda Pharmaceuticals North America, Inc., et al , No.
Read more →LLYThe Hope Murals Project National Art Movement Culminates in Painting Event at Grand Central Terminal on October 23 Chester, N.Y., resident Ellen Mayer wears many hats: professional artist, inventor, wife, mother, grandmother, recent college graduate and, as of...
NEW YORK , Oct. 23, 2014 /PRNewswire/ -- Chester, N.Y., resident Ellen Mayer wears many hats: professional artist, inventor, wife, mother, grandmother, recent college graduate and, as of October 23 , muralist. Mayer is also a cancer survivor and kickboxer who notes, "My true grit
Read more →LLYLilly Reports Third-Quarter 2014 Results Third-quarter 2014 revenue declined 16 percent driven by the impact of U.S. patent expirations for Cymbalta and Evista, partially offset by volume...
INDIANAPOLIS , Oct. 23, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the third quarter of 2014. Certain financial information for 2014 and 2013 is presented on both a reported and a non-GAAP basis. Some numbers in this press rele
Read more →LLYLilly Declares Fourth-Quarter 2014 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2014 of $0.49 per share on outstanding...
INDIANAPOLIS , Oct. 20, 2014 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the fourth quarter of 2014 of $0.49 per share on outstanding common stock. The dividend is payable December 10, 2014 to shareholders of record at
Read more →LLYLilly Announces Plan to Realign Puerto Rico Manufacturing Operations Eli Lilly and Company (NYSE: LLY) today announced plans to conclude production and pursue a sale of one of its three manufacturing plants in Puerto...
INDIANAPOLIS , Oct. 16, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced plans to conclude production and pursue a sale of one of its three manufacturing plants in Puerto Rico . The manufacturing site, located in Guayama, Puerto Rico , will remain in operat
Read more →LLYEuropean Commission Grants Marketing Authorisation to Humalog® 200 units/ml KwikPen™ Insulin Eli Lilly and Company today announced that the European Commission has granted marketing authorisation for Humalog® 200 units/ml KwikPen™ (insulin...
INDIANAPOLIS , Oct. 3, 2014 /PRNewswire/ -- Eli Lilly and Company today announced that the European Commission has granted marketing authorisation for Humalog ® 200 units/ml KwikPen ™ (insulin lispro 200 units/ml) for the treatment of diabetes in adults. Humalog 200 units/ml Kwik
Read more →LLYLilly Confirms Date and Conference Call for Third-Quarter 2014 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2014 on Thursday, October 23, 2014. Lilly will also...
INDIANAPOLIS , Oct. 3, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the third quarter of 2014 on Thursday, October 23 , 2014. Lilly will also conduct a conference call on that day with the investment community and media to furthe
Read more →LLYLilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies Eli Lilly and Company (NYSE: LLY) announced today it will discontinue development of tabalumab -- being studied for the treatment of systemic lupus...
In the ILLUMINATE 1 study, tabalumab did not achieve the primary endpoint, at either dose studied, of statistically significant improvement on SRI-5 (SLE Responder Index-5, a measurement of lupus disease activity and response), compared to standard of care therapy. In ILLUMINATE
Read more →LLYLilly's seventh Global Day of Service rallies 24,000 employees in nearly 60 countries On Oct. 2, some 24,000 Lilly employees spanning nearly 60 countries will participate in the company's seventh Global Day of Service. Building on...
INDIANAPOLIS , Sept. 29, 2014 /PRNewswire/ -- On Oct. 2 , some 24,000 Lilly employees spanning nearly 60 countries will participate in the company's seventh Global Day of Service. Building on Lilly's strong heritage of making life better, employees will join together in a single,
Read more →LLYCYRAMZA™ In Combination With Paclitaxel Significantly Improves Overall Survival In Second-Line Gastric Cancer Patients Eli Lilly and Company (NYSE: LLY) today announced that results of the global Phase III trial of ramucirumab (CYRAMZA™) in combination with paclitaxel ...
INDIANAPOLIS , Sept. 18, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that results of the global Phase III trial of ramucirumab (CYRAMZA™) in combination with paclitaxel in patients with advanced gastric (stomach) cancer or gastroesophageal junction (GE
Read more →LLYFDA Approves Trulicity™ (dulaglutide), Lilly's Once-Weekly Therapy for Adults with Type 2 Diabetes Trulicity™ (dulaglutide), approved today by the U.S. Food and Drug Administration, is the latest Eli Lilly and Company (NYSE: LLY) treatment option...
INDIANAPOLIS , Sept. 18, 2014 /PRNewswire/ -- Trulicity™ (dulaglutide), approved today by the U.S. Food and Drug Administration, is the latest Eli Lilly and Company (NYSE: LLY ) treatment option for adults with type 2 diabetes. Trulicity is indicated as an adjunct to diet and ex
Read more →LLYWorking Mother names Lilly to its 100 Best Companies list for 20 years Working Mother magazine has named Eli Lilly and Company as one of its Working Mother 100 Best Companies 20 years in a row. In observance of the...
INDIANAPOLIS , Sept. 16, 2014 /PRNewswire/ -- Working Mother magazine has named Eli Lilly and Company as one of its Working Mother 100 Best Companies 20 years in a row. In observance of the honor, Lilly is planning a series of digital and employee initiatives. Working Mother ann
Read more →LLYLilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease Eli Lilly and Company (NYSE: LLY) and AstraZeneca today announced an agreement to co-develop and commercialize AZD3293, an oral beta secretase...
INDIANAPOLIS , Sept. 16, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and AstraZeneca today announced an agreement to co-develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alz
Read more →LLYLilly Announces CYRAMZA™ Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint of Overall Survival Eli Lilly and Company (NYSE: LLY) today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA™) in combination with chemotherapy...
INDIANAPOLIS , Sept. 12, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA ™ ) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of
Read more →LLYLilly Highlights Latest Work in Diabetes Discovery and Development at 2014 European Association for the Study of Diabetes Annual Meeting Fifty abstracts designed to advance knowledge in diabetes science will be presented Sept. 15-19 by Eli Lilly and Company (NYSE: LLY) at the 50th...
INDIANAPOLIS , Sept. 9, 2014 /PRNewswire/ -- Fifty abstracts designed to advance knowledge in diabetes science will be presented Sept. 15-19 by Eli Lilly and Company (NYSE: LLY ) at the 50 th European Association for the Study of Diabetes (EASD) Annual Meeting. Notably, the compa
Read more →LLYLilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus® in Phase III Trials in Patients with Type 1 Diabetes Eli Lilly and Company's (NYSE: LLY) basal insulin peglispro (BIL) demonstrated a statistically significant lower hemoglobin A1c (HbA1c) compared with ...
INDIANAPOLIS , Sept. 4, 2014 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY ) basal insulin peglispro (BIL) demonstrated a statistically significant lower hemoglobin A1c (HbA1c) compared with insulin glargine (Lantus ® ) at 26 weeks and 52 weeks, respectively, in the IMAGINE-
Read more →LLYLilly to Participate in Morgan Stanley 2014 Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley 2014 Global Healthcare Conference at the Grand Hyatt in New York, NY, on...
INDIANAPOLIS , Aug. 25, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Morgan Stanley 2014 Global Healthcare Conference at the Grand Hyatt in New York, NY , on Monday, September 8, 2014 . Derica Rice , Lilly's Executive Vice President, Global Serv
Read more →LLYLilly's Ixekizumab Superior to Etanercept and Placebo in Phase 3 Psoriasis Studies Ixekizumab met all primary and key secondary objectives across three pivotal studies of 3,866 patients, the largest Phase 3 moderate-to-severe plaque ...
INDIANAPOLIS , Aug. 21, 2014 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY ) investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies, the company said today in disclosing top-line results fro
Read more →LLYCHMP Recommends Approval of Lilly's Humalog® 200 units/ml KwikPen® Eli Lilly and Company (NYSE: LLY) today announced that the Committee for Medicinal Products for Human Use (CHMP), a division of the European...
INDIANAPOLIS , July 30, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the Committee for Medicinal Products for Human Use (CHMP), a division of the European Medicines Agency, has recommended approval of insulin lispro 200 units/ml (proposed trade nam
Read more →LLYLilly Reports Second-Quarter 2014 Results Second-quarter 2014 revenue declined 17 percent driven by the impact of U.S. patent expirations for Cymbalta and Evista, partially offset by volume...
INDIANAPOLIS , July 24, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the second quarter of 2014. Certain financial information for 2014 and 2013 are presented on both a reported and a non-GAAP basis. Some numbers in this press re
Read more →LLYNew Study Shows Beta-Amyloid Imaging is Associated with Altered Diagnosis and Management of Alzheimer's Disease Eli Lilly and Company (NYSE: LLY) today announced new data showing that beta-amyloid imaging was associated with altered diagnosis and management of...
INDIANAPOLIS , July 16, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced new data showing that beta-amyloid imaging was associated with altered diagnosis and management of patients with Alzheimer's disease. Change in management was observed in both patients
Read more →LLYLilly and Immunocore Enter Immunotherapy Agreement to Co-Discover and Co-Develop Novel Cancer Therapies Eli Lilly and Company (NYSE: LLY) and Immunocore Limited today announced they have entered into a co-discovery and co-development collaboration to...
OXFORD, England and INDIANAPOLIS , July 16, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Immunocore Limited today announced they have entered into a co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapie
Read more →LLYNew Data Shows Cognitive Impairment Precedes and Predicts Subsequent Functional Impairment in Patients with Mild Alzheimer's Disease Today, Eli Lilly and Company (NYSE:LLY) announced results from an analyses of five datasets evaluating the relationship between cognitive and...
INDIANAPOLIS , July 15, 2014 /PRNewswire/ -- Today, Eli Lilly and Company (NYSE: LLY ) announced results from an analyses of five datasets evaluating the relationship between cognitive and functional impairment in patients with mild Alzheimer's disease in the natural course of th
Read more →LLYNew Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice Eli Lilly and Company (NYSE: LLY) today announced results from its non-clinical study in genetically engineered mice examining combination therapy...
INDIANAPOLIS , July 13, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced results from its non-clinical study in genetically engineered mice examining combination therapy with the murine version of the beta-amyloid antibody N3pG and beta-secretase inhibitor
Read more →LLYLilly for Better Health™ expands website's non-product-branded health education resources, focuses on healthy behavior skills Eli Lilly and Company (NYSE: LLY) has rebooted the Lilly for Better Health™ program, with several innovative enhancements to lillyforbetterhealth.com ...
INDIANAPOLIS , July 10, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has rebooted the Lilly for Better Health ™ program, with several innovative enhancements to lillyforbetterhealth.com that help enrich the user experience with Lilly's non-product-branded health educat
Read more →LLYLilly por su Salud™ expande los recursos de educación sobre la salud en español, sin marcas comerciales asociadas, del sitio web, y hace hincapié en las destrezas para lograr conductas saludables Eli Lilly and Company (NYSE: LLY) ha vuelto a lanzar el programa Lilly por su Salud™, con varias mejoras innovadoras a lillyforbetterhealth.com que...
INDIANAPOLIS , 10 de julio de 2014 /PRNewswire-HISPANIC PR WIRE/ -- Eli Lilly and Company (NYSE: LLY ) ha vuelto a lanzar el programa Lilly por su Salud ™, con varias mejoras innovadoras a lillyforbetterhealth.com que brindan al usuario una experiencia más enriquecedora respecto
Read more →LLYLilly Confirms Date and Conference Call for Second-Quarter 2014 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2014 on Thursday, July 24, 2014. Lilly will also...
INDIANAPOLIS , July 9, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the second quarter of 2014 on Thursday, July 24 , 2014. Lilly will also conduct a conference call on that day with the investment community and media to further
Read more →LLYLilly to Showcase Data from its Alzheimer's Disease Portfolio at the Alzheimer's Association International Conference 2014 (AAIC 2014) Eli Lilly and Company (NYSE: LLY) today announced that 23 presentations will be given at the Alzheimer's Association International Conference 2014...
INDIANAPOLIS , July 8, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that 23 presentations will be given at the Alzheimer's Association International Conference 2014 (AAIC 2014) in Copenhagen, Denmark from July 12 – 17, 2014. Of particular interest are t
Read more →LLYNASCAR Driver Ryan Reed Finishes Fourth at the Subway Firecracker 250 at Daytona International Speedway News Highlights: #DiabetesChamp & Lilly #Diabetes ambassador @driverRyanReed finishes 4th at the Subway Firecracker 250 Lilly #Diabetes ambassador &...
INDIANAPOLIS and ALEXANDRIA, Va. , July 7, 2014 /PRNewswire/ -- News Highlights: NASCAR Nationwide Series (NNS) driver and Lilly Diabetes ambassador Ryan Reed finished fourth at the Subway Firecracker 250 at Daytona International Speedway Friday. Reed, who was diagnosed with ty
Read more →LLYDiabetes Scholars Foundation Announces 2014 Scholarship Recipients Managing a chronic disease like type 1 diabetes can be difficult for a person of any age, but can be especially daunting while navigating the halls...
ROLLING MEADOWS , Ill. and INDIANAPOLIS , June 25, 2014 /PRNewswire/ -- Managing a chronic disease like type 1 diabetes can be difficult for a person of any age, but can be especially daunting while navigating the halls of high school. The Diabetes Scholars Foundation (Foundation
Read more →LLYEli Lilly and Company Collaborates with Public and Private Healthcare Organizations to Provide Medical Students an Opportunity to Explore Healthcare Outside the Traditional Learning Environment Students from Marian University College of Osteopathic Medicine are onsite at Eli Lilly and Company (NYSE: LLY) corporate headquarters in...
INDIANAPOLIS , June 23, 2014 /PRNewswire/ -- Students from Marian University College of Osteopathic Medicine are onsite at Eli Lilly and Company (NYSE: LLY ) corporate headquarters in Indianapolis working alongside healthcare professionals in the pharmaceutical industry. Lilly a
Read more →LLYLilly Announces Detailed Results from Two Phase III Studies Testing Both Doses of Dulaglutide vs. Insulin Glargine Eli Lilly and Company (NYSE: LLY) today released detailed results from two AWARD trials that showed treatment with once-weekly dulaglutide 1.5 mg...
SAN FRANCISCO , June 16, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today released detailed results from two AWARD trials that showed treatment with once-weekly dulaglutide 1.5 mg resulted in superior reductions in HbA1c from baseline compared to insulin glargine, wi
Read more →LLYLilly Declares Third-Quarter 2014 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2014 of $0.49 per share on outstanding...
INDIANAPOLIS , June 16, 2014 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the third quarter of 2014 of $0.49 per share on outstanding common stock. The dividend is payable September 10, 2014 to shareholders of record at
Read more →LLYLilly's Once-Weekly Dulaglutide Shows Similar Reductions in Average Blood Glucose Levels as Once-Daily Liraglutide in Head-to-Head Trial Eli Lilly and Company (NYSE: LLY) today released detailed results from dulaglutide's sixth AWARD trial, showing that once-weekly dulaglutide 1.5 mg...
SAN FRANCISCO , June 14, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today released detailed results from dulaglutide's sixth AWARD trial, showing that once-weekly dulaglutide 1.5 mg was non-inferior to once-daily liraglutide 1.8 mg. The non-inferiority study demonstr
Read more →LLYLilly's Basal Insulin Peglispro Shows Novel Mechanism of Action Eli Lilly and Company (NYSE: LLY) today announced new data regarding the mechanism of action of basal insulin peglispro (BIL). When BIL and insulin...
SAN FRANCISCO , June 14, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced new data regarding the mechanism of action of basal insulin peglispro (BIL). When BIL and insulin glargine were each administered to achieve complete suppression of glucose production
Read more →LLYLilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial Eli Lilly and Company (NYSE: LLY) today announced that the Phase III REACH trial of CYRAMZA™ (ramucirumab) in patients with hepatocellular carcinoma, ...
INDIANAPOLIS , June 11, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the Phase III REACH trial of CYRAMZA™ (ramucirumab) in patients with hepatocellular carcinoma, also known as liver cancer, did not meet its primary endpoint; overall survival favo
Read more →LLYLilly to Participate in Goldman Sachs Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 35th Annual Global Healthcare Conference on Wednesday, June 11th, 2014. David Ricks,...
INDIANAPOLIS , June 9, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the Goldman Sachs 35 th Annual Global Healthcare Conference on Wednesday, June 11th, 2014 . David Ricks , Lilly senior vice president and president of Lilly Bio-Medicines, will participate
Read more →LLYLilly to Present New Clinical Data from Diabetes Portfolio with 76 Abstracts at the 74th American Diabetes Association Scientific Sessions® Eli Lilly and Company (NYSE: LLY) today announced 76 abstracts to be presented June 13-17 at the 74th American Diabetes Association Scientific...
INDIANAPOLIS , June 9, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced 76 abstracts to be presented June 13-17 at the 74 th American Diabetes Association Scientific Sessions ® in San Francisco , highlighting the company's long-standing commitment to advanc
Read more →LLYLilly Diabetes Adds NASCAR Nationwide Series Driver Ryan Reed to Annual Diabetes Summer Camp Tour News Highlights: #Lilly #Diabetes boosts Camp Care Package speaker program adding 20-yr-old NASCAR @driverRyanReed; cheers 10 yrs with skier Kris...
INDIANAPOLIS , June 9, 2014 /PRNewswire/ -- News Highlights: When NASCAR Nationwide Series (NNS) driver Ryan Reed set out to plan his summer, canoeing and archery may not have been on his to-do list…but they are now. Today, Lilly Diabetes announced that Ryan will join Olympic c
Read more →LLYLilly Announces Increased Access to Clinical Trials Data for Qualified Researchers Eli Lilly and Company (NYSE: LLY) today announced it will begin sharing its clinical trial data with scientific researchers through...
INDIANAPOLIS , June 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com . This website, which houses data from several clinical trial sponsors
Read more →LLYLilly's CYRAMZA™ (ramucirumab) Significantly Improves Overall Survival In Phase III Non-Small Cell Lung Cancer Study Eli Lilly and Company (NYSE: LLY) today announced detailed results from REVEL, a global Phase III study of CYRAMZA™ (ramucirumab) in combination with ...
CHICAGO , June 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced detailed results from REVEL, a global Phase III study of CYRAMZA ™ (ramucirumab) in combination with chemotherapy in patients with second-line non-small cell lung cancer (NSCLC). Data from t
Read more →LLYThousands to Create Mural Launching National Community Art Movement Honoring Those Touched by Cancer The American Society of Clinical Oncology's (ASCO) Annual Meeting, one of the largest gatherings in cancer prevention, diagnosis and treatment,...
CHICAGO , May 29, 2014 /PRNewswire/ -- The American Society of Clinical Oncology's (ASCO) Annual Meeting, one of the largest gatherings in cancer prevention, diagnosis and treatment, brings together more than 25,000 oncology professionals from May 30 through June 3 to share the l
Read more →LLYLilly Announces Date for Investor Web Call; Plans To Share Phase III Dulaglutide Data Eli Lilly and Company (NYSE: LLY) will conduct a conference call on June 16 for the media and investment community to provide detailed updates for...
INDIANAPOLIS , May 27, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will conduct a conference call on June 16 for the media and investment community to provide detailed updates for dulaglutide, its investigational glucagon-like receptor agonist (GLP-1) being studied fo
Read more →LLYLilly to Participate in Bernstein Strategic Decisions Conference Eli Lilly and Company (NYSE: LLY) will attend the 30th Annual Sanford C. Bernstein Strategic Decisions Conference on Wednesday, May 28, 2014. John C. ...
A live audio webcast will be available on the Webcasts & Presentations section of Lilly's Investor website at http://investor.lilly.com/events.cfm . Subsequently, a replay of the fireside chat with Dr. Lechleiter will be available on this same website for approximately 90 days.
Read more →LLYLilly Announces Date for Investor Webcast To Review Data Presented at ASCO 2014 Eli Lilly and Company (NYSE: LLY) will conduct a conference call on June 3, 2014 for the media and investment community to review select data...
INDIANAPOLIS , May 16, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will conduct a conference call on June 3, 2014 for the media and investment community to review select data presented at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO). Th
Read more →LLYEnglish Court Rules Against Lilly in Alimta Vitamin Dosage Regimen Patent Lawsuit Eli Lilly and Company (NYSE: LLY) today announced that the English High Court has determined that the vitamin dosage regimen patents for Alimta®...
The English court ruled that Alimta's vitamin dosage regimen patent would not be infringed by a generic competitor that had stated its intent to market certain alternative salt forms of pemetrexed in the United Kingdom prior to the U.K. patent's expiration in mid-2021. In additio
Read more →LLYAbemaciclib - Lilly's Oral CDK 4/6 Inhibitor - Shows Single-Agent Activity In A Phase I Study For Patients With A Specific Type Of Lung Cancer Abemaciclib, an oral drug administered twice daily, currently in development by Eli Lilly and Company (NYSE: LLY), has shown evidence of single-agent ...
INDIANAPOLIS , May 14, 2014 /PRNewswire/ -- Abemaciclib, an oral drug administered twice daily, currently in development by Eli Lilly and Company (NYSE: LLY ), has shown evidence of single-agent activity in patients with advanced non-small cell lung cancer in a Phase I study rele
Read more →LLYLilly's Necitumumab Improves Overall Survival In Largest Ever Phase III Study In First-Line Treatment Of Stage IV Squamous Non-Small Cell Lung Cancer Lung cancer patients with metastatic squamous cell carcinoma have seen few treatment advancements over the last two decades, leaving these patients...
INDIANAPOLIS , May 14, 2014 /PRNewswire/ -- Lung cancer patients with metastatic squamous cell carcinoma have seen few treatment advancements over the last two decades, leaving these patients with a poor prognosis. This is in contrast to the progress seen in nonsquamous non-small
Read more →LLYReady to go? The importance of advance planning: Lilly Diabetes and the American College of Endocrinology (ACE) help people with diabetes prep for emergencies News Highlights: @TheAACE, Lilly Diabetes offer emergency tips for people w/ #diabetes at mydiabetesemergencyplan.com, downloadable in both English & ...
LAS VEGAS , May 14, 2014 /PRNewswire/ -- News Highlights: What if you had to leave your house right now in an emergency? Do you have everything ready? What if you have diabetes? Are you prepared to protect your health if you need to or are forced to leave home today? The Americ
Read more →LLYLilly's Basal Insulin Peglispro Shows Superiority in HbA1c Reduction Compared to Insulin Glargine in Three Phase III Trials in Patients with Type 2 Diabetes Eli Lilly and Company (NYSE: LLY) today announced positive top-line results of three completed Phase III clinical trials in patients with type 2...
INDIANAPOLIS , May 12, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced positive top-line results of three completed Phase III clinical trials in patients with type 2 diabetes for basal insulin peglispro (BIL), which is being studied as a once-daily treatme
Read more →LLYLilly Responds to Brazil Court Ruling in Labor Case Eli Lilly and Company (NYSE: LLY) today announced that the 2nd Circuit of the Labor Court of Paulinia in the state of Sao Paulo, Brazil, has ruled...
INDIANAPOLIS , May 9, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the 2nd Circuit of the Labor Court of Paulinia in the state of Sao Paulo, Brazil , has ruled against the company's local subsidiary, Eli Lilly do Brasil, in a labor case alleging so
Read more →LLYFirst Team of Lilly's 2014 Connecting Hearts Abroad Ambassadors on the Ground in Guatemala A team of 10 Eli Lilly and Company (NYSE: LLY) employees from Korea, Russia, Saudi Arabia, Spain, the United States, and Venezuela departed this week ...
INDIANAPOLIS , May 7, 2014 /PRNewswire/ -- A team of 10 Eli Lilly and Company (NYSE: LLY ) employees from Korea, Russia , Saudi Arabia , Spain , the United States , and Venezuela departed this week for a two-week service assignment in an impoverished area of Guatemala City , Guat
Read more →LLYEli Lilly and Company Launches Second Education Program for Medical Students Eli Lilly and Company (NYSE: LLY) announced today the launch of another medical student education program, an internship for aspiring physicians. The ...
INDIANAPOLIS , April 25, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today the launch of another medical student education program, an internship for aspiring physicians. The Lilly Medical Student Intern Program, the second phase of its medical student progr
Read more →LLYLilly Reports First-Quarter 2014 Results Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2014. $ in millions, except per share data First Quarter ...
INDIANAPOLIS , April 24, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the first quarter of 2014. Certain financial information for 2014 and 2013 are presented on both a reported and a non-GAAP basis. Some numbers in this press rel
Read more →LLYLilly Announces Agreement to Acquire Novartis Animal Health Eli Lilly and Company (NYSE: LLY) today announced an agreement to acquire Novartis Animal Health for approximately $5.4 billion in an all-cash...
INDIANAPOLIS , April 22, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced an agreement to acquire Novartis Animal Health for approximately $5.4 billion in an all-cash transaction that will strengthen and diversify Lilly's own animal health business, Elanco.
Read more →LLYLilly's CYRAMZA™ (ramucirumab) Becomes First FDA-Approved Treatment for Advanced Gastric Cancer After Prior Chemotherapy Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA™ (ramucirumab) as a...
INDIANAPOLIS , April 21, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA™ (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesoph
Read more →LLYAmerican College of Endocrinology (ACE) focuses on emergency planning for people with diabetes at National Hurricane Conference News Highlights: @TheAACE attends Hurricane Conference to share planning tips for people w/ #diabetes; prgm w/Lilly Diabetes offering emergency tips...
ORLANDO, Fla. , April 14, 2014 /PRNewswire/ -- News Highlights: For the second consecutive year, the American College of Endocrinology (ACE) will meet this week with federal, state, and local emergency preparedness officials at the National Hurricane Conference in Orlando to hi
Read more →LLYLilly Confirms Date and Conference Call for First-Quarter 2014 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the first quarter of 2014 on Thursday, April 24, 2014. Lilly will also...
INDIANAPOLIS , April 10, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the first quarter of 2014 on Thursday, April 24 , 2014. Lilly will also conduct a conference call on that day with the investment community and media to furthe
Read more →LLYLilly and T1D Exchange Announce Research Collaboration to Inform Development of New Initiatives to Advance Diabetes Care T1D Exchange and Eli Lilly and Company (NYSE: LLY) announced today they have entered into a research collaboration that will enable both...
BOSTON and INDIANAPOLIS , April 9, 2014 /PRNewswire/ -- T1D Exchange and Eli Lilly and Company (NYSE: LLY ) announced today they have entered into a research collaboration that will enable both organizations to gain deeper, real-world insight about the experience of people with t
Read more →LLYLilly Responds to Verdict in Case of Terrence Allen, et al. v. Takeda Eli Lilly and Company (NYSE: LLY) issued the following statement today in response to the verdict in the case of Terrence Allen, et al. v. Takeda...
INDIANAPOLIS , April 8, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) issued the following statement today in response to the verdict in the case of Terrence Allen , et al. v. Takeda Pharmaceuticals North America, Inc., et al. No. 6:12-cv-00064. The jury found in favor
Read more →LLYLilly To Release Early-Stage Pipeline Data Targeting Key Cancer Pathways At AACR 2014 Eli Lilly and Company (NYSE: LLY) will present early-stage data from several targeted cancer therapies – including bemaciclib beh meh sye' klib ...
INDIANAPOLIS , April 6, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present early-stage data from several targeted cancer therapies – including bemaciclib "beh meh sye' klib" (LY2835219), its oral, cell-cycle inhibitor of CDK4/6 – that make up its diverse clinica
Read more →LLYU.S. District Court Upholds Validity of Lilly's Alimta Patent Through 2022 Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of Indiana has ruled in the company's favor...
INDIANAPOLIS , March 31, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. District Court for the Southern District of Indiana has ruled in the company's favor regarding the vitamin dosage regimen patent for Alimta ® (pemetrexed for injection).
Read more →LLYLilly to Participate in Barclays Healthcare Conference Eli Lilly and Company (NYSE: LLY) will attend the Barclays Global Healthcare Conference on Wednesday, March 12, 2014. David Ricks, Lilly senior vice...
INDIANAPOLIS , March 5, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the Barclays Global Healthcare Conference on Wednesday, March 12, 2014 . David Ricks , Lilly senior vice president, and president of Lilly Bio-Medicines, will participate in a fireside cha
Read more →LLYElanco Announces Agreement to Acquire Lohmann Animal Health Elanco, the animal health division of Eli Lilly and Company (NYSE:LLY), today announced an agreement to acquire Lohmann SE (Lohmann Animal Health), a ...
GREENFIELD, IN , Feb. 24, 2014 /PRNewswire/ -- Elanco, the animal health division of Eli Lilly and Company (NYSE: LLY ), today announced an agreement to acquire Lohmann SE (Lohmann Animal Health), a privately-held company headquartered in Cuxhaven, Germany . Lohmann Animal Health
Read more →LLYLilly to Participate in Cowen Healthcare Conference Eli Lilly and Company (NYSE:LLY) will attend the 34th Annual Cowen and Company Healthcare Conference on Tuesday, March 4, 2014. Derica Rice, Lilly...
INDIANAPOLIS , Feb. 21, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will attend the 34 th Annual Cowen and Company Healthcare Conference on Tuesday, March 4, 2014 . Derica Rice , Lilly executive vice president, global services, and chief financial officer, will partic
Read more →LLYLilly Announces Ramucirumab Phase III Lung Cancer Trial Meets Primary Endpoint of Overall Survival Eli Lilly and Company (NYSE: LLY) today announced that the REVEL trial, a global Phase III study of ramucirumab in combination with chemotherapy in...
INDIANAPOLIS , Feb. 19, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the REVEL trial, a global Phase III study of ramucirumab in combination with chemotherapy in patients with second-line non-small cell lung cancer (NSCLC), showed a statistically s
Read more →LLYLilly USA, LLC Launches New Rotation Program for Medical Students Lilly USA, LLC (NYSE: LLY) announced today the launch of a new rotation program for aspiring physicians. The rotation assignments cut across...
INDIANAPOLIS , Feb. 12, 2014 /PRNewswire/ -- Lilly USA , LLC (NYSE: LLY ) announced today the launch of a new rotation program for aspiring physicians. The rotation assignments cut across different aspects of the pharmaceutical company's business – from drug discovery and develop
Read more →LLYLilly to Participate in Leerink Swann Global Healthcare Conference Eli Lilly and Company (NYSE: LLY) will participate in the Leerink Swann Global Healthcare Conference on Wednesday, February 12, 2014. Jan M....
INDIANAPOLIS , Feb. 5, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will participate in the Leerink Swann Global Healthcare Conference on Wednesday, February 12, 2014 . Jan M. Lundberg , Ph.D., executive vice president of science and technology and president of Lilly R
Read more →LLYEli Lilly and Company Provides Statement in Response to Sanofi U.S. Lawsuit Eli Lilly and Company (NYSE: LLY) has provided the following statement regarding a lawsuit filed by Sanofi in the United States District Court for...
INDIANAPOLIS , Jan. 31, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has provided the following statement regarding a lawsuit filed by Sanofi in the United States District Court for the District of Delaware alleging patent infringement with respect to LY2963016, a new
Read more →LLYLilly Reports Fourth-Quarter and Full-Year 2013 Results Fourth-quarter 2013 revenue declined 2 percent driven by Cymbalta U.S. patent expiration, partially offset by growth in other products....
INDIANAPOLIS , Jan. 30, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the fourth quarter and full year of 2013. Certain financial information for 2013 and 2012 are presented on both a reported and a non-GAAP basis. Some numbers in
Read more →LLYU.S. Cross-Country Skier Kris Freeman Named to 2014 Olympic Team News Highlights #T1DiabetesChamp and #Lilly #Diabetes spokesperson Kris Freeman @TeamFreeBirdXC named to #Sochi2014 @USOlympic cross-country ski team ...
INDIANAPOLIS , Jan. 22, 2014 /PRNewswire/ -- News Highlights Today 33-year-old U.S. cross-country skier and Lilly Diabetes ambassador Kris Freeman was named to the 2014 Olympic team. When he travels to Sochi, Russia , in February, it will mark the fourth consecutive Winter Olym
Read more →LLYLilly Announces Acquisition of CGRP Antibody for Migraine Prevention from Arteaus Therapeutics Eli Lilly and Company (NYSE:LLY) today announced that, based on positive Phase 2 data, it has acquired all development rights for a calcitonin...
INDIANAPOLIS , Jan. 13, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that, based on positive Phase 2 data, it has acquired all development rights for a calcitonin gene-related peptide (CGRP) antibody currently being studied as a potential treatment for
Read more →LLYLilly Diabetes to contribute $200,000 to the Diabetes Scholars Foundation Today Lilly Diabetes announced it will renew its commitment to the Diabetes Scholars Foundation (Foundation) scholarship fund for another two years....
INDIANAPOLIS and ROLLING MEADOWS, Ill. , Jan. 9, 2014 /PRNewswire/ -- Today Lilly Diabetes announced it will renew its commitment to the Diabetes Scholars Foundation (Foundation) scholarship fund for another two years. The commitment includes a $200,000 donation ( $100,000 for ea
Read more →LLYLilly Oncology On Canvas: Expressions of a Cancer Journey Reaches Important Milestone With 2014 Competition Some see paint. Others see hope. What do you see? Ten years ago, more than 400 people across 23 countries saw those words and shared their cancer...
INDIANAPOLIS , Jan. 8, 2014 /PRNewswire/ -- Some see paint. Others see hope. What do you see? Ten years ago, more than 400 people across 23 countries saw those words and shared their cancer journeys with the world through art and narrative. While more than 4,100 stories have been
Read more →LLYLilly Announces 2014 Financial Guidance, Reconfirms 2013 Expectations 2014 revenue anticipated to be between $19.2 billion and $19.8 billion. Earnings per share for 2014 are expected to be in the range of $2.77 - $2.85, ...
INDIANAPOLIS , Jan. 7, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its financial guidance for 2014, highlighted key events for the upcoming year and reiterated its strategy to return to growth beginning in 2015. The company also indicated that its 201
Read more →LLYLilly Sets Dates and Conference Calls for 2014 Financial Guidance and Fourth-Quarter 2013 Financial Results Announcements Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2014 on Tuesday, January 7, 2014 and, separately, will announce its...
INDIANAPOLIS , Jan. 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial guidance for 2014 on Tuesday, January 7, 2014 and, separately, will announce its financial results for the fourth quarter and full year of 2013 on Thursday, January 30 , 201
Read more →LLYLilly Diabetes/Disney Custom Books for Type 1 Diabetes Families Now Available Online Lilly Diabetes and Disney today announced that their custom books for children and families with type 1 diabetes are now available online. The...
INDIANAPOLIS , Dec. 19, 2013 /PRNewswire/ -- Lilly Diabetes and Disney today announced that their custom books for children and families with type 1 diabetes are now available online. The digital books explore real-life challenges and stories of children with type 1 diabetes part
Read more →LLYLilly to Present at J.P. Morgan Healthcare Conference Eli Lilly and Company (NYSE:LLY) will present at the 32nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2014. John C. Lechleiter,...
INDIANAPOLIS , Dec. 19, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present at the 32 nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2014 . John C. Lechleiter , Ph.D., Lilly's chairman, president and chief executive officer will make a formal
Read more →LLYLilly Declares First-Quarter 2014 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the first quarter of 2014 of $0.49 per share on outstanding...
INDIANAPOLIS , Dec. 16, 2013 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the first quarter of 2014 of $0.49 per share on outstanding common stock. The dividend is payable March 10, 2014 to shareholders of record at the
Read more →LLYLilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clinical Studies as Add-On Therapy for Major Depressive Disorder Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior ...
INDIANAPOLIS , Dec. 5, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment. When added to a selective sero
Read more →LLYLilly Releases Report on Corporate Responsibility Efforts Eli Lilly and Company (NYSE: LLY) has released its 2012-13 Corporate Responsibility Report. The report offers a comprehensive look at the company's...
INDIANAPOLIS , Dec. 5, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has released its 2012-13 Corporate Responsibility Report . The report offers a comprehensive look at the company's progress on numerous corporate responsibility goals and efforts, including: "Lilly's
Read more →LLYLilly Diabetes Extends National Sponsorship of the American Diabetes Association's Signature Tour de Cure® Cycling Event for a Second Year News Highlights: For a 2nd year, #Lilly #Diabetes supports the American Diabetes Association's Tour de Cure cycling event to help #StopDiabetes New...
INDIANAPOLIS , Nov. 19, 2013 /PRNewswire/ -- News Highlights: Lilly Diabetes today announced it will continue its national sponsorship of the American Diabetes Association's (Association) Tour de Cure ® annual cycling event for a second year in a row. In 2013, more than 65,000
Read more →LLYLilly Statement on Contribution to Indiana Biosciences Research Institute Following is a statement from John C. Lechleiter, Ph.D., chairman and chief executive officer of Eli Lilly and Company (NYSE: LLY), on the company's...
INDIANAPOLIS , Nov. 19, 2013 /PRNewswire/ -- Following is a statement from John C. Lechleiter , Ph.D., chairman and chief executive officer of Eli Lilly and Company (NYSE: LLY ), on the company's investment of $7.5 million toward startup of the Indiana Biosciences Research Instit
Read more →LLYLilly to Present Record-Breaking $12.6 Million Gift to United Way Eli Lilly and Company (NYSE: LLY) today will present a record-breaking gift of $12.6 million to the United Way. As the largest United Way...
INDIANAPOLIS , Nov. 19, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today will present a record-breaking gift of $12.6 million to the United Way. As the largest United Way contribution in the company's history, the donation represents the giving of Lilly employees in
Read more →LLYCialis® (tadalafil) marks 10 years since U.S. approval Cialis is turning 10. As Cialis marks its 10th anniversary this week, Lilly is looking back on the last decade in men's health. Conversations that...
INDIANAPOLIS , Nov. 18, 2013 /PRNewswire/ -- Cialis is turning 10. As Cialis marks its 10 th anniversary this week, Lilly is looking back on the last decade in men's health. Conversations that used to be taboo for men are now taking place in bedrooms and exam rooms. Men with con
Read more →LLYLilly Announces Significant Global Insulin Manufacturing Capacity Investments in Response to Growing Diabetes Epidemic Eli Lilly and Company (NYSE: LLY) today announced it will invest more than $700 million to enhance its global insulin manufacturing capacity in...
INDIANAPOLIS , Nov. 14, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced it will invest more than $700 million to enhance its global insulin manufacturing capacity in Puerto Rico , France and China , as well as in Indianapolis , home to Lilly's global headq
Read more →LLYFDA Approves Addition to CIALIS® (tadalafil) Product Label Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a product label addition for CIALIS to include ...
INDIANAPOLIS , Oct. 25, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the U.S. Food and Drug Administration (FDA) approved a product label addition for CIALIS to include data from a 26-week study that showed CIALIS 5 mg for once daily use started in comb
Read more →LLYLilly announces Tapiero retiring; Zulueta promoted to senior vice president and president of Emerging Markets Eli Lilly and Company (NYSE: LLY) today announced that Alfonso Chito Zulueta will be promoted to senior vice president and president of the...
INDIANAPOLIS , Oct. 24, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that Alfonso "Chito" Zulueta will be promoted to senior vice president and president of the Emerging Markets business effective Jan. 1, 2014 . Zulueta will replace Jacques Tapiero who
Read more →LLYFDA Grants Lilly's Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has assigned Priority Review to the regulatory...
INDIANAPOLIS , Oct. 23, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Food and Drug Administration (FDA) has assigned Priority Review to the regulatory submission for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric
Read more →LLYLilly Reports Third-Quarter 2013 Results Worldwide revenue increased 6 percent, driven by solid growth for Cymbalta, insulins, Animal Health, Alimta, Cialis and Trajenta. Higher revenue and...
INDIANAPOLIS , Oct. 23, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the third quarter of 2013. Certain financial information for 2013 and 2012 is presented on both a reported and a non-GAAP basis. Some numbers in this press rele
Read more →LLYJackson Tai Elected to Lilly Board of Directors The Board of Directors of Eli Lilly and Company (NYSE: LLY) has elected Jackson Tai as a new member, effective November 1, 2013. As a member of...
INDIANAPOLIS , Oct. 22, 2013 /PRNewswire/ -- The Board of Directors of Eli Lilly and Company (NYSE: LLY ) has elected Jackson Tai as a new member, effective November 1, 2013 . As a member of Lilly's board, Mr. Tai will serve on the Audit and Finance Committees. Tai, 63, serves a
Read more →LLYLilly Declares Fourth-Quarter 2013 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2013 of $0.49 per share on outstanding...
INDIANAPOLIS , Oct. 21, 2013 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the fourth quarter of 2013 of $0.49 per share on outstanding common stock. The dividend is payable December 10, 2013 to shareholders of record at
Read more →LLYLilly Confirms Date and Conference Call for Third-Quarter 2013 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2013 on Wednesday, October 23, 2013. Lilly will also...
INDIANAPOLIS , Oct. 15, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the third quarter of 2013 on Wednesday, October 23 , 2013. Lilly will also conduct a conference call on that day with the investment community and media to furt
Read more →LLYLilly's Global Day of Service Supports Indy DO Day Initiative Eli Lilly and Company's (NYSE: LLY) sixth Global Day of Service in Indianapolis will look a little different this year. Lilly employees will join...
INDIANAPOLIS , Oct. 9, 2013 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY ) sixth Global Day of Service in Indianapolis will look a little different this year. Lilly employees will join thousands of other volunteers from local community and civic-based organizations in a cit
Read more →LLYSingle-Agent Ramucirumab Significantly Improves Overall Survival In Advanced Gastric Cancer Patients Eli Lilly and Company (NYSE: LLY) today announced that results from the Phase III REGARD trial of ramucirumab (IMC-1121B) as a single agent in...
INDIANAPOLIS , Oct. 3, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that results from the Phase III REGARD trial of ramucirumab (IMC-1121B) as a single agent in patients with advanced gastric cancer who have had disease progression after initial chemoth
Read more →LLYLilly details progress on achieving strategic business goals and its advancing pipeline to investment community Company aims to overcome patent expirations through targeted growth initiatives, continued expense controls, and maturing Phase 3 pipeline Lilly...
INDIANAPOLIS , Oct. 3, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) expects to launch several new medicines to treat unmet patient needs beginning next year, and return the company to revenue growth and expanding margins after 2014, senior executives told the investme
Read more →LLYLilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year Eli Lilly and Company (NYSE:LLY) today announced that applications for the 2014-2015 school year are now available for the 16th annual Lilly...
INDIANAPOLIS , Oct. 1, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that applications for the 2014-2015 school year are now available for the 16 th annual Lilly Reintegration Scholarship. Since its inception, the program has directed more than four mill
Read more →LLYLilly Disappointed in Medicare Decision to Deny Appropriate Patient Access to Beta-Amyloid Imaging Agents, Including Amyvid™ (Florbetapir F 18 Injection), Despite Support From Experts, Patients and the Alzheimer's Disease Community Eli Lilly and Company (NYSE: LLY) is disappointed that the Centers for Medicare & Medicaid Services (CMS) has denied patient access to beta-amyloid...
Amyvid is a beta-amyloid imaging agent for use in adults with thinking or memory problems who are being assessed for Alzheimer's Disease or other causes of these symptoms. Amyvid is used by doctors in combination with other tests. A positive Amyvid scan does not diagnose Alzheime
Read more →LLYData Presented at 49th EASD Annual Meeting Show Treatment with Lilly's Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes Eli Lilly and Company (NYSE: LLY) today announced positive patient-reported health outcomes from a Phase III clinical trial of dulaglutide, an...
BARCELONA, Spain , Sept. 26, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced positive patient-reported health outcomes from a Phase III clinical trial of dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being st
Read more →LLYLilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint Eli Lilly and Company (NYSE: LLY) today announced top-line results from two global Phase III studies of ramucirumab (IMC-1121B), one in advanced...
INDIANAPOLIS , Sept. 26, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced top-line results from two global Phase III studies of ramucirumab (IMC-1121B), one in advanced gastric cancer and another in metastatic breast cancer. The RAINBOW trial, a global Pha
Read more →LLYLilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting Eli Lilly and Company (NYSE: LLY) today announced that a total of 31 abstracts will be presented at the 49th European Association for the Study of...
INDIANAPOLIS , Sept. 17, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that a total of 31 abstracts will be presented at the 49 th European Association for the Study of Diabetes Annual Meeting in Barcelona , September 23-27 . In seven presentations, Lill
Read more →LLYDr. Marschall S. Runge Elected to Lilly Board of Directors The Board of Directors of Eli Lilly and Company (NYSE: LLY) has elected Marschall S. Runge, M.D., Ph.D., as a new member, effective September 1, 2013....
INDIANAPOLIS , Aug. 28, 2013 /PRNewswire/ -- The Board of Directors of Eli Lilly and Company (NYSE: LLY ) has elected Marschall S. Runge , M.D., Ph.D., as a new member, effective September 1, 2013 . Dr. Runge, 59, is the Executive Dean for the School of Medicine at the University
Read more →LLYLilly Announces Phase III Necitumumab Study Meets Primary Endpoint of Overall Survival Eli Lilly and Company (NYSE: LLY) today announced that SQUIRE, a recently completed Phase III study, met its primary endpoint, finding that patients...
INDIANAPOLIS , Aug. 13, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that SQUIRE, a recently completed Phase III study, met its primary endpoint, finding that patients with stage IV metastatic squamous non-small cell lung cancer (NSCLC) experienced incr
Read more →LLYLilly, Roswell Park Cancer Institute Partner to Train Minority Clinical Trial Investigators In an effort to increase the number of minority investigators in clinical research, Eli Lilly and Company (NYSE: LLY) and The Center for Drug...
INDIANAPOLIS and BUFFALO, N.Y. , Aug. 1, 2013 /PRNewswire/ -- In an effort to increase the number of minority investigators in clinical research, Eli Lilly and Company (NYSE: LLY ) and The Center for Drug Development and Clinical Trials at Roswell Park Cancer Institute (RPCI) tod
Read more →LLYLilly Reports Second-Quarter 2013 Results Worldwide revenue increased 6 percent as growth in key products offset lower Zyprexa revenue following patent expirations in most major markets....
INDIANAPOLIS , July 24, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the second quarter of 2013. Certain financial information for 2013 and 2012 are presented on both a reported and a non-GAAP basis. Some numbers in this press re
Read more →LLYLilly Confirms Date and Conference Call for Second-Quarter 2013 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2013 on Wednesday, July 24, 2013. Lilly will also...
INDIANAPOLIS , July 17, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the second quarter of 2013 on Wednesday, July 24 , 2013. Lilly will also conduct a conference call on that day with the investment community and media to furthe
Read more →LLYNew Study Shows Men Taking Cialis® (tadalafil) Tablets Once Daily Returned to Normal Erectile Function after Incomplete Response to As-Needed PDE5 Inhibitor Therapy Eli Lilly and Company (NYSE: LLY) announced today that study results published in the Journal of Sexual Medicine showed a greater percentage of men...
INDIANAPOLIS , July 16, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that study results published in the Journal of Sexual Medicine showed a greater percentage of men who had an incomplete response to as-needed PDE5 inhibitor treatment returned to norma
Read more →LLY2013 Scholarship Recipients Named by Diabetes Scholars Foundation News Highlights Lilly Diabetes helps fund 21 scholarships for college-bound students with #T1diabetes through #Diabetes Scholars Foundation Lilly...
ROLLING MEADOWS, Ill. and INDIANAPOLIS , July 8, 2013 /PRNewswire/ -- News Highlights After a record number of applications, today the Diabetes Scholars Foundation (Foundation) announced its 2013 college scholarship grantees. The recipients, chosen from more than 1,000 outstand
Read more →LLYLilly Announces Dr. Lechleiter's Return Eli Lilly and Company (NYSE:LLY) today announced that John C. Lechleiter, Ph.D., has returned to his duties as chairman, president, and chief...
INDIANAPOLIS , July 8, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that John C. Lechleiter , Ph.D., has returned to his duties as chairman, president, and chief executive officer. Lechleiter has been on medical leave since his scheduled surgery for a d
Read more →LLYLilly Disappointed in Draft Medicare Coverage Decision for Beta-Amyloid Imaging Agents Eli Lilly and Company (NYSE: LLY) today announced that the Centers for Medicare & Medicaid Services (CMS) has issued a draft decision proposing...
An Amyvid™ (Florbetapir F 18 Injection) beta-amyloid scan is for use in adults with thinking or memory problems who are being assessed for Alzheimer's Disease or other causes of these symptoms. Amyvid is used by doctors in combination with other tests. A positive Amyvid scan does
Read more →LLYLilly to Host Conference Call to Discuss Trial Design of New Solanezumab Phase 3 Study Eli Lilly and Company (NYSE: LLY) will host a conference call to discuss key elements of the trial design for EXPEDITION3, its third Phase 3 trial...
INDIANAPOLIS , July 3, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will host a conference call to discuss key elements of the trial design for EXPEDITION3, its third Phase 3 trial for solanezumab. Lilly's solanezumab is a monoclonal antibody being studied as a potenti
Read more →LLYLilly's Investigational GLP-1 Receptor Agonist, Dulaglutide, Showed Superior Glycemic Control Versus Comparators in Patients with Type 2 Diabetes Eli Lilly and Company (NYSE: LLY) today announced detailed safety and efficacy results from three Phase III AWARD trials for dulaglutide, an...
CHICAGO , June 22, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced detailed safety and efficacy results from three Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a o
Read more →LLYFollow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541 Eli Lilly and Company (NYSE: LLY) today announced results from an additional analysis of Phase II clinical data for LY2605541, an investigational...
CHICAGO , June 22, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced results from an additional analysis of Phase II clinical data for LY2605541, an investigational novel basal insulin analog. The analysis provides more in-depth information about the reducti
Read more →LLYLilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests Eli Lilly and Company (NYSE:LLY) today issued an alert about two illegal scams, purportedly using the name of the company and/or its subsidiary...
INDIANAPOLIS , June 19, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today issued an alert about two illegal scams, purportedly using the name of the company and/or its subsidiary Elanco Animal Health, that are actively targeting the public through postal mail solicita
Read more →LLYLilly Declares Third-Quarter 2013 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2013 of $0.49 per share on outstanding...
INDIANAPOLIS , June 18, 2013 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the third quarter of 2013 of $0.49 per share on outstanding common stock. The dividend is payable September 10, 2013 to shareholders of record at
Read more →LLYLilly Diabetes, Kris Freeman Kick off Summer with 9th Annual Diabetes Summer Camp Tour News Highlights #T1DiabetesChamp Kris Freeman @TeamFreeBirdXC visits 10 #diabetes #camps; has helped inspire more than 6,500 campers through Lilly...
INDIANAPOLIS , June 17, 2013 /PRNewswire/ -- News Highlights When diagnosed with type 1 diabetes at age 19, Kris Freeman was told that his dream of being an Olympic athlete was not possible. Since then, he has transformed himself into one of the premier cross-country skiers in
Read more →LLYLilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimer's Disease Eli Lilly and Company (NYSE: LLY) today announced it has stopped its Phase II study (BACC) for LY2886721, a beta secretase (BACE) inhibitor being...
"While stopping this Phase II study for our BACE inhibitor is disappointing, patient safety is of utmost importance to Lilly," said Jan M. Lundberg , Ph.D., executive vice president, science and technology, and president, Lilly Research Laboratories. "Discovering and developing m
Read more →LLYLilly to Highlight Late-Stage Pipeline Molecules at the 73rd American Diabetes Association Scientific Sessions® Eli Lilly and Company (NYSE: LLY) today announced it will present 13 abstracts on two late-stage investigational medicines from its diabetes pipeline ...
INDIANAPOLIS , June 11, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced it will present 13 abstracts on two late-stage investigational medicines from its diabetes pipeline at the 73 rd American Diabetes Association Scientific Sessions ® in Chicago June 21-
Read more →LLYPRONOUNCE Study Does Not Achieve Primary Superiority Endpoint for ALIMTA® (pemetrexed for injection), Similar PFS and OS Results Were Observed Between the Two Drug and the Three Drug Regimens in the Treatment of NSCLC Eli Lilly and Company (NYSE:LLY) announced results from its PRONOUNCE trial of ALIMTA® (pemetrexed for injection) for treatment of nonsquamous...
CHICAGO , June 3, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced results from its PRONOUNCE trial of ALIMTA® (pemetrexed for injection) for treatment of nonsquamous non-small cell lung cancer (NSCLC) that was presented today at the American Society of Clinical
Read more →LLYNew Mobile App Assists Oncologists In Navigating Ever-Evolving Sea Of Cancer Information Recent advancements in cancer research have come at break-neck speed, yielding data that has provided new hope for cancer patients. Each advancement...
INDIANAPOLIS , May 31, 2013 /PRNewswire/ -- Recent advancements in cancer research have come at break-neck speed, yielding data that has provided new hope for cancer patients. Each advancement comes with an accompanying manuscript and oncologists are presented, each day, with doz
Read more →LLYLilly Statement on Indiana Biosciences Research Institute Eli Lilly and Company (NYSE: LLY) has issued the following statement from Senior Vice President Bart Peterson regarding today's announcement...
INDIANAPOLIS , May 30, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has issued the following statement from Senior Vice President Bart Peterson regarding today's announcement introducing the Indiana Biosciences Research Institute: "The Indiana Biosciences Research Ins
Read more →LLYLilly to Present at Goldman Sachs Global Healthcare Conference Eli Lilly and Company (NYSE:LLY) will present at the Goldman Sachs 34th Annual Global Healthcare Conference on Wednesday, June 12th, 2013. David...
INDIANAPOLIS , May 30, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present at the Goldman Sachs 34 th Annual Global Healthcare Conference on Wednesday, June 12th, 2013 . David Ricks , Lilly senior vice president and president of Lilly Bio-Medicines, will present
Read more →LLYNew Data on FORTEO® (teriparatide [rDNA origin] injection) Show Increased Bone Mineral Density in Men with Glucocorticoid-Induced Osteoporosis Eli Lilly and Company (NYSE: LLY) today announced new data showing that FORTEO significantly increased lumbar spine volumetric bone mineral density...
INDIANAPOLIS , May 29, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced new data showing that FORTEO significantly increased lumbar spine volumetric bone mineral density (vBMD) compared to risedronate in men with glucocorticoid-induced osteoporosis. Glucoco
Read more →LLYFrom Research Labs to Doctors' Offices, Health Care Providers at Lilly Play Important Role in Bringing New and Innovative Medicines to Patients The many health care providers working at Eli Lilly and Company (NYSE:LLY) − including doctors, nurses, and pharmacists − play a vital role in...
INDIANAPOLIS , May 20, 2013 /PRNewswire/ -- The many health care providers working at Eli Lilly and Company (NYSE: LLY ) − including doctors, nurses, and pharmacists − play a vital role in bringing new and innovative medicines to patients. From research labs to doctors' offices,
Read more →LLYLilly Provides Update on CEO Dr. John Lechleiter Eli Lilly and Company (NYSE:LLY) today announced that John C. Lechleiter, Ph.D., chairman, president, and chief executive officer, underwent...
INDIANAPOLIS , May 14, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that John C. Lechleiter , Ph.D., chairman, president, and chief executive officer, underwent scheduled surgery for a dilated aorta on Monday, May 13, 2013 . "Dr. Lechleiter's surgeons
Read more →LLYLilly Oncology to Release New Pipeline Data at ASCO 2013 Eli Lilly and Company (NYSE: LLY) will present data from key molecules that make up its clinical oncology pipeline during the 49th Annual Meeting of...
INDIANAPOLIS , May 14, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present data from key molecules that make up its clinical oncology pipeline during the 49 th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. from May 31 –
Read more →LLYLilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma Eli Lilly and Company (NYSE: LLY) announced today Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a ...
INDIANAPOLIS , May 10, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lympho
Read more →LLYLilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery Eli Lilly and Company (NYSE:LLY) today announced that John C. Lechleiter, Ph.D., chairman, president, and chief executive officer, will undergo...
INDIANAPOLIS , May 6, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that John C. Lechleiter , Ph.D., chairman, president, and chief executive officer, will undergo scheduled surgery for a dilated aorta on Monday, May 13, 2013 . This condition was found d
Read more →LLYLilly Declares Second-Quarter 2013 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the second quarter of 2013 of $0.49 per share on...
INDIANAPOLIS , May 6, 2013 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) today declared a dividend for the second quarter of 2013 of $0.49 per share on outstanding common stock. The dividend is payable June 10, 2013 to shareholders of record at the
Read more →LLYLilly Celebrates National Volunteer Week with Deployment of Global Service Teams Eli Lilly and Company (NYSE: LLY) celebrated National Volunteer Week April 21-27 by sending off the first of 200 volunteers who will serve in...
INDIANAPOLIS , April 26, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) celebrated National Volunteer Week April 21-27 by sending off the first of 200 volunteers who will serve in impoverished communities throughout 2013. They are part of Connecting Hearts Abroad, Lilly'
Read more →LLYLilly Again Named One of DiversityInc's Top 50 Companies for Diversity Eli Lilly and Company (NYSE: LLY) has been named to the DiversityInc Top 50 Companies for Diversity list for the third consecutive year....
INDIANAPOLIS , April 24, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has been named to the DiversityInc "Top 50 Companies for Diversity" list for the third consecutive year. DiversityInc 's "Top 50 Companies for Diversity" is known as a leading assessment of diversit
Read more →LLYLilly Reports First-Quarter 2013 Results Worldwide revenue was flat as growth in key products offset lower Zyprexa revenue following patent expirations. Cymbalta revenue increased 19 percent ...
INDIANAPOLIS , April 24, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the first quarter of 2013. Financial results for 2013 and 2012 are presented on both a reported and a non-GAAP basis. Some numbers in this press release may no
Read more →LLYLilly Acquires Novel Tau Tangle Diagnostic Program to Bolster Alzheimer's Disease Research and Development Eli Lilly and Company (NYSE: LLY) today announced it has acquired two investigational positron emission tomography (PET) tracers from Siemens Medical ...
INDIANAPOLIS , April 17, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced it has acquired two investigational positron emission tomography (PET) tracers from Siemens Medical Solutions USA , Inc. The tracers are intended to image tau (or neurofibrillary) tan
Read more →LLYLilly Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes Eli Lilly and Company (NYSE: LLY) today announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an...
INDIANAPOLIS , April 16, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a
Read more →LLYLilly Debuts Early Oncology Pipeline Data At AACR Annual Meeting Eli Lilly and Company (NYSE: LLY) unveiled data from four key molecules that represent the next generation of its oncology pipeline at the American...
WASHINGTON , April 10, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) unveiled data from four key molecules that represent the next generation of its oncology pipeline at the American Association for Cancer Research (AACR) Annual Meeting held in Washington, D.C. from Apr
Read more →LLYLilly Confirms Date and Conference Call for First-Quarter 2013 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the first quarter of 2013 on Wednesday, April 24, 2013. Lilly will also...
INDIANAPOLIS , April 3, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the first quarter of 2013 on Wednesday, April 24 , 2013. Lilly will also conduct a conference call on that day with the investment community and media to furthe
Read more →LLYPotential Lilly Investment Would Further Expand Indianapolis Insulin Manufacturing Operations Eli Lilly and Company (NYSE: LLY) today announced that it is working closely with the city on a proposal to invest an additional $180 million in the...
INDIANAPOLIS , April 2, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that it is working closely with the city on a proposal to invest an additional $180 million in the company's Indianapolis -based insulin manufacturing operations. The investment is in
Read more →LLYNew Study of Cialis® (tadalafil) Tablets Co-administered with Finasteride Meets Primary Endpoint in Men with Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia Eli Lilly and Company (NYSE: LLY) presented results today at the annual European Association of Urology (EAU) Congress in Milan, Italy, of a study...
INDIANAPOLIS , March 18, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) presented results today at the annual European Association of Urology (EAU) Congress in Milan, Italy , of a study that showed Cialis 5 mg once daily co-administered with finasteride significantly imp
Read more →LLYLilly Sets Date for 2013 Diabetes Pipeline Update to the Media and Investment Community Eli Lilly and Company (NYSE: LLY) will conduct a conference call for the media and investment community to provide a pipeline update for its diabetes ...
INDIANAPOLIS , March 5, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will conduct a conference call for the media and investment community to provide a pipeline update for its diabetes business on Monday, June 24, 2013 . The call, which is being held in conjunction wit
Read more →LLYLilly's Team Solutions and Solutions for Wellness Resources for Serious Mental Illness Added to SAMHSA's Distinguished National Registry Eli Lilly and Company (NYSE: LLY) announced today that the Team Solutions and Solutions for Wellness program resources for individuals living with...
INDIANAPOLIS , Feb. 20, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the Team Solutions and Solutions for Wellness program resources for individuals living with serious mental illnesses, such as bipolar disorder and schizophrenia, have been added t
Read more →LLYLilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab Based on Efficacy Results Eli Lilly and Company (NYSE:LLY) announced today that it will discontinue the Phase 3 rheumatoid arthritis (RA) program for tabalumab, an anti-BAFF...
In December 2012 , Lilly discontinued the Phase 3 RA registration study FLEX-M for lack of treatment effect. FLEX-M was investigating tabalumab in patients with moderate-to-severe RA who had an inadequate response to methotrexate therapy. Based on FLEX-M findings, an interim fut
Read more →LLYLilly Recognized for Fifth Straight Year on NAFE's 'Top 50 Companies for Executive Women' Eli Lilly and Company (NYSE: LLY) has been named to the NAFE Top 50 Companies for Executive Women list for 2013. Compiled by the National Association ...
INDIANAPOLIS , Feb. 5, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has been named to the NAFE Top 50 Companies for Executive Women list for 2013. Compiled by the National Association for Female Executives (NAFE), the list recognizes organizations whose policies and p
Read more →LLYLilly Supports the Medical Community's Testimony on the Clinical Utility of Beta-Amyloid Imaging Agents, Such as Amyvid™ (Florbetapir F 18 Injection), During CMS Public Hearing Leading medical experts in the fields of imaging, neurology and dementia came together today to present evidence supporting the clinical utility of...
INDIANAPOLIS , Jan. 30, 2013 /PRNewswire/ -- Leading medical experts in the fields of imaging, neurology and dementia came together today to present evidence supporting the clinical utility of beta-amyloid imaging agents, such as Amyvid™ (Florbetapir F 18 Injection), during a pub
Read more →LLYLilly Reports Fourth-Quarter and Full-Year 2012 Results, Revises 2013 EPS Guidance Fourth quarter revenue declined 1 percent driven by Zyprexa patent expiration, largely offset by growth in other products. Fourth quarter earnings...
INDIANAPOLIS , Jan. 29, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the fourth quarter and full year of 2012. Financial results for 2012 and 2011 are presented on both a reported and a non-GAAP basis. Some numbers in this press
Read more →LLYAmyvid™ (Florbetapir F 18 Injection) Approved in European Union for Use in Patients With Cognitive Impairment Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Impairment Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, announced today that Amyvid (Florbetapir F ...
INDIANAPOLIS , Jan. 15, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, announced today that Amyvid (Florbetapir F 18 Injection) has received marketing authorization from the European Commission as a
Read more →LLYLilly Diabetes supports Diabetes Scholars Foundation with $100,000 donation in 2013 For a second year in a row, Lilly Diabetes will donate $100,000 to the Diabetes Scholars Foundation (Foundation) scholarship fund. The contribution...
INDIANAPOLIS and ROLLING MEADOWS, Ill. , Jan. 8, 2013 /PRNewswire/ -- For a second year in a row, Lilly Diabetes will donate $100,000 to the Diabetes Scholars Foundation (Foundation) scholarship fund. The contribution will support the Foundation's mission to empower young people
Read more →LLYLilly Comments on 2012 Financial Guidance and Announces 2013 Financial Guidance Company reconfirms 2012 financial expectations, excluding the impact from the delayed enactment of the American Taxpayer Relief Act of 2012. 2013...
INDIANAPOLIS , Jan. 4, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today commented on its 2012 financial guidance, announced its financial guidance for 2013 and reconfirmed its mid-term guidance through 2014. Because the enactment of the American Taxpayer Relief Act
Read more →LLYLeading Dermatologist Michael P. Heffernan, M.D. and Renowned Rheumatologist Alisa E. Koch, M.D. Join Lilly Autoimmune Team Eli Lilly and Company (NYSE: LLY) announced that Michael P. Heffernan, M.D., a nationally recognized expert in complex medical dermatology, psoriasis ...
INDIANAPOLIS , Jan. 3, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced that Michael P. Heffernan , M.D., a nationally recognized expert in complex medical dermatology, psoriasis and clinical trials, has joined its autoimmune team as distinguished medical fellow.
Read more →LLYLilly Reaches Agreement with U.S. Securities and Exchange Commission Eli Lilly and Company (NYSE: LLY) today announced that it has reached an agreement with the U.S. Securities and Exchange Commission (SEC) to settle...
INDIANAPOLIS , Dec. 20, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that it has reached an agreement with the U.S. Securities and Exchange Commission (SEC) to settle issues regarding compliance with the U.S. Foreign Corrupt Practices Act (FCPA). The se
Read more →LLYLilly Sets Dates and Conference Calls for 2013 Financial Guidance and Fourth-Quarter 2012 Financial Results Announcements Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2013 on Friday, January 4, 2013 and, separately, will announce its...
INDIANAPOLIS , Dec. 17, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial guidance for 2013 on Friday, January 4, 2013 and, separately, will announce its financial results for the fourth quarter and full year of 2012 on Tuesday, January 29 , 2013
Read more →LLYLilly Declares First-Quarter 2013 Dividend, Announces New $1.5 Billion Share Repurchase Program The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the first quarter of 2013 of $0.49 per share on outstanding ...
INDIANAPOLIS , Dec. 17, 2012 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) today declared a dividend for the first quarter of 2013 of $0.49 per share on outstanding common stock. The dividend is payable March 8, 2013 to shareholders of record at the
Read more →LLYLilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab Eli Lilly and Company (NYSE: LLY) announced today that it will stop one of three Phase 3 rheumatoid arthritis (RA) registration studies of tabalumab, ...
The FLEX-M study was designed to support registration of tabalumab as a potential treatment for RA, including an assessment of its effect on structural progression. Lilly continues to evaluate tabalumab in two other Phase 3 RA registration studies as well as an open-label extensi
Read more →LLYLilly Provides Update on Next Steps for Solanezumab Eli Lilly and Company (NYSE: LLY) today provided an update on the next steps planned for solanezumab, its Phase 3 monoclonal antibody being studied...
INDIANAPOLIS , Dec. 12, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today provided an update on the next steps planned for solanezumab, its Phase 3 monoclonal antibody being studied as a potential therapy for patients with mild Alzheimer's disease. Following discussio
Read more →LLYLilly Releases Update on Corporate Responsibility Efforts Eli Lilly and Company (NYSE: LLY) has released its 2011/2012 Corporate Responsibility Update (www.lilly.com/Documents/Lilly_2011_2012_CRupdate.pdf)....
INDIANAPOLIS , Dec. 3, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has released its 2011/2012 Corporate Responsibility Update ( www.lilly.com/Documents/Lilly_2011_2012_CRupdate.pdf ). This report highlights progress and initiatives since Lilly's 2010/2011 full Corpora
Read more →LLYLilly publica una actualización sobre sus esfuerzos de responsabilidad corporativa Eli Lilly and Company (NYSE: LLY) ha publicado su Actualización sobre Responsabilidad Corporativa 2011/2012...
-- La compañía comunica avances en numerosos indicadores de desempeño económico, medioambiental y social INDIANÁPOLIS, 3 de diciembre de 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) ha publicado su Actualización sobre Responsabilidad Corporativa 2011/2012 ( www.lilly.
Read more →LLYLilly publie une mise à jour de ses efforts en matière de responsabilité d'entreprise Eli Lilly and Company (NYSE : LLY) a publié une mise à jour de son rapport de responsabilité d'entreprise pour 2011/2012...
-- La société communique sur les progrès réalisés au niveau de nombreux indicateurs de performance économique, environnementale et sociale INDIANAPOLIS , 3 décembre 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE : LLY ) a publié une mise à jour de son rapport de responsabilité
Read more →LLYLilly lanza la actualización de los esfuerzos de responsabilidad corporativa Eli Lilly and Company (NYSE: LLY) ha lanzado su actualización de responsabilidad corporativa 2011/2012...
- La compañía comunica el progreso en varios indicadores de rendimiento económico, medioambiental y social INDIANÁPOLIS, 3 de diciembre de 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) ha lanzado su actualización de responsabilidad corporativa 2011/2012 ( www.lilly.com
Read more →LLYLilly veröffentlicht Aktualisierung über Tätigkeiten im Corporate-Responsibility-Bereich Eli Lilly and Company (NYSE: LLY) hat seinen aktualisierten Corporate-Responsibility-Bericht 2011/2012 veröffentlicht...
- Unternehmen meldet Fortschritte bei zahlreichen ökonomischen, ökologischen und sozialen Leistungskennzahlen INDIANAPOLIS , 3. Dezember 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) hat seinen aktualisierten Corporate-Responsibility-Bericht 2011/2012 veröffentlicht (
Read more →LLYLilly divulga dados atualizados sobre seus esforços para responsabilidade corporativa Eli Lilly and Company (NYSE: LLY) divulgou suas Informações Atualizados sobre Responsabilidade Corporativa (Corporate Responsibility Update) de...
-- A companhia comunica avanços em vários indicadores de desempenho econômico, ambiental e social INDIANÁPOLIS, 3 de dezembro de 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) divulgou suas Informações Atualizados sobre Responsabilidade Corporativa (Corporate Responsibi
Read more →LLYLilly Diabetes Joins the American Diabetes Association as a National Sponsor of the 2013 Tour de Cure® Cycling Event Today Lilly Diabetes announced it has joined the American Diabetes Association (Association) as a national sponsor of the 2013 Tour de Cure, the...
INDIANAPOLIS , Nov. 27, 2012 /PRNewswire/ -- Today Lilly Diabetes announced it has joined the American Diabetes Association (Association) as a national sponsor of the 2013 Tour de Cure, the Association's annual nationwide cycling event that attracts more than 60,000 riders across
Read more →LLYLilly To Present Record-Breaking $12.4 Million Gift To United Way Eli Lilly and Company (NYSE: LLY) will present a record-breaking gift of $12.4 million to the United Way today. As the largest gift in the company's...
INDIANAPOLIS , Nov. 19, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present a record-breaking gift of $12.4 million to the United Way today. As the largest gift in the company's history, the donation represents the contributions of Lilly's U.S. employees and reti
Read more →LLYLilly Recognized as One of the Best Places to Work for LGBT Equality For the seventh consecutive year, Eli Lilly and Company (NYSE: LLY) has received a 100 percent rating on the Human Rights Campaign (HRC) Corporate...
INDIANAPOLIS , Nov. 19, 2012 /PRNewswire/ -- For the seventh consecutive year, Eli Lilly and Company (NYSE: LLY ) has received a 100 percent rating on the Human Rights Campaign (HRC) Corporate Equality Index (CEI) – one of three honors the company recently has earned for lesbian,
Read more →LLYBreast Cancer Survivor Awarded Top Prize In 2012 Oncology On Canvas(SM) Art Competition Quilts are made for dozens of reasons – for warmth, decoration and remembrance – but for a college professor from Utah, quilting became a form of...
INDIANAPOLIS , Nov. 12, 2012 /PRNewswire/ -- Quilts are made for dozens of reasons – for warmth, decoration and remembrance – but for a college professor from Utah , quilting became a form of healing. It was something Judy Elsley , Ph.D., had enjoyed doing for years, but it took
Read more →LLYLilly to Present Phase II Rheumatoid Arthritis and Biomarker Data at ACR For Two Investigational Medicines to Treat Autoimmune Diseases Eli Lilly and Company (NYSE: LLY) will present Phase II data in rheumatoid arthritis (RA) for two of its investigational autoimmune medicines at the...
INDIANAPOLIS , Nov. 9, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present Phase II data in rheumatoid arthritis (RA) for two of its investigational autoimmune medicines at the annual meeting of the American College of Rheumatology (ACR), which takes place Nov. 1
Read more →LLYLilly Statement on Hurricane Sandy Relief Efforts In the aftermath of Hurricane Sandy, the Lilly Foundation is donating $200,000 to the American Red Cross in support of relief efforts in affected...
INDIANAPOLIS , Nov. 1, 2012 /PRNewswire/ -- In the aftermath of Hurricane Sandy, the Lilly Foundation is donating $200,000 to the American Red Cross in support of relief efforts in affected areas of the United States . Additionally, the foundation is contributing a $1 match for e
Read more →LLYLilly to Expand Indianapolis Insulin Manufacturing Operations Local and state government officials joined representatives from Eli Lilly and Company (NYSE: LLY) today to announce a $140 million expansion to the...
INDIANAPOLIS , Nov. 1, 2012 /PRNewswire/ -- Local and state government officials joined representatives from Eli Lilly and Company (NYSE: LLY ) today to announce a $140 million expansion to the company's Indianapolis insulin manufacturing operations. The 80,000-square-foot expans
Read more →LLYLilly Names Melissa Barnes Chief Ethics and Compliance Officer and Senior Vice President; Announces Retirement of Anne Nobles Eli Lilly and Company (NYSE: LLY) today announced that Melissa Barnes will be promoted to chief ethics and compliance officer and senior vice...
INDIANAPOLIS , Oct. 30, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that Melissa Barnes will be promoted to chief ethics and compliance officer and senior vice president of enterprise risk management effective Jan. 1, 2013 . Barnes will replace Anne No
Read more →LLYEuropean Commission approves Cialis® (tadalafil) tablets for the treatment of the signs and symptoms of benign prostatic hyperplasia Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has approved Cialis 5 mg for once daily use for the treatment of the...
INDIANAPOLIS , Oct. 30, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the European Commission has approved Cialis 5 mg for once daily use for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Cialis was approved for ere
Read more →LLYLilly Reports Third-Quarter 2012 Results Worldwide revenue declined 11 percent to $5.443 billion, driven by Zyprexa patent expirations. Cymbalta revenue increased 16 percent due to continued ...
INDIANAPOLIS , Oct. 24, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the third quarter of 2012. Financial results for 2012 and 2011 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordan
Read more →LLYNew Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient® (Prasugrel) or Plavix® (Clopidogrel) Presented at TCT Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) today announced new results of two retrospective, observational, comparative effectiveness ...
MIAMI , Oct. 23, 2012 /PRNewswire/ -- Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY ) today announced new results of two retrospective, observational, comparative effectiveness studies of U.S. hospital data comparing rates of readmission for subsequent heart attack an
Read more →LLYLilly Diabetes Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes Eli Lilly and Company (NYSE: LLY) today announced positive top-line results of three completed Phase III AWARD trials for dulaglutide, an...
INDIANAPOLIS , Oct. 22, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced positive top-line results of three completed Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) analog being studied as a once-week
Read more →LLYAmyvid™ (Florbetapir F 18 Injection) Recommended for Approval in Europe as a Diagnostic Tool for PET Imaging of Beta-Amyloid Plaque Density Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced they received a positive...
INDIANAPOLIS , Oct. 19, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced they received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in Europe , rec
Read more →LLYALIMTA® Extends Survival in Continuation Maintenance Setting for Specific Lung Cancer Patients Eli Lilly and Company (NYSE: LLY) announced today that patients may receive ALIMTA® (pemetrexed for injection) as a maintenance therapy following...
INDIANAPOLIS , Oct. 17, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that patients may receive ALIMTA ® (pemetrexed for injection) as a maintenance therapy following first-line ALIMTA plus cisplatin for locally advanced or metastatic nonsquamous non-sma
Read more →LLYLilly Announces New Data Further Exploring Mechanistic Differences Between FORTEO® (teriparatide [rDNA origin] injection) and Zoledronic Acid Eli Lilly and Company (NYSE: LLY) today presented data comparing the effects of FORTEO and zoledronic acid on transiliac crest bone biopsies at six...
INDIANAPOLIS , Oct. 15, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today presented data comparing the effects of FORTEO and zoledronic acid on transiliac crest bone biopsies at six months in postmenopausal women with osteoporosis, based on additional analysis of data
Read more →LLYLilly Announces Positive Results For Ramucirumab as Single Agent in Phase III Gastric Cancer Trial Eli Lilly and Company (NYSE: LLY) today announced that the REGARD trial, a Phase III study of ramucirumab (IMC-1121B) in patients with metastatic...
INDIANAPOLIS , Oct. 15, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the REGARD trial, a Phase III study of ramucirumab (IMC-1121B) in patients with metastatic gastric cancer, met its primary endpoint of improved overall survival and also showed pr
Read more →LLYLilly Declares Fourth-Quarter 2012 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the fourth quarter of 2012 of $0.49 a share on outstanding...
INDIANAPOLIS , Oct. 15, 2012 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) today declared a dividend for the fourth quarter of 2012 of $0.49 a share on outstanding common stock. The dividend is payable December 10, 2012 to shareholders of record at
Read more →LLYLilly's Fifth Global Day Of Service Focuses On Local Waterways Thousands of employees from Eli Lilly and Company (NYSE: LLY), in a sea of red T-shirts – and other volunteers from numerous neighborhoods,...
INDIANAPOLIS , Oct. 11, 2012 /PRNewswire/ -- Thousands of employees from Eli Lilly and Company (NYSE: LLY ), in a sea of red T-shirts – and other volunteers from numerous neighborhoods, nonprofits and businesses – will work from dawn to dusk on Thursday, October 11 , as part of L
Read more →LLYDiversityInc Names Lilly the Top Company for Working Families Eli Lilly and Company (NYSE: LLY) has been named DiversityInc's 2012 Top Company for Working Families. Known as a leading assessor of diversity...
INDIANAPOLIS , Oct. 10, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has been named DiversityInc 's 2012 Top Company for Working Families. Known as a leading assessor of diversity management globally, DiversityInc has presented special awards to companies on its "Top
Read more →LLYLilly Announces Detailed Results of the Phase 3 Solanezumab EXPEDITION Studies Following a Presentation of the Independent Analyses by the Alzheimer's Disease Cooperative Study (ADCS) Lilly's analysis, as previously reported, showed primary endpoints, both cognitive and functional, were not met in the two Phase 3, double-blind,...
INDIANAPOLIS , Oct. 8, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its detailed results for the Phase 3, double-blind, placebo-controlled EXPEDITION studies in patients with mild-to-moderate Alzheimer's disease. This announcement follows the presentat
Read more →LLYLilly Reintegration Scholarship Applications Available for 2013-2014 Academic Year Eli Lilly and Company (NYSE:LLY) today announced that applications for the 2013-2014 school year are now available for the 15th annual Lilly...
INDIANAPOLIS , Oct. 1, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that applications for the 2013-2014 school year are now available for the 15 th annual Lilly Reintegration Scholarship. The program provides funding for tuition, books and lab fees to p
Read more →LLYLilly Releases Phase II Results for Monoclonal Antibody Ramucirumab in Lung Cancer Eli Lilly and Company (NYSE: LLY) today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung...
INDIANAPOLIS , Sept. 29, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC). Results were presented today during the Lung Cancer – Metastatic Poster
Read more →LLYLilly Confirms Date and Conference Call for Third-Quarter 2012 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2012 on Wednesday, October 24, 2012. Lilly will also...
INDIANAPOLIS , Sept. 24, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the third quarter of 2012 on Wednesday, October 24 , 2012. Lilly will also conduct a conference call on that day with the investment community and media to fur
Read more →LLYCialis® (tadalafil) Tablets Recommended for Approval for the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia in the European Union Eli Lilly and Company (NYSE: LLY) announced today it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP)...
INDIANAPOLIS , Sept. 21, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in the European Union (EU), recommending approval of Cialis 5 mg for once daily use f
Read more →LLYNew International Survey Reveals Multiple Barriers to an Accurate and Timely Alzheimer's Disease Diagnosis Eli Lilly and Company (NYSE: LLY) today announced results from the International Alzheimer's Disease Physician Survey of nearly 1,000 physicians that ...
INDIANAPOLIS , Sept. 19, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced results from the International Alzheimer's Disease Physician Survey of nearly 1,000 physicians that assessed physician attitudes and beliefs on the barriers to a formal Alzheimer's di
Read more →LLYLilly Celebrates 18th Consecutive Year as One of Working Mother's 100 Best Companies Eli Lilly and Company (NYSE: LLY) once again has earned a place among the Working Mother magazine 100 Best Companies of 2012. This is the 18th...
INDIANAPOLIS , Sept. 18, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) once again has earned a place among the Working Mother magazine "100 Best Companies" of 2012. This is the 18 th consecutive year for this honor. For 27 years, the Working Mother 100 Best Companies i
Read more →LLYLilly Announces Results From Lung Cancer Study Eli Lilly and Company (NYSE: LLY) announced today that the Phase III POINTBREAK trial did not meet its primary endpoint of improved overall survival...
INDIANAPOLIS , Sept. 6, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the Phase III POINTBREAK trial did not meet its primary endpoint of improved overall survival for patients with nonsquamous non-small cell lung cancer (NSCLC) who were randomized
Read more →LLYLilly Diabetes Launches Mobile Application for Those Who Support People with Type 1 Diabetes News Highlights Lilly Diabetes launches Lilly Glucagon Mobile App to support #diabetes caregivers Leverage the power and reach of mobile technology...
INDIANAPOLIS , Sept. 4, 2012 /PRNewswire/ -- News Highlights Lilly Diabetes today announced the release of a new mobile application designed for caregivers and healthcare providers who support people with type 1 diabetes. The Lilly Glucagon Mobile App is a tool to teach how to
Read more →LLYmillion adults in the U.S. have difficulty understanding health information; Lilly earns national honor for achievement in health literacy Imagine needing health care but being unable to understand the information you're given by a doctor. For 90 million people in the U.S., it's a...
INDIANAPOLIS , Aug. 30, 2012 /PRNewswire/ -- Imagine needing health care but being unable to understand the information you're given by a doctor. For 90 million people in the U.S., it's a reality with a long-lasting impact on health and finances. Health literacy – defined as the
Read more →LLYNoventa millones de adultos en los EE. UU. tienen dificultad para comprender la información relacionada con la salud; Lilly recibe un premio nacional por sus logros en la alfabetización en salud Imagine necesitar atención médica pero no poder entender la información que le da el médico. Para 90 millones de personas en los EE. UU. es una...
INDIANÁPOLIS, 30 de agosto de 2012 /PRNewswire-HISPANIC PR WIRE/ -- Imagine necesitar atención médica pero no poder entender la información que le da el médico. Para 90 millones de personas en los EE. UU. es una realidad con un impacto de larga duración sobre la salud y las finan
Read more →LLYLilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel Eli Lilly and Company (NYSE: LLY) today announced that Michael J. Harrington will be promoted to senior vice president and general counsel effective...
INDIANAPOLIS , Aug. 30, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that Michael J. Harrington will be promoted to senior vice president and general counsel effective Jan. 1 , 2013. Harrington will replace Robert A. Armitage who will retire at the end
Read more →LLYLilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results Eli Lilly and Company (NYSE: LLY) announced today the decision to stop ongoing clinical studies investigating pomaglumetad methionil, also known as...
Additionally, the recently completed Phase II study, HBCO, which investigated pomaglumetad methionil as an adjunctive treatment with atypical antipsychotics, did not meet its primary endpoint. Lilly is contacting study investigators to outline specific actions related to the clo
Read more →LLYU.S. Court of Appeals Upholds Validity of Lilly's Alimta Compound Patent Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S....
INDIANAPOLIS , Aug. 24, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S. District Court for the District of Delaware that the company's compound patent for Alimta
Read more →LLYEli Lilly and Company Announces Top-Line Results on Solanezumab Phase 3 Clinical Trials in Patients with Alzheimer's Disease Eli Lilly and Company (NYSE: LLY) today announced that the primary endpoints, both cognitive and functional, were not met in either of the two Phase...
INDIANAPOLIS , Aug. 24, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the primary endpoints, both cognitive and functional, were not met in either of the two Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION trials in patients with mi
Read more →LLYLilly Revises 2012 Reported Guidance to Reflect Income from Early Payment of Amylin Obligations Company will recognize income in the third quarter of 2012 of approximately $790 million (pre-tax), or approximately $.43 per share (after-tax). 2012 ...
INDIANAPOLIS , Aug. 9, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has revised certain elements of its 2012 reported financial guidance to reflect additional income the company will recognize as a result of the early payment of financial obligations from Amylin Pharm
Read more →LLYLilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures Eli Lilly and Company (NYSE: LLY) today announced data from a Phase III trial comparing the effects of FORTEO® (teriparatide [rDNA origin] injection) ...
INDIANAPOLIS , Aug. 7, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced data from a Phase III trial comparing the effects of FORTEO ® (teriparatide [rDNA origin] injection) and risedronate on back pain in postmenopausal women with osteoporotic vertebral fra
Read more →LLYLilly Supports Research to Determine What a Dog's Nose Knows About People with Diabetes and Severe Hypoglycemia News Highlights Lilly and ICAN begin research to probe changes in human sweat, detectable by dogs, that signals low sugar in people with T1 #diabetes ...
INDIANAPOLIS , July 30, 2012 /PRNewswire/ -- News Highlights A young black Lab named Pete sleeps at the feet of Dr. Dana Hardin , medical director and pediatric endocrinologist, at Eli Lilly and Company (NYSE: LLY ) campus in Indianapolis . Though he looks at home, Pete is not
Read more →LLYLilly Reports Second-Quarter 2012 Results, Raises 2012 EPS Guidance Worldwide revenue declined 10 percent to $5.6 billion, driven by Zyprexa patent expirations, partially offset by significant growth in other products....
INDIANAPOLIS , July 25, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the second quarter of 2012. Financial results for 2012 and 2011 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accorda
Read more →LLYLilly Confirms Date and Conference Call for Second-Quarter 2012 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2012 on Wednesday, July 25, 2012. Lilly will also...
INDIANAPOLIS , July 12, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the second quarter of 2012 on Wednesday, July 25 , 2012. Lilly will also conduct a conference call on that day with the investment community and media to furthe
Read more →LLYLilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study Eli Lilly and Company (NYSE: LLY) announced today negative clinical trial results from study H8Y-MC-HBBM (HBBM) investigating pomaglumetad methionil, ...
INDIANAPOLIS , July 11, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today negative clinical trial results from study H8Y-MC-HBBM (HBBM) investigating pomaglumetad methionil, also known as mGlu2/3, for the treatment of patients suffering an acute exacerbation
Read more →LLYLilly Obtains Six Months U.S. Pediatric Exclusivity for Cymbalta® (duloxetine HCl) Eli Lilly and Company (NYSE: LLY) announced today that it has met the United States Food and Drug Administration (FDA) requirements for pediatric...
The approval of pediatric exclusivity does not mean that Cymbalta is approved for use in pediatric patients. Cymbalta is FDA-approved only for use in adults aged 18 and older. Based on study results, Lilly will not be seeking a pediatric indication for Cymbalta. About Cymbalta C
Read more →LLYLilly Diabetes Announces Once Upon A Time Contest Winner News Highlights Lilly #Diabetes sending winning family to #FFL12 Once Upon A Time Contest celebrates life with type 1 #diabetes #FFL12 Family wins...
INDIANAPOLIS , July 2, 2012 /PRNewswire/ -- News Highlights Lilly Diabetes today announced Meri Schuhmacher as the winner of its Once Upon A Time Contest. Lilly Diabetes created the Contest to spark a national dialogue about type 1 diabetes by asking family members to write abo
Read more →LLYLilly Statement on Affordable Care Act Ruling by Supreme Court Following is a statement from John C. Lechleiter, Ph.D., chairman, president, and chief executive officer of Eli Lilly and Company, regarding today's ...
INDIANAPOLIS , June 28, 2012 /PRNewswire/ -- Following is a statement from John C. Lechleiter , Ph.D., chairman, president, and chief executive officer of Eli Lilly and Company, regarding today's U.S. Supreme Court ruling to uphold the Affordable Care Act: "In doing so, we will
Read more →LLYDiabetes Scholars Foundation Announces 2012 Scholarship Recipients Today the Diabetes Scholars Foundation (Foundation) announced its 2012 college scholarship grantees. The recipients, all young adults with type 1...
ROLLING MEADOWS, Ill. and INDIANAPOLIS, June 26, 2012 /PRNewswire/ -- Today the Diabetes Scholars Foundation (Foundation) announced its 2012 college scholarship grantees. The recipients, all young adults with type 1 diabetes, hail from cities nationwide and demonstrate a drive to
Read more →LLYLilly Statement on PDUFA Vote by Senate Following is a statement from John C. Lechleiter, Ph.D., chairman, president, and chief executive officer of Eli Lilly and Company (NYSE: LLY),...
INDIANAPOLIS , June 26, 2012 /PRNewswire/ -- Following is a statement from John C. Lechleiter , Ph.D., chairman, president, and chief executive officer of Eli Lilly and Company (NYSE: LLY ), regarding today's Senate vote on S.3187 to reauthorize the Prescription Drug User Fee Act
Read more →LLYLilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2012 of $0.49 a share on outstanding...
INDIANAPOLIS , June 19, 2012 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the third quarter of 2012 of $0.49 a share on outstanding common stock. The dividend is payable September 10, 2012 to shareholders of record at th
Read more →LLYLilly Diabetes Launches 8th Annual Diabetes Summer Camp Tour With Olympian Kris Freeman News Highlights Olympian Kris Freeman visits 10 #diabetes summer #camps; he has shared his #T1 story with nearly 5,000 campers through Lilly's camp...
INDIANAPOLIS , June 18, 2012 /PRNewswire/ -- News Highlights Many children dream of being a superhero when growing up. To those with diabetes, that is exactly what they see in Kris Freeman . Freeman, an Olympic cross country skier with type 1 diabetes, has shared his personal s
Read more →LLYLilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines In support of its commitment to maximize growth opportunities in China, Eli Lilly and Company (NYSE: LLY) today announced an increase of its network...
INDIANAPOLIS and NANTONG, China, June 12, 2012 /PRNewswire/ -- In support of its commitment to maximize growth opportunities in China , Eli Lilly and Company (NYSE: LLY ) today announced an increase of its network of manufacturing capabilities in this key emerging market country
Read more →LLYProject HOPE Presents Dr. Lechleiter, Lilly with Global Health Partner Award Project HOPE presented John C. Lechleiter, Ph.D., chairman, president, and chief executive officer of Eli Lilly and Company (NYSE: LLY) with the...
INDIANAPOLIS , June 12, 2012 /PRNewswire/ -- Project HOPE presented John C. Lechleiter , Ph.D., chairman, president, and chief executive officer of Eli Lilly and Company (NYSE: LLY ) with the inaugural Global Health Partner Award. The award recognizes Dr. Lechleiter's leadership
Read more →LLYPost-hoc analysis of linagliptin phase 3 data in adults with type 2 diabetes and albuminuria presented Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results from a post-hoc analysis, which explored the ...
RIDGEFIELD, Conn. and INDIANAPOLIS , June 9, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY ) today announced results from a post-hoc analysis, which explored the clinical effect of linagliptin on albuminuria in patients with
Read more →LLYLilly CEO Calls for a Health Care Policy Environment That Promotes Medical Innovation Regardless of how the Supreme Court rules on the Affordable Care Act, Eli Lilly and Company (NYSE: LLY) will continue to advocate for reforms that...
NEW YORK , June 6, 2012 /PRNewswire/ -- Regardless of how the Supreme Court rules on the Affordable Care Act, Eli Lilly and Company (NYSE: LLY ) will continue to advocate for reforms that enhance patient access to good health care and medicines, provide consumer choice through ma
Read more →LLYBoehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company to Feature 30 Presentations on Type 1 and Type 2 Diabetes at the 72nd American Diabetes Association Scientific Sessions® Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) are pleased to announce that less than two years after forming a...
RIDGEFIELD, Conn. , and INDIANAPOLIS , June 5, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY ) are pleased to announce that less than two years after forming a strategic alliance aimed at bringing new treatments to patients w
Read more →LLYLung Cancer Study Showed Encouraging Results For ALIMTA-based Regimens And Full-dose Radiation Eli Lilly and Company (NYSE: LLY) announced results of a Phase II trial evaluating ALIMTA® (pemetrexed for injection) in combination with a platinum...
INDIANAPOLIS , June 4, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced results of a Phase II trial evaluating ALIMTA® (pemetrexed for injection) in combination with a platinum chemotherapy and radiation for patients with locally advanced non-small cell lung canc
Read more →LLYPhase III Study: Patients With Most Common Type Of Lung Cancer Lived Longer With ALIMTA-Based Continuation Maintenance Therapy Final results from PARAMOUNT, a Phase III study of ALIMTA® (pemetrexed for injection) in the continuation maintenance setting, demonstrated improved...
INDIANAPOLIS , June 4, 2012 /PRNewswire/ -- Final results from PARAMOUNT, a Phase III study of ALIMTA ® (pemetrexed for injection) in the continuation maintenance setting, demonstrated improved overall survival in patients with advanced nonsquamous non-small cell lung cancer (NSC
Read more →LLYDr. William G. Kaelin Jr. Elected to Lilly Board of Directors The Board of Directors of Eli Lilly and Company (NYSE:LLY) has elected William G. Kaelin Jr., M.D. as a new member, effective June 4, 2012. Dr....
INDIANAPOLIS , June 4, 2012 /PRNewswire/ -- The Board of Directors of Eli Lilly and Company (NYSE: LLY ) has elected William G. Kaelin Jr. , M.D. as a new member, effective June 4, 2012 . Dr. Kaelin, 54, is a Professor in the Department of Medicine at Dana-Farber Cancer Institute
Read more →LLYAmyvid™ (Florbetapir F 18 Injection) Now Available in Select U.S. Markets Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced that Amyvid is available...
INDIANAPOLIS , June 1, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly , today announced that Amyvid is available to imaging centers in markets surrounding 16 manufacturing sites located in Atlanta ;
Read more →LLYNew mobile app helps doctors find clinical trials for cancer patients Today, Eli Lilly and Company (NYSE: LLY) launched a searchable clinical trial mobile application for oncology healthcare professionals. The app –...
INDIANAPOLIS , June 1, 2012 /PRNewswire/ -- Today, Eli Lilly and Company (NYSE: LLY ) launched a searchable clinical trial mobile application for oncology healthcare professionals. The app – available for Apple iPad and iPhone, as well as RIM's BlackBerry and Google's Android pla
Read more →LLYLilly's Commitment to Global Innovation Reinforced with Opening of New Diabetes-Focused Research and Development Center in Shanghai Eli Lilly and Company (NYSE: LLY) today announced it has officially opened the Lilly China Research and Development Center (LCRDC), a key component...
SHANGHAI , May 30, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced it has officially opened the Lilly China Research and Development Center (LCRDC), a key component of its significant and sustainable commitment to China. The goal of the LCRDC is to discove
Read more →LLYNew Phase 3 data for Tradjenta® (linagliptin) tablets in black or African American patients with type 2 diabetes showed significant improvement in blood sugar Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Phase 3 study results for linagliptin 5 mg...
RIDGEFIELD, Conn. and INDIANAPOLIS , May 24, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY ) today announced Phase 3 study results for linagliptin 5 mg once-daily, which showed significant hemoglobin A1c (HbA1c or A1C) reduct
Read more →LLYAmerican College of Endocrinology (ACE) and Lilly Diabetes Offer New Tips to Help People With Diabetes Prepare for Emergencies Today, the American College of Endocrinology (ACE) and Lilly Diabetes launched the EmPower Diabetes Emergency Plan – a newly designed resource to...
PHILADELPHIA , May 23, 2012 /PRNewswire/ -- Today, the American College of Endocrinology (ACE) and Lilly Diabetes launched the "EmPower Diabetes Emergency Plan" – a newly designed resource to help people with diabetes prepare for emergency situations – big or small. (Download at
Read more →LLYLilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting Eli Lilly and Company (NYSE: LLY) today announced that dulaglutide, its investigational, long-acting glucagon-like peptide 1 (GLP-1) analog being...
NEW YORK , May 22, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that dulaglutide, its investigational, long-acting glucagon-like peptide 1 (GLP-1) analog being studied as a once-weekly treatment for type 2 diabetes, met its primary endpoint of non-infer
Read more →LLYLilly Oncology To Disclose New Pipeline Data At ASCO 2012 Eli Lilly and Company (NYSE: LLY) will present data from several molecules that make up its clinical oncology pipeline during the 48th Annual Meeting ...
INDIANAPOLIS , May 14, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present data from several molecules that make up its clinical oncology pipeline during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. from June 1
Read more →LLYLilly Oncology to Highlight Final Results for Phase III Study in Most Common Form of Lung Cancer Eli Lilly and Company (NYSE: LLY) will present data from more than 25 studies at the 48th Annual Meeting of the American Society of Clinical Oncology ...
INDIANAPOLIS , May 14, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present data from more than 25 studies at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1 – 5, 2012, including overall survival results fro
Read more →LLYLilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community Eli Lilly and Company (NYSE: LLY) will conduct a conference call for the investment community to provide a pipeline update on its Lilly Diabetes...
INDIANAPOLIS , May 3, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will conduct a conference call for the investment community to provide a pipeline update on its Lilly Diabetes business on Monday, June 11, 2012 . The call, which is being held in conjunction with the 7
Read more →LLYLilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center Eli Lilly and Company (NYSE: LLY) today applauded law enforcement officials for their successful investigation and the recovery of more than $70...
INDIANAPOLIS , May 3, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today applauded law enforcement officials for their successful investigation and the recovery of more than $70 million in pharmaceuticals stolen from its United States distribution center located in Enf
Read more →LLYLilly Reports Solid Start to the Year With First-Quarter 2012 Results, Raises EPS Guidance Worldwide revenue declined 4 percent in the first quarter of 2012, driven by Zyprexa patent expirations, partially offset by significant growth in...
INDIANAPOLIS , April 25, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the first quarter of 2012. Financial results for 2012 and 2011 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accorda
Read more →LLYDiversityInc Names Lilly a Top Company for Diversity Eli Lilly and Company (NYSE: LLY) has been named to the 2012 DiversityInc Top 50 Companies for Diversity list. Lilly ranked 29th, an increase from...
INDIANAPOLIS , April 25, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has been named to the 2012 DiversityInc Top 50 Companies for Diversity list. Lilly ranked 29th, an increase from its 2011 rating of 39. DiversityInc 's "Top 50 Companies for Diversity" is known as t
Read more →LLYLilly Diabetes and Walgreens Launch Diabetes Hypoglycemia Awareness Campaign Lilly Diabetes and Walgreens are educating people living with diabetes about one of the most common and misunderstood consequences of diabetes:...
INDIANAPOLIS , April 16, 2012 /PRNewswire/ -- Lilly Diabetes and Walgreens are educating people living with diabetes about one of the most common and misunderstood consequences of diabetes: hypoglycemia (low blood sugar). The companies today launched an awareness campaign at 43 W
Read more →LLYReintegration Awards Recognize Service to People With Mental Illness Sixteen people will be honored with prestigious Reintegration Awards for their outstanding efforts to improve the lives of individuals with serious...
CHICAGO , April 16, 2012 /PRNewswire/ -- Sixteen people will be honored with prestigious Reintegration Awards for their outstanding efforts to improve the lives of individuals with serious mental illnesses during the 42nd National Council Mental Health and Addictions Conference ,
Read more →LLYLilly Declares Second-Quarter 2012 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the second quarter of 2012 of $0.49 a share on outstanding...
INDIANAPOLIS , April 16, 2012 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) today declared a dividend for the second quarter of 2012 of $0.49 a share on outstanding common stock. The dividend is payable June 8, 2012 to shareholders of record at the
Read more →LLYLilly Confirms Date and Conference Call for First-Quarter 2012 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the first quarter of 2012 on Wednesday, April 25, 2012. Lilly will also...
INDIANAPOLIS , April 11, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the first quarter of 2012 on Wednesday, April 25 , 2012. Lilly will also conduct a conference call on that day with the investment community and media to furth
Read more →LLYFDA Approves Amyvid™ (Florbetapir F 18 Injection) for Use in Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Decline Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug...
INDIANAPOLIS , April 6, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for b
Read more →LLYLilly Diabetes supports Diabetes Scholars Foundation with $100,000 donation in 2012 Lilly Diabetes today announced a donation of $100,000 to the Diabetes Scholars Foundation (Foundation) scholarship fund. The contribution will...
INDIANAPOLIS and ROLLING MEADOWS, Ill. , April 4, 2012 /PRNewswire/ -- Lilly Diabetes today announced a donation of $100,000 to the Diabetes Scholars Foundation (Foundation) scholarship fund. The contribution will support the Foundation's mission to empower young people with type
Read more →LLYLilly Targets Faulty c-MET Receptor in Cancer Research Studies Presented Today at AACR Meeting Eli Lilly and Company (NYSE: LLY) today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it...
CHICAGO , April 2, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell. Abnormalities in
Read more →LLYLilly's Anti-IL-17 Monoclonal Antibody, Ixekizumab, Met Primary Endpoint in Phase II Study in Patients With Chronic Plaque Psoriasis New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's (NYSE: LLY) ixekizumab (pronounced ix ...
INDIANAPOLIS , March 28, 2012 /PRNewswire/ -- New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's (NYSE: LLY ) ixekizumab (pronounced ix" e kiz' ue mab, previously known as LY2439821), an anti-IL-17 monoclonal antibody, m
Read more →LLYFifth Lilly Oncology on Canvas Art Competition Invites All Touched by Cancer to Share Their Cancer Journeys Get your canvases, paintbrushes and cameras ready -- the subject is cancer and you are the storyteller. Lilly Oncology and the National Coalition for ...
INDIANAPOLIS , Feb. 9, 2012 /PRNewswire/ -- Get your canvases, paintbrushes and cameras ready -- the subject is cancer and you are the storyteller. Lilly Oncology and the National Coalition for Cancer Survivorship (NCCS) today announced the launch of the 2012 Lilly Oncology On Ca
Read more →LLYBoehringer Ingelheim and Lilly's new oral type 2 diabetes treatment for adults, Jentadueto™ (linagliptin/metformin hydrochloride) tablets, now available in U.S. pharmacies Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Jentadueto™ (linagliptin/metformin hydrochloride)...
RIDGEFIELD, Conn. and INDIANAPOLIS , March 7, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY ) today announced Jentadueto™ (linagliptin/metformin hydrochloride) tablets are now available by prescription in many leading chain
Read more →LLYLilly Pledges $100,000 to American Red Cross' Tornado Disaster Relief Efforts The Eli Lilly and Company (NYSE: LLY) Foundation today pledged $100,000 to the American Red Cross for its tornado disaster relief efforts. The...
INDIANAPOLIS , March 5, 2012 /PRNewswire/ -- The Eli Lilly and Company (NYSE: LLY ) Foundation today pledged $100,000 to the American Red Cross for its tornado disaster relief efforts. The donation will support families and communities affected by devastating tornadoes that wreak
Read more →LLYWelcome Back Awards Recognize Outstanding Contributions in the Fight Against Depression Five individuals will be recognized for outstanding achievements in the fight against depression at the 13th annual Welcome Back Awards ceremony on...
WASHINGTON , Feb. 28, 2012 /PRNewswire/ -- Five individuals will be recognized for outstanding achievements in the fight against depression at the 13th annual Welcome Back Awards ceremony on February 29 in Washington, D.C. Since 1998, the Welcome Back Awards have helped to promot
Read more →LLYLilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science Eli Lilly and Company (NYSE:LLY) today announced the launch of its global Innovation Starts Here initiative which supports Lilly's commitment to...
BRUSSELS , Feb. 28, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the launch of its global Innovation Starts Here initiative which supports Lilly's commitment to speeding the delivery of innovative new medicines to patients around the world. Two key com
Read more →LLYLilly Releases Its Most Comprehensive Corporate Responsibility Report Eli Lilly and Company (NYSE: LLY) has released its most comprehensive corporate responsibility report using the Global Reporting Initiative (GRI)...
INDIANAPOLIS , Feb. 14, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has released its most comprehensive corporate responsibility report using the Global Reporting Initiative (GRI) framework, which is designed to help companies report on economic, environmental and soc
Read more →LLYLilly Recognized as a Top Company for Executive Women Eli Lilly and Company (NYSE: LLY) has earned a place on the NAFE Top Companies for Executive Women list for the fourth consecutive year. The 2012...
INDIANAPOLIS , Feb. 7, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has earned a place on the NAFE "Top Companies for Executive Women" list for the fourth consecutive year. The 2012 list, compiled by the National Association for Female Executives (NAFE), recognizes U.
Read more →LLYNew Study Evaluates Cialis® in parallel with Tamsulosin in Men with Signs and Symptoms Suggestive of Benign Prostatic Hyperplasia Eli Lilly and Company (NYSE: LLY) announced today that a Phase III study, published online by European Urology, showed both Cialis® (tadalafil) and...
INDIANAPOLIS , Feb. 7, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that a Phase III study, published online by European Urology , showed both Cialis® (tadalafil) and tamsulosin significantly improved scores on the International Prostate Symptom Score (
Read more →LLYPartnership Between Lilly Diabetes and the American Diabetes Association to Send 89 Children to American Diabetes Association Diabetes Camps in 2012 Lilly Diabetes today announced its commitment to send 89 children to diabetes camp this summer through a collaboration with the American Diabetes...
INDIANAPOLIS and ALEXANDRIA, Va. , Feb. 1, 2012 /PRNewswire/ -- Lilly Diabetes today announced its commitment to send 89 children to diabetes camp this summer through a collaboration with the American Diabetes Association (Association). Lilly Diabetes donated 89 camp scholarship
Read more →LLYLilly Reports Fourth-Quarter and Full-Year 2011 Results Fourth quarter revenue declined two percent driven by Zyprexa and Gemzar patent expirations, partially offset by growth in other products. Fourth...
INDIANAPOLIS , Jan. 31, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the fourth quarter and full year of 2011. Financial results for 2011 and 2010 are presented on both a reported and a non-GAAP basis. Reported results were prepa
Read more →LLYFDA approves Jentadueto™ (linagliptin/metformin hydrochloride) tablets for the treatment of adult patients with type 2 diabetes Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has...
RIDGEFIELD, Conn. , and INDIANAPOLIS , Jan. 30, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY ) today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto™ (linagliptin/metformin hydrochloride) tablet
Read more →LLYElanco Animal Health Announces Lilly's Agreement to Acquire ChemGen Corp. Elanco, the animal health division of Eli Lilly and Company (NYSE: LLY), today announced that Lilly has signed an agreement to acquire ChemGen Corp., ...
GREENFIELD, Ind. , Jan. 24, 2012 /PRNewswire/ -- Elanco, the animal health division of Eli Lilly and Company (NYSE: LLY ), today announced that Lilly has signed an agreement to acquire ChemGen Corp., a privately held bioscience company specializing in the development and commerci
Read more →LLYLilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance Company expects to meet or exceed 2011 EPS guidance. 2012 financial guidance reflects revenue and earnings declines due to Zyprexa patent expiration. ...
INDIANAPOLIS , Jan. 5, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today commented on its 2011 financial guidance and announced its financial guidance for 2012. The company also reconfirmed its mid-term guidance through 2014. For 2011, the company expects to meet or
Read more →LLYLilly Sets Dates and Conference Calls for 2012 Financial Guidance and Fourth-Quarter 2011 Financial Results Announcements Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2012 on Thursday, January 5, 2012 and, separately, will announce its...
INDIANAPOLIS , Dec. 16, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial guidance for 2012 on Thursday, January 5, 2012 and, separately, will announce its financial results for the fourth quarter and full year of 2011 on Tuesday, January 31 , 20
Read more →LLYLilly Recognized as One of the Best Places to Work for LGBT Equality For the sixth consecutive year, Eli Lilly and Company (NYSE: LLY) has received a 100 percent rating on the Human Rights Campaign (HRC) Corporate...
INDIANAPOLIS , Dec. 14, 2011 /PRNewswire/ -- For the sixth consecutive year, Eli Lilly and Company (NYSE: LLY ) has received a 100 percent rating on the Human Rights Campaign (HRC) Corporate Equality Index (CEI) for lesbian, gay, bisexual and transgender (LGBT) equality in the wo
Read more →LLYKatherine Baicker Elected to Lilly Board of Directors Board of Directors of Eli Lilly and Company (NYSE: LLY) has elected Katherine Baicker, Ph.D. as a new member, effective December 12, 2011. Baicker,...
INDIANAPOLIS , Dec. 12, 2011 /PRNewswire/ -- Board of Directors of Eli Lilly and Company (NYSE: LLY ) has elected Katherine Baicker , Ph.D. as a new member, effective December 12, 2011 . Baicker, 40, is Professor of Health Economics in the Department of Health Policy and Manageme
Read more →LLYLilly Oncology Reveals Findings From Study of JAK2 Inhibitor for Blood Cancers at ASH Meeting Eli Lilly and Company (NYSE: LLY) announced data from an oncology pipeline molecule today at the 53rd Annual Meeting of the American Society of...
SAN DIEGO , Dec. 12, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced data from an oncology pipeline molecule today at the 53rd Annual Meeting of the American Society of Hematology (ASH). At the meeting, Lilly Oncology presented Phase I data from the investigatio
Read more →LLYLilly Declares First-Quarter 2012 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the first quarter of 2012 of $0.49 a share on outstanding...
INDIANAPOLIS , Dec. 12, 2011 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) today declared a dividend for the first quarter of 2012 of $0.49 a share on outstanding common stock. The dividend is payable March 9, 2012 to shareholders of record at the
Read more →LLYLilly for Better Health™ Expands Website to Include Spanish Health Information and Interactive Tools Lilly for Better Health™, a program of Lilly USA, LLC, (NYSE: LLY) that helps individuals live healthier, more active lives, has launched an expanded ...
INDIANAPOLIS , Dec. 9, 2011 /PRNewswire/ -- Lilly for Better Health ™, a program of Lilly USA , LLC, (NYSE: LLY ) that helps individuals live healthier, more active lives, has launched an expanded Spanish portal on www.lillyforbetterhealth.com . The newly enhanced En Espanol sec
Read more →LLYLilly for Better Health™ expande su sitio web para incluir información de salud y herramientas interactivas en español Lilly for Better Health™, un programa de Lilly USA, LLC, (NYSE: LLY) que ayuda a las personas a llevar vidas más saludables y activas, ha inaugurado...
INDIANÁPOLIS, 9 de diciembre de 2011 /PRNewswire-HISPANIC PR WIRE/ -- Lilly for Better Health ™, un programa de Lilly USA , LLC, (NYSE: LLY ) que ayuda a las personas a llevar vidas más saludables y activas, ha inaugurado un portal ampliado en español, en www.lillyforbetterhealth
Read more →LLYTaking Sex Off Their To-Do List: Most Couples Prefer Spontaneity in the Bedroom Sex is spontaneous, or unplanned, for the majority of men and women in the U.S. and around the world, a recent survey found. In the U.S., 76 percent...
INDIANAPOLIS , Dec. 8, 2011 /PRNewswire/ -- Sex is spontaneous, or unplanned, for the majority of men and women in the U.S. and around the world, a recent survey found. In the U.S., 76 percent of all respondents said they do not plan ahead for sex, compared to the global average
Read more →LLYEli Lilly and Company Named a Top Global Company for Leaders Eli Lilly and Company (NYSE: LLY) has been named one of the top 25 global companies for leaders by Aon Hewitt in partnership with FORTUNE and the RBL ...
INDIANAPOLIS , Dec. 1, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has been named one of the top 25 global companies for leaders by Aon Hewitt in partnership with FORTUNE and the RBL Group. Lilly ranked 16th on the Global 25 list and 12th on the North American list.
Read more →LLYLilly Announces First and Only International, Prospective Observational Study Designed to Understand Barriers to Progression of Insulin Treatment Eli Lilly and Company (NYSE: LLY) today announced it is conducting the first major international, prospective observational study designed to...
INDIANAPOLIS , Dec. 1, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced it is conducting the first major international, prospective observational study designed to understand the real-world obstacles that people with type 2 diabetes face that prevent them f
Read more →LLYLilly Provides Additional Funding to Infectious Disease Research Institute to Identify New Tuberculosis Therapies Eli Lilly and Company (NYSE: LLY) today announced that it is providing more than $4 million in additional funding to the Infectious Disease Research...
SEATTLE , Nov. 17, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that it is providing more than $4 million in additional funding to the Infectious Disease Research Institute. The funding will allow IDRI to continue its early phase drug discovery efforts
Read more →LLYNew Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI An analysis of the TRITON-TIMI 38 trial presented today in an oral session at the American Heart Association (AHA) Scientific Sessions meeting...
ORLANDO, Fla. , Nov. 16, 2011 /PRNewswire/ -- An analysis of the TRITON-TIMI 38 trial presented today in an oral session at the American Heart Association (AHA) Scientific Sessions meeting examined the effect of Effient® (prasugrel) on cardiovascular (CV) events (CV death, myocar
Read more →LLYF.A.C.E. Diabetes and Anthony Anderson Ask Americans to Rethink Generation D For the second year in a row, award-winning actor and comedian Anthony Anderson is teaming up with Eli Lilly and Company's Fearless African-Americans ...
INDIANAPOLIS , Nov. 11, 2011 /PRNewswire/ -- For the second year in a row, award-winning actor and comedian Anthony Anderson is teaming up with Eli Lilly and Company's F earless A frican-Americans C onnected and E mpowered (F.A.C.E.) Diabetes initiative to remove the stereotype o
Read more →LLYLilly CEO Lechleiter Outlines Opportunities for Improved Health and Economic Growth in Asia-Pacific Region Eli Lilly and Company (NYSE: LLY) Chairman, President and Chief Executive Officer John C. Lechleiter, Ph.D., today said new trade agreements,...
HONOLULU , Nov. 10, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) Chairman, President and Chief Executive Officer John C. Lechleiter , Ph.D., today said new trade agreements, effective public policies, and continued collaboration to bring innovation to patients are need
Read more →LLYLilly to Recognize Employees Who Have Served Our Country Through the Military U.S. military veterans employed by Eli Lilly and Company (NYSE: LLY) will be recognized for their service to the country during a special Veterans...
INDIANAPOLIS , Nov. 9, 2011 /PRNewswire/ -- U.S. military veterans employed by Eli Lilly and Company (NYSE: LLY ) will be recognized for their service to the country during a special Veterans Recognition Event at the Lilly Corporate Center 4 p.m. Monday, Nov. 14 . The event is sp
Read more →LLYLilly Surpasses United Way 2011 Campaign Goal Eli Lilly and Company (NYSE: LLY) Chairman, President and Chief Executive Officer John Lechleiter Ph.D. today will present a $12.3 million check to...
INDIANAPOLIS , Nov. 8, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) Chairman, President and Chief Executive Officer John Lechleiter Ph.D. today will present a $12.3 million check to the United Way. The check represents the contributions of Lilly's U.S. employees and re
Read more →LLYLilly CEO Says Appropriate Assessment of Both Benefits and Risks Critical in Regulatory Process To sustain medical innovation, the FDA must accelerate the adoption of a Benefit-Risk framework to inform decision-making in the regulatory process,...
In an address at the FDA News Fourth Annual Risk Management and Drug Safety Summit, Lechleiter called for a regulatory process that focuses both on recognizing and appreciating benefits while identifying and minimizing risks. Such a balanced approach would help increase the flow
Read more →LLYALIMTA First Chemotherapy Approved in Europe as Continuation Maintenance Therapy for Most Common Form of Lung Cancer Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has granted approval for the use of ALIMTA® (pemetrexed for injection) ...
INDIANAPOLIS , Oct. 28, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the European Commission has granted approval for the use of ALIMTA® (pemetrexed for injection) as a single agent for continuation maintenance therapy in patients with a particular
Read more →LLYLilly Foundation Commits US $30 Million to The Lilly MDR-TB Partnership The Eli Lilly and Company Foundation has committed US $30 million in funding to further support The Lilly MDR-TB Partnership in its fight against...
LILLE, France , Oct. 27, 2011 /PRNewswire/ -- The Eli Lilly and Company Foundation has committed US $30 million in funding to further support The Lilly MDR-TB Partnership in its fight against multidrug-resistant tuberculosis – a disease that disproportionately affects developing
Read more →LLYLilly Provides Update on 2011 Financial Guidance Due to Xigris Withdrawal Eli Lilly and Company (NYSE:LLY) has updated its full-year 2011 financial guidance as a result of the announced withdrawal of the company's Xigris®...
INDIANAPOLIS , Oct. 25, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has updated its full-year 2011 financial guidance as a result of the announced withdrawal of the company's Xigris ® product. Lilly expects to incur a charge in the fourth quarter of 2011 for asset im
Read more →LLYLilly Reports Third-Quarter 2011 Results Third-quarter 2011 revenue grew 9 percent to $6.148 billion due to increased demand for several key brands and favorable exchange rates. Revenue for...
INDIANAPOLIS , Oct. 20, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the third quarter of 2011. Financial results for 2011 and 2010 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordan
Read more →LLYLilly Declares Fourth-Quarter 2011 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the fourth quarter of 2011 of $0.49 a share on outstanding...
INDIANAPOLIS , Oct. 17, 2011 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) today declared a dividend for the fourth quarter of 2011 of $0.49 a share on outstanding common stock. This is the same dividend as was paid in the first three quarters of 20
Read more →LLYNew Study Shows Cialis® Significantly Improved Study Endpoints in Men with Both Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia Eli Lilly and Company (NYSE: LLY) announced today that a pivotal Phase III study of Cialis® (tadalafil) tablets 5 mg for once daily use met its...
INDIANAPOLIS , Oct. 12, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that a pivotal Phase III study of Cialis® (tadalafil) tablets 5 mg for once daily use met its co-primary endpoints, significantly improving measures of both erectile dysfunction (ED) a
Read more →LLYLilly Announces Changes in Senior Management Eli Lilly and Company (NYSE: LLY) today announced key appointments due to the December 31 retirements of longtime senior leaders, Bryce D. Carmine...
INDIANAPOLIS , Oct. 11, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced key appointments due to the December 31 retirements of longtime senior leaders, Bryce D. Carmine and Frank Deane , Ph.D. Carmine, whose Lilly career spans 36 years, has led Lilly Bio-
Read more →LLYLilly Confirms Date and Conference Call for Third-Quarter 2011 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2011 on Thursday, October 20, 2011. Lilly will also...
INDIANAPOLIS , Oct. 10, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the third quarter of 2011 on Thursday, October 20, 2011 . Lilly will also conduct a conference call on that day with the investment community and media to furth
Read more →LLYCialis® for Once Daily Use Now FDA-Approved to Treat Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) and Men With Both Erectile Dysfunction (ED) and Signs and Symptoms of BPH Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Cialis® (tadalafil) tablets for once...
INDIANAPOLIS , Oct. 7, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the U.S. Food and Drug Administration (FDA) has approved Cialis® (tadalafil) tablets for once daily use for the treatment of men who have both erectile dysfunction and the signs an
Read more →LLY2011 Lilly Global Day of Service Focuses on Healthy Outdoor Living Thousands of volunteers from Eli Lilly and Company (NYSE: LLY) will work from dawn to dusk on Thursday, October 6, with Keep Indianapolis Beautiful,...
INDIANAPOLIS , Oct. 4, 2011 /PRNewswire/ -- Thousands of volunteers from Eli Lilly and Company (NYSE: LLY ) will work from dawn to dusk on Thursday, October 6 , with Keep Indianapolis Beautiful, Inc. (KIB), and 30 partner organizations to revitalize four Indianapolis corridors du
Read more →LLYLilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities Eli Lilly and Company (NYSE:LLY) today announced that it is improving its environmental footprint by achieving two of the company's three...
INDIANAPOLIS , Oct. 4, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that it is improving its environmental footprint by achieving two of the company's three environmental goals ahead of schedule. Through the end of 2010, the company reduced the amount o
Read more →LLYLilly Launches Open Innovation Drug Discovery Platform to Help Find Potential New Medicines Where Medical Need is Great Eli Lilly and Company (NYSE: LLY) today announced the launch of a new open innovation platform designed to help build the company's pipeline of...
INDIANAPOLIS , Sept. 26, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the launch of a new open innovation platform designed to help build the company's pipeline of tomorrow and, from a philanthropic perspective, identify molecules that may have applicat
Read more →LLYALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for Deadly Form of Lung Cancer Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP)...
INDIANAPOLIS , Sept. 26, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of ALIMTA® (pemetrexed for injection) as con
Read more →LLYALIMTA Helped Keep Most Common Form of Lung Cancer at Bay In Elderly Patients Eli Lilly and Company (NYSE: LLY) announced today that a new subgroup analysis of data from the pivotal Phase III PARAMOUNT study showed that...
INDIANAPOLIS , Sept. 26, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that a new subgroup analysis of data from the pivotal Phase III PARAMOUNT study showed that continuation maintenance therapy with ALIMTA ® (pemetrexed for injection) also reduces the
Read more →LLYLung Cancer Study Reveals Similar Outcomes for African-American and Caucasian Patients Treated With Alimta® Lung cancer, the leading cause of cancer death in the U.S., takes a particularly heavy toll on African Americans. Despite their lower smoking rates,...
INDIANAPOLIS , Sept. 20, 2011 /PRNewswire/ -- Lung cancer, the leading cause of cancer death in the U.S., takes a particularly heavy toll on African Americans. Despite their lower smoking rates, African Americans are more likely than Caucasians to develop and die from lung cancer
Read more →LLYLilly Steps Up Efforts to Improve Diversity in Clinical Trials Racial and ethnic minorities are more likely to develop cancer and die from it than the general U.S. population. However, as the next generation of...
INDIANAPOLIS , Sept. 20, 2011 /PRNewswire/ -- Racial and ethnic minorities are more likely to develop cancer and die from it than the general U.S. population. However, as the next generation of cancer medicines are being evaluated, only 17 percent of clinical trial participants a
Read more →LLYLilly Named One of America's Best Adoption-Friendly Workplaces Eli Lilly and Company (NYSE: LLY) has been named to the 2011 Best Adoption-Friendly Workplaces List by the Dave Thomas Foundation for Adoption. This...
INDIANAPOLIS , Sept. 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has been named to the 2011 Best Adoption-Friendly Workplaces List by the Dave Thomas Foundation for Adoption. This is the fifth consecutive year that Lilly has been ranked in the top 100. Rankings f
Read more →LLYEli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference Eli Lilly and Company (NYSE: LLY) will bring one of its patient education programs to Washington, D.C., September 21-24 during the 2011 Annual...
INDIANAPOLIS , Sept. 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will bring one of its patient education programs to Washington, D.C. , September 21-24 during the 2011 Annual Legislative Conference presented by the Congressional Black Caucus Foundation at the Walt
Read more →LLYResearch Suggests FORTEO® Significantly Increases Bone Strength Eli Lilly and Company (NYSE: LLY) today presented a study that assessed the effects of 18 months of treatment with FORTEO® (teriparatide [rDNA...
SAN DIEGO , Sept. 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today presented a study that assessed the effects of 18 months of treatment with FORTEO ® (teriparatide [rDNA origin] injection) on vertebral and proximal femoral strength, and the relationship of these
Read more →LLYNew Data Explore Mechanistic Differences Between FORTEO® and Zoledronic Acid Eli Lilly and Company (NYSE: LLY) today presented data comparing the mechanisms of action of FORTEO® (teriparatide [rDNA origin] injection) and...
SAN DIEGO , Sept. 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today presented data comparing the mechanisms of action of FORTEO® (teriparatide [rDNA origin] injection) and zoledronic acid based on data that evaluated histomorphometric measurements of bone remodeli
Read more →LLYA Win for Innovation: President Signs America Invents Act Today's historic signing of the America Invents Act represents a huge win for innovators and improves U.S. competiveness globally by aligning new...
INDIANAPOLIS , Sept. 16, 2011 /PRNewswire/ -- Today's historic signing of the America Invents Act represents a huge win for innovators and improves U.S. competiveness globally by aligning new patent laws more closely with those from other countries, said John Lechleiter , Ph.D.,
Read more →LLYLilly Celebrates 17th Consecutive Year as One of Working Mother 100 Best Companies Eli Lilly and Company (NYSE: LLY) has once again been selected one of the 100 Best Companies by Working Mother magazine. This is the 17th...
INDIANAPOLIS , Sept. 16, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has once again been selected one of the "100 Best Companies" by Working Mother magazine. This is the 17th consecutive year for this honor. In its 26th year, the Working Mother 100 Best Companies ini
Read more →LLYLilly Invests $30 Million in Partnership to Address Non-Communicable Diseases Eli Lilly and Company (NYSE: LLY) announced today a $30 million commitment over five years to fight the rising burden of non-communicable diseases in ...
INDIANAPOLIS , Sept. 13, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today a $30 million commitment over five years to fight the rising burden of non-communicable diseases in developing nations. Lilly is launching The Lilly NCD Partnership, which combines th
Read more →LLYLilly-sponsored Summit to Help Youth Focus on Their Potential The annual Center for Leadership Development (CLD) Corporate Youth Summit, sponsored and hosted by Eli Lilly and Company, will be Saturday, September ...
INDIANAPOLIS , Sept. 12, 2011 /PRNewswire/ -- The annual Center for Leadership Development (CLD) Corporate Youth Summit, sponsored and hosted by Eli Lilly and Company, will be Saturday, September 17 , at the Lilly Corporate Center. This year's theme is "From Classroom Potential t
Read more →LLYLilly Health Channel Debuts on YouTube On the heels of launching its enhanced Lilly for Better Health™ program, Lilly USA, LLC, (NYSE: LLY) introduces the Lilly Health Channel on YouTube – ...
INDIANAPOLIS , Sept. 8, 2011 /PRNewswire/ -- On the heels of launching its enhanced Lilly for Better Health ™ program, Lilly USA , LLC, (NYSE: LLY ) introduces the Lilly Health Channel on YouTube – www.youtube.com/lillyhealth – featuring videos on health and wellness, employee an
Read more →LLYBoehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will present the latest data from their diabetes portfolio at the 47th Annual Meeting of...
RIDGEFIELD, Conn. and INDIANAPOLIS , Sept. 7, 2011 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY ) will present the latest data from their diabetes portfolio at the 47th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Lis
Read more →LLYLinagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today received Marketing Authorization from the European Commission for linagliptin 5 mg...
RIDGEFIELD, Conn. , and INDIANAPOLIS , Aug. 25, 2011 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY ) today received Marketing Authorization from the European Commission for linagliptin 5 mg film-coated tablets (to be marketed under the trade name Traje
Read more →LLYThe American Diabetes Association and Eli Lilly and Company Encourage African Americans to Learn About Diabetes Through a Familiar Face The 14th annual Victory Over Diabetes event, hosted by the American Diabetes Association (the Association), will take place in Atlanta on August 20,...
ATLANTA , Aug. 17, 2011 /PRNewswire/ -- The 14th annual Victory Over Diabetes event, hosted by the American Diabetes Association (the Association), will take place in Atlanta on August 20 , featuring educational workshops, free health screenings and resources designed to encourag
Read more →LLYEffient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study A new post-hoc sub-analysis of an important set of patients from the TRITON-TIMI 38 study – those identified as the core clinical cohort population ...
INDIANAPOLIS and TOKYO , Aug. 15, 2011 /PRNewswire/ -- A new post-hoc sub-analysis of an important set of patients from the TRITON-TIMI 38 study – those identified as the "core clinical cohort" population – showed that treatment with prasugrel (in combination with aspirin) was as
Read more →LLYLilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion Eli Lilly and Company (NYSE: LLY) today announced that data on EVISTA® (raloxifene HCl tablets) therapy for more than three years was published...
INDIANAPOLIS , Aug. 9, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that data on EVISTA® (raloxifene HCl tablets) therapy for more than three years was published online in Current Medical Research & Opinion . The review includes summaries of previously
Read more →LLYU.S. Court of Appeals Affirms Validity of Lilly's Strattera Patent Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has overturned a prior ruling by the U.S....
INDIANAPOLIS , July 29, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Court of Appeals for the Federal Circuit has overturned a prior ruling by the U.S. District Court for the District of New Jersey and has upheld the validity of the compan
Read more →LLYEli Lilly India and Lupin Announce Strategic Collaboration to Help Fight the Battle Against Diabetes Eli Lilly India (Lilly) and Lupin Limited (Lupin) today announced they have entered into a strategic collaboration to promote and distribute Lilly's...
NEW DELHI and MUMBAI, India , July 29, 2011 /PRNewswire/ -- Eli Lilly India (Lilly) and Lupin Limited (Lupin) today announced they have entered into a strategic collaboration to promote and distribute Lilly's Huminsulin range of products, including Huminsulin R™, Huminsulin NPH™,
Read more →LLYLilly Launches Physician Payment Registry Eli Lilly and Company (NYSE: LLY) today announced the launch of a physician payment registry (www.lillyphysicianpaymentregistry.com) to help the...
INDIANAPOLIS , July 27, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced the launch of a physician payment registry ( www.lillyphysicianpaymentregistry.com ) to help the public better understand how the company works with U.S. physicians and compensates the
Read more →LLYLilly Global gibt Mitarbeitern mehr Möglichkeiten zu gemeinnütziger Arbeit - Durch ein neues Programm leiten Mitarbeiter die finanziellen Mittel von Lilly an globale Gesundheits-, Ernährungs-, Bildungs- und Umweltprogramme...
INDIANAPOLIS , July 25, 2011 /PRNewswire/ -- - Durch ein neues Programm leiten Mitarbeiter die finanziellen Mittel von Lilly an globale Gesundheits-, Ernährungs-, Bildungs- und Umweltprogramme weiter. Zum ersten Mal können Mitarbeiter von Eli Lilly and Company (NYSE: LLY ) welt
Read more →LLYLe programme Global Giving de Lilly fait de chaque employé un philanthrope - Grâce à un nouveau programme, les employés de Lilly, dans le monde entier, peuvent contribuer à des programmes mondiaux consacrés aux problèmes de...
INDIANAPOLIS , July 25, 2011 /PRNewswire/ -- - Grâce à un nouveau programme, les employés de Lilly, dans le monde entier, peuvent contribuer à des programmes mondiaux consacrés aux problèmes de santé, de malnutrition, d ' éducation et d ' environnement Pour la première fois, le
Read more →LLYPrograma Lilly Global Giving coloca o poder da filantropia em mãos de funcionários Pela primeira vez, funcionários da Eli Lilly and Company (NYSE: LLY) no mundo inteiro podem fazer doações para mais de 800 projetos populares em todo ...
INDIANÁPOLIS, 25 de julho de 2011 /PRNewswire/ -- Pela primeira vez, funcionários da Eli Lilly and Company (NYSE: LLY ) no mundo inteiro podem fazer doações para mais de 800 projetos populares em todo o globo e suas doações são igualadas pela Eli Lilly and Company Foundation – do
Read more →LLYLilly Global Giving sitúa el poder de la filantropía en manos de los empleados - Por medio del nuevo programa, los empleados de todo el mundo enviarán partes de forma directa de los dólares filantrópicos de Lilly a los programas ...
INDIANÁPOLIS, July 25, 2011 /PRNewswire/ -- - Por medio del nuevo programa, los empleados de todo el mundo enviarán partes de forma directa de los dólares filantrópicos de Lilly a los programas mundiales que están dirigidos a ocuparse de la salud, hambruna, educación y entorno
Read more →LLYLilly Global Giving pone el poder de la filantropía en manos de los empleados Por primera vez, los empleados de Eli Lilly and Company (NYSE: LLY) de todo el mundo pueden hacer donaciones para más de 800 proyectos comunitarios...
INDIANÁPOLIS, 25 de julio de 2011 /PRNewswire/ -- Por primera vez, los empleados de Eli Lilly and Company (NYSE: LLY) de todo el mundo pueden hacer donaciones para más de 800 proyectos comunitarios de todo el planeta y lograr que sus aportes sean equiparados por la Eli Lilly and
Read more →LLYLilly Global Giving Puts Power of Philanthropy in Employees' Hands For the first time, Eli Lilly and Company (NYSE: LLY) employees worldwide can donate to more than 800 grassroots projects across the globe and have...
INDIANAPOLIS , July 25, 2011 /PRNewswire/ -- For the first time, Eli Lilly and Company (NYSE: LLY ) employees worldwide can donate to more than 800 grassroots projects across the globe and have their donations matched by the Eli Lilly and Company Foundation—doubling the value and
Read more →LLYLilly Reports Second-Quarter 2011 Results Second-quarter 2011 revenue grew 9 percent to $6.253 billion due to increased demand and favorable exchange rates. Q2 expense growth driven primarily ...
INDIANAPOLIS , July 21, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the second quarter of 2011. Financial results for 2011 and 2010 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accorda
Read more →LLYLilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimer's Disease Research Data were presented today from the first of two Phase III trials of semagacestat, including data from a 32 week follow-up period after dosing was...
INDIANAPOLIS , July 19, 2011 /PRNewswire/ -- Data were presented today from the first of two Phase III trials of semagacestat, including data from a 32 week follow-up period after dosing was halted in August 2010 . Semagacestat is a gamma secretase inhibitor that had been studied
Read more →LLYFlorbetapir Imaging to Autopsy Study Awarded Alzheimer's Association's 2011 de Leon Prize in Neuroimaging The study, Use of Florbetapir-PET for Imaging beta-amyloid Pathology, published in the Jan. 19, 2011 issue of the Journal of the American Medical...
INDIANAPOLIS , July 18, 2011 /PRNewswire/ -- The study, "Use of Florbetapir-PET for Imaging beta-amyloid Pathology," published in the Jan. 19, 2011 issue of the Journal of the American Medical Association , has been selected by the Alzheimer's Association as the winner of the 201
Read more →LLYLilly and Argonne National Laboratory Announce $2 Million Upgrade to Lilly's Beamline Capabilities Eli Lilly and Company (NYSE: LLY) and the U.S. Department of Energy's Argonne National Laboratory announced today the completion of Lilly's $2...
INDIANAPOLIS , July 14, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and the U.S. Department of Energy's Argonne National Laboratory announced today the completion of Lilly's $2 million upgrade to the company's research-guided beamline, located at the Advanced Photon S
Read more →LLYLilly Donation to Patient Advocate Foundation Expands Services and Access for Patients With Most Common Form of Lung Cancer Eli Lilly and Company (NYSE: LLY) announced that it has made a charitable contribution to the Patient Advocate Foundation (PAF). The donation will...
INDIANAPOLIS , July 13, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced that it has made a charitable contribution to the Patient Advocate Foundation (PAF). The donation will enable expansion of the foundation's patient services programs, including Case Manageme
Read more →LLYLilly Confirms Date and Conference Call for Second-Quarter 2011 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2011 on Thursday, July 21, 2011. Lilly will also...
INDIANAPOLIS , July 12, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the second quarter of 2011 on Thursday, July 21, 2011 . Lilly will also conduct a conference call on that day with the investment community and media to further
Read more →LLYLilly CEO empfiehlt Einbeziehung von Biopharmazeutika in transatlantische Handels- und Wirtschaftsgespräche Größere Kooperation in der Biopharmazie würde zu technologischem Fortschritt, Beschäftigungswachstum und gesellschaftlichem Nutzen führen John C....
BERLIN , July 11, 2011 /PRNewswire/ -- Größere Kooperation in der Biopharmazie würde zu technologischem Fortschritt, Beschäftigungswachstum und gesellschaftlichem Nutzen führen John C. Lechleiter , Ph.D., Chairman, President und Chief Executive Officer von Eli Lilly and Company
Read more →LLYLilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions John C. Lechleiter, Ph.D., chairman, president and chief executive officer of Eli Lilly and Company (NYSE: LLY), today urged that biopharmaceuticals...
BERLIN , July 11, 2011 /PRNewswire/ -- John C. Lechleiter , Ph.D., chairman, president and chief executive officer of Eli Lilly and Company (NYSE: LLY ), today urged that biopharmaceuticals be included in transatlantic trade and economic discussions. Lechleiter participated in th
Read more →LLYCEO von Lilly ruft zu verbessertem Dialog in Deutschland zwischen der Industrie, der Regierung und dem Gesundheitswesen auf - Der Aufruf an die Konferenz des Industrieverbands legt den Fokus auf Deutschlands Erbe als wichtiger Pharmastandort und das Bedürfnis nach besserer ...
BERLIN , July 7, 2011 /PRNewswire/ -- - Der Aufruf an die Konferenz des Industrieverbands legt den Fokus auf Deutschlands Erbe als wichtiger Pharmastandort und das Bedürfnis nach besserer Zusammenarbeit und Kommunikation, um medizinische Innovation voranzutreiben In einer Rede
Read more →LLYLilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System In an address to the Federation of German Industries Conference in Germany today, John C. Lechleiter, Ph.D., chairman, president and chief executive...
BERLIN , July 7, 2011 /PRNewswire/ -- In an address to the Federation of German Industries Conference in Germany today, John C. Lechleiter , Ph.D., chairman, president and chief executive officer of Eli Lilly and Company, offered to help build a new level of trust between the bio
Read more →LLYLilly Quality Leader Walsh Appointed to Company's Executive Committee Fionnuala Walsh, Ph.D., will join the executive committee of Eli Lilly and Company (NYSE: LLY) on July 1. Walsh will continue in her current role as...
INDIANAPOLIS , July 1, 2011 /PRNewswire/ -- Fionnuala Walsh , Ph.D., will join the executive committee of Eli Lilly and Company (NYSE: LLY ) on July 1 . Walsh will continue in her current role as Lilly's senior vice president of global quality, reporting to John Lechleiter , Ph.
Read more →LLYLilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations Company remains committed to speeding innovation to patients and delivering value to customers. R&D pipeline boasts 70 potential medicines in...
NEW YORK , June 30, 2011 /PRNewswire/ -- At its meeting today with the investment community aptly entitled "Bridging to the Future," Eli Lilly and Company (NYSE: LLY ) highlighted how its transformation efforts and innovation-based strategy will enable it to overcome upcoming pa
Read more →LLYNewly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men Eli Lilly and Company (NYSE: LLY) announced that a pivotal Phase III Axiron study, published on the Clinical Endocrinology website, showed that...
INDIANAPOLIS , June 28, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced that a pivotal Phase III Axiron study, published on the Clinical Endocrinology website, showed that Axiron® (testosterone) topical solution CIII, when applied to the underarm, met the primar
Read more →LLYLilly Announces New Investment to Further Boost Its Biotechnology Capabilities Today at the BIO International Convention, Eli Lilly and Company (NYSE: LLY) announced a multi-million dollar investment to expand its existing...
WASHINGTON , June 28, 2011 /PRNewswire/ -- Today at the BIO International Convention, Eli Lilly and Company (NYSE: LLY ) announced a multi-million dollar investment to expand its existing biotechnology capabilities. This investment is further fueling research and development of m
Read more →LLYAnalysis Compares Cost-Effectiveness of Premixed Insulin Analogs to Long-Acting Insulin Analogs in the Long-Term Treatment of Type 2 Diabetes in the U.S. Eli Lilly and Company (NYSE: LLY) today announced results from an analysis designed to evaluate the cost-effectiveness of insulin lispro mix 75/25...
SAN DIEGO and INDIANAPOLIS , June 24, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced results from an analysis designed to evaluate the cost-effectiveness of insulin lispro mix 75/25 and insulin lispro mix 50/50 versus long-acting insulin analog (LAIA). T
Read more →LLYLilly Declares Third-Quarter 2011 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the third quarter of 2011 of $0.49 a share on outstanding...
INDIANAPOLIS , June 20, 2011 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) today declared a dividend for the third quarter of 2011 of $0.49 a share on outstanding common stock. The dividend is payable September 9, 2011 to shareholders of record at
Read more →LLYLilly for Better Health™ Launches Enhanced Multi-Channel Patient Education Platform Lilly for Better Health™, a program of Lilly USA, LLC, (NYSE: LLY) that helps Americans live healthier, more active lives, launches an enhanced...
INDIANAPOLIS , June 14, 2011 /PRNewswire/ -- Lilly for Better Health ™, a program of Lilly USA, LLC, (NYSE: LLY ) that helps Americans live healthier, more active lives, launches an enhanced multi-channel platform designed to reach patients where they like to receive health infor
Read more →LLYSynthes and Lilly Sign Development and Collaboration Agreement Synthes, Inc. (SIX: SYST.VX) and Eli Lilly and Company (NYSE: LLY) today announced the signing of an exclusive worldwide collaboration agreement to...
WEST CHESTER, Pa. and INDIANAPOLIS , June 9, 2011 /PRNewswire/ -- Synthes, Inc. (SIX: SYST.VX) and Eli Lilly and Company (NYSE: LLY ) today announced the signing of an exclusive worldwide collaboration agreement to address the needs of patients who are cared for by orthopedic sur
Read more →LLYFDA Approves Updates to Lilly's Humalog® (insulin lispro injection [rDNA origin]) Label Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental new drug...
INDIANAPOLIS , June 8, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental new drug application (sNDA) with the following updates to the Humalog label: Based on the updated l
Read more →LLYU.S. District Court Rules in Favor of Lilly in Amylin Litigation Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of California ruled in Lilly's favor,...
INDIANAPOLIS , June 8, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. District Court for the Southern District of California ruled in Lilly's favor, vacating a temporary restraining order and denying a request by Amylin Pharmaceuticals for a
Read more →LLYNew Study Released Today Showed Patients With Deadly Form of Lung Cancer Lived Longer Without Disease Worsening Eli Lilly and Company (NYSE: LLY) announced today that PARAMOUNT, its Phase III study evaluating ALIMTA® (pemetrexed for injection) in the...
INDIANAPOLIS , June 5, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that PARAMOUNT, its Phase III study evaluating ALIMTA® (pemetrexed for injection) in the continuation maintenance setting, met its primary endpoint of progression-free survival, or the
Read more →LLYCorrection: Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcomas In the press release, Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcomas, issued May 19, 2011, by Eli Lilly and Company (NYSE: LLY),...
INDIANAPOLIS , May 27, 2011 /PRNewswire/ -- In the press release, "Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcomas," issued May 19, 2011 , by Eli Lilly and Company (NYSE: LLY ), the following sentence has been amended to: The best overall responses were as follows
Read more →LLYLilly Comments on Court Ruling in Amylin Litigation Eli Lilly and Company (NYSE: LLY) today commented on a ruling issued by the U.S. District Court for the Southern District of California granting a...
INDIANAPOLIS , May 25, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today commented on a ruling issued by the U.S. District Court for the Southern District of California granting a request by Amylin Pharmaceuticals for a temporary restraining order (TRO) related to lit
Read more →LLYLilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement Eli Lilly and Company (NYSE: LLY) today announced that it has signed agreements with private investors Care Capital and NovaQuest Capital to...
INDIANAPOLIS , May 23, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that it has signed agreements with private investors Care Capital and NovaQuest Capital to establish BioCritica Inc., a newly-formed and privately-held biotechnology company. BioCritica
Read more →LLYStudy Determined Best Dose and Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients Eli Lilly and Company (NYSE: LLY) announced Phase I data on LY2127399, a human monoclonal antibody that neutralizes B-cell activating factor (BAFF),...
INDIANAPOLIS , May 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced Phase I data on LY2127399, a human monoclonal antibody that neutralizes B-cell activating factor (BAFF), for use in combination with bortezomib in patients with previously-treated multiple my
Read more →LLYLilly Presents Data on Cixutumumab in Five Subtypes of Sarcoma Eli Lilly and Company (NYSE: LLY) announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from...
INDIANAPOLIS , May 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from connective tissues in the body. Study results demonstrated that 57 percent of patients w
Read more →LLYDavid M. Kendall, M.D., Named Distinguished Medical Fellow at Lilly Eli Lilly and Company (NYSE: LLY) today announced that David M. Kendall, M.D., currently chief scientific and medical officer of the American...
INDIANAPOLIS , May 18, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that David M. Kendall , M.D., currently chief scientific and medical officer of the American Diabetes Association, has been named distinguished medical fellow for Lilly. He will transit
Read more →LLYLilly Provides Statement in Response to Amylin Lawsuit Eli Lilly and Company (NYSE: LLY) has provided the following statement in response to a lawsuit and motion for temporary restraining order filed by...
INDIANAPOLIS , May 16, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has provided the following statement in response to a lawsuit and motion for temporary restraining order filed by Amylin Pharmaceuticals, Inc. against Lilly. The action was filed in the United States D
Read more →LLYLilly USA, LLC Launches TruAssist for Patients Lilly USA has launched www.LillyTruAssist.com and 1-855-LLYTRUE (1-855-559-8783), a website and call center for health care providers and patients to ...
INDIANAPOLIS , May 16, 2011 /PRNewswire/ -- Lilly USA has launched www.LillyTruAssist.com and 1-855-LLYTRUE (1-855-559-8783), a website and call center for health care providers and patients to access information about Lilly's patient assistance programs, which help connect patie
Read more →LLYLilly Oncology to Present New Data on Nine of Its Pipeline Molecules at ASCO 2011 Data on nine Lilly Oncology molecules in development will be presented during the 47th Annual Meeting of the American Society of Clinical Oncology...
INDIANAPOLIS , May 16, 2011 /PRNewswire/ -- Data on nine Lilly Oncology molecules in development will be presented during the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. from June 3 – 7, 2011. Lilly Oncology's pipeline is one of t
Read more →LLYLilly Oncology to Unveil Data From More Than 30 Studies at ASCO Eli Lilly and Company (NYSE: LLY) will present data from more than 30 studies at the 47th Annual Meeting of the American Society of Clinical Oncology ...
INDIANAPOLIS , May 16, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will present data from more than 30 studies at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. , from June 3 – 7, 2011, including results from PARAMOUNT, a
Read more →LLYLilly Provides Its Perspective in Response to Amylin Lawsuit Eli Lilly and Company (NYSE: LLY) has provided additional perspective in response to Amylin Pharmaceuticals, Inc.'s lawsuit filed in the United...
INDIANAPOLIS , May 16, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has provided additional perspective in response to Amylin Pharmaceuticals, Inc.'s lawsuit filed in the United States District Court for the Southern District of California . The lawsuit alleges that Li
Read more →LLYEli Lilly and Company Invests $2.5 Million to Launch The Mind Trust's Grow What Works Campaign Eli Lilly and Company (NYSE: LLY) and The Mind Trust, an Indianapolis-based nonprofit that supports bold, new education reform, today announced the...
INDIANAPOLIS , May 5, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and The Mind Trust, an Indianapolis -based nonprofit that supports bold, new education reform, today announced the launch of The Mind Trust's Grow What Works campaign. Grow What Works seeks to raise and
Read more →LLYU.S. District Court Order Maintains Patent Exclusivity for Lilly's Cymbalta Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of Indiana has issued an order that...
INDIANAPOLIS , April 27, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. District Court for the Southern District of Indiana has issued an order that prohibits the remaining defendants in the Cymbalta® (duloxetine hydrochloride) patent litiga
Read more →LLYLilly and Medtronic Announce Drug-Device Collaboration for Parkinson's Disease Eli Lilly and Company (NYSE: LLY) and Medtronic, Inc. (NYSE: MDT) today announced they have entered into a collaboration to research and develop a...
INDIANAPOLIS and MINNEAPOLIS , April 26, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Medtronic, Inc. (NYSE: MDT ) today announced they have entered into a collaboration to research and develop a new approach to treating Parkinson's disease that involves delivering
Read more →LLYLilly Reports First-Quarter 2011 Results First quarter 2011 revenue grew 6 percent to $5.8 billion, driven by increased demand in international markets. Company delivered first quarter...
INDIANAPOLIS , April 18, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the first quarter of 2011. Financial results for 2011 and 2010 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accorda
Read more →LLYLilly Declares Second-Quarter 2011 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the second quarter of 2011 of $0.49 a share on outstanding...
INDIANAPOLIS , April 18, 2011 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) today declared a dividend for the second quarter of 2011 of $0.49 a share on outstanding common stock. The dividend is payable June 10, 2011 to shareholders of record at th
Read more →LLYLilly Receives Complete Response Letter From FDA for Liprotamase for the Treatment of Exocrine Pancreatic Insufficiency Eli Lilly and Company (NYSE: LLY) has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug...
INDIANAPOLIS , April 15, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT)
Read more →LLYAmerican College of Endocrinology (ACE) and Lilly Diabetes Offer Free Checklist to Help People With Diabetes Prepare Before Disaster Strikes It was one of the most memorable winters in recent history with snowstorms wreaking havoc across the US causing transportation delays, power...
SAN DIEGO , April 14, 2011 /PRNewswire/ -- It was one of the most memorable winters in recent history with snowstorms wreaking havoc across the US causing transportation delays, power outrages, and structural damage. With tornado season set to start this month, Americans now have
Read more →LLYLilly Confirms Date and Conference Call for First-Quarter 2011 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the first quarter of 2011 on Monday, April 18, 2011. Lilly will also...
INDIANAPOLIS , April 6, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the first quarter of 2011 on Monday, April 18, 2011 . Lilly will also conduct a conference call on that day with the investment community and media to further d
Read more →LLYTwo Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer Eli Lilly and Company (NYSE: LLY) announced results today from two preclinical studies of molecules that target genetic mutations and disable...
ORLANDO, Fla. , April 4, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced results today from two preclinical studies of molecules that target genetic mutations and disable specific signaling pathways that can lead to cancer. The studies evaluated two unique molec
Read more →LLYAxiron® (Testosterone) Topical Solution CIII Now Available in Pharmacies Eli Lilly and Company (NYSE: LLY) announced today that Axiron® (testosterone) topical solution is available in pharmacies throughout the United...
INDIANAPOLIS , April 1, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that Axiron® (testosterone) topical solution is available in pharmacies throughout the United States . Axiron is a prescription medicine used to treat adult males that have low or no t
Read more →LLYLilly's Connecting Hearts Abroad Program Sends Employees on Global Service Assignments Eli Lilly and Company's (NYSE: LLY) new global service program, Connecting Hearts Abroad, is set to launch. Through the program, the company is...
INDIANAPOLIS , March 31, 2011 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY ) new global service program, Connecting Hearts Abroad, is set to launch. Through the program, the company is sending 200 Lilly Ambassadors to assist people and communities that often lack basic reso
Read more →LLYLilly and Avid Receive Complete Response Letter from FDA for Amyvid™ (florbetapir F 18 injection) Eli Lilly and Company (NYSE: LLY) and its wholly owned subsidiary, Avid Radiopharmaceuticals, Inc., have received a complete response letter from the ...
INDIANAPOLIS and PHILADELPHIA , March 18, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and its wholly owned subsidiary, Avid Radiopharmaceuticals, Inc., have received a complete response letter from the U.S. Food and Drug Administration (FDA) for their New Drug Applica
Read more →LLYLilly Announces Important Action Regarding Recall of Alcohol Prep Pads Made by Triad Group Included in Forteo Starter Kits Eli Lilly and Company (NYSE: LLY) announced today that patients should not use the alcohol prep pads made by the Triad Group that are contained in...
INDIANAPOLIS, March 17, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that patients should not use the alcohol prep pads made by the Triad Group that are contained in the black starter kits for Forteo® [teriparatide (rDNA origin) injection] in the United
Read more →LLYNAFE Names Lilly to Top 50 Companies for Executive Women Eli Lilly and Company (NYSE: LLY) has been named to the 2011 NAFE Top 50 Companies for Executive Women by the National Association for Female...
INDIANAPOLIS , March 15, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) has been named to the 2011 NAFE Top 50 Companies for Executive Women by the National Association for Female Executives (NAFE). The list recognizes organizations whose policies and practices encourage
Read more →LLYLilly Announces New Vice President of Oncology Research Eli Lilly and Company (NYSE: LLY) today announced that Greg Plowman, M.D., Ph.D., will lead Lilly's oncology research efforts as the vice president,...
INDIANAPOLIS , March 10, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that Greg Plowman , M.D., Ph.D., will lead Lilly's oncology research efforts as the vice president, oncology research and senior vice president of ImClone Systems research. In this i
Read more →LLYLilly CEO Calls for Biopharmaceutical Industry Changes and Policies That Encourage Medical Innovation To address growing unmet medical needs and strengthen the global economy, new approaches to biopharmaceutical research and policies that support...
TOKYO , March 9, 2011 /PRNewswire/ -- To address growing unmet medical needs and strengthen the global economy, new approaches to biopharmaceutical research and policies that support innovation are critical, according to John Lechleiter , Ph.D., chairman, president and CEO of Eli
Read more →LLYLilly Marks Major Milestone for Mirror Portfolio with Agreement by Independent Fund to License First Two Investigational Medicines Eli Lilly and Company (NYSE: LLY) announced today that the Mirror Portfolio, a concept created by Lilly to access innovation being developed outside...
INDIANAPOLIS , Feb. 15, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced today that the Mirror Portfolio, a concept created by Lilly to access innovation being developed outside the company's walls, has achieved a significant milestone. One of the independent ven
Read more →LLYLilly Announces Senior Leadership Changes Eli Lilly and Company (NYSE: LLY) today announced that Sue Mahony, currently senior vice president of human resources and diversity, has been named...
INDIANAPOLIS , Feb. 11, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that Sue Mahony , currently senior vice president of human resources and diversity, has been named senior vice president and president of Lilly Oncology. In this new role she continue
Read more →LLYLilly CEO Says Industry, Public Policy Must Pave Way For Innovation A new approach to research, along with public policies that support medical innovation, will help biopharmaceutical companies address stubborn...
LONDON , Feb. 10, 2011 /PRNewswire/ -- A new approach to research, along with public policies that support medical innovation, will help biopharmaceutical companies address stubborn diseases with potentially devastating personal and financial consequences, such as cancer and Alzh
Read more →LLYLilly and the Juvenile Diabetes Research Foundation Partner to Fund Regenerative Medicine Research in Type 1 Diabetes Eli Lilly and Company (NYSE: LLY) and the Juvenile Diabetes Research Foundation (JDRF) today announced that they have signed an agreement to fund...
INDIANAPOLIS and NEW YORK , Feb. 3, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and the Juvenile Diabetes Research Foundation (JDRF) today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to rege
Read more →LLYLilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab Eli Lilly and Company (NYSE: LLY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that they have stopped enrollment in one of their two...
INDIANAPOLIS and PRINCETON, N.J. , Feb. 2, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Bristol-Myers Squibb Company (NYSE: BMY ) announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigation
Read more →LLYLilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance Higher volume drove four percent revenue growth in Q4. Gross margin improvements in Q4 led to growth in operating income. Fourth quarter earnings per ...
INDIANAPOLIS , Jan. 27, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the fourth quarter and full year of 2010. Financial results for 2010 and 2009 are presented on both a reported and a non-GAAP basis. Reported results were prepa
Read more →LLYPresident of Lilly Oncology Announces Resignation Eli Lilly and Company (NYSE: LLY) today announced that John H. Johnson, senior vice president and president of Lilly Oncology, has resigned effective ...
INDIANAPOLIS , Jan. 25, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that John H. Johnson , senior vice president and president of Lilly Oncology, has resigned effective January 28, 2011 . A successor will be announced in the coming weeks. Lilly acquir
Read more →LLYStatement from Lilly and Avid on FDA Advisory Committee Recommendation for Amyvid™ (Florbetapir) NDA The U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee decided today that it could not...
INDIANAPOLIS and PHILADELPHIA , Jan. 20, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee decided today that it could not recommend approval of Amyvid™ (florbetapir) at this time based on the current
Read more →LLYNew Online Resource Available Specifically for Patients and Their Caregivers Following a Heart Stent Procedure Today, patient support group Mended Hearts, in partnership with Daiichi Sankyo, Inc. and Eli Lilly and Company, launched the Stent Hub – an online...
PARSIPPANY, N.J. and INDIANAPOLIS , Jan. 18, 2011 /PRNewswire/ -- Today, patient support group Mended Hearts, in partnership with Daiichi Sankyo, Inc. and Eli Lilly and Company, launched the Stent Hub – an online resource for acute coronary syndrome (ACS) patients who were treate
Read more →LLYLilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2010 Financial Results Announcement Eli Lilly and Company (NYSE: LLY) will announce its financial results for the fourth quarter and full year of 2010 on Thursday, January 27, 2011....
INDIANAPOLIS , Jan. 18, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) will announce its financial results for the fourth quarter and full year of 2010 on Thursday, January 27, 2011 . Lilly will also conduct a conference call on that day with the investment community and
Read more →LLYStatement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application for Treatment of Exocrine Pancreatic Insufficiency Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee voted today to...
INDIANAPOLIS , Jan. 12, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) announced the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee voted today to recommend non-approval of liprotamase, a non-porcine pancreatic enzyme replacement therap
Read more →LLYLilly and Boehringer Ingelheim Announce Strategic Alliance to Bring New Diabetes Treatments to Patients Worldwide Major diabetes care agreement centers on four pipeline compounds representing several of the largest and most promising product classes. Companies...
INDIANAPOLIS and INGELHEIM, Germany , Jan. 11, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Boehringer Ingelheim today announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development.
Read more →LLYLilly Announces Completion of Avid Acquisition and FDA Priority Review for florbetapir Eli Lilly and Company (NYSE: LLY) today announced that it has completed the acquisition of Avid Radiopharmaceuticals, Inc., a privately held company...
INDIANAPOLIS , Dec. 20, 2010 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) today announced that it has completed the acquisition of Avid Radiopharmaceuticals, Inc., a privately held company developing novel molecular imaging compounds intended for the detection and
Read more →LLYLilly Statement Regarding President Obama's Meeting With U.S. Business Leaders Eli Lilly and Company (NYSE: LLY) today issued the following statement from John Lechleiter, Ph.D., chairman, president, and chief executive officer...
INDIANAPOLIS , Dec. 15, 2010 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today issued the following statement from John Lechleiter , Ph.D., chairman, president, and chief executive officer about his meeting today with President Obama and other business leaders regarding ec
Read more →LLYLilly Declares First-Quarter 2011 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the first quarter of 2011 of $0.49 a share on outstanding...
INDIANAPOLIS , Dec. 13, 2010 /PRNewswire-FirstCall/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) today declared a dividend for the first quarter of 2011 of $0.49 a share on outstanding common stock. The dividend is payable March 10, 2011 to shareholders of rec
Read more →LLYLilly Suspends Phase III Trial in Metastatic Melanoma Eli Lilly and Company announced today that it has suspended its global Phase III study evaluating tasisulam, an investigational, small-molecule...
INDIANAPOLIS , Dec. 13, 2010 /PRNewswire/ -- Eli Lilly and Company announced today that it has suspended its global Phase III study evaluating tasisulam, an investigational, small-molecule anti-cancer compound, as a second-line treatment for those with unresectable or metastatic
Read more →LLYLilly and Acrux Receive FDA Approval for Axiron® (Testosterone) Topical Solution CIII Eli Lilly and Company (NYSE: LLY) and Acrux (ASX: ACR) announced that the U.S. Food and Drug Administration (FDA) has approved Axiron® (testosterone) ...
INDIANAPOLIS, Ind. and MELBOURNE, Australia , Nov. 23, 2010 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) and Acrux (ASX: ACR) announced that the U.S. Food and Drug Administration (FDA) has approved Axiron® (testosterone) topical solution CIII for replacement thera
Read more →LLYMortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery New results from an observational substudy from TRITON–TIMI 38 presented today at the American Heart Association (AHA) Scientific Sessions annual...
CHICAGO , Nov. 16, 2010 /PRNewswire-FirstCall/ -- New results from an observational substudy from TRITON–TIMI 38 presented today at the American Heart Association (AHA) Scientific Sessions annual meeting showed that patients treated with Efient®/Effient® (prasugrel) prior to coro
Read more →LLYU.S. District Court Rules from Bench in Lilly's Favor, Confirms Validity of Alimta Patent Eli Lilly and Company (NYSE: LLY) today announced that the trial on the validity of the compound patent for Alimta® (pemetrexed for injection) before ...
"We are pleased that the District Court has now confirmed the validity of Alimta's compound patent," said Robert A. Armitage , senior vice president and general counsel for Lilly. "We continue to emphasize that protection of intellectual property rights is extremely important to
Read more →LLYGiving Thanks and Eating Well: F.A.C.E. Diabetes and Anthony Anderson Encourage African Americans to 'Make Over Your Sunday Meal' In recognition of November as National Diabetes Awareness Month and the start of the holiday season, Eli Lilly and Company and actor Anthony Anderson ...
NEW YORK , Nov. 10, 2010 /PRNewswire/ -- In recognition of November as National Diabetes Awareness Month and the start of the holiday season, Eli Lilly and Company and actor Anthony Anderson are encouraging African Americans to "Make Over Your Sunday Meal" as part of F.A.C.E. Dia
Read more →LLYLilly to Acquire Avid Radiopharmaceuticals Eli Lilly and Company (NYSE: LLY) today announced that it has signed a definitive merger agreement to acquire Avid Radiopharmaceuticals, Inc., a...
INDIANAPOLIS and PHILADELPHIA , Nov. 8, 2010 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) today announced that it has signed a definitive merger agreement to acquire Avid Radiopharmaceuticals, Inc., a privately held company developing novel molecular imaging compo
Read more →LLYFDA Approves Cymbalta® for the Management of Chronic Musculoskeletal Pain Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the...
INDIANAPOLIS , Nov. 4, 2010 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) announced that the U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the management of chronic musculoskeletal pain. This has been established in studies in
Read more →LLYLilly Surpasses United Way 2010 Campaign Goal Eli Lilly and Company (NYSE: LLY) Chairman, President and Chief Executive Officer John Lechleiter Ph.D. today presented an $11.6 million check to the ...
INDIANAPOLIS , Nov. 4, 2010 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) Chairman, President and Chief Executive Officer John Lechleiter Ph.D. today presented an $11.6 million check to the United Way. The check represents the contributions of Lilly's U.S. employees and reti
Read more →LLYLilly CEO Calls for a 'Wave of Invention' to Reduce the Toll of Diabetes In a speech to the Cleveland Clinic Medical Innovation Summit, John C. Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company (NYSE: ...
CLEVELAND , Nov. 3, 2010 /PRNewswire/ -- In a speech to the Cleveland Clinic Medical Innovation Summit, John C. Lechleiter , Ph.D., chairman, president and CEO of Eli Lilly and Company (NYSE: LLY ) today described the "paradox of progress" against diabetes, noting that "for all o
Read more →LLYEli Lilly and Company to Open a Diabetes-Focused Research Center in China Eli Lilly and Company (NYSE: LLY) announced today plans to open a research center focused on diabetes in China, where the incidence of the disease...
INDIANAPOLIS , Nov. 2, 2010 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) announced today plans to open a research center focused on diabetes in China, where the incidence of the disease has reached epidemic proportions. The center, to open in Shanghai in the seco
Read more →LLYThe Welcome Back Awards Seeks Nominations to Honor Leaders in the Depression Community The Welcome Back Awards is now accepting nominations to honor individuals dedicated to improving the lives of those suffering from depression. The...
NEW YORK , Nov. 1, 2010 /PRNewswire/ -- The Welcome Back Awards is now accepting nominations to honor individuals dedicated to improving the lives of those suffering from depression. The Welcome Back Awards , now in its 13th year, is a program established by Eli Lilly and Company
Read more →LLYLilly CEO: 'Are We Getting Our Money's Worth from Medical Innovation?' In a speech to the Dallas Friday Group today, John C. Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company (NYSE: LLY), said that...
DALLAS , Oct. 29 /PRNewswire/ -- In a speech to the Dallas Friday Group today, John C. Lechleiter , Ph.D., chairman, president and CEO of Eli Lilly and Company (NYSE: LLY ), said that the value of medical innovation – particularly innovative medicines – far outstrips its cost. Le
Read more →LLYLilly Reports Third-Quarter 2010 Results Total revenue growth of 2 percent driven by higher demand in international markets Animal Health revenue increased 12 percent Q3 earnings per share...
INDIANAPOLIS , Oct. 21 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) today announced financial results for the third quarter of 2010. Financial results for 2010 and 2009 are presented on both a reported and a non-GAAP basis. Reported results were prepared in acco
Read more →LLYLife Becomes Art: Cancer Survivor Awarded Top Prize in 2010 Oncology On Canvas(SM) Art Competition Following her lung cancer diagnosis, a woman who had spent nearly 30 years in nursing felt as if her life had been cut up, rearranged and become a...
INDIANAPOLIS , Oct. 20 /PRNewswire/ -- Following her lung cancer diagnosis, a woman who had spent nearly 30 years in nursing felt as if her life had been "cut up, rearranged and become a different picture." An amateur artist, Annette Zalewski , of Peoria, Ariz. , sought to expres
Read more →LLYLa vida se convierte en arte: sobreviviente del cáncer recibe el primer premio del concurso de arte Oncology On Canvas(SM) de 2010 Después que le diagnosticaron cáncer pulmonar, una mujer que había pasado casi 30 años dedicada a la enfermería se sintió como si su vida se la...
INDIANÁPOLIS, 20 de octubre /PRNewswire-HISPANIC PR WIRE/ -- Después que le diagnosticaron cáncer pulmonar, una mujer que había pasado casi 30 años dedicada a la enfermería se sintió como si su vida se la hubieran "cortado, reorganizado y convertido en un cuadro distinto". Annett
Read more →LLYMacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the Protege Data Monitoring Committee (DMC), composed of independent...
ROCKVILLE, Md. and INDIANAPOLIS , Oct. 20 /PRNewswire-FirstCall/ -- MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY ) today announced that the Protege Data Monitoring Committee (DMC), composed of independent experts in the fields of diabetes and biostatistics, has complete
Read more →LLYHealth Care Coordination Program Honored With URAC National Best Practices Award URAC, a leading independent health care quality accrediting organization, has awarded the Oklahoma Medical Risk Management (MRM) program the Bronze...
The Oklahoma Health Care Authority (OHCA) and Oklahoma Department of Mental Health and Substance Abuse Services (ODMHSAS) developed the program in partnership with research firm Care Management Technologies. Eli Lilly and Company, an Indianapolis -based pharmaceutical company, pr
Read more →LLYEli Lilly and Company Announces 2010 Lilly Reintegration Awards Recipients For the 14th straight year, Eli Lilly and Company honors mental health professionals and individuals for their exceptional contributions and...
INDIANAPOLIS , Oct. 18 /PRNewswire/ -- For the 14th straight year, Eli Lilly and Company honors mental health professionals and individuals for their exceptional contributions and achievements in helping those battling serious mental illness. Since 1996, the Lilly Reintegration
Read more →LLYLilly Declares Fourth-Quarter 2010 Dividend The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the fourth quarter of 2010 of $0.49 a share on outstanding...
INDIANAPOLIS , Oct. 18 /PRNewswire-FirstCall/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) today declared a dividend for the fourth quarter of 2010 of $0.49 a share on outstanding common stock. This is the same dividend as was paid in the first three quarters o
Read more →LLYNew FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research Eli Lilly and Company (NYSE: LLY) today announced that a total of 14 U.S. and global studies involving its osteoporosis medications, FORTEO®...
INDIANAPOLIS , Oct. 14 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) today announced that a total of 14 U.S. and global studies involving its osteoporosis medications, FORTEO® [teriparatide (rDNA origin) injection] and EVISTA® (raloxifene HCl tablets), will be pres
Read more →LLYLilly's Online Interactive Health Education Answers Program Receives NCQA Recertification Lilly's (NYSE: LLY) Health Education Answers program, an interactive online health and wellness tool, has received Health Information Product...
INDIANAPOLIS , Oct. 11 /PRNewswire-FirstCall/ -- Lilly's (NYSE: LLY ) Health Education Answers program, an interactive online health and wellness tool, has received Health Information Product Recertification from the National Committee for Quality Assurance (NCQA). The certificat
Read more →LLYLilly Presents New Data in Head and Neck Cancer - a Difficult-To-Treat Cancer With Poor Survival Rates Eli Lilly and Company (NYSE: LLY) announced today that its global Phase III trial evaluating ALIMTA® (pemetrexed for injection) in combination with...
INDIANAPOLIS , Oct. 11 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) announced today that its global Phase III trial evaluating ALIMTA® (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the hea
Read more →LLYThe Interchange of Art and Nature: A Greener Welcome From sunup to sundown October 7, 2010, more than 8,000 volunteers from Eli Lilly and Company and six partner companies will use shovels, trowels, and ...
INDIANAPOLIS , Oct. 6 /PRNewswire/ -- From sunup to sundown October 7, 2010 , more than 8,000 volunteers from Eli Lilly and Company and six partner companies will use shovels, trowels, and rakes to transform the western gateway to Indianapolis into 'A Greener Welcome.' The projec
Read more →LLYLilly premiada por el Consejo Nacional Hispano de Personas Adultas Mayores por su continuo compromiso con la salud de los adultos mayores Eli Lilly and Company (NYSE: LLY) recibió el Premio del Presidente del Consejo Nacional Hispano de Personas Adultas Mayores (National Hispanic...
WASHINGTON , 29 de septiembre /PRNewswire-HISPANIC PR WIRE/ -- Eli Lilly and Company (NYSE: LLY ) recibió el Premio del Presidente del Consejo Nacional Hispano de Personas Adultas Mayores (National Hispanic Council on Aging, NHCOA) en su conferencia anual en Washington, D.C. Lil
Read more →LLYLilly Recognized by the National Hispanic Council on Aging for Ongoing Commitment to the Health of Older Adults Eli Lilly and Company (NYSE: LLY) was given the President's Award by the National Hispanic Council on Aging (NHCOA) at its annual conference in...
WASHINGTON , Sept. 29 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) was given the President's Award by the National Hispanic Council on Aging (NHCOA) at its annual conference in Washington, D.C. Lilly has developed a successful partnership with the NHCOA to addres
Read more →LLYEli Lilly and Company Researchers Begin Working at New State-of-the-Art Lab Located in the Heart of New York City Eli Lilly and Company (NYSE: LLY) announced today that approximately 140 of its scientists have begun working at its new state-of-the-art cancer...
NEW YORK , Sept. 28 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) announced today that approximately 140 of its scientists have begun working at its new state-of-the-art cancer research facility in New York City that is focused on speeding to market a new generatio
Read more →LLYLilly CEO Says Regional Innovation Clusters Can Renew the Nation's Economy In the keynote address to a conference on Regional Innovation Clusters today, John C. Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and ...
WASHINGTON , Sept. 23 /PRNewswire/ -- In the keynote address to a conference on Regional Innovation Clusters today, John C. Lechleiter , Ph.D., chairman, president and CEO of Eli Lilly and Company (NYSE: LLY ), argued for federal policies that further encourage regional economic
Read more →LLYEli Lilly and Company Encourages African-Americans to Get a Check-up and Face Diabetes Angie Stone and Anthony Anderson, spokespeople for Lilly's Fearless African-Americans Connected and Empowered (F.A.C.E.) Diabetes initiative, are...
INDIANAPOLIS , Sept. 23 /PRNewswire/ -- Angie Stone and Anthony Anderson , spokespeople for Lilly's F earless A frican-Americans C onnected and E mpowered (F.A.C.E.) Diabetes initiative, are teaming up with The Tom Joyner Morning Show (TJMS) for the 9th annual Take a Loved One to
Read more →LLYLilly Celebrates 16th Consecutive Year as One of 100 Best Companies for Working Mothers Eli Lilly and Company (NYSE: LLY) has been selected as one of the 100 Best Companies for Working Mothers by Working Mother magazine for the 16th...
INDIANAPOLIS , Sept. 22 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) has been selected as one of the 100 Best Companies for Working Mothers by Working Mother magazine for the 16th consecutive year. (Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO ) (L
Read more →LLYJeffrey A. Winton Named Vice President of Communications at Eli Lilly and Company Eli Lilly and Company (NYSE: LLY) today announced that pharmaceutical industry veteran Jeffrey A. Winton has been named vice president of...
INDIANAPOLIS , Sept. 21 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) today announced that pharmaceutical industry veteran Jeffrey A. Winton has been named vice president of communications. Winton will assume this role on October 11 , and will become a member of th
Read more →LLYLilly Recognized with World Business and Development Award for Tuberculosis Initiative An eminent international panel of judges has selected Eli Lilly and Company (NYSE: LLY) to receive a World Business and Development Award for...
NEW YORK , Sept. 21 /PRNewswire-FirstCall/ -- An eminent international panel of judges has selected Eli Lilly and Company (NYSE: LLY ) to receive a World Business and Development Award for demonstrating what can be achieved through successful partnerships in the battle against mu
Read more →LLYPhase II Study Showed Switching ACS-PCI Patients to Effient®/aspirin from Plavix®/aspirin Regimen Reduced Maximum Platelet Aggregation After One Week A study evaluating the level of platelet aggregation achieved after switching from Plavix® (clopidogrel) 75 mg once-daily maintenance dosing plus...
PARSIPPANY, N.J. and INDIANAPOLIS , Sept. 13 /PRNewswire-FirstCall/ -- A study evaluating the level of platelet aggregation achieved after switching from Plavix ® (clopidogrel) 75 mg once-daily maintenance dosing plus aspirin to Effient® (prasugrel) 10 mg once-daily maintenance d
Read more →LLYU.S. Court of Appeals Reverses Third-Party Payor Class Certification Suit Against Lilly Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Second Circuit has agreed with Lilly's position that a class ...
INDIANAPOLIS , Sept. 10 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Court of Appeals for the Second Circuit has agreed with Lilly's position that a class should not have been certified in a pending third-party payor suit, in which un
Read more →LLYU.S. Court of Appeals Upholds Validity of Lilly's Evista Patents Through March of 2014 Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S....
INDIANAPOLIS , Sept. 1 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S. District Court for the Southern District of Indiana that the company's method-of-use
Read more →LLYStatement from Eli Lilly and Company Regarding Approval Recommendation from FDA Advisory Committee for Expanding the Pain Indications for Cymbalta® to a Broader Pain Population The U.S. Food and Drug Administration (FDA) Anesthetic and Life Support Drugs Advisory Committee voted today 8-6 in favor of expanding the pain...
BETHESDA, Md. , Aug. 19 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) Anesthetic and Life Support Drugs Advisory Committee voted today 8-6 in favor of expanding the pain indications for Eli Lilly and Company's (NYSE: LLY ) Cymbalta® (duloxetine HCl) to a b
Read more →LLYLilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials Eli Lilly and Company (NYSE: LLY) will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for...
INDIANAPOLIS , Aug. 17 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary results from two ongoing long-term Phase III
Read more →LLYU.S. District Court Rules Against Lilly Regarding Strattera Patent Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the District of New Jersey has ruled against the company in its...
INDIANAPOLIS , Aug. 12 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) today announced that the U.S. District Court for the District of New Jersey has ruled against the company in its patent litigation for Strattera® (atomoxetine). In the case of Eli Lilly and Compan
Read more →LLYThe American Diabetes Association and Eli Lilly and Company Encourage African-Americans to Face the Music about Diabetes Management The 12th annual Victory Over Diabetes event, hosted by the American Diabetes Association (the Association), will take place in Atlanta on August 7,...
ATLANTA , Aug. 5 /PRNewswire-FirstCall/ -- The 12th annual Victory Over Diabetes event, hosted by the American Diabetes Association (the Association), will take place in Atlanta on August 7 , featuring Eli Lilly and Company's F earless A frican-Americans C onnected and E mpowered
Read more →LLYLilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection) | Eli Lilly and Company
Eli Lilly announced its fourth FDA approval for ALIMTA as a maintenance therapy for nonsquamous non-small cell lung cancer patients. This approval represents a significant advancement in treatment options, allowing for improved survival following initial chemotherapy.
Read more →LLYFDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression | Eli Lilly and Company
The FDA has approved Symbyax as the first medication for treatment-resistant depression, offering a new option for patients. Eli Lilly also received approvals for new indications for Zyprexa and fluoxetine, enhancing treatment choices for clinicians and patients.
Read more →LLYFDA Grants Lilly's ALIMTA(R) (Pemetrexed for Injection) Third U.S. Approval | Eli Lilly and Company
Eli Lilly's ALIMTA (pemetrexed for injection) received FDA approval for first-line treatment of nonsquamous non-small cell lung cancer (NSCLC), marking its third U.S. indication. The approval is based on a Phase III study showing comparable survival rates and reduced toxicity compared to GEMZAR.
Read more →LLYFDA Approves Cymbalta(R) for the Management of Fibromyalgia | Eli Lilly and Company
The FDA has approved Cymbalta for managing fibromyalgia, marking it as the first effective serotonin-norepinephrine reuptake inhibitor for this condition. This approval offers a new treatment option for patients suffering from chronic pain associated with fibromyalgia.
Read more →LLYFDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents | Eli Lilly and Company
The FDA has approved Strattera for the maintenance treatment of ADHD in children and adolescents, marking it as the first non-stimulant option. A large study demonstrated its efficacy in reducing relapse rates, providing a long-term treatment solution for ADHD symptoms.
Read more →LLYFDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder | Eli Lilly and Company
The FDA has approved Cymbalta for the maintenance treatment of major depressive disorder in adults, highlighting its efficacy in delaying relapse. The approval is supported by clinical trial data and recommendations from the American Psychiatric Association.
Read more →LLYFDA Approves Lilly's Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women | Eli Lilly and Company
The FDA has approved Eli Lilly's EVISTA for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and those at high risk. This approval offers a new treatment option addressing significant health concerns, although it includes a boxed warning for certain patients.
Read more →LLYFDA Approves Cymbalta® for Treatment of Generalized Anxiety Disorder | Eli Lilly and Company
The FDA has approved Cymbalta for treating generalized anxiety disorder, a condition affecting over 6.5 million adults annually. Clinical trials showed significant improvements in anxiety symptoms and daily functioning. Cymbalta is already approved for other conditions, providing a new treatment option for patients with GAD.
Read more →LLYFDA Approves Lilly's Gemzar(R) For Ovarian Cancer Treatment | Eli Lilly and Company
The FDA has approved Eli Lilly's GEMZAR for treating recurrent ovarian cancer in combination with carboplatin. This approval marks a significant advancement in treatment, showing improved progression-free survival rates. GEMZAR is already a successful drug, generating substantial sales and is approved in over 90 countries.
Read more →LLYFDA Approves Lilly's Cymbalta for the Treatment of Depression | Eli Lilly and Company
The FDA has approved Cymbalta (duloxetine HCl) for treating major depressive disorder, offering a new option for addressing both emotional and physical symptoms. The drug has shown effectiveness in clinical trials, although its safety in children remains unstudied.
Read more →LLYStudy Data Shows Newly Approved Gemzar Combination Represents Valuable Therapy Option for Frontline Treatment in Metastatic Breast Cancer | Eli Lilly and Company
New data shows that the Gemzar/Taxol combination significantly improves survival rates in metastatic breast cancer patients compared to Taxol alone. The FDA has approved this combination as a new standard treatment, highlighting its efficacy and manageable side effects.
Read more →LLYCialis® (tadalafil) marks 10 years since U.S. approval | Eli Lilly and Company
Cialis celebrates its 10th anniversary since FDA approval, highlighting its impact on men's health and erectile dysfunction treatment. It has become a market leader, treating millions and offering unique dosing options. The drug's success is marked by significant sales growth and recognition in the medical community.
Read more →Competitive Position
How LLY ranks across every disease it competes inCompetitive Position is a premium feature
See how LLY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial